assay_id,src_id,assay_type,bao_format,assay_tax_id,doc_id,description,assay_test_type,assay_category,assay_organism,assay_strain,assay_tissue,assay_cell_type,assay_subcellular_fraction
1,1,B,BAO_0000019,,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,,,,,
2,1,F,BAO_0000219,,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,,,,,
3,1,B,BAO_0000019,,15453,,,,,,,,
4,1,B,BAO_0000249,9913.0,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,,Bos taurus,,,,
5,1,F,BAO_0000219,9606.0,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,Homo sapiens,,,143B,
6,1,F,BAO_0000219,9606.0,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,Homo sapiens,,,143B,
7,1,F,BAO_0000219,10090.0,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,,Mus musculus,,,143B,
8,1,F,BAO_0000219,9606.0,17774,In vitro cell cytotoxicity was determined against 143B cell line,,,Homo sapiens,,,143B,
9,1,F,BAO_0000219,9606.0,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,,Homo sapiens,,,143B,
10,1,F,BAO_0000219,9606.0,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,Homo sapiens,,,143B,
11,1,F,BAO_0000219,9606.0,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,Homo sapiens,,,143B,
12,1,F,BAO_0000219,9606.0,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,,Homo sapiens,,,143B,
13,1,F,BAO_0000218,1280.0,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Staphylococcus aureus,,,,
14,1,F,BAO_0000218,1280.0,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Staphylococcus aureus,,,,
15,1,F,BAO_0000218,1280.0,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Staphylococcus aureus,,,,
16,1,F,BAO_0000218,1280.0,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,Staphylococcus aureus,,,,
17,1,A,BAO_0000357,10116.0,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,,Rattus norvegicus,,,,
18,1,B,BAO_0000357,,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,
19,1,B,BAO_0000019,,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,,,,,
20,1,B,BAO_0000357,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,
21,1,B,BAO_0000357,,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,
22,1,B,BAO_0000357,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,
23,1,B,BAO_0000357,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,,,,
24,1,B,BAO_0000357,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,,,,
25,1,B,BAO_0000219,,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,,,,,
26,1,B,BAO_0000357,9986.0,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,,Oryctolagus cuniculus,,,,
27,1,B,BAO_0000357,9986.0,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,,Oryctolagus cuniculus,,,,
28,1,B,BAO_0000219,,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,,,,,
29,1,B,BAO_0000357,3847.0,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,,soya bean,,,,
30,1,B,BAO_0000357,3847.0,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,,Glycine max,,,,
31,1,B,BAO_0000357,3847.0,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,,Glycine max,,,,
32,1,B,BAO_0000357,3847.0,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,,Glycine max,,,,
33,1,B,BAO_0000357,3847.0,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,,Glycine max,,,,
34,1,B,BAO_0000357,3847.0,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,,Glycine max,,,,
35,1,B,BAO_0000357,3847.0,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,,Glycine max,,,,
36,1,A,BAO_0000019,10116.0,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,,Rattus norvegicus,,,,
37,1,B,BAO_0000019,562.0,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,,Escherichia coli,,,,
38,1,B,BAO_0000019,,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,,,,,,,
39,1,B,BAO_0000225,,3782,Dissociation constant towards 16S rRNA construct A,,,,,,,
40,1,B,BAO_0000225,,3782,Dissociation constant towards 16S rRNA construct B,,,,,,,
41,1,B,BAO_0000225,562.0,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,,Escherichia coli,,,,
42,1,B,BAO_0000225,562.0,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,,Escherichia coli,,,,
43,1,B,BAO_0000019,,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,
44,1,B,BAO_0000019,,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,
45,1,B,BAO_0000019,9606.0,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,Homo sapiens,,,,
46,1,B,BAO_0000019,9606.0,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,Homo sapiens,,,,
47,1,B,BAO_0000019,10116.0,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,Rattus norvegicus,,,,
48,1,B,BAO_0000019,10116.0,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,Rattus norvegicus,,,,
49,1,B,BAO_0000019,10116.0,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,Rattus norvegicus,,,,
50,1,B,BAO_0000019,10116.0,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,Rattus norvegicus,,,,
51,1,B,BAO_0000019,,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,
52,1,B,BAO_0000357,,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,,,,,
53,1,B,BAO_0000357,,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,,,,,
54,1,B,BAO_0000357,,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,,,,,
55,1,B,BAO_0000249,10116.0,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,,Rattus norvegicus,,,,Membranes
56,1,F,BAO_0000219,9606.0,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,,Homo sapiens,,,1A9,
57,1,F,BAO_0000219,10116.0,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,,Rattus norvegicus,,,Oocytes,
58,1,F,BAO_0000219,10116.0,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,,Rattus norvegicus,,,Oocytes,
59,1,F,BAO_0000219,10116.0,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,,Rattus norvegicus,,,Oocytes,
60,1,F,BAO_0000219,9606.0,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,,Homo sapiens,,,1A9,
61,1,F,BAO_0000219,9606.0,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,,Homo sapiens,,,1A9,
62,1,F,BAO_0000219,9606.0,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,,,Homo sapiens,,,1A9,
63,1,F,BAO_0000219,9606.0,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,,Homo sapiens,,,1A9,
64,1,F,BAO_0000219,9606.0,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,,,Homo sapiens,,,1A9,
65,1,F,BAO_0000219,9606.0,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,,Homo sapiens,,,1A9,
66,1,F,BAO_0000219,9606.0,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,,Homo sapiens,,,1A9,
67,1,F,BAO_0000219,9606.0,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,,Homo sapiens,,,1A9,
68,1,F,BAO_0000219,9606.0,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,,Homo sapiens,,,1A9,
69,1,F,BAO_0000219,9606.0,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,,,Homo sapiens,,,1A9,
70,1,F,BAO_0000219,9606.0,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,,Homo sapiens,,,1A9,
71,1,F,BAO_0000219,9606.0,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,,Homo sapiens,,,1A9,
72,1,F,BAO_0000219,9606.0,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,,Homo sapiens,,,1A9,
73,1,F,BAO_0000219,9606.0,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,,Homo sapiens,,,1A9,
74,1,F,BAO_0000219,9606.0,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,,Homo sapiens,,,1A9,
75,1,F,BAO_0000219,9606.0,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,,Homo sapiens,,,1A9,
76,1,F,BAO_0000219,9606.0,17721,Inhibitory concentration against Jurkat cells,,,Homo sapiens,,,Jurkat,
77,1,F,BAO_0000019,,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,,,,,
78,1,A,BAO_0000357,10116.0,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,,Rattus norvegicus,,,,
79,1,B,BAO_0000357,,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,,,,
80,1,B,BAO_0000357,,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,,,,
81,1,B,BAO_0000357,,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,,,,,
82,1,B,BAO_0000251,5476.0,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,,Candida albicans,,,,Microsomes
83,1,B,BAO_0000251,5476.0,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,,Candida albicans,,,,Microsomes
84,1,B,BAO_0000251,4932.0,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,,Saccharomyces cerevisiae,,,,Microsomes
85,1,B,BAO_0000251,4932.0,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,,Saccharomyces cerevisiae,,,,Microsomes
86,1,B,BAO_0000251,9823.0,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,,Sus scrofa,,Liver,,Microsomes
87,1,B,BAO_0000019,10116.0,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,,Rattus norvegicus,,,,
88,1,B,BAO_0000019,10116.0,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,,Rattus norvegicus,,,,
89,1,B,BAO_0000019,10116.0,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,,Rattus norvegicus,,,,
90,1,B,BAO_0000251,10116.0,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,,Rattus norvegicus,,Liver,,Microsomes
91,1,B,BAO_0000251,10116.0,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,Rattus norvegicus,,Liver,,Microsomes
92,1,B,BAO_0000251,10116.0,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,Rattus norvegicus,,Liver,,Microsomes
93,1,B,BAO_0000357,,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,,,,,
94,1,B,BAO_0000357,,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,,,,,
95,1,F,BAO_0000219,9606.0,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,Homo sapiens,,,HepG2,
96,1,F,BAO_0000219,9606.0,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,,Homo sapiens,,,HepG2,
97,1,F,BAO_0000219,9606.0,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,,Homo sapiens,,,HepG2,
98,1,F,BAO_0000219,9606.0,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,,Homo sapiens,,,HepG2,
99,1,F,BAO_0000219,9606.0,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,,Homo sapiens,,,HepG2,
100,1,F,BAO_0000218,10407.0,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,Hepatitis B virus,,,,
101,1,F,BAO_0000219,9606.0,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,,Homo sapiens,,,HepG2,
102,1,F,BAO_0000219,9606.0,1717,Concentration required to inhibit 50% of 2.2.15 cell line,,,Homo sapiens,,,HepG2,
103,1,A,BAO_0000219,9606.0,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,,Homo sapiens,,,HepG2,
104,1,F,BAO_0000218,9606.0,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,,Homo sapiens,,,2.2.15,
105,1,F,BAO_0000218,9606.0,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,,Homo sapiens,,,2.2.15,
106,1,F,BAO_0000218,10407.0,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,,Hepatitis B virus,,,2.2.15,
107,1,F,BAO_0000218,9606.0,1593,In vitro anti-HBV activity in 2.2.15 cells,,,Homo sapiens,,,2.2.15,
108,1,F,BAO_0000218,9606.0,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,,Homo sapiens,,,2.2.15,
109,1,F,BAO_0000218,9606.0,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,,Homo sapiens,,,2.2.15,
110,1,F,BAO_0000218,9606.0,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,,Homo sapiens,,,2.2.15,
111,1,F,BAO_0000218,9606.0,1593,Cytotoxicity in 2.2.15 cells,,,Homo sapiens,,,2.2.15,
112,1,F,BAO_0000218,9606.0,1593,Cytotoxicity in 2.2.15 cells; Not determined,,,Homo sapiens,,,2.2.15,
113,1,F,BAO_0000218,9606.0,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,,Homo sapiens,,,2.2.15,
114,1,F,BAO_0000218,9606.0,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,,Homo sapiens,,,2.2.15,
115,1,F,BAO_0000218,9606.0,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,,Homo sapiens,,,2.2.15,
116,1,F,BAO_0000219,9606.0,14764,Antiviral activity against HBV was determined in 2.215 cell line,,,Homo sapiens,,,HepG2,
117,1,B,BAO_0000251,9606.0,6531,Inhibition of 20-HETE synthesis in human renal microsomes,,,Homo sapiens,,,,Microsomes
118,1,B,BAO_0000019,,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,,,,,
119,1,F,BAO_0000219,9606.0,17072,Inhibitory concentration against 2008 (ovarian) cells,,,Homo sapiens,,,2008,
120,1,F,BAO_0000219,9606.0,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,,Homo sapiens,,,2008,
121,1,F,BAO_0000219,9606.0,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,,Homo sapiens,,,2008,
122,1,F,BAO_0000219,9606.0,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,,Homo sapiens,,,2008,
123,1,F,BAO_0000219,9606.0,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,,Homo sapiens,,,2008,
124,1,F,BAO_0000219,9606.0,10797,In vitro inhibition of 2008/R ovarian cancer cell line,,,Homo sapiens,,,2008/R,
125,1,F,BAO_0000219,9606.0,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,,Homo sapiens,,,2008/R,
126,1,F,BAO_0000219,9606.0,10797,In vitro inhibition of 2008/S ovarian cancer cell line,,,Homo sapiens,,,2008/S,
127,1,F,BAO_0000219,9606.0,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,,Homo sapiens,,,2008/S,
128,1,B,BAO_0000220,9606.0,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,,Homo sapiens,,,,
129,1,B,BAO_0000220,9606.0,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,,Homo sapiens,,,,
130,1,B,BAO_0000220,,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,,,,,,,
131,1,B,BAO_0000220,,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,,,,,
132,1,B,BAO_0000220,,3260,Inhibitory activity against 20S proteosome,,,,,,,
133,1,B,BAO_0000019,9606.0,3451,Compound was tested for inhibitory activity against tryptase,,,Homo sapiens,,,,
134,1,F,BAO_0000219,9606.0,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,,Homo sapiens,,,HepG2,
135,1,F,BAO_0000219,9606.0,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,,Homo sapiens,,,HepG2,
136,1,B,BAO_0000019,,3676,Compound was tested for the inhibition of Alpha-glucosidase,,,,,,,
137,1,B,BAO_0000357,,6043,Inhibitory concentration against human neutrophil elastase (HNE),,,,,,,
138,1,F,BAO_0000218,10116.0,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,,Rattus norvegicus,,Heart,,
139,1,F,BAO_0000019,,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,
140,1,F,BAO_0000019,,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,
141,1,B,BAO_0000357,,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,
142,1,F,BAO_0000019,,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,
143,1,F,BAO_0000219,10090.0,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,,Mus musculus,,,P338,
144,1,F,BAO_0000219,10090.0,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,,Mus musculus,,,P338,
145,1,F,BAO_0000219,9606.0,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,,Homo sapiens,,,PBL,
146,1,F,BAO_0000019,9940.0,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,,Ovis aries,,,,
147,1,F,BAO_0000019,9940.0,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,,Ovis aries,,,,
148,1,B,BAO_0000357,,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,,,,,
149,1,F,BAO_0000019,9606.0,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,,Homo sapiens,,,,
150,1,F,BAO_0000019,9606.0,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,,Homo sapiens,,,,
151,1,F,BAO_0000219,9606.0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,,Homo sapiens,,,CCRF-CEM,
152,1,F,BAO_0000219,9606.0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,,Homo sapiens,,,CCRF-CEM,
153,1,F,BAO_0000219,9606.0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,,Homo sapiens,,,CCRF-CEM,
154,1,F,BAO_0000219,9606.0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,,Homo sapiens,,,CCRF-CEM,
155,1,F,BAO_0000019,9606.0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,,Homo sapiens,,,,
156,1,F,BAO_0000019,9606.0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,,Homo sapiens,,,,
157,1,B,BAO_0000249,,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,,,,,
158,1,F,BAO_0000218,1314.0,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,,Streptococcus pyogenes,,,,
159,1,F,BAO_0000218,10335.0,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,,Human herpesvirus 3,,,,
160,1,F,BAO_0000218,10335.0,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,,vericilla zoster virus,,,HEL,
161,1,F,BAO_0000218,10335.0,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,,,vericilla zoster virus,,,,
162,1,F,BAO_0000218,10335.0,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,,,vericilla zoster virus,,,,
163,1,F,BAO_0000218,561.0,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,,escherichia cloac,,,,
164,1,B,BAO_0000019,,9707,Ratio of Ki at A2 to Ki at A1 receptors,,,,,,,
165,1,B,BAO_0000249,5476.0,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,,Candida albicans,,,,
166,1,B,BAO_0000357,284593.0,2205,"Inhibition of 1,3-beta-glucan synthase",,,Candida glabrata CBS 138,,,,
167,1,F,BAO_0000219,9606.0,11900,Inhibition of growth of 1-87 human tumor cell line,,,Homo sapiens,,,1-87 tumor cell line,
168,1,B,BAO_0000219,10116.0,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,,Rattus norvegicus,,,,
169,1,B,BAO_0000357,3847.0,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),,,Glycine max,,,,
170,1,B,BAO_0000357,3847.0,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,,Glycine max,,,,
171,1,B,BAO_0000357,3847.0,16474,% inhibition against soybean 1-lipoxygenase (SLO),,,Glycine max,,,,
172,1,B,BAO_0000357,3847.0,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,,Glycine max,,,,
173,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,,Glycine max,,,,
174,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,,Glycine max,,,,
175,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,,Glycine max,,,,
176,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,,Glycine max,,,,
177,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,,Glycine max,,,,
178,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,,Glycine max,,,,
179,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,,Glycine max,,,,
180,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,,Glycine max,,,,
181,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,,Glycine max,,,,
182,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,,Glycine max,,,,
183,1,B,BAO_0000357,3847.0,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,,Glycine max,,,,
184,1,B,BAO_0000019,10090.0,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,,Mus musculus,,,,
185,1,F,BAO_0000219,10090.0,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,,Mus musculus,,,C3H 10T1/2,
186,1,F,BAO_0000019,,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,,,,,
187,1,B,BAO_0000357,,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,,,,
188,1,B,BAO_0000357,,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,,,,
189,1,B,BAO_0000357,,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,,,,,
190,1,B,BAO_0000357,,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,,,,,
191,1,B,BAO_0000357,,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,,,,,
192,1,F,BAO_0000019,9913.0,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,,Bos taurus,,,,
193,1,B,BAO_0000357,10116.0,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,,Rattus norvegicus,,,,
194,1,B,BAO_0000357,10116.0,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,,Rattus norvegicus,,Adrenal gland,,
195,1,B,BAO_0000357,10116.0,9066,Inhibition of rat adrenal 11-beta-hydroxylase,,,Rattus norvegicus,,,,
196,1,B,BAO_0000357,10116.0,8394,Inhibition of rat adrenal 11-beta-hydroxylase,,,Rattus norvegicus,,,,
197,1,B,BAO_0000357,10116.0,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,,Rattus norvegicus,,,,
198,1,B,BAO_0000019,,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,,,,,
199,1,B,BAO_0000357,,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,,,,
200,1,B,BAO_0000357,,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,,,,
201,1,F,BAO_0000019,,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,,,,,
202,1,B,BAO_0000019,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,
203,1,B,BAO_0000019,,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,,,,,,,
204,1,F,BAO_0000019,,12079,Inhibitory concentration against human platelet 12-lipoxygenase,,,,,,,
205,1,B,BAO_0000019,,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,,,,,
206,1,F,BAO_0000019,9606.0,12079,Inhibitory concentration against human platelet 12-lipoxygenase,,,Homo sapiens,,,,
207,1,B,BAO_0000019,,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,,,,,
208,1,B,BAO_0000357,,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,,,,,
209,1,B,BAO_0000019,,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,,,,,
210,1,B,BAO_0000019,,1630,Inhibitory activity against human platelet 12-lipoxygenase,,,,,,,
211,1,B,BAO_0000019,,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,,,,,
212,1,B,BAO_0000019,,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,,,,,
213,1,B,BAO_0000019,,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,,,,,
214,1,B,BAO_0000019,,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,,,,,
215,1,B,BAO_0000357,,10091,Inhibitory activity towards porcine 12-lipoxygenase,,,,,,,
216,1,B,BAO_0000357,,11966,Tested for inhibition against porcine 12-LO,,,,,,,
217,1,B,BAO_0000019,,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,,,,,
218,1,B,BAO_0000019,,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,,,,,
219,1,B,BAO_0000019,,10193,In vitro inhibition of rat platelet 12-lipoxygenase,,,,,,,
220,1,B,BAO_0000019,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,
221,1,B,BAO_0000019,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,,,,,
222,1,B,BAO_0000019,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,,,,,
223,1,B,BAO_0000019,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,
224,1,B,BAO_0000019,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,,,,,
225,1,B,BAO_0000019,,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,,,,,
226,1,F,BAO_0000219,9606.0,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,,Homo sapiens,,,41M,
227,1,F,BAO_0000219,9606.0,12989,In vitro antitumor activity against 41M cell line.,,,Homo sapiens,,,41M,
228,1,F,BAO_0000219,9606.0,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,,Homo sapiens,,,41M,
229,1,F,BAO_0000219,9606.0,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,,Homo sapiens,,,41M,
230,1,F,BAO_0000219,9606.0,12989,In vitro antitumor activity against 41McisR cell line.,,,Homo sapiens,,,41M,
231,1,F,BAO_0000219,9606.0,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,,Homo sapiens,,,41M,
232,1,F,BAO_0000219,9606.0,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,,Homo sapiens,,,41M,
233,1,B,BAO_0000357,9606.0,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,,Homo sapiens,,,,
234,1,B,BAO_0000357,9606.0,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,Homo sapiens,,,,
235,1,B,BAO_0000357,,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,,,,,
236,1,B,BAO_0000357,,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,,,,
237,1,B,BAO_0000357,,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,,,,,
238,1,B,BAO_0000357,,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,,,,
239,1,B,BAO_0000357,,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,,,,
240,1,B,BAO_0000357,562.0,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,Escherichia coli,,,,
241,1,B,BAO_0000357,562.0,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,Escherichia coli,,,,
242,1,B,BAO_0000357,562.0,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,,Escherichia coli,,,,
243,1,B,BAO_0000357,,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,,,,
244,1,B,BAO_0000357,,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,,,,,
245,1,B,BAO_0000357,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,Sus scrofa,,,,
246,1,B,BAO_0000019,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,,Sus scrofa,,,,
247,1,B,BAO_0000357,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,,Sus scrofa,,,,
248,1,B,BAO_0000357,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,,Sus scrofa,,,,
249,1,B,BAO_0000357,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,Sus scrofa,,,,
250,1,B,BAO_0000019,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,Sus scrofa,,,,
251,1,B,BAO_0000019,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,,Sus scrofa,,,,
252,1,B,BAO_0000019,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,,Sus scrofa,,,,
253,1,B,BAO_0000019,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,,Sus scrofa,,,,
254,1,B,BAO_0000019,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,,Sus scrofa,,,,
255,1,B,BAO_0000357,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,Sus scrofa,,,,
256,1,B,BAO_0000019,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,Sus scrofa,,,,
257,1,B,BAO_0000357,,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,,,,,
258,1,B,BAO_0000019,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,,Sus scrofa,,,,
259,1,B,BAO_0000019,9823.0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,,Sus scrofa,,,,
260,1,B,BAO_0000357,4932.0,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,,Saccharomyces cerevisiae,,,,
261,1,B,BAO_0000019,10116.0,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,Rattus norvegicus,,,,
262,1,B,BAO_0000019,10116.0,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,Rattus norvegicus,,,,
263,1,B,BAO_0000019,10116.0,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,,Rattus norvegicus,,,,
264,1,F,BAO_0000019,,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,,,,
265,1,F,BAO_0000019,,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,,,,
266,1,F,BAO_0000221,10141.0,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,,Cavia porcellus,,Ileum,,
267,1,F,BAO_0000019,,12211,Stimulatory activity of intragastric pressure was tested in the rat,,,,,,,
268,1,B,BAO_0000357,,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,,,,,
269,1,F,BAO_0000218,10116.0,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,,Rattus norvegicus,,,,
270,1,F,BAO_0000019,,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,,,,
271,1,B,BAO_0000357,9606.0,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,,Homo sapiens,,,,
272,1,B,BAO_0000357,9606.0,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,,Homo sapiens,,,,
273,1,F,BAO_0000019,,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,,,,,
274,1,B,BAO_0000357,,11863,Inhibition constant of high-affinity 5-HT uptake,,,,,,,
275,1,F,BAO_0000019,,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,,,,,
276,1,F,BAO_0000019,,11863,Maximum rate was determined for high affinity transport of 5-HT,,,,,,,
277,1,F,BAO_0000019,,4639,Compound was tested for agonistic activity against 5-HT uptake,,,,,,,
278,1,B,BAO_0000019,,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,,,,,
279,1,B,BAO_0000357,9913.0,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,,Bos taurus,,,,
280,1,B,BAO_0000224,10116.0,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,Rattus norvegicus,,,,
281,1,B,BAO_0000224,,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,,,,,
282,1,B,BAO_0000249,,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,,,,,Membranes
283,1,B,BAO_0000249,,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,,,,,Membranes
284,1,B,BAO_0000019,,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,
285,1,F,BAO_0000019,,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,,,,,
286,1,B,BAO_0000221,,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,Hippocampus,,
287,1,B,BAO_0000221,,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,Hippocampus,,
288,1,B,BAO_0000221,,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,Hippocampus,,
289,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),In vivo,,,,,,
290,1,F,BAO_0000019,10141.0,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,,Cavia porcellus,,,,
291,1,B,BAO_0000219,,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,,CHO,
292,1,B,BAO_0000357,,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,,,,,
293,1,F,BAO_0000019,10116.0,15363,Efficacy against 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,,,,
294,1,F,BAO_0000019,,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,,,,,
295,1,F,BAO_0000019,,15329,Relative potency towards 5-HT2A receptor of rat tail artery,,,,,,,
296,1,F,BAO_0000019,,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,,,,
297,1,F,BAO_0000019,,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,,,,,
298,1,F,BAO_0000019,,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,,,,,
299,1,F,BAO_0000019,,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,,,,
300,1,F,BAO_0000221,10141.0,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,Cavia porcellus,,Ileum,,
301,1,F,BAO_0000221,10141.0,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,,Cavia porcellus,,Ileum,,
302,1,F,BAO_0000221,10141.0,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,Cavia porcellus,,Ileum,,
303,1,B,BAO_0000357,,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,,,,,
304,1,F,BAO_0000019,10116.0,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,Rattus norvegicus,,,,
305,1,B,BAO_0000357,,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,
306,1,B,BAO_0000019,9031.0,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,,Gallus gallus,,,,
307,1,F,BAO_0000019,9606.0,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,,Homo sapiens,,,,
308,1,F,BAO_0000019,9606.0,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,Homo sapiens,,,,
309,1,B,BAO_0000219,9606.0,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,,Homo sapiens,,,HL-60,
310,1,B,BAO_0000019,9606.0,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,,Homo sapiens,,,,
311,1,B,BAO_0000019,9606.0,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,Homo sapiens,,,,
312,1,B,BAO_0000219,9606.0,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,,Homo sapiens,,,Oocytes,
313,1,F,BAO_0000220,,16575,Chymotryptic inhibitory activity against 26S proteasome,,,,,,,
314,1,B,BAO_0000220,,15407,Inhibitory activity against 26S proteasome degradation of IkB,,,,,,,
315,1,F,BAO_0000219,9606.0,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,,,Homo sapiens,,,A2780,
316,1,F,BAO_0000219,9606.0,10797,In vitro inhibition of 2780/S ovarian cancer cell line,,,Homo sapiens,,,A2780,
317,1,F,BAO_0000019,9606.0,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,,Homo sapiens,,,,
318,1,B,BAO_0000225,,16037,Association constant for binding to AATT 28-mer AATT hairpin,,,,,,,
319,1,B,BAO_0000225,,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,,,,,
320,1,B,BAO_0000225,,16037,Reaction Rate Parameter for 28-mer AATT hairpin,,,,,,,
321,1,B,BAO_0000225,,16037,Reaction Rate Parameter for 28-mer AATT hairpin,,,,,,,
322,1,F,BAO_0000019,9606.0,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,,Homo sapiens,,,,
323,1,F,BAO_0000019,9606.0,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,,Homo sapiens,,,,
324,1,F,BAO_0000019,9606.0,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,,Homo sapiens,,,,
325,1,F,BAO_0000019,10029.0,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,,,Cricetulus griseus,,,,
326,1,F,BAO_0000019,10029.0,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,,Cricetulus griseus,,,,
327,1,F,BAO_0000019,10029.0,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,,Cricetulus griseus,,,,
328,1,B,BAO_0000357,,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,,,,,
329,1,B,BAO_0000357,9606.0,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,,Homo sapiens,,,,
330,1,B,BAO_0000019,10116.0,9964,Selectivity ratio of ID50 in liver and heart,,,Rattus norvegicus,,,,
331,1,B,BAO_0000019,,9964,"Selectivity, ratio of relative ID50 in liver and heart",,,,,,,
332,1,B,BAO_0000019,,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,,,,,
333,1,B,BAO_0000218,,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,
334,1,B,BAO_0000218,,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,
335,1,B,BAO_0000218,,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,,,,,,
336,1,F,BAO_0000218,,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,,,,,,
337,1,B,BAO_0000019,,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,,,,,
338,1,B,BAO_0000019,,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,,,,,
339,1,B,BAO_0000019,9606.0,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,,Homo sapiens,,,,
340,1,B,BAO_0000019,,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,,,,
341,1,F,BAO_0000019,,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,,,,
342,1,B,BAO_0000019,,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,,,,,
343,1,B,BAO_0000218,10116.0,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,,Rattus norvegicus,,,,
344,1,B,BAO_0000218,,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,In vivo,,,,,,
345,1,B,BAO_0000218,,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,
346,1,B,BAO_0000218,10116.0,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,,Rattus norvegicus,,,,
347,1,B,BAO_0000019,,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,,,,
348,1,F,BAO_0000019,,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,,,,
349,1,B,BAO_0000019,10116.0,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,,Rattus norvegicus,,,,
350,1,B,BAO_0000357,562.0,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,Escherichia coli,,,,
351,1,B,BAO_0000357,562.0,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,Escherichia coli,,,,
352,1,B,BAO_0000357,562.0,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,Escherichia coli,,,,
353,1,B,BAO_0000357,562.0,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,Escherichia coli,,,,
354,1,B,BAO_0000357,,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,,,,,
355,1,B,BAO_0000357,,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,,,,,
356,1,B,BAO_0000357,,166,Inhibition constant against 3-dehydroquinate synthase,,,,,,,
357,1,B,BAO_0000357,,166,Association rate constant against 3-dehydroquinate synthase,,,,,,,
358,1,B,BAO_0000357,,166,Rate constant against 3-dehydroquinate synthase,,,,,,,
359,1,B,BAO_0000019,,3548,Inhibitory activity against fuc-TVII,,,,,,,
360,1,B,BAO_0000251,10116.0,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Rattus norvegicus,,Liver,,Microsomes
361,1,B,BAO_0000251,10116.0,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Rattus norvegicus,,Liver,,Microsomes
362,1,B,BAO_0000251,10116.0,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Rattus norvegicus,,Liver,,Microsomes
363,1,B,BAO_0000251,10116.0,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Rattus norvegicus,,Liver,,Microsomes
364,1,B,BAO_0000251,10116.0,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,Rattus norvegicus,,Liver,,Microsomes
365,1,B,BAO_0000251,10116.0,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,,Rattus norvegicus,,Liver,,Microsomes
366,1,B,BAO_0000251,10116.0,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,,Rattus norvegicus,,Liver,,Microsomes
367,1,B,BAO_0000251,10116.0,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,,Rattus norvegicus,,Liver,,Microsomes
368,1,B,BAO_0000251,10116.0,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,,Rattus norvegicus,,Liver,,Microsomes
369,1,B,BAO_0000251,10116.0,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,,Rattus norvegicus,,Liver,,Microsomes
370,1,B,BAO_0000251,10116.0,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,,Rattus norvegicus,,Liver,,Microsomes
371,1,B,BAO_0000224,,3003,Inhibitory activity against 3-phosphoglycerate kinase.,,,,,,,
372,1,B,BAO_0000224,,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,,,,,
373,1,B,BAO_0000224,,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,,,,,
374,1,B,BAO_0000357,9606.0,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,,Homo sapiens,,,,
375,1,F,BAO_0000219,9606.0,6072,Cytotoxicity on 3677 melanoma cells,,,Homo sapiens,,,3677 melanoma cell line,
376,1,F,BAO_0000219,9606.0,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,,Homo sapiens,,,3677 melanoma cell line,
377,1,F,BAO_0000219,10090.0,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,,Mus musculus,,,MC-38,
378,1,F,BAO_0000019,9606.0,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,,Homo sapiens,,,,
379,1,F,BAO_0000218,,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,,,,,B16,
380,1,F,BAO_0000218,,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,,,,,B16,
381,1,F,BAO_0000019,12131.0,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,,Human rhinovirus 14,,,,
382,1,F,BAO_0000218,169066.0,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,,Human rhinovirus sp.,,,,
383,1,F,BAO_0000218,169066.0,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,,human rhinovirus type 14,,,,
384,1,F,BAO_0000218,169066.0,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,,human rhinovirus type 14,,,,
385,1,F,BAO_0000019,12131.0,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,Human rhinovirus 14,,,,
386,1,F,BAO_0000019,12131.0,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,Human rhinovirus 14,,,,
387,1,F,BAO_0000019,12131.0,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,Human rhinovirus 14,,,,
388,1,F,BAO_0000019,12131.0,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,,Human rhinovirus 14,,,,
389,1,F,BAO_0000218,12059.0,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,,Enterovirus,,,,
390,1,F,BAO_0000218,12059.0,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,,Enterovirus,,,,
391,1,F,BAO_0000218,12059.0,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,,Enterovirus,,,,
392,1,F,BAO_0000218,12059.0,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,,Enterovirus,,,,
393,1,B,BAO_0000357,147712.0,13748,Inhibition of human rhinovirus 3C protease,,,Human rhinovirus B,,,,
394,1,B,BAO_0000019,9606.0,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,,Homo sapiens,,,,
395,1,F,BAO_0000218,10090.0,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,,Mus musculus,,,3EM 37,
396,1,F,BAO_0000218,10090.0,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,,Mus musculus,,,3EM 37,
397,1,F,BAO_0000218,10090.0,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,,Mus musculus,,,3EM 37,
398,1,F,BAO_0000218,10090.0,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,,Mus musculus,,,3EM 37,
399,1,F,BAO_0000218,10090.0,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,,Mus musculus,,,3EM 37,
400,1,F,BAO_0000218,10090.0,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,,Mus musculus,,,3EM 37,
401,1,F,BAO_0000218,10090.0,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,Mus musculus,,,3LL cell line,
402,1,F,BAO_0000218,10090.0,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,Mus musculus,,,3LL cell line,
403,1,F,BAO_0000218,10090.0,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,,Mus musculus,,,3LL cell line,
404,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,,Mus musculus,,,3LL cell line,
405,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,,Mus musculus,,,3LL cell line,
406,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,,Mus musculus,,,3LL cell line,
407,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,,Mus musculus,,,3LL cell line,
408,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,,Mus musculus,,,3LL cell line,
409,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,,Mus musculus,,,3LL cell line,
410,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,,Mus musculus,,,3LL cell line,
411,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,,Mus musculus,,,3LL cell line,
412,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,Mus musculus,,,3LL cell line,
413,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,,Mus musculus,,,3LL cell line,
414,1,F,BAO_0000219,10090.0,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,,Mus musculus,,,3LL cell line,
415,1,F,BAO_0000219,10090.0,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,,Mus musculus,,,3LL cell line,
416,1,F,BAO_0000219,10090.0,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,,Mus musculus,,,3LL cell line,
417,1,F,BAO_0000219,10090.0,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,Mus musculus,,,3LL cell line,
418,1,F,BAO_0000219,10090.0,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,,Mus musculus,,,3LL cell line,
419,1,F,BAO_0000219,10090.0,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,,Mus musculus,,,3LL cell line,
420,1,F,BAO_0000219,10090.0,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,,Mus musculus,,,3LL cell line,
421,1,F,BAO_0000219,10090.0,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,,Mus musculus,,,3LL cell line,
422,1,F,BAO_0000219,10090.0,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,,Mus musculus,,,3LL cell line,
423,1,F,BAO_0000219,10090.0,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,,Mus musculus,,,3LL cell line,
424,1,F,BAO_0000219,10090.0,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,,Mus musculus,,,3LL cell line,
425,1,F,BAO_0000219,10090.0,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,,Mus musculus,,,3LL cell line,
426,1,F,BAO_0000219,10090.0,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,,Mus musculus,,,3LL cell line,
427,1,F,BAO_0000219,10090.0,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,,Mus musculus,,,3LL cell line,
428,1,F,BAO_0000219,10090.0,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,,Mus musculus,,,3LL cell line,
429,1,F,BAO_0000219,10090.0,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,,Mus musculus,,,3LL cell line,
430,1,F,BAO_0000219,9606.0,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,,Homo sapiens,,,3LLD122,
431,1,F,BAO_0000218,,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,,,,,
432,1,F,BAO_0000218,,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,,,,,
433,1,F,BAO_0000218,,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,,,,,
434,1,F,BAO_0000218,,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,,,,,
435,1,F,BAO_0000219,10090.0,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,Mus musculus,,,NIH3T3,
436,1,F,BAO_0000219,10090.0,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,Mus musculus,,,NIH3T3,
437,1,F,BAO_0000219,,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,,,,,NIH3T3,
438,1,F,BAO_0000219,10090.0,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,,Mus musculus,,,NIH3T3,
439,1,F,BAO_0000219,10090.0,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,,Mus musculus,,,NIH3T3,
440,1,F,BAO_0000219,10090.0,17642,Effective dose against murine 3T3 fibroblasts cells,,,Mus musculus,,,NIH3T3,
441,1,F,BAO_0000219,10090.0,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,,Mus musculus,,,NIH3T3,
442,1,F,BAO_0000219,10090.0,12340,Cytotoxic effect on 3T3 cells,,,Mus musculus,,,NIH3T3,
443,1,F,BAO_0000219,10090.0,12340,Cytotoxic effect on 3T3 cells,,,Mus musculus,,,NIH3T3,
444,1,F,BAO_0000219,10090.0,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,,Mus musculus,,,NIH3T3,
445,1,F,BAO_0000219,10090.0,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,Mus musculus,,,NIH3T3,
446,1,F,BAO_0000219,10090.0,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,,Mus musculus,,,NIH3T3,
447,1,F,BAO_0000219,10090.0,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,,Mus musculus,,,NIH3T3,
448,1,F,BAO_0000219,10090.0,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,,Mus musculus,,,NIH3T3,
449,1,F,BAO_0000219,10090.0,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,,Mus musculus,,,NIH3T3,
450,1,F,BAO_0000219,10090.0,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,,Mus musculus,,,NIH3T3,
451,1,F,BAO_0000219,10090.0,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,,Mus musculus,,,NIH3T3,
452,1,F,BAO_0000219,10090.0,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,,Mus musculus,,,NIH3T3,
453,1,F,BAO_0000218,10090.0,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,,Mus musculus,,,NIH3T3,
454,1,F,BAO_0000219,10090.0,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,,Mus musculus,,,,
455,1,F,BAO_0000219,10090.0,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,,Mus musculus,,,NIH3T3,
456,1,F,BAO_0000219,10090.0,14892,Inhibitory activity against 3T3 cell line,,,Mus musculus,,,NIH3T3,
457,1,F,BAO_0000219,10090.0,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,,Mus musculus,,,NIH3T3,
458,1,F,BAO_0000019,,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,,,,,
459,1,F,BAO_0000219,10090.0,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,,Mus musculus,,,NIH3T3,
460,1,F,BAO_0000219,10090.0,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,,Mus musculus,,,NIH3T3,
461,1,F,BAO_0000019,,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,,,,,
462,1,F,BAO_0000019,,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,,,,,
463,1,F,BAO_0000219,10090.0,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,Mus musculus,,,NIH3T3,
464,1,F,BAO_0000219,10090.0,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,,Mus musculus,,,NIH3T3,
465,1,F,BAO_0000219,9606.0,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,,Homo sapiens,,,NIH3T3,
466,1,F,BAO_0000219,9606.0,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,,Homo sapiens,,,NIH3T3,
467,1,F,BAO_0000219,9606.0,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,,Homo sapiens,,,NIH3T3,
468,1,F,BAO_0000219,9606.0,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,,Homo sapiens,,,NIH3T3,
469,1,F,BAO_0000219,10090.0,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,,Mus musculus,,,NIH3T3,
470,1,F,BAO_0000219,10090.0,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,,Mus musculus,,,NIH3T3,
471,1,F,BAO_0000219,10090.0,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,,Mus musculus,,,NIH3T3,
472,1,F,BAO_0000219,10090.0,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,,Mus musculus,,,NIH3T3,
473,1,F,BAO_0000219,10090.0,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,,Mus musculus,,,NIH3T3,
474,1,F,BAO_0000219,10090.0,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,,Mus musculus,,,NIH3T3,
475,1,A,BAO_0000219,10090.0,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,,Mus musculus,,,NIH3T3,
476,1,F,BAO_0000219,10090.0,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,,Mus musculus,,,NIH3T3,
477,1,F,BAO_0000219,10090.0,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,,Mus musculus,,,NIH3T3,
478,1,F,BAO_0000219,10090.0,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,Mus musculus,,,NIH3T3,
479,1,F,BAO_0000219,10090.0,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,Mus musculus,,,NIH3T3,
480,1,F,BAO_0000219,10090.0,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,Mus musculus,,,NIH3T3,
481,1,F,BAO_0000219,10090.0,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,Mus musculus,,,NIH3T3,
482,1,F,BAO_0000219,10090.0,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,Mus musculus,,,NIH3T3,
483,1,F,BAO_0000219,10090.0,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,,,Mus musculus,,,NIH3T3,
484,1,F,BAO_0000219,10090.0,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,,Mus musculus,,,NIH3T3,
485,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,,,3T3-L1,
486,1,F,BAO_0000219,10090.0,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,,Mus musculus,,,3T3-L1,
487,1,F,BAO_0000219,10090.0,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,,Mus musculus,,,3T3-L1,
488,1,F,BAO_0000219,10090.0,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,,Mus musculus,,,3T3-L1,
489,1,F,BAO_0000219,10090.0,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,,Mus musculus,,,3T3-L1,
490,1,F,BAO_0000218,10090.0,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,,Mus musculus,,,3T3-L1,
491,1,F,BAO_0000218,10090.0,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,,Mus musculus,,,3T3-L1,
492,1,F,BAO_0000219,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,,,,,3T3-L1,
493,1,F,BAO_0000219,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,,,3T3-L1,
494,1,F,BAO_0000219,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,,,3T3-L1,
495,1,F,BAO_0000219,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,,,3T3-L1,
496,1,F,BAO_0000219,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,,,3T3-L1,
497,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,,,,,3T3-L1,
498,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,,,,,3T3-L1,
499,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,,,3T3-L1,
500,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,,,3T3-L1,
501,1,F,BAO_0000218,,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,,,3T3-L1,
502,1,F,BAO_0000218,,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,,,3T3-L1,
503,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,,,3T3-L1,
504,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,,,3T3-L1,
505,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,,,,,3T3-L1,
506,1,F,BAO_0000218,,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,,,3T3-L1,
507,1,F,BAO_0000218,,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,,,3T3-L1,
508,1,F,BAO_0000218,,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,,,3T3-L1,
509,1,F,BAO_0000219,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,,,3T3-L1,
510,1,F,BAO_0000219,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,,,3T3-L1,
511,1,F,BAO_0000219,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,,,3T3-L1,
512,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,,,3T3-L1,
513,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,,,3T3-L1,
514,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,,,3T3-L1,
515,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,,,3T3-L1,
516,1,F,BAO_0000218,,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,,,3T3-L1,
517,1,F,BAO_0000219,,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,,,,,3T3-L1,
518,1,F,BAO_0000219,10090.0,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,,Mus musculus,,,3T3-L1,
519,1,F,BAO_0000219,,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,,,,,3T3-L1,
520,1,F,BAO_0000219,10090.0,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,,Mus musculus,,,3T3-L1,
521,1,F,BAO_0000219,10090.0,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,,Mus musculus,,,3T3-L1,
522,1,F,BAO_0000219,10090.0,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,,Mus musculus,,,3T3-L1,
523,1,F,BAO_0000219,10090.0,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,Mus musculus,,,3T3-L1,
524,1,F,BAO_0000219,10090.0,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,Mus musculus,,,3T3-L1,
525,1,F,BAO_0000219,10090.0,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,,Mus musculus,,,3T3-L1,
526,1,F,BAO_0000219,10090.0,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,,Mus musculus,,,3T3-L1,
527,1,F,BAO_0000219,10090.0,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,,Mus musculus,,,3T3-L1,
528,1,F,BAO_0000219,10090.0,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,,Mus musculus,,,3T3-L1,
529,1,F,BAO_0000219,10116.0,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,,,Rattus norvegicus,,,3Y1 cell line,
530,1,F,BAO_0000219,10116.0,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,,Rattus norvegicus,,,3Y1 cell line,
531,1,F,BAO_0000219,10116.0,15899,Cytotoxicity in 3Y1 cells.,,,Rattus norvegicus,,,3Y1 cell line,
532,1,F,BAO_0000219,10116.0,15899,Cytostatic effect in 3Y1 cells.,,,Rattus norvegicus,,,3Y1 cell line,
533,1,F,BAO_0000219,10116.0,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,,Rattus norvegicus,,,3Y1 cell line,
534,1,F,BAO_0000219,10116.0,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,,Rattus norvegicus,,,3Y1 cell line,
535,1,B,BAO_0000019,,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,,,,,
536,1,B,BAO_0000019,,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,,,,
537,1,B,BAO_0000019,,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,,,,
538,1,B,BAO_0000019,9823.0,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,,Sus scrofa,,,,
539,1,B,BAO_0000019,,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,,,,,
540,1,B,BAO_0000019,,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,,,,,
541,1,B,BAO_0000019,,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,,,,,
542,1,B,BAO_0000019,,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,,,,,
543,1,B,BAO_0000019,,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,,,,,
544,1,B,BAO_0000357,,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,,,,,
545,1,B,BAO_0000019,,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,,,,,
546,1,B,BAO_0000019,,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,,,,,
547,1,B,BAO_0000019,9823.0,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,,Sus scrofa,,,,
548,1,B,BAO_0000019,,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,,,,,
549,1,B,BAO_0000357,,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,,,,,
550,1,B,BAO_0000019,,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,,,,,
551,1,B,BAO_0000019,,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,,,,,
552,1,B,BAO_0000224,,6455,Binding affinity against melatonin (MT1) receptor (pC1),,,,,,,
553,1,B,BAO_0000019,,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,,,,,
554,1,B,BAO_0000019,,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,,,,,
555,1,B,BAO_0000019,,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,,,,,
556,1,B,BAO_0000357,,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,,,,,
557,1,B,BAO_0000357,,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,,,,,
558,1,B,BAO_0000221,,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,,,Hippocampus,,
559,1,B,BAO_0000357,,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,,,,,
560,1,B,BAO_0000357,,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,
561,1,B,BAO_0000019,,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,,,,,
562,1,B,BAO_0000221,,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,,Hippocampus,,
563,1,B,BAO_0000221,,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,,Hippocampus,,
564,1,B,BAO_0000221,,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,Hippocampus,,
565,1,B,BAO_0000221,,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,Hippocampus,,
566,1,B,BAO_0000221,,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,Hippocampus,,
567,1,B,BAO_0000221,,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,Hippocampus,,
568,1,B,BAO_0000221,,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,Hippocampus,,
569,1,B,BAO_0000221,,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,,Hippocampus,,
570,1,B,BAO_0000221,,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,,,Hippocampus,,
571,1,B,BAO_0000249,10116.0,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,,Rattus norvegicus,,,,Membranes
572,1,B,BAO_0000221,9913.0,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,,Bos taurus,,Hippocampus,,
573,1,B,BAO_0000221,,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,,,Hippocampus,,
574,1,B,BAO_0000221,,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,,,Hippocampus,,
575,1,B,BAO_0000221,,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,,,Hippocampus,,
576,1,B,BAO_0000221,,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,,,Hippocampus,,
577,1,B,BAO_0000219,,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,,,,,CHO,
578,1,B,BAO_0000221,,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,,Hippocampus,,
579,1,B,BAO_0000221,,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,,Hippocampus,,
580,1,B,BAO_0000219,,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,,CHO,
581,1,B,BAO_0000221,,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,,,Hippocampus,,
582,1,B,BAO_0000357,,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,,,,
583,1,B,BAO_0000221,,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,Hippocampus,,
584,1,B,BAO_0000221,,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,Hippocampus,,
585,1,B,BAO_0000221,,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,Hippocampus,,
586,1,B,BAO_0000221,,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,Hippocampus,,
587,1,B,BAO_0000221,,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,,Hippocampus,,
588,1,B,BAO_0000218,,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,,,Hippocampus,,
589,1,B,BAO_0000221,,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,Hippocampus,,
590,1,B,BAO_0000219,9606.0,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,,Homo sapiens,,,CHO,
591,1,F,BAO_0000019,10141.0,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,,Cavia porcellus,,,,
592,1,F,BAO_0000019,10141.0,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,,Cavia porcellus,,,,
593,1,F,BAO_0000221,10141.0,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,,Cavia porcellus,,Hippocampus,,
594,1,B,BAO_0000221,10141.0,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,Cavia porcellus,,Ileum,,
595,1,B,BAO_0000221,10141.0,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,Cavia porcellus,,Ileum,,
596,1,B,BAO_0000221,10141.0,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,Cavia porcellus,,Ileum,,
597,1,B,BAO_0000221,10141.0,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,Cavia porcellus,,Ileum,,
598,1,B,BAO_0000221,10141.0,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,Cavia porcellus,,Ileum,,
599,1,B,BAO_0000221,10141.0,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,,Cavia porcellus,,Ileum,,
600,1,B,BAO_0000357,10141.0,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Cavia porcellus,,,,
601,1,B,BAO_0000357,10141.0,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,,Cavia porcellus,,,,
602,1,B,BAO_0000357,10141.0,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,,Cavia porcellus,,,,
603,1,B,BAO_0000221,10141.0,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,Cavia porcellus,,Hippocampus,,
604,1,F,BAO_0000221,10141.0,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,Cavia porcellus,,Hippocampus,,
605,1,B,BAO_0000218,10029.0,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,Cricetulus griseus,,,CHO,
606,1,B,BAO_0000357,,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,,,,,
607,1,F,BAO_0000219,,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,,,,,HeLa,
608,1,F,BAO_0000219,,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,,,,,HeLa,
609,1,F,BAO_0000019,,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,,,,
610,1,F,BAO_0000219,,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,,,CHO,
611,1,F,BAO_0000219,,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,,,CHO,
612,1,F,BAO_0000219,,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,,,,,CHO,
613,1,F,BAO_0000219,,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,,,,,CHO,
614,1,B,BAO_0000219,,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,,CHO,
615,1,B,BAO_0000219,,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,,CHO,
616,1,B,BAO_0000219,,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,,,,,CHO,
617,1,F,BAO_0000219,,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,,,,,
618,1,B,BAO_0000219,9606.0,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,Homo sapiens,,,HeLa,
619,1,B,BAO_0000219,9606.0,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,,Homo sapiens,,,HeLa,
620,1,B,BAO_0000219,9606.0,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,,,CHO,
621,1,B,BAO_0000219,9606.0,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,Homo sapiens,,,CHO,
622,1,F,BAO_0000019,,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,,,,
623,1,F,BAO_0000019,,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,,,,
624,1,F,BAO_0000019,,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,
625,1,F,BAO_0000219,,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,,,CHO,
626,1,F,BAO_0000219,9606.0,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,Homo sapiens,,,CHO,
627,1,F,BAO_0000219,,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,,,CHO,
628,1,F,BAO_0000219,9606.0,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,Homo sapiens,,,CHO,
629,1,F,BAO_0000219,,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,,,CHO,
630,1,F,BAO_0000219,,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,,,,,CHO,
631,1,F,BAO_0000219,9606.0,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,Homo sapiens,,,CHO,
632,1,F,BAO_0000219,,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,,,CHO,
633,1,F,BAO_0000219,9606.0,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,Homo sapiens,,,CHO,
634,1,F,BAO_0000019,9606.0,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,,Homo sapiens,,,,
635,1,F,BAO_0000019,9606.0,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,Homo sapiens,,,,
636,1,F,BAO_0000019,9606.0,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,,Homo sapiens,,,,
637,1,F,BAO_0000019,9606.0,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,,Homo sapiens,,,,
638,1,F,BAO_0000219,,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,,,CHO,
639,1,F,BAO_0000219,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,,,CHO,
640,1,F,BAO_0000219,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,,,CHO,
641,1,F,BAO_0000219,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,,,CHO,
642,1,F,BAO_0000219,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,,,CHO,
643,1,F,BAO_0000219,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,,,,,CHO,
644,1,F,BAO_0000219,,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,,,CHO,
645,1,F,BAO_0000219,,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,,,CHO,
646,1,F,BAO_0000219,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,,,CHO,
647,1,F,BAO_0000219,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,,,,,CHO,
648,1,F,BAO_0000219,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,,,CHO,
649,1,F,BAO_0000219,,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,,,CHO,
650,1,F,BAO_0000019,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,
651,1,F,BAO_0000019,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,
652,1,F,BAO_0000019,,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,,,,
653,1,F,BAO_0000219,,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,,HEK293,
654,1,F,BAO_0000019,9606.0,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,,Homo sapiens,,,,
655,1,F,BAO_0000019,,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,,,,,
656,1,F,BAO_0000019,9606.0,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,,Homo sapiens,,,,
657,1,F,BAO_0000019,9606.0,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,,Homo sapiens,,,,
658,1,F,BAO_0000019,,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,
659,1,F,BAO_0000019,,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,,,,,
660,1,F,BAO_0000019,,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,
661,1,F,BAO_0000019,,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,
662,1,F,BAO_0000019,,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,,,,,
663,1,F,BAO_0000019,9606.0,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,,Homo sapiens,,,,
664,1,F,BAO_0000019,9606.0,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,,Homo sapiens,,,,
665,1,F,BAO_0000019,,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,,,,,
666,1,F,BAO_0000019,,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,,,,
667,1,F,BAO_0000019,,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,,,,,
668,1,F,BAO_0000219,,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,,,,,CHO,
669,1,F,BAO_0000219,,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,,,,,CHO,
670,1,B,BAO_0000357,,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,
671,1,B,BAO_0000357,,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,
672,1,F,BAO_0000019,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,
673,1,F,BAO_0000019,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,,,,,
674,1,F,BAO_0000019,,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,,,,
675,1,F,BAO_0000019,9606.0,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,,Homo sapiens,,,,
676,1,F,BAO_0000019,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,
677,1,F,BAO_0000019,9606.0,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,,Homo sapiens,,,,
678,1,F,BAO_0000019,9606.0,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,Homo sapiens,,,,
679,1,F,BAO_0000019,9606.0,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,Homo sapiens,,,,
680,1,F,BAO_0000019,9606.0,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,,Homo sapiens,,,,
681,1,F,BAO_0000019,9606.0,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,,Homo sapiens,,,,
682,1,F,BAO_0000019,9606.0,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,Homo sapiens,,,,
683,1,F,BAO_0000019,9606.0,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,Homo sapiens,,,,
684,1,F,BAO_0000019,9606.0,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,,Homo sapiens,,,,
685,1,B,BAO_0000357,9606.0,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,,,,
686,1,B,BAO_0000219,,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,,CHO,
687,1,B,BAO_0000219,,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,,,,,HEK293,
688,1,B,BAO_0000219,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,,,,,CHO,
689,1,F,BAO_0000219,,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,,,CHO,
690,1,B,BAO_0000357,,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,,,,,
691,1,B,BAO_0000357,9606.0,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,,,,
692,1,B,BAO_0000219,,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,,,,,CHO,
693,1,B,BAO_0000219,,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,,CHO,
694,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,,Rattus norvegicus,,,,
695,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,In vivo,,Rattus norvegicus,,,,
696,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,In vivo,,Rattus norvegicus,,,,
697,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,,Rattus norvegicus,,,,
698,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,In vivo,,Rattus norvegicus,,,,
699,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,,Rattus norvegicus,,,,
700,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,In vivo,,Rattus norvegicus,,,,
701,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,In vivo,,Rattus norvegicus,,,,
702,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,In vivo,,Rattus norvegicus,,,,
703,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,In vivo,,Rattus norvegicus,,,,
704,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,In vivo,,Rattus norvegicus,,,,
705,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,In vivo,,Rattus norvegicus,,,,
706,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,In vivo,,Rattus norvegicus,,,,
707,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,In vivo,,Rattus norvegicus,,,,
708,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,In vivo,,Rattus norvegicus,,,,
709,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,In vivo,,Rattus norvegicus,,,,
710,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,In vivo,,Rattus norvegicus,,,,
711,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,In vivo,,Rattus norvegicus,,,,
712,1,F,BAO_0000218,10116.0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,,Rattus norvegicus,,,,
713,1,B,BAO_0000019,,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,,,,,
714,1,B,BAO_0000249,,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,,,Hypothalamus,,
715,1,B,BAO_0000019,,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,,,,,
716,1,B,BAO_0000019,,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,,,,,
717,1,B,BAO_0000019,,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,,,,
718,1,B,BAO_0000357,,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,,,,,
719,1,B,BAO_0000357,,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,,,,,
720,1,F,BAO_0000019,,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,,,,,
721,1,F,BAO_0000019,,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,
722,1,F,BAO_0000019,,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,
723,1,F,BAO_0000019,,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,
724,1,F,BAO_0000019,10141.0,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,,Cavia porcellus,,,,
725,1,F,BAO_0000019,10141.0,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,,Cavia porcellus,,,,
726,1,B,BAO_0000019,10141.0,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,,Cavia porcellus,,,,
727,1,B,BAO_0000357,10141.0,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,Cavia porcellus,,,,
728,1,B,BAO_0000357,9606.0,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,,,Homo sapiens,,,,
729,1,B,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,,,,
730,1,F,BAO_0000218,,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,,,,
731,1,B,BAO_0000357,,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,,,,,
732,1,F,BAO_0000218,,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,,,,
733,1,B,BAO_0000019,9823.0,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,Sus scrofa,,,,
734,1,B,BAO_0000357,,11006,In vitro inhibition of rat 5-Lipoxygenase,,,,,,,
735,1,B,BAO_0000357,10116.0,11481,Inhibitory activity against 5-Lipoxygenase,,,Rattus norvegicus,,,,
736,1,B,BAO_0000219,,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,,,,,RBL-1,
737,1,B,BAO_0000219,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,,,RBL-1,
738,1,B,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,,,,,RBL-1,
739,1,B,BAO_0000019,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,,,,,
740,1,B,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,,,,,
741,1,B,BAO_0000357,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,,,,
742,1,B,BAO_0000219,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,,,RBL-1,
743,1,B,BAO_0000357,,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,,,,,
744,1,B,BAO_0000019,10116.0,11481,Ratio of IC50 against 5-LO and COX,,,Rattus norvegicus,,,,
745,1,B,BAO_0000357,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,,,,
746,1,B,BAO_0000357,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,,,,,
747,1,B,BAO_0000219,,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,,,,,
748,1,F,BAO_0000019,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,,,,,
749,1,B,BAO_0000357,,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,,,Prostate gland,,
750,1,B,BAO_0000019,8932.0,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,,Columba livia,,,,
751,1,B,BAO_0000019,8932.0,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,,Columba livia,,,,
752,1,B,BAO_0000019,8932.0,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,,Columba livia,,,,
753,1,B,BAO_0000357,,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,,,,,
754,1,F,BAO_0000019,10116.0,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,,Rattus norvegicus,,,,
755,1,F,BAO_0000019,10116.0,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,Rattus norvegicus,,,,
756,1,F,BAO_0000019,10116.0,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,Rattus norvegicus,,,,
757,1,B,BAO_0000221,,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,,,Hippocampus,,
758,1,B,BAO_0000357,,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,,,,,
759,1,B,BAO_0000019,9986.0,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,,,,
760,1,B,BAO_0000019,9986.0,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,,,,
761,1,B,BAO_0000019,9986.0,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,,,,
762,1,B,BAO_0000019,9986.0,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,,,,
763,1,B,BAO_0000221,,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,,Hippocampus,,
764,1,B,BAO_0000221,,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,,Hippocampus,,
765,1,B,BAO_0000221,,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,,Hippocampus,,
766,1,B,BAO_0000249,,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,,,,,Membranes
767,1,B,BAO_0000249,10116.0,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,,Rattus norvegicus,,,,
768,1,B,BAO_0000019,10116.0,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,,Rattus norvegicus,,,,
769,1,B,BAO_0000019,10116.0,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,,Rattus norvegicus,,,,
770,1,B,BAO_0000224,,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,,,,,
771,1,B,BAO_0000221,,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,,,Hippocampus,,
772,1,B,BAO_0000221,,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,,,Hippocampus,,
773,1,B,BAO_0000224,,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,,,,,
774,1,B,BAO_0000019,,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,,,,,
775,1,B,BAO_0000249,10116.0,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,,Rattus norvegicus,,,,
776,1,B,BAO_0000019,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,
777,1,B,BAO_0000019,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,
778,1,B,BAO_0000221,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,,Brain,,
779,1,B,BAO_0000221,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,,Brain,,
780,1,B,BAO_0000019,,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,,,,,
781,1,B,BAO_0000224,10116.0,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,,Rattus norvegicus,,,,
782,1,B,BAO_0000224,,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,,,,,
783,1,B,BAO_0000224,,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,
784,1,B,BAO_0000224,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,
785,1,B,BAO_0000224,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,
786,1,B,BAO_0000019,,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,,,,
787,1,B,BAO_0000019,,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,,,,
788,1,B,BAO_0000224,,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,,,,,
789,1,B,BAO_0000019,10116.0,3070,Affinity for 5-hydroxytryptamine 1 receptor,,,Rattus norvegicus,,,,
790,1,B,BAO_0000221,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,,,Brain,,
791,1,B,BAO_0000221,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,,Brain,,
792,1,B,BAO_0000224,,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,,,,,
793,1,B,BAO_0000221,,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,,,Brain,,
794,1,B,BAO_0000019,,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,
795,1,B,BAO_0000019,10116.0,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,,Rattus norvegicus,,,,
796,1,B,BAO_0000019,,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,,,,,
797,1,B,BAO_0000019,10116.0,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,,Rattus norvegicus,,,,
798,1,B,BAO_0000019,10116.0,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,,Rattus norvegicus,,,,
799,1,B,BAO_0000019,,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,,,,,
800,1,B,BAO_0000221,,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,,,Brain,,
801,1,B,BAO_0000019,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,,,,,
802,1,B,BAO_0000220,,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,,,Brain,,
803,1,B,BAO_0000221,,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,,,Brain,,
804,1,B,BAO_0000019,,4639,Compound was tested for binding affinity against 5-HT1 receptor,,,,,,,
805,1,B,BAO_0000019,,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,,,,,
806,1,B,BAO_0000357,,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,,,,
807,1,F,BAO_0000249,,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,,,,
808,1,F,BAO_0000218,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,,,,,,
809,1,F,BAO_0000218,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,,,,,,
810,1,F,BAO_0000019,,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,,,,,
811,1,F,BAO_0000218,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,,,,,,
812,1,F,BAO_0000218,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,,,,,,
813,1,F,BAO_0000019,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,,,,,
814,1,F,BAO_0000219,,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,,,,,
815,1,F,BAO_0000219,,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,,,,,
816,1,F,BAO_0000219,,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,,,,,
817,1,B,BAO_0000249,,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,,,,,
818,1,B,BAO_0000221,,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,,,Hippocampus,,
819,1,B,BAO_0000221,,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,,,Hippocampus,,
820,1,B,BAO_0000249,,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,,,,,Membranes
821,1,B,BAO_0000221,10116.0,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,,Rattus norvegicus,,Hippocampus,,
822,1,B,BAO_0000221,10116.0,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,Rattus norvegicus,,Hippocampus,,
823,1,B,BAO_0000221,,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,,,Hippocampus,,
824,1,B,BAO_0000221,10116.0,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,,Rattus norvegicus,,Hippocampus,,
825,1,B,BAO_0000221,10116.0,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,Rattus norvegicus,,Hippocampus,,
826,1,B,BAO_0000357,,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,,,,,
827,1,B,BAO_0000249,,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,,,,,
828,1,B,BAO_0000249,,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,,,Hippocampus,,
829,1,B,BAO_0000221,,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
830,1,B,BAO_0000221,,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,,,Hippocampus,,
831,1,B,BAO_0000221,,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,,,Hippocampus,,
832,1,B,BAO_0000357,,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,,,,,
833,1,B,BAO_0000019,,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,,,,,
834,1,B,BAO_0000221,,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,,,Hippocampus,,
835,1,B,BAO_0000249,,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,,,,,
836,1,B,BAO_0000249,,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,,,Hippocampus,,
837,1,B,BAO_0000019,10116.0,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,,Rattus norvegicus,,,,
838,1,B,BAO_0000019,10116.0,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,,Rattus norvegicus,,,,
839,1,B,BAO_0000249,,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,,,,,
840,1,B,BAO_0000019,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,,,,,
841,1,B,BAO_0000249,,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,,,,
842,1,B,BAO_0000221,,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
843,1,B,BAO_0000019,,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,
844,1,B,BAO_0000221,,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,,,Hippocampus,,
845,1,B,BAO_0000221,,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,,,Hippocampus,,
846,1,B,BAO_0000357,,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,,,,,
847,1,B,BAO_0000221,,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,,,Hippocampus,,
848,1,B,BAO_0000357,,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,,,,,
849,1,B,BAO_0000357,,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,,,,
850,1,B,BAO_0000019,,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,
851,1,F,BAO_0000019,,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,
852,1,B,BAO_0000019,,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,
853,1,B,BAO_0000221,,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,,,Hippocampus,,
854,1,B,BAO_0000019,,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,,,,,
855,1,B,BAO_0000019,,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,,,,,
856,1,B,BAO_0000019,,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,,,,,
857,1,B,BAO_0000019,,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,,,,
858,1,B,BAO_0000357,,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,
859,1,B,BAO_0000221,,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,,,Hippocampus,,
860,1,B,BAO_0000357,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,,,,,
861,1,B,BAO_0000357,,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,,,,,
862,1,B,BAO_0000357,,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,,,,
863,1,B,BAO_0000249,,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,,,Hippocampus,,
864,1,B,BAO_0000221,10116.0,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,Rattus norvegicus,,Hippocampus,,
865,1,B,BAO_0000357,,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,,,,,
866,1,B,BAO_0000357,,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,,,,,
867,1,F,BAO_0000249,10116.0,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,Rattus norvegicus,,,,
868,1,B,BAO_0000221,,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,,,Hippocampus,,
869,1,F,BAO_0000221,,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
870,1,F,BAO_0000221,,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
871,1,B,BAO_0000357,10116.0,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,,,,
872,1,B,BAO_0000019,10116.0,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,,,,
873,1,B,BAO_0000221,,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,,Hippocampus,,
874,1,B,BAO_0000357,10116.0,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,,Rattus norvegicus,,,,
875,1,B,BAO_0000221,,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,,,Hippocampus,,
876,1,B,BAO_0000219,,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,,CHO,
877,1,F,BAO_0000219,,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,,,CHO,
878,1,F,BAO_0000219,,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,,,CHO,
879,1,B,BAO_0000357,,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,
880,1,B,BAO_0000357,,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,,,,,
881,1,F,BAO_0000019,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,
882,1,B,BAO_0000219,,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,,,,,CHO,
883,1,B,BAO_0000357,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,,,,,
884,1,B,BAO_0000357,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,,,,,
885,1,B,BAO_0000357,,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,
886,1,B,BAO_0000357,,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,,,,,
887,1,B,BAO_0000357,,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,,,,,
888,1,B,BAO_0000357,,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,
889,1,F,BAO_0000219,,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,,HEK293,
890,1,B,BAO_0000019,,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,,,,,
891,1,B,BAO_0000357,,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,,,,,
892,1,F,BAO_0000019,,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,,,,
893,1,F,BAO_0000019,,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,,,,,
894,1,B,BAO_0000219,,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,,,,,HeLa,
895,1,B,BAO_0000219,,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,,,,,CHO,
896,1,B,BAO_0000357,9606.0,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,,Homo sapiens,,,,
897,1,B,BAO_0000357,,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,,,,,
898,1,B,BAO_0000357,9606.0,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Homo sapiens,,,,
899,1,B,BAO_0000219,,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,,,,,HeLa,
900,1,B,BAO_0000357,,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,
901,1,B,BAO_0000219,,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,,,,,CHO,
902,1,B,BAO_0000219,,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,,CHO,
903,1,B,BAO_0000357,,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,,,,,
904,1,B,BAO_0000219,,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,,,,,CHO,
905,1,B,BAO_0000219,,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,,,,,CHO,
906,1,B,BAO_0000357,,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,,,,,
907,1,B,BAO_0000219,9606.0,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,Homo sapiens,,,CHO,
908,1,B,BAO_0000019,,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,,,,,
909,1,B,BAO_0000357,,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,,,,
910,1,B,BAO_0000357,,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,,,,
911,1,B,BAO_0000357,,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,,,,
912,1,B,BAO_0000219,,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,,,,,HeLa,
913,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,,,,,
914,1,B,BAO_0000357,,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,
915,1,B,BAO_0000357,,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,
916,1,B,BAO_0000357,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,,,,,
917,1,B,BAO_0000219,,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,,,,,Cell line,
918,1,B,BAO_0000019,,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,,,,,
919,1,B,BAO_0000357,,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,
920,1,B,BAO_0000357,,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,
921,1,B,BAO_0000357,,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,
922,1,B,BAO_0000357,,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,,,,,
923,1,B,BAO_0000357,,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,
924,1,B,BAO_0000357,,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,,,,,
925,1,B,BAO_0000357,,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,
926,1,B,BAO_0000357,,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,,,,
927,1,B,BAO_0000357,,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,
928,1,B,BAO_0000357,,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,,,,
929,1,B,BAO_0000357,,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,
930,1,B,BAO_0000219,,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,,,,,
931,1,B,BAO_0000357,9606.0,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,Homo sapiens,,,,
932,1,B,BAO_0000357,,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,,,,
933,1,B,BAO_0000357,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,,,,,
934,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,,,,
935,1,B,BAO_0000219,,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,,,,,CHO-K1,
936,1,F,BAO_0000219,,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,,,,,CHO-K1,
937,1,B,BAO_0000019,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,,,,,
938,1,B,BAO_0000019,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,,,,,
939,1,B,BAO_0000019,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,,,,,
940,1,B,BAO_0000019,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,,,,,
941,1,B,BAO_0000219,9606.0,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,Homo sapiens,,,HeLa,
942,1,B,BAO_0000357,,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,,,,
943,1,B,BAO_0000357,,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,,,,,
944,1,B,BAO_0000357,,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,,,,,
945,1,B,BAO_0000357,9606.0,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,,,,
946,1,B,BAO_0000357,,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,,,,
947,1,B,BAO_0000357,10116.0,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,,Rattus norvegicus,,,,
948,1,B,BAO_0000219,,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,,,,,CHO,
949,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,,,,,
950,1,B,BAO_0000357,,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,,,,
951,1,B,BAO_0000357,,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,,,,,
952,1,B,BAO_0000357,,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,,,,,
953,1,B,BAO_0000219,,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,,,,,HeLa,
954,1,B,BAO_0000219,9606.0,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,,Homo sapiens,,,HeLa,
955,1,B,BAO_0000357,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,
956,1,B,BAO_0000357,,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,,,,,
957,1,B,BAO_0000357,9606.0,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,,,Homo sapiens,,,,
958,1,B,BAO_0000019,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,,,,,
959,1,B,BAO_0000019,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,,,,,
960,1,B,BAO_0000357,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,,,,,
961,1,B,BAO_0000357,9606.0,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,,,,
962,1,F,BAO_0000019,,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,,,,,
963,1,B,BAO_0000019,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,,,,,
964,1,B,BAO_0000357,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,
965,1,B,BAO_0000357,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,,,,,
966,1,B,BAO_0000219,,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,,,HeLa,
967,1,B,BAO_0000219,,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,,,,,HeLa,
968,1,B,BAO_0000219,,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,,,HeLa,
969,1,B,BAO_0000219,,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,,,HeLa,
970,1,F,BAO_0000019,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,
971,1,F,BAO_0000019,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,
972,1,F,BAO_0000019,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,
973,1,F,BAO_0000218,,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,In vivo,,,,,,
974,1,B,BAO_0000019,,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,,,,,
975,1,F,BAO_0000019,,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,,,,,
976,1,F,BAO_0000019,,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,,,,,
977,1,B,BAO_0000357,,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,,,,
978,1,F,BAO_0000219,,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,,HEK293,
979,1,F,BAO_0000019,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,,,,,
980,1,F,BAO_0000019,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,,,,,
981,1,F,BAO_0000019,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,,,,,
982,1,F,BAO_0000019,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,,,,,
983,1,F,BAO_0000219,,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,,,CHO,
984,1,F,BAO_0000019,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,,,,,
985,1,F,BAO_0000019,9606.0,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,,Homo sapiens,,,,
986,1,F,BAO_0000019,9606.0,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,,Homo sapiens,,,,
987,1,B,BAO_0000219,,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,,,,,CHO,
988,1,B,BAO_0000019,,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,,,,,
989,1,F,BAO_0000019,9606.0,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,Homo sapiens,,,,
990,1,F,BAO_0000019,9606.0,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,Homo sapiens,,,,
991,1,F,BAO_0000019,,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,
992,1,F,BAO_0000019,,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,
993,1,F,BAO_0000019,,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,,,,
994,1,F,BAO_0000019,,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,
995,1,F,BAO_0000019,,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,
996,1,F,BAO_0000019,,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,
997,1,F,BAO_0000019,,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,,,,
998,1,F,BAO_0000219,9606.0,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,Homo sapiens,,,HeLa,
999,1,F,BAO_0000219,9606.0,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,Homo sapiens,,,HeLa,
1000,1,F,BAO_0000219,9606.0,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,Homo sapiens,,,HeLa,
1001,1,F,BAO_0000019,,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,,,,,
1002,1,F,BAO_0000019,,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,
1003,1,F,BAO_0000219,,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,,HEK293,
1004,1,F,BAO_0000219,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,,,CHO,
1005,1,F,BAO_0000219,,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,,,,CHO,
1006,1,F,BAO_0000219,9606.0,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,,Homo sapiens,,,CHO,
1007,1,F,BAO_0000219,,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,,,CHO,
1008,1,F,BAO_0000219,,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,,,,,
1009,1,F,BAO_0000219,,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,,,,,
1010,1,F,BAO_0000019,,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,
1011,1,B,BAO_0000219,,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,In vitro,,,,,,
1012,1,B,BAO_0000219,,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,In vitro,,,,,,
1013,1,B,BAO_0000357,,12861,Binding activity radioligand.,,,,,,,
1014,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,
1015,1,B,BAO_0000357,,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,,,,
1016,1,B,BAO_0000357,,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,,,,
1017,1,B,BAO_0000357,,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,
1018,1,B,BAO_0000357,9606.0,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,,,,
1019,1,B,BAO_0000357,,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,,,,,
1020,1,B,BAO_0000219,9606.0,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,Homo sapiens,,,CHO,
1021,1,F,BAO_0000019,,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,,,,,
1022,1,F,BAO_0000019,,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,,,,,
1023,1,B,BAO_0000019,,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,,,,,
1024,1,B,BAO_0000219,9606.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,,Homo sapiens,,,HEK293,
1025,1,B,BAO_0000219,,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,,,,,HEK293,
1026,1,B,BAO_0000219,,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,,,,,HEK293,
1027,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,,,HEK293,
1028,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,,,,,HEK293,
1029,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,,,,,HEK293,
1030,1,B,BAO_0000357,,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,,,,
1031,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,,,HEK293,
1032,1,B,BAO_0000219,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,,,,,HEK293,
1033,1,B,BAO_0000219,,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,,,,,
1034,1,B,BAO_0000357,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,,,,,
1035,1,B,BAO_0000219,,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,,,HeLa,
1036,1,B,BAO_0000019,,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,,,,
1037,1,B,BAO_0000219,,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,,,,,HEK293,
1038,1,B,BAO_0000219,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,,,,,HEK293,
1039,1,B,BAO_0000219,,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,,,,,
1040,1,B,BAO_0000219,9606.0,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,,Homo sapiens,,,HeLa,
1041,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,,,,,HEK293,
1042,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,,,,,HEK293,
1043,1,B,BAO_0000357,,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,,,,,
1044,1,B,BAO_0000357,9606.0,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,,Homo sapiens,,,,
1045,1,B,BAO_0000357,,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,,,,
1046,1,B,BAO_0000357,,5254,Binding affinity against 5-HT1D receptor,,,,,,,
1047,1,B,BAO_0000357,,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,
1048,1,B,BAO_0000357,,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,
1049,1,B,BAO_0000357,9606.0,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,Homo sapiens,,,,
1050,1,B,BAO_0000357,,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,
1051,1,F,BAO_0000218,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,In vivo,,,,,,
1052,1,F,BAO_0000218,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,In vivo,,,,,,
1053,1,F,BAO_0000218,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,In vivo,,,,,,
1054,1,F,BAO_0000218,10090.0,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,,Mus musculus,,,,
1055,1,F,BAO_0000218,10090.0,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,,Mus musculus,,,,
1056,1,F,BAO_0000218,10090.0,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,,Mus musculus,,,,
1057,1,F,BAO_0000218,10090.0,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,,Mus musculus,,,,
1058,1,F,BAO_0000218,10090.0,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,,Mus musculus,,,,
1059,1,F,BAO_0000218,10090.0,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,,Mus musculus,,,,
1060,1,B,BAO_0000221,,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,,,Hippocampus,,
1061,1,B,BAO_0000357,,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,,,,,
1062,1,B,BAO_0000221,10090.0,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,Mus musculus,,Hippocampus,,
1063,1,B,BAO_0000221,,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,,,Hippocampus,,
1064,1,B,BAO_0000221,10090.0,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,Mus musculus,,Hippocampus,,
1065,1,B,BAO_0000221,,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,,,Hippocampus,,
1066,1,B,BAO_0000357,,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,,,,,
1067,1,B,BAO_0000221,10090.0,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,Mus musculus,,Hippocampus,,
1068,1,B,BAO_0000357,9823.0,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,,Sus scrofa,,,,
1069,1,B,BAO_0000357,9823.0,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,,Sus scrofa,,,,
1070,1,B,BAO_0000019,9823.0,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,,Sus scrofa,,,,
1071,1,B,BAO_0000357,9823.0,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,,,Sus scrofa,,,,
1072,1,B,BAO_0000019,9823.0,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,Sus scrofa,,,,
1073,1,B,BAO_0000019,9823.0,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,Sus scrofa,,,,
1074,1,B,BAO_0000019,9823.0,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,,Sus scrofa,,,,
1075,1,B,BAO_0000357,9823.0,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,,Sus scrofa,,,,
1076,1,B,BAO_0000357,9823.0,12861,Binding activity radioligand.,,,Sus scrofa,,,,
1077,1,B,BAO_0000019,9823.0,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,Sus scrofa,,,,
1078,1,B,BAO_0000019,9823.0,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,Sus scrofa,,,,
1079,1,B,BAO_0000019,,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,,,,,
1080,1,B,BAO_0000019,9823.0,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,,Sus scrofa,,,,
1081,1,B,BAO_0000221,9823.0,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,,Sus scrofa,,Hippocampus,,
1082,1,B,BAO_0000249,9823.0,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,,Sus scrofa,,,,
1083,1,B,BAO_0000019,9823.0,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,,Sus scrofa,,,,
1084,1,F,BAO_0000019,9823.0,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,,Sus scrofa,,,,
1085,1,B,BAO_0000019,9986.0,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,,Oryctolagus cuniculus,,,,
1086,1,B,BAO_0000249,10116.0,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,,Rattus norvegicus,,,,
1087,1,B,BAO_0000221,10116.0,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,,Rattus norvegicus,,Hippocampus,,
1088,1,B,BAO_0000357,,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,,,,,
1089,1,F,BAO_0000249,10116.0,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,Rattus norvegicus,,,,Membranes
1090,1,F,BAO_0000249,10116.0,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,Rattus norvegicus,,Hippocampus,,Membranes
1091,1,B,BAO_0000221,,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,,Hippocampus,,
1092,1,B,BAO_0000221,10116.0,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,,Rattus norvegicus,,Hippocampus,,
1093,1,B,BAO_0000019,,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,,,,,
1094,1,B,BAO_0000357,,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,,,,,
1095,1,B,BAO_0000357,,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,,,,
1096,1,B,BAO_0000219,,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,,,,
1097,1,B,BAO_0000357,,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,,,,,
1098,1,B,BAO_0000249,,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,,,,Membranes
1099,1,B,BAO_0000249,,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,,,,Membranes
1100,1,B,BAO_0000249,,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,,,,,Membranes
1101,1,B,BAO_0000357,10116.0,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,,Rattus norvegicus,,,,
1102,1,B,BAO_0000357,,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,,,,,
1103,1,B,BAO_0000357,,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,,,,,
1104,1,B,BAO_0000221,,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,,,Hippocampus,,
1105,1,B,BAO_0000221,,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,,,Hippocampus,,
1106,1,B,BAO_0000221,,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
1107,1,B,BAO_0000357,10116.0,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,,,,
1108,1,B,BAO_0000357,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,,,,,
1109,1,B,BAO_0000249,,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,,,,,
1110,1,B,BAO_0000357,,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,
1111,1,B,BAO_0000357,,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,,,,,
1112,1,B,BAO_0000019,,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,,,,
1113,1,B,BAO_0000221,10116.0,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,Rattus norvegicus,,Brain,,
1114,1,B,BAO_0000221,,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,,Brain,,
1115,1,B,BAO_0000249,,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,,,,,
1116,1,B,BAO_0000221,10116.0,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,,Rattus norvegicus,,Hippocampus,,
1117,1,B,BAO_0000221,,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,,,Hippocampus,,
1118,1,B,BAO_0000249,,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,,,,,
1119,1,B,BAO_0000249,,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,,,Striatum,,
1120,1,B,BAO_0000249,10116.0,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,,Rattus norvegicus,,,,Membranes
1121,1,B,BAO_0000249,10116.0,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,,Rattus norvegicus,,,,Membranes
1122,1,B,BAO_0000221,,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,Hippocampus,,
1123,1,B,BAO_0000221,,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,,,Hippocampus,,
1124,1,B,BAO_0000221,,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,,,Hippocampus,,
1125,1,B,BAO_0000249,,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,,
1126,1,B,BAO_0000221,,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,,Hippocampus,,
1127,1,B,BAO_0000221,,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,,,Hippocampus,,
1128,1,B,BAO_0000221,,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,,,Hippocampus,,
1129,1,B,BAO_0000221,,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,,,Hippocampus,,
1130,1,B,BAO_0000019,,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,,,,,
1131,1,B,BAO_0000357,,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,,,,,
1132,1,B,BAO_0000019,10116.0,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,,Rattus norvegicus,,,,
1133,1,B,BAO_0000019,10116.0,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,,Rattus norvegicus,,,,
1134,1,B,BAO_0000019,10116.0,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,,Rattus norvegicus,,,,
1135,1,B,BAO_0000219,10116.0,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,Rattus norvegicus,,,CHO-K1,
1136,1,B,BAO_0000357,,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,
1137,1,B,BAO_0000221,10116.0,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,,Rattus norvegicus,,Hippocampus,,
1138,1,B,BAO_0000221,,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,,,Hippocampus,,
1139,1,B,BAO_0000019,,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,
1140,1,B,BAO_0000019,,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,,,,,
1141,1,B,BAO_0000019,,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,,,,,
1142,1,B,BAO_0000221,,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,,,Hippocampus,,
1143,1,B,BAO_0000357,,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,,,,,
1144,1,B,BAO_0000019,,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,,,,,
1145,1,B,BAO_0000357,10116.0,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,,Rattus norvegicus,,,,
1146,1,B,BAO_0000357,,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,,,,
1147,1,B,BAO_0000249,,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,,,Striatum,,Membranes
1148,1,B,BAO_0000357,,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,,,,,
1149,1,B,BAO_0000218,,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),In vivo,,,,,,
1150,1,B,BAO_0000221,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,,,Brain,,
1151,1,B,BAO_0000357,10116.0,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,,,,
1152,1,B,BAO_0000249,,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,,,,,
1153,1,B,BAO_0000249,10116.0,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,,Rattus norvegicus,,,,Membranes
1154,1,B,BAO_0000221,,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,,Hippocampus,,
1155,1,B,BAO_0000221,,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,,Hippocampus,,
1156,1,B,BAO_0000357,,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,,,,
1157,1,B,BAO_0000249,,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,,,,,
1158,1,B,BAO_0000357,,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,,,,
1159,1,B,BAO_0000019,,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,,,,,
1160,1,B,BAO_0000019,,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,,,,,
1161,1,B,BAO_0000019,10116.0,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,,,,
1162,1,B,BAO_0000019,,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,,,,,
1163,1,B,BAO_0000357,,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,,,,,
1164,1,B,BAO_0000221,,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,,Hippocampus,,
1165,1,B,BAO_0000357,,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,,,,,
1166,1,B,BAO_0000219,,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,,,,,CHO,
1167,1,B,BAO_0000019,,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,,,,,
1168,1,B,BAO_0000221,,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,,,Hippocampus,,
1169,1,B,BAO_0000019,,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,,,,
1170,1,B,BAO_0000019,,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,,,,
1171,1,B,BAO_0000357,,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,
1172,1,B,BAO_0000221,,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,,,Brain,,
1173,1,B,BAO_0000221,,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,,Hippocampus,,
1174,1,B,BAO_0000019,,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,,,,,
1175,1,B,BAO_0000221,,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,,,Hippocampus,,
1176,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,,,Hippocampus,,
1177,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,,,Hippocampus,,
1178,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,,,Hippocampus,,
1179,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,,,Hippocampus,,
1180,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,,,Hippocampus,,
1181,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,,,Hippocampus,,
1182,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,,,Hippocampus,,
1183,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,,,Hippocampus,,
1184,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,,,Hippocampus,,
1185,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,,,Hippocampus,,
1186,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,,,Hippocampus,,
1187,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,,,Hippocampus,,
1188,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,,,Hippocampus,,
1189,1,B,BAO_0000221,10116.0,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,Rattus norvegicus,,Hippocampus,,
1190,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,,,Hippocampus,,
1191,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,,,Hippocampus,,
1192,1,B,BAO_0000019,,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,,,,,
1193,1,B,BAO_0000019,,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,,,,,
1194,1,B,BAO_0000019,,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,,,,,
1195,1,B,BAO_0000019,,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,,,,,
1196,1,B,BAO_0000221,,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,,Brain,,
1197,1,B,BAO_0000019,,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,,,,,
1198,1,B,BAO_0000019,,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,,,,,
1199,1,B,BAO_0000019,,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,,,,,
1200,1,B,BAO_0000219,,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,,,,,CHO,
1201,1,B,BAO_0000249,,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,,,,,
1202,1,B,BAO_0000019,,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,,,,
1203,1,B,BAO_0000218,,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,,,,CHO,
1204,1,B,BAO_0000218,,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,,,,,
1205,1,B,BAO_0000357,10116.0,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,,Rattus norvegicus,,,,
1206,1,B,BAO_0000249,,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,,Membranes
1207,1,B,BAO_0000249,,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,,,,,
1208,1,B,BAO_0000249,,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,,,,,
1209,1,B,BAO_0000219,9606.0,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,Homo sapiens,,,CHO,
1210,1,B,BAO_0000249,,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,,,,,
1211,1,B,BAO_0000221,10116.0,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,,Rattus norvegicus,,Hippocampus,,
1212,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,
1213,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,,,,,
1214,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,,,,,
1215,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,,,,,
1216,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,,,,,
1217,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,,,,,
1218,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,,,,,
1219,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,,,,,
1220,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,,,,,
1221,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,,,,,
1222,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,,,,,
1223,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,,,,,
1224,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,,,,,
1225,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,,,,,
1226,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,,,,,
1227,1,B,BAO_0000019,,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,
1228,1,B,BAO_0000357,,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,,,,,
1229,1,B,BAO_0000357,,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,,,,,
1230,1,B,BAO_0000019,,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,,,,,
1231,1,B,BAO_0000221,,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,,Hippocampus,,
1232,1,B,BAO_0000019,,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,,,,,
1233,1,B,BAO_0000219,10116.0,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,Rattus norvegicus,,,CHO-K1,
1234,1,B,BAO_0000019,,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,,,,,
1235,1,B,BAO_0000019,,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,,,,,
1236,1,B,BAO_0000357,,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,,,,,
1237,1,B,BAO_0000357,,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,,,,,
1238,1,B,BAO_0000357,,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,,,,,
1239,1,B,BAO_0000019,,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,,,,,
1240,1,B,BAO_0000019,10116.0,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,Rattus norvegicus,,,,
1241,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,In vivo,,,,,,
1242,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),In vivo,,,,,,
1243,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),In vivo,,,,,,
1244,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),In vivo,,,,,,
1245,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),In vivo,,,,,,
1246,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),In vivo,,,,,,
1247,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),In vivo,,,,,,
1248,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),In vivo,,,,,,
1249,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),In vivo,,,,,,
1250,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),In vivo,,,,,,
1251,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),In vivo,,,,,,
1252,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),In vivo,,,,,,
1253,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),In vivo,,,,,,
1254,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),In vivo,,,,,,
1255,1,F,BAO_0000218,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,In vivo,,,,,,
1256,1,F,BAO_0000249,10116.0,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,Rattus norvegicus,,,,Membranes
1257,1,B,BAO_0000019,,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,,,,,
1258,1,B,BAO_0000019,,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,,,,
1259,1,B,BAO_0000357,,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,,,,,
1260,1,F,BAO_0000249,,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,,,,
1261,1,B,BAO_0000221,,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
1262,1,B,BAO_0000249,,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,,,Hippocampus,,
1263,1,B,BAO_0000221,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,,,Brain,,
1264,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,,,,
1265,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,,,,,
1266,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,,,,,
1267,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,,,,
1268,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,,,,
1269,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,,,,,
1270,1,F,BAO_0000019,10116.0,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,,Rattus norvegicus,,,,
1271,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,,,,
1272,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,,,,,
1273,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,,,,,
1274,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,,,,,
1275,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,,,,,
1276,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,,,,
1277,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,,,,,
1278,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,,,,
1279,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,,,,,
1280,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,,,,,
1281,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,,,,
1282,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,,,,,
1283,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,,,,,
1284,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,,,,,
1285,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,,,,,
1286,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,,,,
1287,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,,,,
1288,1,B,BAO_0000221,,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,,,Hippocampus,,
1289,1,B,BAO_0000221,,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,,,Hippocampus,,
1290,1,B,BAO_0000249,10116.0,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,,Rattus norvegicus,,,,Membranes
1291,1,B,BAO_0000221,,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,,,Hippocampus,,
1292,1,B,BAO_0000221,,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,,,Hippocampus,,
1293,1,B,BAO_0000221,,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,,,Hippocampus,,
1294,1,F,BAO_0000249,10116.0,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,Rattus norvegicus,,,,
1295,1,B,BAO_0000357,,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,,,,,
1296,1,B,BAO_0000019,,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,,,,
1297,1,F,BAO_0000019,,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,,,,
1298,1,B,BAO_0000357,,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,,,,
1299,1,B,BAO_0000221,,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,,,Hippocampus,,
1300,1,B,BAO_0000221,,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,,Hippocampus,,
1301,1,B,BAO_0000221,,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,,Hippocampus,,
1302,1,B,BAO_0000357,10116.0,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,,,,
1303,1,B,BAO_0000221,,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,,,Hippocampus,,
1304,1,B,BAO_0000221,,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
1305,1,B,BAO_0000221,,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
1306,1,B,BAO_0000221,,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,,Hippocampus,,
1307,1,B,BAO_0000221,,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,,,Hippocampus,,
1308,1,B,BAO_0000221,,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,,,Hippocampus,,
1309,1,B,BAO_0000221,,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,,,Brain,,
1310,1,B,BAO_0000357,,9919,Affinity for 5-hydroxytryptamine 1A receptor site,,,,,,,
1311,1,B,BAO_0000357,,9919,Affinity for 5-hydroxytryptamine 1A receptor site,,,,,,,
1312,1,B,BAO_0000221,,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,,,Hippocampus,,
1313,1,B,BAO_0000357,,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,,,,,
1314,1,B,BAO_0000357,,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,,,,,
1315,1,B,BAO_0000221,10116.0,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,,Rattus norvegicus,,Hippocampus,,
1316,1,B,BAO_0000249,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,,,,,
1317,1,B,BAO_0000019,10116.0,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,Rattus norvegicus,,,,
1318,1,B,BAO_0000221,,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,,,Hippocampus,,
1319,1,B,BAO_0000357,,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,,,,,
1320,1,B,BAO_0000357,,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,,,,,
1321,1,B,BAO_0000357,,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,,,,,
1322,1,B,BAO_0000019,10116.0,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,,,,
1323,1,B,BAO_0000221,,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,,,Hippocampus,,
1324,1,B,BAO_0000357,,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,,,,,
1325,1,B,BAO_0000221,,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,,Brain,,
1326,1,B,BAO_0000221,,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,,Brain,,
1327,1,B,BAO_0000357,,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,,,,,
1328,1,B,BAO_0000357,,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,,,,,
1329,1,B,BAO_0000357,,14875,GTPgammaS radioligand binding assay,,,,,,,
1330,1,B,BAO_0000357,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,,,,
1331,1,F,BAO_0000019,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,,,,,
1332,1,F,BAO_0000019,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,,,,,
1333,1,B,BAO_0000357,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,,,,
1334,1,B,BAO_0000357,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,,,,
1335,1,F,BAO_0000019,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,,,,,
1336,1,B,BAO_0000219,,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,,,,,HeLa,
1337,1,B,BAO_0000219,,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,,,,,HeLa,
1338,1,B,BAO_0000357,9606.0,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,,Homo sapiens,,,,
1339,1,B,BAO_0000219,,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,,,,CHO,
1340,1,B,BAO_0000019,,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,,,,,
1341,1,B,BAO_0000019,,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,,,,,
1342,1,B,BAO_0000357,9606.0,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,,,,
1343,1,B,BAO_0000219,,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,,,,
1344,1,B,BAO_0000357,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,
1345,1,B,BAO_0000357,,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,,,,,
1346,1,B,BAO_0000357,,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,,,,
1347,1,B,BAO_0000357,,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,,,,
1348,1,B,BAO_0000357,,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,,,,,
1349,1,B,BAO_0000357,,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,,,,,
1350,1,B,BAO_0000357,,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,,,,,
1351,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,,,,,
1352,1,B,BAO_0000357,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,,,,,
1353,1,F,BAO_0000219,,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,,,,,CHO-K1,
1354,1,F,BAO_0000019,,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,,,,,
1355,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,,,,,
1356,1,B,BAO_0000357,,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,,,,
1357,1,B,BAO_0000357,,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,,,,,
1358,1,B,BAO_0000219,9606.0,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,,Homo sapiens,,,,
1359,1,B,BAO_0000357,9606.0,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,,,,
1360,1,B,BAO_0000357,9606.0,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,,,Homo sapiens,,,,
1361,1,B,BAO_0000357,9606.0,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,,,,
1362,1,B,BAO_0000219,,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,,,,,CHO,
1363,1,B,BAO_0000019,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,,,,,
1364,1,B,BAO_0000219,,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,,,HeLa,
1365,1,B,BAO_0000219,,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,,,,,HeLa,
1366,1,B,BAO_0000219,,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,,,HeLa,
1367,1,B,BAO_0000357,9606.0,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,,Homo sapiens,,,,
1368,1,B,BAO_0000219,,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,,,,,CHO-K1,
1369,1,B,BAO_0000357,,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,,,,,
1370,1,B,BAO_0000357,,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,,,,,
1371,1,B,BAO_0000219,,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,,,,,CHO-K1,
1372,1,B,BAO_0000357,9606.0,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,,,,
1373,1,B,BAO_0000357,9606.0,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,,,,
1374,1,B,BAO_0000219,9606.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,Homo sapiens,,,CHO,
1375,1,B,BAO_0000357,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,,,,,
1376,1,B,BAO_0000219,,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,,,,,CHO,
1377,1,B,BAO_0000219,,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,,,,,CHO,
1378,1,B,BAO_0000219,,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,,,,,CHO,
1379,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,,,CHO,
1380,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,,,CHO,
1381,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,,,CHO,
1382,1,B,BAO_0000219,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,,,,,CHO,
1383,1,B,BAO_0000357,9606.0,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,Homo sapiens,,,,
1384,1,B,BAO_0000219,,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,,,CHO,
1385,1,B,BAO_0000357,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,,,,,
1386,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,,,CHO,
1387,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,,,,,CHO,
1388,1,F,BAO_0000019,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,,,,,
1389,1,F,BAO_0000019,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,,,,,
1390,1,F,BAO_0000219,,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,,,CHO,
1391,1,F,BAO_0000219,,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,,,CHO,
1392,1,F,BAO_0000019,,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,,,,,
1393,1,B,BAO_0000219,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,,,,,CHO,
1394,1,B,BAO_0000357,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,
1395,1,F,BAO_0000019,9986.0,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,,Oryctolagus cuniculus,,,,
1396,1,B,BAO_0000019,9986.0,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,,Oryctolagus cuniculus,,,,
1397,1,B,BAO_0000019,9986.0,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,,Oryctolagus cuniculus,,,,
1398,1,B,BAO_0000019,9986.0,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,,Oryctolagus cuniculus,,,,
1399,1,B,BAO_0000357,,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,,,,,
1400,1,B,BAO_0000357,,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,,,,,,,
1401,1,B,BAO_0000019,10116.0,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,,Rattus norvegicus,,Striatum,,
1402,1,B,BAO_0000357,,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,,,,
1403,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,,,,,
1404,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,,,,,
1405,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,,,,,
1406,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,,,,,
1407,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,,,,,
1408,1,B,BAO_0000357,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,,,,,
1409,1,B,BAO_0000249,,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,,,Hippocampus,,
1410,1,B,BAO_0000019,,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,,,,
1411,1,B,BAO_0000221,,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,,,Hippocampus,,
1412,1,B,BAO_0000221,,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,,,Hippocampus,,
1413,1,B,BAO_0000221,,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,Hippocampus,,
1414,1,B,BAO_0000221,,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,,,Hippocampus,,
1415,1,B,BAO_0000221,,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,,,Hippocampus,,
1416,1,B,BAO_0000221,,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,,,Hippocampus,,
1417,1,B,BAO_0000221,,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,,,Hippocampus,,
1418,1,B,BAO_0000221,,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,,,Hippocampus,,
1419,1,B,BAO_0000249,,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,,,,
1420,1,B,BAO_0000249,,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,,,,,
1421,1,B,BAO_0000249,,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,,,,,
1422,1,B,BAO_0000357,,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,,,,,
1423,1,B,BAO_0000221,,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,,,Hippocampus,,
1424,1,B,BAO_0000221,,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,,,Hippocampus,,
1425,1,B,BAO_0000221,10116.0,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,,Hippocampus,,
1426,1,F,BAO_0000019,,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,,,,
1427,1,B,BAO_0000221,,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,,Hippocampus,,
1428,1,B,BAO_0000221,10116.0,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,,Rattus norvegicus,,Hippocampus,,
1429,1,B,BAO_0000249,,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,,,,,
1430,1,B,BAO_0000221,,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,,,Hippocampus,,
1431,1,B,BAO_0000221,,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,,Hippocampus,,
1432,1,F,BAO_0000221,,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,,,Hippocampus,,
1433,1,B,BAO_0000357,,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,,,,,
1434,1,B,BAO_0000221,10116.0,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,,Rattus norvegicus,,Hippocampus,,
1435,1,B,BAO_0000357,,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,,,,,
1436,1,B,BAO_0000019,,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,,,,,
1437,1,B,BAO_0000019,,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,,,,,
1438,1,B,BAO_0000219,,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,,,,,CHO,
1439,1,B,BAO_0000357,,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,,,,,
1440,1,B,BAO_0000357,,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,,,,,
1441,1,B,BAO_0000221,10116.0,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,,Hippocampus,,
1442,1,B,BAO_0000221,,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
1443,1,B,BAO_0000221,,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,,,Hippocampus,,
1444,1,B,BAO_0000221,,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,,,Hippocampus,,
1445,1,B,BAO_0000019,,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,,,,,
1446,1,B,BAO_0000357,,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,,,,,
1447,1,B,BAO_0000357,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,,,,
1448,1,B,BAO_0000221,,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,,,Hippocampus,,
1449,1,B,BAO_0000249,,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,,,,,
1450,1,B,BAO_0000357,10116.0,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,,Rattus norvegicus,,,,
1451,1,B,BAO_0000221,,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,,,Hippocampus,,
1452,1,B,BAO_0000221,,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,,,Hippocampus,,
1453,1,B,BAO_0000357,,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,,,,,
1454,1,B,BAO_0000249,,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,,,,,
1455,1,B,BAO_0000249,,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,,,,,
1456,1,B,BAO_0000357,,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,,,,,
1457,1,B,BAO_0000019,10116.0,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,,Rattus norvegicus,,,,
1458,1,B,BAO_0000019,,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,,,,
1459,1,B,BAO_0000221,,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
1460,1,B,BAO_0000221,,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,,Hippocampus,,
1461,1,B,BAO_0000221,10116.0,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,,Rattus norvegicus,,Hippocampus,,
1462,1,B,BAO_0000357,,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,
1463,1,B,BAO_0000221,10116.0,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,,Rattus norvegicus,,Hippocampus,,
1464,1,B,BAO_0000221,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,,,Hippocampus,,
1465,1,B,BAO_0000221,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,,,Hippocampus,,
1466,1,B,BAO_0000221,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,,,Hippocampus,,
1467,1,B,BAO_0000221,,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,,Hippocampus,,
1468,1,B,BAO_0000219,,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,,,,,CHO,
1469,1,B,BAO_0000357,,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,,,,
1470,1,B,BAO_0000357,,10058,The inhibition activity of 5-HT1A at 1 uM,,,,,,,
1471,1,B,BAO_0000219,,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,,,,,CHO-K1,
1472,1,B,BAO_0000249,,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,,,,,
1473,1,B,BAO_0000357,,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,,,,,
1474,1,B,BAO_0000221,,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,,Hippocampus,,
1475,1,B,BAO_0000221,,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,,Hippocampus,,
1476,1,F,BAO_0000249,10116.0,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,,Rattus norvegicus,,,,Membranes
1477,1,F,BAO_0000249,10116.0,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,Rattus norvegicus,,Hippocampus,,Membranes
1478,1,B,BAO_0000019,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,,,,,
1479,1,B,BAO_0000019,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,,,,,
1480,1,B,BAO_0000019,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,,,,,
1481,1,B,BAO_0000019,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,,,,,
1482,1,B,BAO_0000249,,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,,,,,
1483,1,B,BAO_0000249,,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,,,,,
1484,1,B,BAO_0000019,10116.0,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,,Rattus norvegicus,,,,
1485,1,B,BAO_0000221,,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,,,Hippocampus,,
1486,1,B,BAO_0000221,,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,,,Hippocampus,,
1487,1,B,BAO_0000221,10116.0,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,,Rattus norvegicus,,Hippocampus,,
1488,1,F,BAO_0000019,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,,,,
1489,1,F,BAO_0000019,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,,,,,
1490,1,B,BAO_0000357,,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,,,,,
1491,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,,,Hippocampus,,
1492,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,,,Hippocampus,,
1493,1,B,BAO_0000221,,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,,,Hippocampus,,
1494,1,B,BAO_0000357,,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,,,,,
1495,1,B,BAO_0000249,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,,,,
1496,1,F,BAO_0000249,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,,,,
1497,1,B,BAO_0000249,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,,,,
1498,1,F,BAO_0000249,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,,,,
1499,1,F,BAO_0000249,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,,,,
1500,1,B,BAO_0000249,,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,,Brain,,
1501,1,B,BAO_0000019,,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,,,,,
1502,1,F,BAO_0000019,,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,,,,,
1503,1,B,BAO_0000221,,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,,Hippocampus,,
1504,1,B,BAO_0000019,,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,,,,,
1505,1,B,BAO_0000249,,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,,,,,
1506,1,B,BAO_0000019,,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,,,,,
1507,1,B,BAO_0000221,,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,,,Hippocampus,,
1508,1,B,BAO_0000221,,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,,,Hippocampus,,
1509,1,B,BAO_0000357,,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,,,,,
1510,1,B,BAO_0000357,10116.0,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,Rattus norvegicus,,,,
1511,1,B,BAO_0000019,10116.0,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,,Rattus norvegicus,,,,
1512,1,B,BAO_0000019,,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,,,,,
1513,1,B,BAO_0000357,,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,
1514,1,B,BAO_0000019,,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,,,,,
1515,1,B,BAO_0000221,,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,,Hippocampus,,
1516,1,B,BAO_0000019,,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,,,,,
1517,1,B,BAO_0000357,,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,,,,
1518,1,B,BAO_0000249,10116.0,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,,Rattus norvegicus,,,,Membranes
1519,1,B,BAO_0000249,,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,,,,
1520,1,B,BAO_0000019,,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,,,,,
1521,1,B,BAO_0000019,,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,
1522,1,B,BAO_0000221,10116.0,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,,Rattus norvegicus,,Hippocampus,,
1523,1,B,BAO_0000221,10116.0,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,,Rattus norvegicus,,Hippocampus,,
1524,1,B,BAO_0000221,,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,,,Hippocampus,,
1525,1,B,BAO_0000357,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,
1526,1,B,BAO_0000357,,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,,,,,
1527,1,B,BAO_0000019,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,,,,,
1528,1,F,BAO_0000019,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,,,,
1529,1,B,BAO_0000357,10116.0,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,Rattus norvegicus,,,,
1530,1,B,BAO_0000249,,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,,Membranes
1531,1,B,BAO_0000221,,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,,,Brain,,
1532,1,B,BAO_0000019,10116.0,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,,Rattus norvegicus,,,,
1533,1,F,BAO_0000019,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,,,,
1534,1,B,BAO_0000221,,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,,Brain,,
1535,1,B,BAO_0000019,,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,,,,,
1536,1,B,BAO_0000357,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,
1537,1,B,BAO_0000357,,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,,,,,
1538,1,B,BAO_0000357,,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,
1539,1,B,BAO_0000357,,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,
1540,1,B,BAO_0000249,,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,,,,,Brain membranes
1541,1,B,BAO_0000357,,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,,,,,
1542,1,B,BAO_0000357,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,,,,,
1543,1,B,BAO_0000357,,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,,,,,
1544,1,B,BAO_0000357,,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,
1545,1,B,BAO_0000357,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,,,,,
1546,1,B,BAO_0000357,,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,
1547,1,B,BAO_0000357,,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,,,,,
1548,1,B,BAO_0000357,9606.0,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,,Homo sapiens,,,,
1549,1,B,BAO_0000357,9606.0,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,,Homo sapiens,,,,
1550,1,B,BAO_0000219,,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,,CHO,
1551,1,B,BAO_0000219,,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,,,,,
1552,1,B,BAO_0000218,,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,In vivo,,,,,,
1553,1,B,BAO_0000221,,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,,Hippocampus,,
1554,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,,,,,
1555,1,B,BAO_0000357,,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,,,,,
1556,1,B,BAO_0000357,,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,,,,
1557,1,B,BAO_0000357,,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,,,,
1558,1,B,BAO_0000357,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,,,,,
1559,1,B,BAO_0000357,,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,,,,
1560,1,B,BAO_0000357,,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,,,,,
1561,1,B,BAO_0000357,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,,,,,
1562,1,B,BAO_0000357,,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,,,,,
1563,1,B,BAO_0000219,10090.0,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,,Mus musculus,,,CHO,
1564,1,B,BAO_0000357,,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,,,,
1565,1,B,BAO_0000357,,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,,,,,
1566,1,B,BAO_0000357,,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,
1567,1,B,BAO_0000357,,13033,Binding affinity against serotonergic 5-HT1a receptor,,,,,,,
1568,1,B,BAO_0000357,,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,,,,,
1569,1,B,BAO_0000357,10090.0,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,,,Mus musculus,,,,
1570,1,B,BAO_0000357,,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,,,,
1571,1,B,BAO_0000357,,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,,,,,
1572,1,B,BAO_0000219,,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,,CHO,
1573,1,B,BAO_0000219,,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,,CHO,
1574,1,B,BAO_0000357,,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,,,,,
1575,1,B,BAO_0000357,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,,,,,
1576,1,B,BAO_0000218,,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,,,,,
1577,1,B,BAO_0000357,,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,,,,,
1578,1,B,BAO_0000357,,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,,,,,
1579,1,B,BAO_0000357,10090.0,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,,,Mus musculus,,,,
1580,1,B,BAO_0000357,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,,,,
1581,1,B,BAO_0000357,,12146,Tested against 5-hydroxytryptamine 1A receptor,,,,,,,
1582,1,B,BAO_0000357,,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,
1583,1,B,BAO_0000019,9986.0,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,,Oryctolagus cuniculus,,,,
1584,1,B,BAO_0000019,9986.0,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,,Oryctolagus cuniculus,,,,
1585,1,B,BAO_0000219,9593.0,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,Gorilla gorilla,,,HEK293,
1586,1,F,BAO_0000218,10141.0,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,,Cavia porcellus,,,,
1587,1,F,BAO_0000218,10141.0,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,,Cavia porcellus,,,,
1588,1,F,BAO_0000019,10141.0,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,,Cavia porcellus,,,,
1589,1,F,BAO_0000019,10141.0,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,,Cavia porcellus,,,,
1590,1,F,BAO_0000019,10141.0,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,,Cavia porcellus,,,,
1591,1,F,BAO_0000019,10141.0,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,,Cavia porcellus,,,,
1592,1,F,BAO_0000019,,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,,,,,
1593,1,F,BAO_0000019,,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,,,,,
1594,1,F,BAO_0000019,,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,,,,,
1595,1,F,BAO_0000019,9606.0,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,,Homo sapiens,,,,
1596,1,F,BAO_0000219,9606.0,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,,Homo sapiens,,,CHO-K1,
1597,1,F,BAO_0000219,,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,,,,,CHO,
1598,1,B,BAO_0000357,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,,,,
1599,1,F,BAO_0000019,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,,,,,
1600,1,F,BAO_0000219,,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,,,,,CHO,
1601,1,F,BAO_0000219,,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,,,,,CHO,
1602,1,F,BAO_0000219,,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,,,,,CHO,
1603,1,F,BAO_0000219,,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,,,,,CHO,
1604,1,F,BAO_0000219,,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,,,,,CHO,
1605,1,F,BAO_0000019,,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,
1606,1,F,BAO_0000019,,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,
1607,1,B,BAO_0000357,9606.0,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,,Homo sapiens,,,,
1608,1,B,BAO_0000219,,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,,,,,CHO,
1609,1,B,BAO_0000357,,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,,,,,
1610,1,B,BAO_0000357,9606.0,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,,,Homo sapiens,,,,
1611,1,B,BAO_0000219,9606.0,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,Homo sapiens,,,CHO,
1612,1,B,BAO_0000219,,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,,,,,CHO,
1613,1,B,BAO_0000357,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,,,,,
1614,1,B,BAO_0000219,,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,,,CHO,
1615,1,B,BAO_0000219,,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,,,CHO,
1616,1,B,BAO_0000219,,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,,,CHO,
1617,1,B,BAO_0000219,,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,,,,,CHO,
1618,1,B,BAO_0000219,,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,,,,CHO,
1619,1,B,BAO_0000357,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,,,,,
1620,1,B,BAO_0000357,,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,,,,,
1621,1,F,BAO_0000019,9986.0,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,Oryctolagus cuniculus,,,,
1622,1,F,BAO_0000019,9986.0,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,Oryctolagus cuniculus,,,,
1623,1,B,BAO_0000357,,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,,,,,
1624,1,B,BAO_0000357,,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,,,,,
1625,1,B,BAO_0000357,,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,,,,,
1626,1,B,BAO_0000357,9913.0,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,,Bos taurus,,,,
1627,1,B,BAO_0000357,9913.0,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,,Bos taurus,,,,
1628,1,B,BAO_0000019,9913.0,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,Bos taurus,,Striatum,,
1629,1,B,BAO_0000357,9913.0,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,,Bos taurus,,,,
1630,1,B,BAO_0000019,9913.0,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,,Bos taurus,,,,
1631,1,B,BAO_0000357,9913.0,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,Bos taurus,,,,
1632,1,B,BAO_0000357,9913.0,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,Bos taurus,,,,
1633,1,B,BAO_0000357,9913.0,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,Bos taurus,,,,
1634,1,B,BAO_0000357,9913.0,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,Bos taurus,,,,
1635,1,B,BAO_0000357,9913.0,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,,Bos taurus,,,,
1636,1,B,BAO_0000357,9913.0,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,,Bos taurus,,,,
1637,1,B,BAO_0000357,9913.0,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,Bos taurus,,,,
1638,1,B,BAO_0000357,9913.0,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,,Bos taurus,,,,
1639,1,B,BAO_0000019,9913.0,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,Bos taurus,,Striatum,,
1640,1,B,BAO_0000019,9913.0,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,,Bos taurus,,,,
1641,1,B,BAO_0000357,9913.0,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,,Bos taurus,,,,
1642,1,B,BAO_0000357,9913.0,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,Bos taurus,,,,
1643,1,B,BAO_0000249,9913.0,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,,Bos taurus,,,,
1644,1,B,BAO_0000249,9913.0,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,,Bos taurus,,,,
1645,1,F,BAO_0000019,9913.0,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Bos taurus,,,,
1646,1,B,BAO_0000019,9913.0,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,,Bos taurus,,,,
1647,1,F,BAO_0000019,9913.0,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Bos taurus,,,,
1648,1,F,BAO_0000019,9913.0,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Bos taurus,,,,
1649,1,F,BAO_0000019,9913.0,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,Bos taurus,,,,
1650,1,B,BAO_0000219,9593.0,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,Gorilla gorilla,,,HEK293,
1651,1,B,BAO_0000019,10141.0,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,,Cavia porcellus,,,,
1652,1,B,BAO_0000019,10141.0,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,,Cavia porcellus,,,,
1653,1,F,BAO_0000019,10141.0,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,,Cavia porcellus,,,,
1654,1,F,BAO_0000019,10141.0,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Cavia porcellus,,,,
1655,1,F,BAO_0000019,10141.0,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,,Cavia porcellus,,,,
1656,1,F,BAO_0000019,10141.0,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,,Cavia porcellus,,,,
1657,1,F,BAO_0000019,10141.0,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,,Cavia porcellus,,,,
1658,1,B,BAO_0000357,10141.0,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,,,Cavia porcellus,,,,
1659,1,B,BAO_0000357,10141.0,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,,Cavia porcellus,,,,
1660,1,F,BAO_0000218,10141.0,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Cavia porcellus,,,,
1661,1,F,BAO_0000218,10141.0,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Cavia porcellus,,,,
1662,1,F,BAO_0000218,10141.0,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,Cavia porcellus,,,,
1663,1,F,BAO_0000218,10141.0,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,,Cavia porcellus,,,,
1664,1,B,BAO_0000019,10141.0,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,,Cavia porcellus,,,,
1665,1,B,BAO_0000357,10141.0,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,,Cavia porcellus,,,,
1666,1,B,BAO_0000019,10141.0,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,,Cavia porcellus,,,,
1667,1,B,BAO_0000357,10141.0,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,,Cavia porcellus,,Striatum,,
1668,1,B,BAO_0000357,10141.0,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,,Cavia porcellus,,,,
1669,1,B,BAO_0000357,,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,
1670,1,B,BAO_0000357,,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,,,,,
1671,1,F,BAO_0000019,,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,,,,,
1672,1,F,BAO_0000019,,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,
1673,1,F,BAO_0000019,,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,,,,,
1674,1,F,BAO_0000219,9606.0,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,,Homo sapiens,,,CHO,
1675,1,F,BAO_0000219,,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,,,,,CHO,
1676,1,B,BAO_0000219,,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,,,CHO,
1677,1,B,BAO_0000219,,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,,,,,CHO,
1678,1,F,BAO_0000219,,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,,,,CHO,
1679,1,F,BAO_0000219,9606.0,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,Homo sapiens,,,CHO,
1680,1,F,BAO_0000219,,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,,,,,CHO,
1681,1,F,BAO_0000219,,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,,,,,CHO,
1682,1,F,BAO_0000219,,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,,,,,CHO,
1683,1,F,BAO_0000219,,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,,,,,CHO,
1684,1,F,BAO_0000019,,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,,,,,
1685,1,F,BAO_0000219,,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,,,CHO,
1686,1,F,BAO_0000219,9606.0,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,Homo sapiens,,,CHO,
1687,1,F,BAO_0000219,9606.0,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,Homo sapiens,,,CHO,
1688,1,F,BAO_0000019,,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,
1689,1,F,BAO_0000019,,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,,,,,
1690,1,F,BAO_0000019,9606.0,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,,Homo sapiens,,,,
1691,1,F,BAO_0000219,9606.0,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,,Homo sapiens,,,CHO,
1692,1,F,BAO_0000019,,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,,,,,
1693,1,B,BAO_0000219,,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),In vitro,,,,,,
1694,1,B,BAO_0000219,,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,,,,,CHO,
1695,1,B,BAO_0000357,,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,,,,,
1696,1,B,BAO_0000219,9606.0,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,Homo sapiens,,,CHO,
1697,1,B,BAO_0000219,,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,,,,,CHO,
1698,1,B,BAO_0000357,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,,,,,
1699,1,B,BAO_0000219,,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,,,CHO,
1700,1,B,BAO_0000219,,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,,,CHO,
1701,1,B,BAO_0000219,,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,,,CHO,
1702,1,B,BAO_0000219,9606.0,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,Homo sapiens,,,CHO,
1703,1,B,BAO_0000219,9606.0,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,Homo sapiens,,,CHO,
1704,1,B,BAO_0000219,,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,,,CHO,
1705,1,B,BAO_0000219,,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,,,,CHO,
1706,1,B,BAO_0000357,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,,,,,
1707,1,B,BAO_0000219,9606.0,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,,Homo sapiens,,,CHO,
1708,1,B,BAO_0000219,,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,,,,CHO,
1709,1,B,BAO_0000019,,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,,,,,
1710,1,B,BAO_0000357,9606.0,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,,,,
1711,1,B,BAO_0000357,,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,,,,,
1712,1,B,BAO_0000219,,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,,,,
1713,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,,,,,
1714,1,B,BAO_0000357,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,,,,,
1715,1,B,BAO_0000357,,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,,,,,
1716,1,B,BAO_0000357,,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,,,,,
1717,1,B,BAO_0000357,,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,,,,,
1718,1,B,BAO_0000357,,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,,,,
1719,1,B,BAO_0000357,,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,,,,,
1720,1,B,BAO_0000357,,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,,,,,
1721,1,B,BAO_0000357,,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,,,,,
1722,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,,,,,
1723,1,F,BAO_0000219,,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,,,,,CHO-K1,
1724,1,B,BAO_0000219,9606.0,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),In vitro,,Homo sapiens,,,,
1725,1,B,BAO_0000357,9606.0,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,,,,
1726,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,
1727,1,B,BAO_0000357,,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,,,,
1728,1,B,BAO_0000357,,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,,,,,
1729,1,B,BAO_0000219,9606.0,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,,Homo sapiens,,,,
1730,1,B,BAO_0000357,9606.0,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,,,,
1731,1,B,BAO_0000357,,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,,,,,
1732,1,B,BAO_0000357,9606.0,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,,,Homo sapiens,,,,
1733,1,B,BAO_0000357,9606.0,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,,,,
1734,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,
1735,1,B,BAO_0000019,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,,,,,
1736,1,B,BAO_0000357,9606.0,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,,Homo sapiens,,,,
1737,1,B,BAO_0000219,,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,,,,,CHO-K1,
1738,1,B,BAO_0000219,,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,,,,,CHO-K1,
1739,1,B,BAO_0000219,,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,,,,,CHO,
1740,1,F,BAO_0000019,,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,,,,,
1741,1,B,BAO_0000357,,12861,Binding activity radioligand.,,,,,,,
1742,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,
1743,1,B,BAO_0000219,,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,,,,,CHO-K1,
1744,1,B,BAO_0000357,,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,,,,
1745,1,B,BAO_0000357,,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,,,,
1746,1,B,BAO_0000357,,14499,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,,,,,
1747,1,B,BAO_0000357,9606.0,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,,,,
1748,1,B,BAO_0000219,9606.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,Homo sapiens,,,CHO,
1749,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,,,,,CHO,
1750,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,,CHO,
1751,1,B,BAO_0000357,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,,,,
1752,1,B,BAO_0000219,,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,,,,,CHO,
1753,1,B,BAO_0000219,,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,,,,,CHO,
1754,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,,,HEK293,
1755,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,,,HEK293,
1756,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,,,,,HEK293,
1757,1,B,BAO_0000219,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,,,,,CHO,
1758,1,B,BAO_0000357,9606.0,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,Homo sapiens,,,,
1759,1,B,BAO_0000219,,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,,,,,CHO,
1760,1,B,BAO_0000357,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,,,,,
1761,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,,,,,CHO,
1762,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,,,,,CHO,
1763,1,F,BAO_0000019,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,,,,,
1764,1,F,BAO_0000019,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,,,,,
1765,1,B,BAO_0000357,,5254,Binding affinity against 5-HT2C receptor,,,,,,,
1766,1,B,BAO_0000357,,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,
1767,1,B,BAO_0000357,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,,,,
1768,1,F,BAO_0000019,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,,,,
1769,1,B,BAO_0000019,,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,,,,,
1770,1,B,BAO_0000357,,9098,Binding affinity towards 5-HT1B was determined,,,,,,,
1771,1,B,BAO_0000019,,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,,,,,
1772,1,B,BAO_0000019,,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,,,,,
1773,1,B,BAO_0000019,,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,,,,,
1774,1,B,BAO_0000019,,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,
1775,1,B,BAO_0000019,10116.0,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,,Rattus norvegicus,,,,
1776,1,B,BAO_0000357,,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,,,,
1777,1,B,BAO_0000357,,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,,,,,
1778,1,B,BAO_0000249,,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,,,,
1779,1,B,BAO_0000019,,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,,,Striatum,,
1780,1,B,BAO_0000357,10116.0,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,,Rattus norvegicus,,,,
1781,1,B,BAO_0000019,,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,,,,,
1782,1,B,BAO_0000019,,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,,,Striatum,,
1783,1,B,BAO_0000019,,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,,,Striatum,,
1784,1,B,BAO_0000357,,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,,,Striatum,,
1785,1,B,BAO_0000249,,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,,,,
1786,1,B,BAO_0000357,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,,,,,
1787,1,B,BAO_0000019,,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,,,Striatum,,
1788,1,B,BAO_0000019,,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,,,Striatum,,
1789,1,B,BAO_0000019,,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,,,,,
1790,1,B,BAO_0000357,,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,,,,,
1791,1,B,BAO_0000357,,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,,,,
1792,1,B,BAO_0000357,10116.0,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,,Rattus norvegicus,,,,
1793,1,B,BAO_0000357,,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,,,Striatum,,
1794,1,B,BAO_0000357,,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,,,Striatum,,
1795,1,B,BAO_0000357,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,,,,
1796,1,B,BAO_0000357,,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,,,,
1797,1,B,BAO_0000019,,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,,,,,
1798,1,B,BAO_0000019,,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,,,,,
1799,1,B,BAO_0000019,,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,,,Striatum,,
1800,1,B,BAO_0000019,,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,,,,,
1801,1,B,BAO_0000019,,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,,,,,
1802,1,B,BAO_0000357,,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,,,,,
1803,1,B,BAO_0000249,,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,,,,
1804,1,B,BAO_0000357,,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,,,,,
1805,1,B,BAO_0000357,,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,,,,,
1806,1,B,BAO_0000249,10116.0,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,,Rattus norvegicus,,,,
1807,1,B,BAO_0000357,10116.0,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,Rattus norvegicus,,,,
1808,1,B,BAO_0000019,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,,,,,
1809,1,B,BAO_0000357,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,,,,,
1810,1,B,BAO_0000357,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,,,,,
1811,1,B,BAO_0000019,,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,,,Striatum,,
1812,1,B,BAO_0000357,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,,,,,
1813,1,B,BAO_0000249,,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,,Brain,,
1814,1,B,BAO_0000019,,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,,,,,
1815,1,B,BAO_0000249,,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,,Brain,,
1816,1,B,BAO_0000357,,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,,,,,
1817,1,B,BAO_0000357,,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,,,,,
1818,1,B,BAO_0000019,10116.0,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,,Rattus norvegicus,,,,
1819,1,B,BAO_0000357,,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,,,,,,,
1820,1,B,BAO_0000019,,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,,,,,
1821,1,B,BAO_0000249,10116.0,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,,Rattus norvegicus,,,,
1822,1,B,BAO_0000357,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,,,,
1823,1,B,BAO_0000357,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,
1824,1,B,BAO_0000019,,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,,,,,
1825,1,B,BAO_0000357,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,
1826,1,B,BAO_0000249,,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,,,,,Brain membranes
1827,1,B,BAO_0000357,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,,,,,
1828,1,B,BAO_0000357,,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,,,,,
1829,1,B,BAO_0000357,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,,,,,
1830,1,B,BAO_0000357,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,,,,,
1831,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,,,,,
1832,1,B,BAO_0000357,,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,,,,,
1833,1,B,BAO_0000357,,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,,,,,
1834,1,B,BAO_0000357,,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,,,,,
1835,1,B,BAO_0000357,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,,,,,
1836,1,B,BAO_0000357,,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,
1837,1,B,BAO_0000357,,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,,,,,
1838,1,B,BAO_0000357,,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,
1839,1,B,BAO_0000357,,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,,,,,
1840,1,B,BAO_0000224,,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,,,,,
1841,1,B,BAO_0000357,9913.0,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,,Bos taurus,,,,
1842,1,B,BAO_0000357,9823.0,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,Sus scrofa,,,,
1843,1,B,BAO_0000357,9823.0,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,,Sus scrofa,,,,
1844,1,B,BAO_0000357,9823.0,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,Sus scrofa,,,,
1845,1,B,BAO_0000357,9823.0,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,Sus scrofa,,,,
1846,1,B,BAO_0000357,9823.0,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,,Sus scrofa,,,,
1847,1,B,BAO_0000357,9823.0,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,,Sus scrofa,,,,
1848,1,B,BAO_0000357,9823.0,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,,Sus scrofa,,,,
1849,1,B,BAO_0000357,9823.0,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,,Sus scrofa,,,,
1850,1,B,BAO_0000019,9823.0,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,,Sus scrofa,,,,
1851,1,B,BAO_0000357,9823.0,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,,Sus scrofa,,,,
1852,1,B,BAO_0000019,9986.0,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,,,,
1853,1,B,BAO_0000357,10116.0,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,,Rattus norvegicus,,,,
1854,1,B,BAO_0000357,10116.0,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,Rattus norvegicus,,,,
1855,1,B,BAO_0000357,10116.0,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,Rattus norvegicus,,,,
1856,1,B,BAO_0000019,10116.0,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,,Rattus norvegicus,,,,
1857,1,B,BAO_0000357,10116.0,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,,Rattus norvegicus,,,,
1858,1,B,BAO_0000357,10116.0,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,Rattus norvegicus,,,,
1859,1,B,BAO_0000019,10116.0,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,,Rattus norvegicus,,,,
1860,1,B,BAO_0000357,10116.0,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,,,Rattus norvegicus,,,,
1861,1,B,BAO_0000019,10116.0,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Rattus norvegicus,,,,
1862,1,B,BAO_0000019,10116.0,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Rattus norvegicus,,,,
1863,1,B,BAO_0000019,10116.0,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Rattus norvegicus,,,,
1864,1,B,BAO_0000019,10116.0,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,Rattus norvegicus,,,,
1865,1,B,BAO_0000357,10116.0,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,,Rattus norvegicus,,,,
1866,1,B,BAO_0000249,10116.0,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,,Rattus norvegicus,,,,
1867,1,B,BAO_0000357,,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,,,,,
1868,1,B,BAO_0000357,10116.0,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,,Rattus norvegicus,,,,
1869,1,B,BAO_0000019,10116.0,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,,Rattus norvegicus,,,,
1870,1,B,BAO_0000219,10116.0,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,,Rattus norvegicus,,,HEK293,
1871,1,B,BAO_0000357,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,,,,
1872,1,B,BAO_0000357,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,,,,
1873,1,B,BAO_0000357,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,,,,
1874,1,B,BAO_0000357,,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,,,,
1875,1,B,BAO_0000357,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,,,,
1876,1,B,BAO_0000357,,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,,,,
1877,1,B,BAO_0000357,,13033,Binding affinity against serotonergic 5-HT1c receptor,,,,,,,
1878,1,B,BAO_0000357,,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,,,,,
1879,1,B,BAO_0000357,,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,,,,,
1880,1,B,BAO_0000019,9986.0,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,Oryctolagus cuniculus,,,,
1881,1,B,BAO_0000224,,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,,,,,
1882,1,B,BAO_0000224,,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,,,,,
1883,1,B,BAO_0000019,,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,,,,,
1884,1,B,BAO_0000019,10116.0,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,,Rattus norvegicus,,,,
1885,1,B,BAO_0000249,10116.0,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,,Rattus norvegicus,,,,
1886,1,B,BAO_0000221,10116.0,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,,Rattus norvegicus,,Brain,,
1887,1,B,BAO_0000224,,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,,,,,
1888,1,B,BAO_0000224,,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,,,,,
1889,1,B,BAO_0000019,,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,,,,,
1890,1,B,BAO_0000224,,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,
1891,1,B,BAO_0000224,,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,,,,,
1892,1,B,BAO_0000224,,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,,,,
1893,1,B,BAO_0000019,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,
1894,1,B,BAO_0000019,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,
1895,1,B,BAO_0000019,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,,,,,
1896,1,B,BAO_0000019,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,,,,,
1897,1,B,BAO_0000019,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,
1898,1,B,BAO_0000019,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,,,,,
1899,1,B,BAO_0000019,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,,,,,
1900,1,B,BAO_0000019,,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,,,,,
1901,1,B,BAO_0000019,,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,
1902,1,B,BAO_0000019,,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,
1903,1,B,BAO_0000019,,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,,,,,
1904,1,B,BAO_0000019,,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,,,,,
1905,1,B,BAO_0000221,10116.0,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,Rattus norvegicus,,Brain,,
1906,1,B,BAO_0000221,,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,,,Brain,,
1907,1,B,BAO_0000249,,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,,,,Membranes
1908,1,B,BAO_0000249,,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,,,,Membranes
1909,1,B,BAO_0000224,,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,,,,,
1910,1,B,BAO_0000249,,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,,,,Membranes
1911,1,B,BAO_0000224,,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,,,,,
1912,1,B,BAO_0000224,,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,
1913,1,B,BAO_0000224,10116.0,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,,,,
1914,1,B,BAO_0000224,,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,
1915,1,B,BAO_0000019,,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,,,,,
1916,1,B,BAO_0000224,,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,,,,
1917,1,B,BAO_0000224,,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,,,,
1918,1,B,BAO_0000224,,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,,,,
1919,1,B,BAO_0000224,,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,,,,,
1920,1,B,BAO_0000224,,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,,,,,
1921,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,,,,,
1922,1,B,BAO_0000019,,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,,,,,
1923,1,B,BAO_0000224,,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,,,,,
1924,1,B,BAO_0000224,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,,,,
1925,1,B,BAO_0000224,,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,,,,,
1926,1,B,BAO_0000224,,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,,,,
1927,1,B,BAO_0000249,,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,,,,,Membranes
1928,1,B,BAO_0000249,,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,,,,,Membranes
1929,1,B,BAO_0000224,,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,,,,,
1930,1,B,BAO_0000019,,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,,,,,
1931,1,B,BAO_0000224,10116.0,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,,,,
1932,1,B,BAO_0000224,,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,,,,
1933,1,B,BAO_0000224,,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,,,,
1934,1,B,BAO_0000019,,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,,,,,
1935,1,B,BAO_0000019,,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,
1936,1,B,BAO_0000019,,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,,,,,
1937,1,B,BAO_0000219,10116.0,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,Rattus norvegicus,,,CHO-K1,
1938,1,B,BAO_0000249,,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,,,,Membranes
1939,1,B,BAO_0000224,,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,,,,,
1940,1,B,BAO_0000249,,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,,,,,Brain membranes
1941,1,B,BAO_0000219,,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,,,,
1942,1,B,BAO_0000224,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,
1943,1,B,BAO_0000224,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,,,,
1944,1,B,BAO_0000224,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,,,,
1945,1,B,BAO_0000249,,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,,,,,Membranes
1946,1,B,BAO_0000249,,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,,,,,Membranes
1947,1,F,BAO_0000019,,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,,,Thoracic aorta,,
1948,1,B,BAO_0000019,,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,,,,,
1949,1,B,BAO_0000224,,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,,,,
1950,1,B,BAO_0000357,,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,,,,
1951,1,B,BAO_0000357,,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,,,,
1952,1,B,BAO_0000357,,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,,,,,
1953,1,B,BAO_0000357,,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,,,,,,,
1954,1,B,BAO_0000249,,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,
1955,1,B,BAO_0000249,,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,
1956,1,B,BAO_0000357,,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,,,Striatum,,
1957,1,F,BAO_0000019,,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,,,,,
1958,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,,,,,
1959,1,B,BAO_0000357,,12861,Binding activity radioligand.,,,,,,,
1960,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,
1961,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,
1962,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,,,,
1963,1,B,BAO_0000249,,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,
1964,1,B,BAO_0000019,,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,,,,,
1965,1,B,BAO_0000249,,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,,,,,
1966,1,B,BAO_0000357,,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,,,,,
1967,1,B,BAO_0000357,9823.0,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,,Sus scrofa,,,,
1968,1,B,BAO_0000357,9986.0,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,,,Oryctolagus cuniculus,,,,
1969,1,B,BAO_0000019,9986.0,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,,,,
1970,1,B,BAO_0000357,9986.0,13047,The compound was tested for binding affinity against 5-HT1D receptor,,,Oryctolagus cuniculus,,,,
1971,1,B,BAO_0000357,,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,,,,,
1972,1,F,BAO_0000019,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,,,,,
1973,1,F,BAO_0000019,,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,,,,,
1974,1,B,BAO_0000357,,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,,,,,
1975,1,B,BAO_0000019,,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,
1976,1,B,BAO_0000249,,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,,,,
1977,1,B,BAO_0000357,,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,,,,,
1978,1,B,BAO_0000019,,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,,,,,
1979,1,B,BAO_0000357,,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,,,,,
1980,1,B,BAO_0000357,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,
1981,1,B,BAO_0000357,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,,,,,
1982,1,B,BAO_0000357,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,,,,,
1983,1,B,BAO_0000357,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,,,,,
1984,1,B,BAO_0000357,,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,,,,,
1985,1,B,BAO_0000357,,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,
1986,1,B,BAO_0000357,,12146,Tested against 5-hydroxytryptamine 1D receptor,,,,,,,
1987,1,B,BAO_0000357,,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,,,,,
1988,1,B,BAO_0000219,,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,,,HEK293,
1989,1,B,BAO_0000357,9606.0,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,,,Homo sapiens,,,,
1990,1,B,BAO_0000357,,15250,,,,,,,,
1991,1,B,BAO_0000219,,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,,,CHO-K1,
1992,1,B,BAO_0000219,,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,,,CHO-K1,
1993,1,B,BAO_0000219,,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,,,,,HEK293,
1994,1,B,BAO_0000219,,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,,,HEK293,
1995,1,B,BAO_0000019,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,,,,
1996,1,B,BAO_0000357,,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,,,,,
1997,1,B,BAO_0000357,,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,,,,,
1998,1,B,BAO_0000357,,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,,,,,
1999,1,B,BAO_0000219,,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,,,,,CHO-K1,
2000,1,B,BAO_0000219,,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,,,CHO-K1,
2001,1,F,BAO_0000019,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,,,,,
2002,1,F,BAO_0000019,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,
2003,1,F,BAO_0000019,,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,
2004,1,F,BAO_0000019,,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,
2005,1,F,BAO_0000019,,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,
2006,1,B,BAO_0000357,,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,,,,,
2007,1,B,BAO_0000357,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,,,,,
2008,1,B,BAO_0000357,,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,,,,,
2009,1,B,BAO_0000357,,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,,,,,
2010,1,B,BAO_0000219,,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,,,,,CHO,
2011,1,B,BAO_0000219,9606.0,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,,Homo sapiens,,,,
2012,1,B,BAO_0000357,,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,,,,,
2013,1,B,BAO_0000019,9986.0,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,,,,
2014,1,B,BAO_0000357,,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,,,,,
2015,1,B,BAO_0000357,,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,,,,
2016,1,B,BAO_0000357,,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,,,,
2017,1,B,BAO_0000357,,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,,,,,
2018,1,B,BAO_0000357,,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,,,,,
2019,1,B,BAO_0000357,,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,,,,,
2020,1,F,BAO_0000019,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,
2021,1,B,BAO_0000219,,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,,,,,HEK293,
2022,1,B,BAO_0000219,,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,,,HEK293,
2023,1,B,BAO_0000219,,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,,,CHO,
2024,1,B,BAO_0000019,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,,,,
2025,1,B,BAO_0000357,,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,
2026,1,B,BAO_0000357,,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,
2027,1,B,BAO_0000357,,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,
2028,1,B,BAO_0000357,,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,,,,,
2029,1,B,BAO_0000357,,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,
2030,1,B,BAO_0000219,,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,,,,,CHO,
2031,1,B,BAO_0000219,,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,,,,,CHO-K1,
2032,1,B,BAO_0000219,,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,,,,,CHO-K1,
2033,1,F,BAO_0000019,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,
2034,1,B,BAO_0000219,,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,,,,,CHO-K1,
2035,1,B,BAO_0000357,,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,,,,,
2036,1,B,BAO_0000219,,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,,,CHO,
2037,1,F,BAO_0000219,,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,,,,,CHO-K1,
2038,1,F,BAO_0000219,,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,,,,,CHO-K1,
2039,1,F,BAO_0000219,,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,,,,,CHO-K1,
2040,1,F,BAO_0000219,,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,,,,,CHO-K1,
2041,1,B,BAO_0000357,,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,,,,,
2042,1,B,BAO_0000019,9986.0,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,,,,
2043,1,B,BAO_0000357,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,,,,,
2044,1,B,BAO_0000357,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,,,,,
2045,1,B,BAO_0000357,,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,,,,,
2046,1,B,BAO_0000219,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,,,,,CHO,
2047,1,B,BAO_0000357,9606.0,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,,Homo sapiens,,,,
2048,1,B,BAO_0000357,,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,,,,,
2049,1,B,BAO_0000357,9606.0,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,,Homo sapiens,,,,
2050,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,,,,,
2051,1,B,BAO_0000019,,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,,,,,
2052,1,B,BAO_0000357,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,,,,,
2053,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,,,,,
2054,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,,,,,
2055,1,B,BAO_0000219,9606.0,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,,Homo sapiens,,,CHO,
2056,1,B,BAO_0000357,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,,,,,
2057,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,,CHO,
2058,1,B,BAO_0000219,,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,,,,,CHO,
2059,1,B,BAO_0000219,,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,,,CHO,
2060,1,B,BAO_0000357,,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,,,,,
2061,1,B,BAO_0000219,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,,,,,CHO,
2062,1,B,BAO_0000357,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,,,,,
2063,1,B,BAO_0000219,,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,,,,,CHO,
2064,1,B,BAO_0000357,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,,,,,
2065,1,B,BAO_0000357,,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,,,,,
2066,1,B,BAO_0000219,,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,,,,,CHO,
2067,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,,,,,CHO,
2068,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,,,,,CHO,
2069,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,,,,,
2070,1,B,BAO_0000357,,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,,,,,
2071,1,B,BAO_0000357,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,,,,,
2072,1,B,BAO_0000357,,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,,,,,
2073,1,F,BAO_0000019,,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,,,,,
2074,1,F,BAO_0000019,,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,,,,,
2075,1,F,BAO_0000019,,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,,,,,
2076,1,F,BAO_0000019,,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,,,,,
2077,1,F,BAO_0000019,,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,,,,,
2078,1,B,BAO_0000357,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,,,,,
2079,1,B,BAO_0000219,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,,,,,CHO,
2080,1,B,BAO_0000357,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,,,,,
2081,1,B,BAO_0000219,,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,,,,,CHO,
2082,1,B,BAO_0000357,,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,,,,,
2083,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,,,,,
2084,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,,,,,
2085,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,,,,,
2086,1,B,BAO_0000357,,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,,,,,
2087,1,B,BAO_0000019,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,,,,,
2088,1,B,BAO_0000357,,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,,,,,
2089,1,B,BAO_0000357,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,,,,,
2090,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,,CHO,
2091,1,B,BAO_0000219,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,,,,,CHO,
2092,1,B,BAO_0000357,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,,,,,
2093,1,B,BAO_0000219,,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,,,,,CHO,
2094,1,B,BAO_0000357,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,,,,,
2095,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,,,,,CHO,
2096,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,,,CHO,
2097,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,,,CHO,
2098,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,,,,,
2099,1,B,BAO_0000357,,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,,,,,
2100,1,B,BAO_0000357,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,,,,,
2101,1,B,BAO_0000019,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,,,,,
2102,1,B,BAO_0000019,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,,,,
2103,1,B,BAO_0000019,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,
2104,1,B,BAO_0000019,,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,,,,
2105,1,F,BAO_0000218,,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",In vivo,,,,,,
2106,1,F,BAO_0000019,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,
2107,1,B,BAO_0000019,,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,,,,,
2108,1,B,BAO_0000019,9913.0,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,,Bos taurus,,,,
2109,1,B,BAO_0000019,9913.0,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,,Bos taurus,,,,
2110,1,B,BAO_0000019,9913.0,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,,Bos taurus,,,,
2111,1,B,BAO_0000019,,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,,,,,
2112,1,B,BAO_0000019,10141.0,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,,Cavia porcellus,,,,
2113,1,B,BAO_0000019,10141.0,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,,Cavia porcellus,,,,
2114,1,B,BAO_0000019,10141.0,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,,Cavia porcellus,,,,
2115,1,B,BAO_0000224,,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,,,,,
2116,1,B,BAO_0000224,,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,
2117,1,B,BAO_0000224,,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,,,,,
2118,1,B,BAO_0000357,,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,,,,
2119,1,B,BAO_0000218,,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,,,,,,
2120,1,B,BAO_0000019,,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,,,,,
2121,1,B,BAO_0000224,,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,,,,,
2122,1,B,BAO_0000019,10090.0,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,,Mus musculus,,,,
2123,1,B,BAO_0000218,,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,,,,,,
2124,1,B,BAO_0000019,10090.0,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,,Mus musculus,,,,
2125,1,B,BAO_0000224,,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,
2126,1,B,BAO_0000224,,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,,,,,
2127,1,B,BAO_0000224,,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,,,,,
2128,1,B,BAO_0000019,10090.0,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,Mus musculus,,,,
2129,1,B,BAO_0000224,9823.0,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,,Sus scrofa,,,,
2130,1,B,BAO_0000224,9823.0,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,,Sus scrofa,,,,
2131,1,B,BAO_0000221,,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,,,,
2132,1,B,BAO_0000221,,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,,,,
2133,1,B,BAO_0000357,9823.0,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,,Sus scrofa,,,,
2134,1,B,BAO_0000019,,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,,,,
2135,1,B,BAO_0000019,,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,,,,
2136,1,B,BAO_0000019,,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,,,,,
2137,1,B,BAO_0000224,,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,,,,
2138,1,B,BAO_0000019,10116.0,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,,Rattus norvegicus,,,,
2139,1,B,BAO_0000019,,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,,,,,
2140,1,B,BAO_0000019,,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,,,,,
2141,1,F,BAO_0000019,,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,,,,,
2142,1,B,BAO_0000019,,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,,,,,
2143,1,B,BAO_0000224,,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,,,,,
2144,1,B,BAO_0000224,10116.0,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,Rattus norvegicus,,,,
2145,1,B,BAO_0000224,,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,,,,,
2146,1,B,BAO_0000224,,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,,,,,
2147,1,B,BAO_0000224,,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,,,,,
2148,1,B,BAO_0000224,,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,,,,
2149,1,B,BAO_0000224,,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,,,,
2150,1,B,BAO_0000224,,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,,,,
2151,1,B,BAO_0000224,,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,,,,,
2152,1,B,BAO_0000224,,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,,,,,
2153,1,B,BAO_0000224,,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,
2154,1,F,BAO_0000019,,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,,,,,
2155,1,F,BAO_0000019,,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,,,,,
2156,1,B,BAO_0000221,,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,,,Hippocampus,,
2157,1,B,BAO_0000221,,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,,,Hippocampus,,
2158,1,B,BAO_0000221,10116.0,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,,Rattus norvegicus,,Brain,,
2159,1,B,BAO_0000019,,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,
2160,1,B,BAO_0000249,,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,,,,Membranes
2161,1,B,BAO_0000249,,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,,,,Membranes
2162,1,B,BAO_0000019,,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,,,,,
2163,1,F,BAO_0000019,,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,,,,,
2164,1,B,BAO_0000221,10116.0,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,Rattus norvegicus,,Brain,,
2165,1,B,BAO_0000249,10116.0,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,,Rattus norvegicus,,,,Membranes
2166,1,B,BAO_0000221,,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,,,Brain,,
2167,1,F,BAO_0000019,,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,,,,
2168,1,F,BAO_0000019,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,,,,,
2169,1,F,BAO_0000019,,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,
2170,1,F,BAO_0000019,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,,,,
2171,1,F,BAO_0000019,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,,,,
2172,1,F,BAO_0000019,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,
2173,1,B,BAO_0000220,,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,,,Brain,,
2174,1,B,BAO_0000019,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,
2175,1,B,BAO_0000249,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,,Brain,,
2176,1,B,BAO_0000019,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,,,,,
2177,1,B,BAO_0000019,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,
2178,1,B,BAO_0000019,10116.0,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,,,,
2179,1,B,BAO_0000019,,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,,,,,
2180,1,B,BAO_0000019,,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,,,,,
2181,1,F,BAO_0000019,,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,,,,,
2182,1,B,BAO_0000019,,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,,,,,
2183,1,B,BAO_0000224,10116.0,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,,Rattus norvegicus,,,,
2184,1,B,BAO_0000019,10116.0,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,,,,
2185,1,B,BAO_0000019,10116.0,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,,,,
2186,1,B,BAO_0000019,10116.0,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,,Rattus norvegicus,,,,
2187,1,B,BAO_0000224,,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,,,,,
2188,1,B,BAO_0000249,,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,,,,,
2189,1,B,BAO_0000019,,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,,,,,
2190,1,B,BAO_0000019,,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,,,,,
2191,1,B,BAO_0000224,,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,,,,,
2192,1,B,BAO_0000221,,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,,,Brain,,
2193,1,F,BAO_0000019,,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,,,,
2194,1,B,BAO_0000019,,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,
2195,1,B,BAO_0000019,,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,
2196,1,B,BAO_0000019,,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,
2197,1,B,BAO_0000019,,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,
2198,1,B,BAO_0000019,,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,
2199,1,B,BAO_0000019,,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,
2200,1,B,BAO_0000224,,9523,Hill coefficient of compound was determined,,,,,,,
2201,1,B,BAO_0000019,,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,,,,,
2202,1,B,BAO_0000019,10116.0,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,,Rattus norvegicus,,,,
2203,1,B,BAO_0000019,,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,,,,,
2204,1,B,BAO_0000019,,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,,,,,
2205,1,B,BAO_0000357,,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,,,,,
2206,1,B,BAO_0000019,,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,,,,,
2207,1,B,BAO_0000019,,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,,,,,
2208,1,B,BAO_0000224,10116.0,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,,Rattus norvegicus,,,,
2209,1,B,BAO_0000224,,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,,,,,
2210,1,B,BAO_0000224,,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,,,,,
2211,1,B,BAO_0000019,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,
2212,1,B,BAO_0000224,,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,,,,,
2213,1,B,BAO_0000219,,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,,,,,
2214,1,B,BAO_0000219,,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,,,,,
2215,1,B,BAO_0000224,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,
2216,1,B,BAO_0000224,,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,,,,,
2217,1,B,BAO_0000224,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,
2218,1,B,BAO_0000224,,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,
2219,1,B,BAO_0000249,,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,,,,,Brain membranes
2220,1,B,BAO_0000224,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,,,,,
2221,1,B,BAO_0000224,,17066,Binding affinity towards 5-HT2 receptor,,,,,,,
2222,1,B,BAO_0000224,,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,
2223,1,B,BAO_0000224,,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,,,,,
2224,1,B,BAO_0000224,,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,,,,,
2225,1,B,BAO_0000224,,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,
2226,1,B,BAO_0000224,,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,,,,,
2227,1,B,BAO_0000224,,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,,,,,
2228,1,B,BAO_0000224,,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,
2229,1,B,BAO_0000019,,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,
2230,1,B,BAO_0000224,,1263,5-hydroxytryptamine 2 receptor binding affinity,,,,,,,
2231,1,B,BAO_0000357,,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,,,,,
2232,1,B,BAO_0000357,,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,,,,,
2233,1,B,BAO_0000224,,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,,,,
2234,1,B,BAO_0000224,,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,,,,,
2235,1,B,BAO_0000224,,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,,,,
2236,1,B,BAO_0000357,,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,,,,,
2237,1,B,BAO_0000357,,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,
2238,1,B,BAO_0000357,,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,
2239,1,B,BAO_0000357,,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,,,,
2240,1,B,BAO_0000357,,13033,Binding affinity against serotonergic 5-HT2 receptor,,,,,,,
2241,1,B,BAO_0000357,,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,,,,,
2242,1,B,BAO_0000357,,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,,,,,
2243,1,B,BAO_0000357,,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,,,,,
2244,1,B,BAO_0000218,,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,,,,,
2245,1,B,BAO_0000224,9606.0,13378,Inhibitory activity against cloned human 5-HT2 receptor,,,Homo sapiens,,,,
2246,1,B,BAO_0000219,9606.0,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,,Homo sapiens,,,CHO,
2247,1,B,BAO_0000219,9606.0,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,,Homo sapiens,,,CHO,
2248,1,B,BAO_0000219,9606.0,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,,Homo sapiens,,,CHO,
2249,1,B,BAO_0000219,9606.0,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,,Homo sapiens,,,CHO,
2250,1,B,BAO_0000224,,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,
2251,1,B,BAO_0000224,,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,,,,,
2252,1,B,BAO_0000357,,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,
2253,1,B,BAO_0000224,,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,,,,,
2254,1,B,BAO_0000357,,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,,,,,
2255,1,B,BAO_0000357,,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,
2256,1,B,BAO_0000019,,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,,,,,
2257,1,B,BAO_0000357,10141.0,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,Cavia porcellus,,,,
2258,1,B,BAO_0000357,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,
2259,1,B,BAO_0000357,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,
2260,1,B,BAO_0000357,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,
2261,1,B,BAO_0000357,,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,,,,,
2262,1,B,BAO_0000219,,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,,,CHO,
2263,1,F,BAO_0000219,9606.0,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,,Homo sapiens,,,CHO,
2264,1,F,BAO_0000219,,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,,,,
2265,1,F,BAO_0000219,,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,,,,,
2266,1,F,BAO_0000219,,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,,,,
2267,1,B,BAO_0000219,,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,,,,,CHO,
2268,1,B,BAO_0000219,,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,,,,,CHO,
2269,1,B,BAO_0000357,,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,,,,,
2270,1,B,BAO_0000357,9606.0,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,,,,
2271,1,B,BAO_0000219,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,,CHO,
2272,1,B,BAO_0000219,,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,,,,,
2273,1,B,BAO_0000357,,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,,,,,
2274,1,B,BAO_0000219,,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,,,,,CHO,
2275,1,B,BAO_0000219,,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,,,,,CHO,
2276,1,B,BAO_0000219,,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,,,,,L929,
2277,1,B,BAO_0000219,,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,,CHO,
2278,1,F,BAO_0000019,,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,,,,,
2279,1,F,BAO_0000019,,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,
2280,1,B,BAO_0000219,,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,,,CHO,
2281,1,B,BAO_0000219,,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,,,,,CHO,
2282,1,F,BAO_0000019,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,,,,,
2283,1,F,BAO_0000019,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,,,,,
2284,1,F,BAO_0000019,,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,
2285,1,B,BAO_0000357,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,,,,,
2286,1,B,BAO_0000357,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,
2287,1,B,BAO_0000357,,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,,,,,
2288,1,B,BAO_0000357,,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,,,,,
2289,1,B,BAO_0000357,,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,,,,,
2290,1,B,BAO_0000219,,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,,CHO,
2291,1,B,BAO_0000357,,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,,,,,
2292,1,B,BAO_0000019,9606.0,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,,Homo sapiens,,,,
2293,1,B,BAO_0000357,,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,,,,,
2294,1,B,BAO_0000357,9606.0,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,,,,
2295,1,B,BAO_0000357,,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,,,,
2296,1,B,BAO_0000219,,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,,,,,CHO,
2297,1,B,BAO_0000219,,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,,,,,,,
2298,1,B,BAO_0000357,,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,,,,,
2299,1,B,BAO_0000357,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,,,,
2300,1,B,BAO_0000357,9606.0,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,,,,
2301,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,
2302,1,B,BAO_0000219,,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,,,,,
2303,1,B,BAO_0000357,,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,,,,,
2304,1,B,BAO_0000357,,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,,,,,
2305,1,B,BAO_0000019,,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,,,,,
2306,1,B,BAO_0000357,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,,,,,
2307,1,B,BAO_0000219,,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,,,,,HEK293,
2308,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,,,,,
2309,1,B,BAO_0000357,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,
2310,1,B,BAO_0000357,9606.0,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,Homo sapiens,,,,
2311,1,B,BAO_0000219,9606.0,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,,Homo sapiens,,,CHO,
2312,1,B,BAO_0000357,,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,
2313,1,B,BAO_0000357,9606.0,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,,,,
2314,1,B,BAO_0000357,,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,,,,,
2315,1,B,BAO_0000357,9606.0,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,,,,
2316,1,B,BAO_0000357,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,,,,,
2317,1,B,BAO_0000357,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,
2318,1,B,BAO_0000019,,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,,,,,
2319,1,B,BAO_0000019,10116.0,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,,Rattus norvegicus,,,,
2320,1,B,BAO_0000224,,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,,,,,
2321,1,B,BAO_0000019,,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,,,,
2322,1,B,BAO_0000019,,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,,,,
2323,1,B,BAO_0000224,,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,,,,,
2324,1,B,BAO_0000019,,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,,,,
2325,1,B,BAO_0000019,,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,,,,,
2326,1,B,BAO_0000019,,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,,,,,
2327,1,B,BAO_0000019,,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,,,,
2328,1,B,BAO_0000224,,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,,,,
2329,1,B,BAO_0000224,,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,,,,
2330,1,B,BAO_0000224,,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,
2331,1,B,BAO_0000224,,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,
2332,1,B,BAO_0000219,,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,,,,
2333,1,B,BAO_0000224,10116.0,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,,,,
2334,1,B,BAO_0000224,10116.0,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,,Rattus norvegicus,,,,
2335,1,B,BAO_0000224,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,
2336,1,B,BAO_0000224,,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,,,,,
2337,1,B,BAO_0000219,10116.0,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,Rattus norvegicus,,,CHO-K1,
2338,1,B,BAO_0000219,10116.0,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,Rattus norvegicus,,,CHO-K1,
2339,1,B,BAO_0000019,10116.0,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,,Rattus norvegicus,,,,
2340,1,B,BAO_0000019,,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,,,,,
2341,1,B,BAO_0000019,10116.0,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,,Rattus norvegicus,,,,
2342,1,B,BAO_0000224,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,
2343,1,B,BAO_0000224,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,,,,
2344,1,B,BAO_0000019,,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,,,,,
2345,1,B,BAO_0000019,,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,,,,,
2346,1,B,BAO_0000224,,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,
2347,1,B,BAO_0000224,10116.0,3070,Affinity for 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,,,,
2348,1,B,BAO_0000224,,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,,,,,
2349,1,B,BAO_0000019,,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,,,,,
2350,1,B,BAO_0000019,,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,,,,,
2351,1,B,BAO_0000019,,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,,,,,
2352,1,B,BAO_0000224,,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,,,,,
2353,1,B,BAO_0000218,,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),In vivo,,,,,,
2354,1,B,BAO_0000221,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,,,Brain,,
2355,1,B,BAO_0000224,,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,,,,,
2356,1,B,BAO_0000019,,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,,,,
2357,1,B,BAO_0000019,,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,,,,
2358,1,B,BAO_0000019,,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,,,Frontal cortex,,
2359,1,B,BAO_0000224,,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,,,,
2360,1,B,BAO_0000224,,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,,,,
2361,1,B,BAO_0000224,10116.0,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,,Rattus norvegicus,,,,
2362,1,B,BAO_0000019,,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,,,,,
2363,1,B,BAO_0000019,10116.0,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,,Rattus norvegicus,,Striatum,,
2364,1,B,BAO_0000019,,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,,,,
2365,1,B,BAO_0000019,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,
2366,1,B,BAO_0000224,,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,
2367,1,B,BAO_0000224,,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,,,,
2368,1,B,BAO_0000019,10116.0,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,,Rattus norvegicus,,,,
2369,1,B,BAO_0000019,10116.0,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,,Rattus norvegicus,,,,
2370,1,B,BAO_0000019,,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,,,,
2371,1,B,BAO_0000019,,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,,,,,
2372,1,B,BAO_0000019,,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,,,,
2373,1,B,BAO_0000019,,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,,,,,
2374,1,B,BAO_0000249,,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,,,,,
2375,1,B,BAO_0000019,,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,,,,,
2376,1,B,BAO_0000019,,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,,,,,
2377,1,B,BAO_0000019,,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,,,,,
2378,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,,,,,
2379,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,,,,,
2380,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,,,,,
2381,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,,,,,
2382,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,,,,,
2383,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,,,,,
2384,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,,,,,
2385,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,,,,,
2386,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,,,,,
2387,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,,,,,
2388,1,B,BAO_0000019,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,,,,,
2389,1,B,BAO_0000019,,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,,,,,
2390,1,B,BAO_0000249,,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,,,,,
2391,1,B,BAO_0000249,,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,,,,,
2392,1,B,BAO_0000224,,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,,,,,
2393,1,B,BAO_0000224,10116.0,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,,,,
2394,1,B,BAO_0000224,,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,
2395,1,B,BAO_0000019,,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,,,,,
2396,1,B,BAO_0000224,,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,,,,,
2397,1,B,BAO_0000019,,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,
2398,1,B,BAO_0000019,,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,,,,,
2399,1,B,BAO_0000019,,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,,,,,
2400,1,B,BAO_0000019,,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,,,,,
2401,1,B,BAO_0000224,,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,,,,,
2402,1,B,BAO_0000224,,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,,,,,
2403,1,B,BAO_0000019,,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,,,,,
2404,1,B,BAO_0000221,,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,,,Brain,,
2405,1,B,BAO_0000224,,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,,,,,
2406,1,B,BAO_0000224,,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,,,,,
2407,1,B,BAO_0000224,10116.0,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,Rattus norvegicus,,,,
2408,1,B,BAO_0000019,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,,,,,
2409,1,B,BAO_0000224,,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,,,,,
2410,1,B,BAO_0000224,,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,
2411,1,F,BAO_0000019,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,
2412,1,F,BAO_0000019,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,
2413,1,F,BAO_0000218,,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,,,,,,
2414,1,F,BAO_0000218,,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,,,,,,
2415,1,F,BAO_0000218,,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,,,,,,
2416,1,F,BAO_0000218,,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,,,,,,
2417,1,B,BAO_0000221,,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,,,Brain,,
2418,1,B,BAO_0000019,10116.0,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,Rattus norvegicus,,,,
2419,1,B,BAO_0000019,,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,,,,,
2420,1,B,BAO_0000357,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,,,,,
2421,1,B,BAO_0000019,10116.0,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,,Rattus norvegicus,,,,
2422,1,B,BAO_0000357,10116.0,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,Rattus norvegicus,,,,
2423,1,B,BAO_0000019,,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,,,,,
2424,1,B,BAO_0000357,,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,,,,,
2425,1,B,BAO_0000357,10116.0,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,,,,
2426,1,B,BAO_0000019,,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,,,,,
2427,1,B,BAO_0000019,,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,,,,
2428,1,B,BAO_0000019,,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,,,,,
2429,1,B,BAO_0000019,10116.0,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,,,,
2430,1,B,BAO_0000249,,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,,,,,Membranes
2431,1,B,BAO_0000019,,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,,,,,
2432,1,B,BAO_0000019,,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,,,,,
2433,1,B,BAO_0000219,,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,,,,CHO,
2434,1,B,BAO_0000357,,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,,,,,
2435,1,B,BAO_0000357,,15577,Serotonergic activity of the compound.,,,,,,,
2436,1,B,BAO_0000249,,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,,,,,
2437,1,B,BAO_0000019,10116.0,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,,Rattus norvegicus,,,,
2438,1,B,BAO_0000249,,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,,,,,
2439,1,F,BAO_0000019,10116.0,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Rattus norvegicus,,,,
2440,1,F,BAO_0000019,10116.0,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Rattus norvegicus,,,,
2441,1,F,BAO_0000019,10116.0,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Rattus norvegicus,,,,
2442,1,B,BAO_0000357,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,
2443,1,B,BAO_0000357,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,,,,,
2444,1,B,BAO_0000357,,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,
2445,1,B,BAO_0000357,,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,,,,,
2446,1,B,BAO_0000357,,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,,,,,
2447,1,B,BAO_0000357,,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,,,,,
2448,1,B,BAO_0000357,,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,,,,,
2449,1,B,BAO_0000357,9606.0,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,,Homo sapiens,,,,
2450,1,B,BAO_0000357,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,,,,,
2451,1,B,BAO_0000357,,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,
2452,1,B,BAO_0000357,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,,,,,
2453,1,B,BAO_0000357,,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,,,,,
2454,1,B,BAO_0000357,,5163,Affinity for 5-hydroxytryptamine 2A receptor,,,,,,,
2455,1,B,BAO_0000219,,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,,,,,NIH3T3,
2456,1,B,BAO_0000357,,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,,,,,
2457,1,B,BAO_0000357,,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,,,,,
2458,1,B,BAO_0000357,,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,,,,,
2459,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,,,,,
2460,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,,,,,
2461,1,F,BAO_0000019,,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,,,,,
2462,1,B,BAO_0000357,,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,,,,,
2463,1,B,BAO_0000357,,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,,,,,
2464,1,B,BAO_0000357,,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,,,,,
2465,1,B,BAO_0000357,,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,
2466,1,B,BAO_0000357,,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,,,,,
2467,1,B,BAO_0000357,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,,,,,
2468,1,B,BAO_0000219,10090.0,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,,Mus musculus,,,CHO,
2469,1,B,BAO_0000357,,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,,,,
2470,1,B,BAO_0000357,,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,,,,,,,
2471,1,B,BAO_0000357,,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,,,,,
2472,1,B,BAO_0000357,,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,,,,,
2473,1,B,BAO_0000357,,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,,,,,
2474,1,B,BAO_0000357,,3269,Affinity against 5-hydroxytryptamine 2A receptor,,,,,,,
2475,1,B,BAO_0000357,9606.0,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,,,Homo sapiens,,,,
2476,1,B,BAO_0000357,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,,,,
2477,1,B,BAO_0000357,,12146,Tested against 5-hydroxytryptamine 2A receptor,,,,,,,
2478,1,B,BAO_0000224,,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,,,,
2479,1,B,BAO_0000224,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,,,,,
2480,1,B,BAO_0000224,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,,,,,
2481,1,B,BAO_0000224,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,,,,
2482,1,B,BAO_0000357,,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,,,,,
2483,1,B,BAO_0000219,9606.0,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,,Homo sapiens,,,HEK293,
2484,1,F,BAO_0000219,9606.0,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,,Homo sapiens,,,CHO,
2485,1,B,BAO_0000357,,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,,,,,
2486,1,B,BAO_0000357,9606.0,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,,Homo sapiens,,,,
2487,1,F,BAO_0000019,,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,,,,,
2488,1,F,BAO_0000019,,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,,,,,
2489,1,F,BAO_0000019,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,,,,,
2490,1,F,BAO_0000019,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,,,,,
2491,1,F,BAO_0000019,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,,,,,
2492,1,F,BAO_0000019,,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,,,,
2493,1,B,BAO_0000357,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,,,,,
2494,1,B,BAO_0000357,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,,,,,
2495,1,B,BAO_0000357,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,,,,
2496,1,B,BAO_0000357,,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,,,,,
2497,1,B,BAO_0000357,,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,,,,,
2498,1,B,BAO_0000357,,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,,,,,
2499,1,B,BAO_0000019,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,,,,,
2500,1,B,BAO_0000019,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,,,,,
2501,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,,NIH3T3,
2502,1,F,BAO_0000219,,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,,,,CHO,
2503,1,F,BAO_0000219,9606.0,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,Homo sapiens,,,CHO,
2504,1,B,BAO_0000224,,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,,,,,
2505,1,B,BAO_0000357,,12861,Binding activity radioligand.,,,,,,,
2506,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,
2507,1,B,BAO_0000219,,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,,,L929,
2508,1,B,BAO_0000219,,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,,,L929,
2509,1,B,BAO_0000219,,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,,,,,L929,
2510,1,B,BAO_0000219,,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,,,,,L929,
2511,1,B,BAO_0000357,,5254,Binding affinity against 5-HT2A receptor,,,,,,,
2512,1,B,BAO_0000357,,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,
2513,1,B,BAO_0000219,,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,,,HEK293,
2514,1,B,BAO_0000219,,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,,,HEK293,
2515,1,B,BAO_0000219,9606.0,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,,Homo sapiens,,,HEK293,
2516,1,B,BAO_0000219,9606.0,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,Homo sapiens,,,HEK293,
2517,1,B,BAO_0000357,,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,,,,,
2518,1,B,BAO_0000219,9606.0,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,Homo sapiens,,,HEK293,
2519,1,B,BAO_0000219,9606.0,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,Homo sapiens,,,HEK293,
2520,1,B,BAO_0000219,9606.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,,Homo sapiens,,,HEK293,
2521,1,B,BAO_0000357,,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,,,,,
2522,1,B,BAO_0000219,,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,,,HEK293,
2523,1,B,BAO_0000219,,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,,,HEK293,
2524,1,B,BAO_0000219,,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,,,,,HEK293,
2525,1,B,BAO_0000219,9606.0,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,,Homo sapiens,,,HEK293,
2526,1,B,BAO_0000219,,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,,,,,HEK293,
2527,1,B,BAO_0000219,,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,,,,,HEK293,
2528,1,B,BAO_0000219,9606.0,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,,Homo sapiens,,,HEK293,
2529,1,B,BAO_0000219,,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,,,,,HEK293,
2530,1,B,BAO_0000219,,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,,,,,HEK293,
2531,1,B,BAO_0000219,9606.0,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,Homo sapiens,,,HEK293,
2532,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,,,NIH3T3,
2533,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,,NIH3T3,
2534,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,,NIH3T3,
2535,1,B,BAO_0000219,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,,,,,HEK293,
2536,1,B,BAO_0000219,,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,,,,,CHO-K1,
2537,1,B,BAO_0000219,,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,,,,,CHO-K1,
2538,1,B,BAO_0000357,9606.0,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,Homo sapiens,,,,
2539,1,B,BAO_0000219,,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,,,,,HEK293,
2540,1,B,BAO_0000219,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,,,HEK293,
2541,1,B,BAO_0000219,9606.0,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,Homo sapiens,,,CHO,
2542,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,,,,,HEK293,
2543,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,,,,,HEK293,
2544,1,F,BAO_0000219,,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,,,,,NIH3T3,
2545,1,B,BAO_0000219,,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,,,,,NIH3T3,
2546,1,F,BAO_0000019,,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,,,,,
2547,1,B,BAO_0000357,,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,,,,,
2548,1,B,BAO_0000357,,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,,,,,
2549,1,B,BAO_0000357,9986.0,16312,Binding affinity against rabbit aorta 5-HT2A receptor,,,Oryctolagus cuniculus,,,,
2550,1,B,BAO_0000357,9986.0,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,,Oryctolagus cuniculus,,,,
2551,1,B,BAO_0000357,9986.0,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,,Oryctolagus cuniculus,,,,
2552,1,B,BAO_0000019,9986.0,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,,,,
2553,1,B,BAO_0000357,9986.0,13047,The compound was tested for binding affinity against 5-HT2A receptor,,,Oryctolagus cuniculus,,,,
2554,1,B,BAO_0000219,,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,,,,,CHO-K1,
2555,1,B,BAO_0000019,,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,,,,,
2556,1,B,BAO_0000019,,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,,,,
2557,1,B,BAO_0000019,,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,,,Stomach,,
2558,1,B,BAO_0000019,10116.0,13463,Binding affinity for 5-HT 2A in rat stomach fundus,,,Rattus norvegicus,,Stomach,,
2559,1,B,BAO_0000019,,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,,,,
2560,1,B,BAO_0000219,,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,,,,,NIH3T3,
2561,1,F,BAO_0000019,,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,,,,,
2562,1,F,BAO_0000019,,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,,,,,
2563,1,B,BAO_0000357,,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,,,,
2564,1,B,BAO_0000357,,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,,,,,
2565,1,F,BAO_0000019,10116.0,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,,Rattus norvegicus,,,,
2566,1,B,BAO_0000357,,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,
2567,1,B,BAO_0000357,,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,
2568,1,B,BAO_0000357,,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,
2569,1,F,BAO_0000219,,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,,,,
2570,1,F,BAO_0000019,,15363,Efficacy at 5-hydroxytryptamine 2A receptor,,,,,,,
2571,1,B,BAO_0000357,,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,,,,,
2572,1,B,BAO_0000357,10116.0,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,Rattus norvegicus,,,,
2573,1,B,BAO_0000357,10116.0,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,,Rattus norvegicus,,,,
2574,1,F,BAO_0000219,10116.0,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,Rattus norvegicus,,,,
2575,1,F,BAO_0000219,,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,,,,
2576,1,B,BAO_0000019,,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,,,,,
2577,1,B,BAO_0000019,,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,,,,,
2578,1,B,BAO_0000249,,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,,,,,
2579,1,B,BAO_0000357,,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,,,,,
2580,1,B,BAO_0000019,,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,,,,,
2581,1,B,BAO_0000357,,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,
2582,1,B,BAO_0000019,,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,,,,,
2583,1,B,BAO_0000357,,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,,,,
2584,1,B,BAO_0000019,,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,
2585,1,B,BAO_0000019,,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,,,,,
2586,1,B,BAO_0000019,10116.0,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,,,,
2587,1,B,BAO_0000249,,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,
2588,1,B,BAO_0000019,10116.0,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,Rattus norvegicus,,,,
2589,1,B,BAO_0000357,,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,,,,,
2590,1,B,BAO_0000357,10116.0,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,,,,
2591,1,B,BAO_0000019,10116.0,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,,Rattus norvegicus,,,,
2592,1,B,BAO_0000357,,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,,,,,
2593,1,B,BAO_0000357,,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,,,,,
2594,1,B,BAO_0000019,10116.0,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,,Rattus norvegicus,,,,
2595,1,B,BAO_0000357,,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,,,,,
2596,1,B,BAO_0000019,,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,,,,,
2597,1,B,BAO_0000019,,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,,,,,
2598,1,B,BAO_0000019,,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,,,,,
2599,1,B,BAO_0000019,,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,,,,
2600,1,B,BAO_0000019,,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,,,,,
2601,1,B,BAO_0000019,,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,,,,
2602,1,B,BAO_0000019,,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,,,,
2603,1,B,BAO_0000019,,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,,,,,
2604,1,B,BAO_0000219,,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,,,,,NIH3T3,
2605,1,B,BAO_0000357,,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,,,,,
2606,1,B,BAO_0000019,10116.0,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,Rattus norvegicus,,,,
2607,1,B,BAO_0000019,10116.0,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,Rattus norvegicus,,,,
2608,1,B,BAO_0000221,,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,,,Brain,,
2609,1,B,BAO_0000357,,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,,,,,
2610,1,B,BAO_0000219,,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,,,,,NIH3T3,
2611,1,F,BAO_0000221,,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,,,,,
2612,1,B,BAO_0000357,,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,,,,,
2613,1,B,BAO_0000357,,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,
2614,1,B,BAO_0000019,,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,,,,,
2615,1,B,BAO_0000019,,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,,,,,
2616,1,B,BAO_0000357,,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,
2617,1,B,BAO_0000219,10116.0,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,,Rattus norvegicus,,,NIH3T3,
2618,1,B,BAO_0000357,,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,
2619,1,B,BAO_0000357,,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,
2620,1,B,BAO_0000019,10116.0,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,,,,
2621,1,B,BAO_0000357,,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,
2622,1,B,BAO_0000219,,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,,CHO,
2623,1,B,BAO_0000019,,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,,,,,
2624,1,B,BAO_0000357,,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,,,,
2625,1,B,BAO_0000357,,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,,,,,
2626,1,B,BAO_0000357,10116.0,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,,,,
2627,1,B,BAO_0000019,,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,,,,,
2628,1,B,BAO_0000019,,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,,,,,
2629,1,B,BAO_0000019,,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,,,,,
2630,1,B,BAO_0000019,,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,,,,,
2631,1,B,BAO_0000357,,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,,,,,
2632,1,B,BAO_0000357,,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,,,,,
2633,1,B,BAO_0000357,10116.0,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,,Rattus norvegicus,,,,
2634,1,B,BAO_0000357,,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,
2635,1,B,BAO_0000357,,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,,,,,
2636,1,B,BAO_0000219,,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,,,,,NIH3T3,
2637,1,B,BAO_0000357,,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,
2638,1,B,BAO_0000357,,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,
2639,1,B,BAO_0000357,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,,,,,
2640,1,B,BAO_0000357,10116.0,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,,Rattus norvegicus,,,,
2641,1,B,BAO_0000357,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,,,,,
2642,1,B,BAO_0000357,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,,,,,
2643,1,B,BAO_0000357,,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,,,,,
2644,1,B,BAO_0000357,,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,,,,,
2645,1,B,BAO_0000357,,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,,,,
2646,1,B,BAO_0000219,,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,,,,,NIH3T3,
2647,1,B,BAO_0000357,10116.0,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,Rattus norvegicus,,,,
2648,1,B,BAO_0000019,,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,,,Caudate-putamen,,
2649,1,B,BAO_0000357,,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,,,,,
2650,1,B,BAO_0000357,,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,,,,,
2651,1,B,BAO_0000357,,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,,,,,
2652,1,B,BAO_0000019,,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,,,,,
2653,1,B,BAO_0000357,,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,,,,,
2654,1,B,BAO_0000221,10116.0,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,,Hippocampus,,
2655,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,,,,
2656,1,B,BAO_0000357,,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,,,,,
2657,1,B,BAO_0000357,,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,,,,,
2658,1,B,BAO_0000219,,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,,,,,NIH3T3,
2659,1,B,BAO_0000019,,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,,,,,
2660,1,B,BAO_0000357,,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,,,,
2661,1,B,BAO_0000019,,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,,,,
2662,1,B,BAO_0000221,,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,,,Brain,,
2663,1,B,BAO_0000249,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,
2664,1,B,BAO_0000249,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,
2665,1,B,BAO_0000019,10116.0,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,,Rattus norvegicus,,,,
2666,1,B,BAO_0000249,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,
2667,1,B,BAO_0000249,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,
2668,1,B,BAO_0000249,,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,
2669,1,B,BAO_0000019,10116.0,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,,Rattus norvegicus,,,,
2670,1,B,BAO_0000019,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,,,,,
2671,1,B,BAO_0000019,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,,,,,
2672,1,B,BAO_0000019,10116.0,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,Rattus norvegicus,,,,
2673,1,B,BAO_0000019,10116.0,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,,Rattus norvegicus,,,,
2674,1,B,BAO_0000224,10116.0,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,,Rattus norvegicus,,,,
2675,1,B,BAO_0000357,,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,
2676,1,B,BAO_0000357,,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,
2677,1,B,BAO_0000357,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,,,,,
2678,1,B,BAO_0000357,10116.0,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,,Rattus norvegicus,,,,
2679,1,B,BAO_0000357,,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,,,,,
2680,1,B,BAO_0000357,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,
2681,1,B,BAO_0000019,10116.0,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,Rattus norvegicus,,,,
2682,1,B,BAO_0000019,,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,,,,,
2683,1,B,BAO_0000019,,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,,,,,
2684,1,B,BAO_0000019,,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,,,,,
2685,1,B,BAO_0000219,,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,,,,,CHO,
2686,1,B,BAO_0000019,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,,,,
2687,1,B,BAO_0000019,,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,,,,
2688,1,B,BAO_0000357,,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,,,,,
2689,1,B,BAO_0000019,,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,,,,,
2690,1,B,BAO_0000019,,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,,,,,
2691,1,B,BAO_0000218,,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,,,,,
2692,1,B,BAO_0000218,,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,,,,,
2693,1,B,BAO_0000218,,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,,,,,
2694,1,B,BAO_0000357,,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,,,,,
2695,1,B,BAO_0000357,,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,,,,,,,
2696,1,B,BAO_0000224,,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,,,,
2697,1,B,BAO_0000224,,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,,,,
2698,1,B,BAO_0000224,,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,,,,,
2699,1,B,BAO_0000357,,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,,,,,
2700,1,B,BAO_0000357,,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,,,,,
2701,1,F,BAO_0000019,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,,,,,
2702,1,F,BAO_0000019,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,,,,,
2703,1,F,BAO_0000019,,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,,,,,
2704,1,F,BAO_0000019,,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,,,Thoracic aorta,,
2705,1,F,BAO_0000019,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,,,Thoracic aorta,,
2706,1,F,BAO_0000019,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,,,Thoracic aorta,,
2707,1,B,BAO_0000357,,12861,Binding activity radioligand.,,,,,,,
2708,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,
2709,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,,,,
2710,1,B,BAO_0000019,,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,,,,,
2711,1,B,BAO_0000219,,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,,,,,N1E-115,
2712,1,B,BAO_0000219,,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,,,,,N1E-115,
2713,1,B,BAO_0000019,,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,,,,,
2714,1,F,BAO_0000019,10116.0,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,,Rattus norvegicus,,,,
2715,1,B,BAO_0000357,,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,,,,,
2716,1,B,BAO_0000357,,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,
2717,1,B,BAO_0000357,,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,,,,,
2718,1,B,BAO_0000019,,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,,,,
2719,1,B,BAO_0000019,,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,,,,,
2720,1,B,BAO_0000019,,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,,,,
2721,1,B,BAO_0000357,,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,,,,
2722,1,B,BAO_0000357,,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,,,,
2723,1,B,BAO_0000019,,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,,,,,
2724,1,B,BAO_0000019,,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,,,,,
2725,1,B,BAO_0000219,,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,,,,,HEK293,
2726,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,,,,,
2727,1,B,BAO_0000357,9606.0,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,,Homo sapiens,,,,
2728,1,B,BAO_0000357,,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,,,,,
2729,1,B,BAO_0000357,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,,,,,
2730,1,B,BAO_0000357,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,
2731,1,B,BAO_0000357,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,,,,
2732,1,B,BAO_0000219,,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,,,CHO,
2733,1,B,BAO_0000219,,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,,,,,CHO,
2734,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,,NIH3T3,
2735,1,F,BAO_0000219,9606.0,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,Homo sapiens,,,CHO,
2736,1,B,BAO_0000019,,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,,,,
2737,1,B,BAO_0000357,,12861,Binding activity radioligand.,,,,,,,
2738,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,
2739,1,B,BAO_0000219,,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,,,,,CHO,
2740,1,B,BAO_0000219,,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,,,,,CHO,
2741,1,B,BAO_0000219,,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,,,,,CHO,
2742,1,B,BAO_0000357,,5254,Binding affinity against 5-HT2C receptor,,,,,,,
2743,1,B,BAO_0000219,,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,,,HEK293,
2744,1,B,BAO_0000219,9606.0,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,,Homo sapiens,,,HEK293,
2745,1,B,BAO_0000219,9606.0,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,Homo sapiens,,,HEK293,
2746,1,B,BAO_0000357,,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,,,,,
2747,1,B,BAO_0000219,9606.0,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,Homo sapiens,,,HEK293,
2748,1,B,BAO_0000219,9606.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,,Homo sapiens,,,HEK293,
2749,1,B,BAO_0000219,9606.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,,Homo sapiens,,,HEK293,
2750,1,B,BAO_0000357,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,,,,,
2751,1,B,BAO_0000219,,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,,,,,HEK293,
2752,1,B,BAO_0000219,,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,,,,,HEK293,
2753,1,B,BAO_0000219,,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,,HEK293,
2754,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,,HEK293,
2755,1,B,BAO_0000219,,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,,,,,HEK293,
2756,1,B,BAO_0000219,,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,,,,,HEK293,
2757,1,B,BAO_0000219,,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,,,,,HEK293,
2758,1,B,BAO_0000219,9606.0,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,,Homo sapiens,,,HEK293,
2759,1,B,BAO_0000219,,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,,,,,HEK293,
2760,1,B,BAO_0000219,,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,,,,,HEK293,
2761,1,B,BAO_0000219,,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,,,,,HEK293,
2762,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,,,NIH3T3,
2763,1,B,BAO_0000219,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,,,,,HEK293,
2764,1,B,BAO_0000219,,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,,,,,CHO-K1,
2765,1,B,BAO_0000357,9606.0,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,,,Homo sapiens,,,,
2766,1,B,BAO_0000357,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,,,,,
2767,1,B,BAO_0000219,,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,,,,,HEK293,
2768,1,B,BAO_0000219,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,,,,,HEK293,
2769,1,B,BAO_0000219,,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,,,,,HeLa,
2770,1,F,BAO_0000019,,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,,,,,
2771,1,F,BAO_0000221,,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,,,Hippocampus,,
2772,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,,,,,HEK293,
2773,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,,,,,HEK293,
2774,1,B,BAO_0000357,,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,,,,,
2775,1,B,BAO_0000019,,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,,,Stomach,,
2776,1,B,BAO_0000019,,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,,,Stomach,,
2777,1,F,BAO_0000219,,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,,,,,A9,
2778,1,B,BAO_0000219,,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,,,NIH3T3,
2779,1,B,BAO_0000219,,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,,,,,NIH3T3,
2780,1,B,BAO_0000219,,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,,,NIH3T3,
2781,1,F,BAO_0000019,,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,,,,,
2782,1,B,BAO_0000019,10090.0,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,,Mus musculus,,Stomach,,
2783,1,B,BAO_0000019,10116.0,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,,Rattus norvegicus,,Stomach,,
2784,1,B,BAO_0000357,,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,,,,,
2785,1,B,BAO_0000357,9823.0,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,,,Sus scrofa,,,,
2786,1,B,BAO_0000357,,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,
2787,1,B,BAO_0000019,,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,,,,,
2788,1,B,BAO_0000019,,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,,,,,
2789,1,B,BAO_0000249,,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,,,,,
2790,1,B,BAO_0000357,,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,,,,,
2791,1,B,BAO_0000357,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,
2792,1,B,BAO_0000357,,12861,Binding activity radioligand.,,,,,,,
2793,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,
2794,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,,,,
2795,1,B,BAO_0000249,,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,,,,,
2796,1,B,BAO_0000249,,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,,,,,
2797,1,F,BAO_0000019,9823.0,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,Sus scrofa,,,,
2798,1,F,BAO_0000019,9823.0,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,Sus scrofa,,,,
2799,1,B,BAO_0000357,9823.0,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,,Sus scrofa,,,,
2800,1,B,BAO_0000019,9823.0,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,,Sus scrofa,,,,
2801,1,B,BAO_0000357,9823.0,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,,Sus scrofa,,,,
2802,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,
2803,1,F,BAO_0000019,,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,,,,,
2804,1,B,BAO_0000357,,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,,,,,
2805,1,B,BAO_0000357,,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,,,,,
2806,1,B,BAO_0000357,,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,,,,,
2807,1,B,BAO_0000357,10116.0,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,,Rattus norvegicus,,,,
2808,1,B,BAO_0000357,10116.0,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,,Rattus norvegicus,,,,
2809,1,B,BAO_0000249,10116.0,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,,Rattus norvegicus,,,,Brain membranes
2810,1,B,BAO_0000357,,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,,,,,
2811,1,B,BAO_0000019,,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,,,,,
2812,1,B,BAO_0000019,,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,,,,,
2813,1,B,BAO_0000219,,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,In vitro,,,,,,
2814,1,B,BAO_0000219,,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,,,,,NIH3T3,
2815,1,B,BAO_0000357,,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,,,,,
2816,1,B,BAO_0000357,,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,,,,,
2817,1,B,BAO_0000219,,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,,,,,NIH3T3,
2818,1,B,BAO_0000357,,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,,,,,
2819,1,B,BAO_0000357,,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,
2820,1,B,BAO_0000357,,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,
2821,1,B,BAO_0000357,,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,
2822,1,B,BAO_0000357,,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,,,,,
2823,1,B,BAO_0000019,,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,,,,,
2824,1,B,BAO_0000019,,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,,,,,
2825,1,B,BAO_0000019,,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,,,,,
2826,1,B,BAO_0000219,,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,,,,,A9,
2827,1,B,BAO_0000357,,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,
2828,1,B,BAO_0000357,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,,,,,
2829,1,B,BAO_0000219,,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,In vitro,,,,,,
2830,1,B,BAO_0000219,,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,,,,,
2831,1,B,BAO_0000019,,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,,,Caudate-putamen,,
2832,1,B,BAO_0000357,,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,,,,,
2833,1,B,BAO_0000019,,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,,,,,
2834,1,B,BAO_0000357,,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,,,,,
2835,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,,,,,
2836,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,,,,,
2837,1,B,BAO_0000219,,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,,,,,
2838,1,B,BAO_0000357,,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,,,,,
2839,1,B,BAO_0000357,10116.0,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,,Rattus norvegicus,,,,
2840,1,B,BAO_0000357,,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,,,,,
2841,1,B,BAO_0000357,,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,,,,,
2842,1,B,BAO_0000219,,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,,,,,
2843,1,B,BAO_0000019,10116.0,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,,Rattus norvegicus,,,,
2844,1,B,BAO_0000357,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,
2845,1,B,BAO_0000019,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,,,,,
2846,1,B,BAO_0000357,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,,,,,
2847,1,B,BAO_0000357,,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,,,,
2848,1,B,BAO_0000357,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,,,,,
2849,1,B,BAO_0000019,,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,,,,,
2850,1,B,BAO_0000019,,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,,,,,
2851,1,B,BAO_0000019,,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,,,,,
2852,1,B,BAO_0000019,,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,,,,,
2853,1,B,BAO_0000357,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,,,,,
2854,1,B,BAO_0000019,10116.0,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,,Rattus norvegicus,,,,
2855,1,B,BAO_0000357,,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,,,,
2856,1,B,BAO_0000219,,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,,,,,CHO-K1,
2857,1,B,BAO_0000357,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,
2858,1,B,BAO_0000357,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,,,,,
2859,1,F,BAO_0000019,,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,,,,,
2860,1,B,BAO_0000357,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,
2861,1,B,BAO_0000357,,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,
2862,1,B,BAO_0000357,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,,,,,
2863,1,B,BAO_0000357,,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,,,,,
2864,1,B,BAO_0000357,,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,,,,,
2865,1,B,BAO_0000019,9606.0,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,,Homo sapiens,,,,
2866,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,,,,,
2867,1,B,BAO_0000357,,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,,,,
2868,1,B,BAO_0000357,,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,,,,
2869,1,B,BAO_0000357,,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,,,,,
2870,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,,,,,
2871,1,B,BAO_0000357,9606.0,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,,Homo sapiens,,,,
2872,1,B,BAO_0000219,9606.0,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,Homo sapiens,,,HEK293,
2873,1,B,BAO_0000219,9606.0,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,Homo sapiens,,,HEK293,
2874,1,F,BAO_0000219,9606.0,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,Homo sapiens,,,CHO,
2875,1,F,BAO_0000219,9606.0,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,Homo sapiens,,,CHO,
2876,1,B,BAO_0000219,,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,,,HEK293,
2877,1,B,BAO_0000219,,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,,,,,HEK293,
2878,1,B,BAO_0000219,,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,,,,,HEK293,
2879,1,B,BAO_0000219,9606.0,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,,Homo sapiens,,,HEK293,
2880,1,B,BAO_0000219,9606.0,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,,Homo sapiens,,,HEK293,
2881,1,B,BAO_0000357,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,,,,,
2882,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,,,,,HEK293,
2883,1,B,BAO_0000219,,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,,,,,HEK293,
2884,1,B,BAO_0000219,,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,,,,,HEK293,
2885,1,B,BAO_0000219,,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,,,,,HEK293,
2886,1,B,BAO_0000219,9606.0,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,,Homo sapiens,,,HEK293,
2887,1,B,BAO_0000219,9606.0,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,,Homo sapiens,,,HEK293,
2888,1,B,BAO_0000219,,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,,,,,HEK293,
2889,1,B,BAO_0000219,,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,,,,,CHO-K1,
2890,1,B,BAO_0000357,,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,,,,,,,
2891,1,B,BAO_0000219,,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,,,,,HEK293,
2892,1,B,BAO_0000219,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,,,HEK293,
2893,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,,,,,HEK293,
2894,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,,,HEK293,
2895,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,,,HEK293,
2896,1,B,BAO_0000019,9986.0,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,,Oryctolagus cuniculus,,,,
2897,1,B,BAO_0000019,,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,,,Stomach,,
2898,1,B,BAO_0000357,,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,,,Stomach,,
2899,1,B,BAO_0000357,,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,,,Stomach,,
2900,1,F,BAO_0000019,10116.0,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,,Rattus norvegicus,,Stomach,,
2901,1,F,BAO_0000019,10116.0,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,,,Rattus norvegicus,,,,
2902,1,F,BAO_0000019,,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,,,Stomach,,
2903,1,B,BAO_0000357,10116.0,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,,Rattus norvegicus,,Stomach,,
2904,1,F,BAO_0000019,,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,,,,,
2905,1,F,BAO_0000019,,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,,,,,
2906,1,F,BAO_0000019,,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,,,,,
2907,1,B,BAO_0000357,10116.0,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Rattus norvegicus,,Stomach,,
2908,1,B,BAO_0000357,10116.0,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Rattus norvegicus,,Stomach,,
2909,1,B,BAO_0000357,10116.0,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Rattus norvegicus,,Stomach,,
2910,1,B,BAO_0000357,10116.0,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,Rattus norvegicus,,Stomach,,
2911,1,F,BAO_0000019,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,,Stomach,,
2912,1,F,BAO_0000019,,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,,Stomach,,
2913,1,F,BAO_0000019,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,,,Stomach,,
2914,1,F,BAO_0000019,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,,,Stomach,,
2915,1,F,BAO_0000019,10116.0,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,,Rattus norvegicus,,Stomach,,
2916,1,F,BAO_0000019,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,,,Thoracic aorta,,
2917,1,B,BAO_0000357,,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,
2918,1,B,BAO_0000357,,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,,,,,
2919,1,B,BAO_0000357,,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,
2920,1,B,BAO_0000357,,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,
2922,1,F,BAO_0000019,10116.0,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,Rattus norvegicus,,Stomach,,
2923,1,B,BAO_0000357,,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,
2924,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,,,,,
2925,1,B,BAO_0000357,,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,,,,,
2926,1,B,BAO_0000357,,4687,Evaluated for the binding affinity to 5-HT 2B receptor,,,,,,,
2927,1,B,BAO_0000357,,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,,,,,
2928,1,B,BAO_0000357,,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,,,,,,,
2929,1,B,BAO_0000357,,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,,,,,
2930,1,B,BAO_0000357,,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,,,,,
2931,1,B,BAO_0000357,,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,,,,,
2932,1,B,BAO_0000357,9913.0,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,Bos taurus,,,,
2933,1,B,BAO_0000357,9913.0,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,,Bos taurus,,,,
2934,1,B,BAO_0000357,9913.0,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,,Bos taurus,,,,
2935,1,B,BAO_0000357,9913.0,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,,Bos taurus,,,,
2936,1,B,BAO_0000357,9913.0,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,,Bos taurus,,,,
2937,1,B,BAO_0000357,9913.0,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,Bos taurus,,,,
2938,1,B,BAO_0000357,9913.0,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,Bos taurus,,,,
2939,1,B,BAO_0000019,10141.0,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,,Cavia porcellus,,,,
2940,1,B,BAO_0000357,10141.0,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,,Cavia porcellus,,Striatum,,
2941,1,B,BAO_0000357,,5254,Binding affinity against 5-HT1A receptor,,,,,,,
2942,1,F,BAO_0000219,,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,,,,,CHO,
2943,1,F,BAO_0000219,9606.0,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,,Homo sapiens,,,CHO,
2944,1,F,BAO_0000219,,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,,,,,
2945,1,B,BAO_0000219,,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,,,,,CHO,
2946,1,B,BAO_0000219,,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,,,,,CHO,
2947,1,B,BAO_0000357,9606.0,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,,,Homo sapiens,,,,
2948,1,B,BAO_0000357,,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,,,,,
2949,1,B,BAO_0000019,,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,,,,
2950,1,B,BAO_0000357,,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,,,,,
2951,1,B,BAO_0000357,,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,,,,
2952,1,B,BAO_0000357,,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,,,,
2953,1,B,BAO_0000219,,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,,,,,CHO,
2954,1,B,BAO_0000219,,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,,,,,CHO,
2955,1,B,BAO_0000219,,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,,,CHO,
2956,1,B,BAO_0000219,,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,,,,,CHO,
2957,1,B,BAO_0000357,9606.0,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,,Homo sapiens,,,,
2958,1,F,BAO_0000019,,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,,,,,
2959,1,F,BAO_0000019,,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,
2960,1,B,BAO_0000219,10116.0,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,,Rattus norvegicus,,,CHO,
2961,1,F,BAO_0000019,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,,,,,
2962,1,F,BAO_0000019,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,,,,,
2963,1,F,BAO_0000019,,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,
2964,1,B,BAO_0000357,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,,,,,
2965,1,B,BAO_0000357,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,,,,,
2966,1,B,BAO_0000357,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,,,,,
2967,1,B,BAO_0000357,,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,,,,,
2968,1,B,BAO_0000357,,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,,,,,
2969,1,B,BAO_0000219,,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,,,CHO,
2970,1,B,BAO_0000019,9606.0,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,,Homo sapiens,,,,
2971,1,B,BAO_0000357,,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,,,,,
2972,1,B,BAO_0000357,9606.0,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,,Homo sapiens,,,,
2973,1,B,BAO_0000357,,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,,,,,
2974,1,B,BAO_0000249,10116.0,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,,Rattus norvegicus,,,,Membranes
2975,1,B,BAO_0000223,,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,,,,,
2976,1,B,BAO_0000019,10116.0,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,,Rattus norvegicus,,,,
2977,1,B,BAO_0000019,,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,,,,,
2978,1,B,BAO_0000019,,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,,,,,
2979,1,B,BAO_0000219,,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,,,,,
2980,1,B,BAO_0000019,,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,,,,,
2981,1,B,BAO_0000019,,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,,,,,
2982,1,B,BAO_0000223,,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,,,,,
2983,1,B,BAO_0000223,,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,,,,,
2984,1,B,BAO_0000223,,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,,,,,
2985,1,B,BAO_0000249,,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,,,,
2986,1,B,BAO_0000249,,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,,,,
2987,1,B,BAO_0000249,,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,,,,,Membranes
2988,1,B,BAO_0000223,,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,,,,,
2989,1,B,BAO_0000019,,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,,,,
2990,1,B,BAO_0000223,,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,,,,,
2991,1,B,BAO_0000223,,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,,,,,
2992,1,B,BAO_0000019,,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,,,,,
2993,1,B,BAO_0000019,10116.0,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,,Rattus norvegicus,,,,
2994,1,B,BAO_0000249,,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,
2995,1,B,BAO_0000223,,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,,,,
2996,1,B,BAO_0000019,,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,,,,,
2997,1,B,BAO_0000019,,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,,,,,
2998,1,B,BAO_0000019,,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,,,,,
2999,1,B,BAO_0000249,,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,,,,
3000,1,B,BAO_0000249,,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,,,,
3001,1,B,BAO_0000019,,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,,,,
3002,1,B,BAO_0000019,,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,,,,
3003,1,B,BAO_0000249,,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,,,,,Membranes
3004,1,B,BAO_0000223,10116.0,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3005,1,B,BAO_0000221,,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,,,Brain,,
3006,1,B,BAO_0000019,,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,,,,,
3007,1,B,BAO_0000223,,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,,,,,
3008,1,B,BAO_0000223,,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,,,,
3009,1,B,BAO_0000223,,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,,,,,
3010,1,B,BAO_0000223,,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,,,,,
3011,1,B,BAO_0000223,,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,,,,,
3012,1,B,BAO_0000019,,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,,,,,
3013,1,B,BAO_0000019,,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,,,,,
3014,1,B,BAO_0000223,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,,,,,
3015,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,,,,
3016,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,,,,
3017,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,,,,
3018,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,,,,
3019,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,,,,
3020,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,,,,
3021,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,,,,
3022,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,In vivo,,,,,,
3023,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,,,,
3024,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,,,,
3025,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,,,,
3026,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,,,,
3027,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,,,,
3028,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,,,,
3029,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,,,,
3030,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,,,,
3031,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,,,,
3032,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,,,,
3033,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,,,,
3034,1,F,BAO_0000019,,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,,,,,
3035,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,,,,,
3036,1,B,BAO_0000019,10116.0,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3037,1,B,BAO_0000223,,12861,Binding activity radioligand.,,,,,,,
3038,1,B,BAO_0000249,,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,,,,,Brain membranes
3039,1,B,BAO_0000249,,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,,,,,Brain membranes
3040,1,B,BAO_0000357,,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,,,,,
3041,1,B,BAO_0000357,,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,,,,,
3042,1,B,BAO_0000357,,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,,,,,
3043,1,B,BAO_0000357,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,,,,,
3044,1,B,BAO_0000357,,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,,,,,
3045,1,B,BAO_0000357,,5163,Affinity for 5-hydroxytryptamine 2C receptor,,,,,,,
3046,1,B,BAO_0000357,,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,
3047,1,B,BAO_0000357,,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,,,,,
3048,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,,,,,
3049,1,B,BAO_0000357,,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,,,,,
3050,1,B,BAO_0000357,,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,,,,,
3051,1,B,BAO_0000357,,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,,,,,
3052,1,B,BAO_0000357,,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,,,,,
3053,1,B,BAO_0000357,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,,,,,
3054,1,B,BAO_0000357,,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,,,,,
3055,1,B,BAO_0000357,,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,,,,,
3056,1,B,BAO_0000357,,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,,,,,
3057,1,B,BAO_0000357,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,,,,,
3058,1,B,BAO_0000357,,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,,,,,
3059,1,B,BAO_0000357,,3269,Affinity against 5-hydroxytryptamine 2C receptor,,,,,,,
3060,1,B,BAO_0000357,9606.0,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,,,Homo sapiens,,,,
3061,1,B,BAO_0000357,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,,,,,
3062,1,B,BAO_0000357,9913.0,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,,Bos taurus,,,,
3063,1,B,BAO_0000357,9913.0,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,,Bos taurus,,,,
3064,1,F,BAO_0000019,10141.0,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,,Cavia porcellus,,,,
3065,1,B,BAO_0000221,10141.0,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,Cavia porcellus,,Ileum,,
3066,1,F,BAO_0000019,10141.0,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,,Cavia porcellus,,,,
3067,1,F,BAO_0000019,10141.0,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,,Cavia porcellus,,,,
3068,1,B,BAO_0000221,10141.0,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,Cavia porcellus,,Ileum,,
3069,1,B,BAO_0000221,10141.0,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,,Cavia porcellus,,Ileum,,
3070,1,F,BAO_0000019,10141.0,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,,Cavia porcellus,,,,
3071,1,F,BAO_0000019,10141.0,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,,Cavia porcellus,,,,
3072,1,F,BAO_0000019,10141.0,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,,Cavia porcellus,,,,
3073,1,F,BAO_0000019,10141.0,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,,Cavia porcellus,,,,
3074,1,F,BAO_0000019,10141.0,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,,Cavia porcellus,,,,
3075,1,F,BAO_0000019,10141.0,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,,Cavia porcellus,,,,
3076,1,F,BAO_0000221,10141.0,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,,Cavia porcellus,,Ileum,,
3077,1,F,BAO_0000221,10141.0,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,,Cavia porcellus,,Ileum,,
3078,1,F,BAO_0000221,10141.0,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,,Cavia porcellus,,Ileum,,
3079,1,B,BAO_0000221,10141.0,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,,Cavia porcellus,,Ileum,,
3080,1,B,BAO_0000221,10141.0,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,,Cavia porcellus,,Ileum,,
3081,1,B,BAO_0000223,10141.0,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,,Cavia porcellus,,,,
3082,1,B,BAO_0000221,10141.0,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,Cavia porcellus,,Ileum,,
3083,1,F,BAO_0000221,10141.0,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,Cavia porcellus,,Ileum,,
3084,1,F,BAO_0000221,10141.0,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,,Cavia porcellus,,Ileum,,
3085,1,F,BAO_0000221,10141.0,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,,Cavia porcellus,,Ileum,,
3086,1,F,BAO_0000221,10141.0,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,,Cavia porcellus,,Ileum,,
3087,1,F,BAO_0000221,10141.0,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,,Cavia porcellus,,Ileum,,
3088,1,B,BAO_0000221,10141.0,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,Cavia porcellus,,Ileum,,
3089,1,F,BAO_0000221,10141.0,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,Cavia porcellus,,Ileum,,
3090,1,B,BAO_0000221,10141.0,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,Cavia porcellus,,Ileum,,
3091,1,B,BAO_0000221,10141.0,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,,Cavia porcellus,,Ileum,,
3092,1,B,BAO_0000221,10141.0,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,,Cavia porcellus,,Ileum,,
3093,1,B,BAO_0000221,10141.0,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,,Cavia porcellus,,Ileum,,
3094,1,B,BAO_0000019,10141.0,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,Cavia porcellus,,,,
3095,1,B,BAO_0000357,,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,,,,,
3096,1,B,BAO_0000223,9606.0,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,,Homo sapiens,,,,
3097,1,B,BAO_0000223,,6013,Binding affinity towards 5-HT3 receptor,,,,,,,
3098,1,B,BAO_0000223,,12861,Binding activity radioligand.,,,,,,,
3099,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,,,,,
3100,1,B,BAO_0000223,,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,,,,
3101,1,B,BAO_0000223,,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,,,,
3102,1,B,BAO_0000223,,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,,,,,
3103,1,B,BAO_0000019,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,,,,,
3104,1,B,BAO_0000219,,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,,,,,NG108-15,
3105,1,B,BAO_0000218,,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",In vivo,,,,,,
3106,1,B,BAO_0000019,,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,,,,
3107,1,B,BAO_0000224,,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,,,,,
3108,1,B,BAO_0000224,,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,,,,,
3109,1,B,BAO_0000019,,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,,,,
3110,1,B,BAO_0000019,,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,,,,
3111,1,F,BAO_0000218,,12918,5-hydroxytryptamine 3 receptor agonism in mouse,,,,,,,
3112,1,B,BAO_0000219,,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,,,,,
3113,1,B,BAO_0000019,,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,,,,
3114,1,B,BAO_0000019,,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,,,,
3115,1,B,BAO_0000224,,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,,,,,
3116,1,B,BAO_0000219,,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,,,,
3117,1,B,BAO_0000219,,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,,,,
3118,1,B,BAO_0000224,,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,,,,,
3119,1,B,BAO_0000219,,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,In vitro,,,,,,
3120,1,B,BAO_0000219,,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,,,,,N1E-115,
3121,1,B,BAO_0000019,,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,,,,
3122,1,B,BAO_0000219,,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,,,,,
3123,1,B,BAO_0000357,10090.0,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,,Mus musculus,,,,
3124,1,B,BAO_0000019,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,
3125,1,B,BAO_0000357,9823.0,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,,Sus scrofa,,,,
3126,1,B,BAO_0000357,9823.0,12861,Binding activity radioligand.,,,Sus scrofa,,,,
3127,1,B,BAO_0000223,9986.0,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,,Oryctolagus cuniculus,,,,
3128,1,B,BAO_0000223,9986.0,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,Oryctolagus cuniculus,,,,
3129,1,B,BAO_0000223,9986.0,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,,Oryctolagus cuniculus,,,,
3130,1,B,BAO_0000019,9986.0,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,Oryctolagus cuniculus,,,,
3131,1,F,BAO_0000019,9986.0,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,Oryctolagus cuniculus,,,,
3132,1,F,BAO_0000019,9986.0,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,Oryctolagus cuniculus,,,,
3133,1,F,BAO_0000221,9986.0,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,Oryctolagus cuniculus,,Ileum,,
3134,1,F,BAO_0000019,9986.0,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,Oryctolagus cuniculus,,,,
3135,1,F,BAO_0000019,9986.0,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,Oryctolagus cuniculus,,,,
3136,1,F,BAO_0000019,9986.0,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,Oryctolagus cuniculus,,,,
3137,1,F,BAO_0000019,9986.0,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,Oryctolagus cuniculus,,,,
3138,1,B,BAO_0000219,9986.0,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,,Oryctolagus cuniculus,,,CHO,
3139,1,B,BAO_0000019,10116.0,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3140,1,B,BAO_0000019,,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,,,,,
3141,1,B,BAO_0000357,,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,,,,,
3142,1,B,BAO_0000019,10116.0,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,,Rattus norvegicus,,,,
3143,1,B,BAO_0000019,,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,,,,,
3144,1,F,BAO_0000218,,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",In vivo,,,,Heart,,
3145,1,F,BAO_0000019,,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,,,Heart,,
3146,1,F,BAO_0000019,,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,,,Heart,,
3147,1,F,BAO_0000019,,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,,,Heart,,
3148,1,F,BAO_0000019,,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,,,Heart,,
3149,1,F,BAO_0000019,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,
3150,1,F,BAO_0000019,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,
3151,1,F,BAO_0000019,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,
3152,1,F,BAO_0000019,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,
3153,1,F,BAO_0000218,10116.0,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),In vivo,,Rattus norvegicus,,,,
3154,1,F,BAO_0000218,,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),In vivo,,,,,,
3155,1,F,BAO_0000218,10116.0,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,Rattus norvegicus,,,,
3156,1,F,BAO_0000019,10116.0,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,,Rattus norvegicus,,,,
3157,1,F,BAO_0000218,10116.0,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,In vivo,,Rattus norvegicus,,,,
3158,1,F,BAO_0000019,10116.0,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,,Rattus norvegicus,,,,
3159,1,B,BAO_0000019,,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,,,,
3160,1,B,BAO_0000019,10116.0,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3161,1,B,BAO_0000223,,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,,,,,
3162,1,B,BAO_0000019,,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,,,,,
3163,1,B,BAO_0000019,,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,,,,,
3164,1,B,BAO_0000249,,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,,,,,
3165,1,B,BAO_0000019,,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,,,,,
3166,1,B,BAO_0000249,,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,,,Brain,,
3167,1,B,BAO_0000221,,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,,,Brain,,
3168,1,B,BAO_0000249,,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,
3169,1,B,BAO_0000249,,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,
3170,1,B,BAO_0000019,,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,,,,,
3171,1,B,BAO_0000019,10116.0,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,,Rattus norvegicus,,,,
3172,1,B,BAO_0000019,10116.0,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,,Rattus norvegicus,,,,
3173,1,B,BAO_0000223,10116.0,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3174,1,B,BAO_0000019,,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,,,,
3175,1,B,BAO_0000249,,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,,,,,Membranes
3176,1,B,BAO_0000019,10116.0,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,,Rattus norvegicus,,,,
3177,1,B,BAO_0000223,,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,,,,
3178,1,B,BAO_0000223,10116.0,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3179,1,B,BAO_0000219,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,,,,,NG108-15,
3180,1,B,BAO_0000219,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,,,,,NG108-15,
3181,1,B,BAO_0000019,,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,,,,,
3182,1,B,BAO_0000019,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,,,,,
3183,1,B,BAO_0000019,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,,,,,
3184,1,B,BAO_0000019,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,,,,,
3185,1,F,BAO_0000019,,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,,,,,
3186,1,F,BAO_0000019,10116.0,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,,Rattus norvegicus,,,,
3187,1,F,BAO_0000019,,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,,,,,
3188,1,F,BAO_0000218,,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,,,,,
3189,1,F,BAO_0000218,,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,In vivo,,,,,,
3190,1,F,BAO_0000218,,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,,,,,
3191,1,F,BAO_0000218,,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3192,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3193,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),In vivo,,,,,,
3194,1,F,BAO_0000218,10116.0,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,Rattus norvegicus,,,,
3195,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3196,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,In vivo,,,,,,
3197,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3198,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3199,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3200,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3201,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3202,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3203,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3204,1,F,BAO_0000218,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3205,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3206,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3207,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3208,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,In vivo,,,,,,
3209,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,In vivo,,,,,,
3210,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,In vivo,,,,,,
3211,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,In vivo,,,,,,
3212,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,In vivo,,,,,,
3213,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3214,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3215,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3216,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3217,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3218,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3219,1,F,BAO_0000218,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,,,,,,
3220,1,F,BAO_0000218,,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,,,,,
3221,1,F,BAO_0000218,,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,,,,,
3222,1,F,BAO_0000218,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,In vivo,,,,,,
3223,1,F,BAO_0000218,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,In vivo,,,,,,
3224,1,F,BAO_0000218,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,In vivo,,,,,,
3225,1,F,BAO_0000218,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,In vivo,,,,,,
3226,1,F,BAO_0000218,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,In vivo,,,,,,
3227,1,F,BAO_0000218,,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),In vivo,,,,,,
3228,1,F,BAO_0000019,,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,,,,
3229,1,F,BAO_0000019,,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,,,,
3230,1,B,BAO_0000223,10116.0,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3231,1,F,BAO_0000019,,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,,,,,
3232,1,B,BAO_0000221,,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,,,Hippocampus,,
3233,1,B,BAO_0000019,10116.0,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,,Rattus norvegicus,,,,
3234,1,B,BAO_0000019,10116.0,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3235,1,B,BAO_0000223,,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,,,,,
3236,1,B,BAO_0000019,,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,,,,,
3237,1,B,BAO_0000019,,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,,,,,
3238,1,B,BAO_0000019,,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,,,,,
3239,1,B,BAO_0000019,,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,,,,,
3240,1,B,BAO_0000019,,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,,,,
3241,1,F,BAO_0000221,10141.0,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,,Cavia porcellus,,Ileum,,
3242,1,F,BAO_0000221,10141.0,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,,Cavia porcellus,,Ileum,,
3243,1,F,BAO_0000221,10141.0,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,,Cavia porcellus,,Ileum,,
3244,1,F,BAO_0000221,10141.0,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,,Cavia porcellus,,Ileum,,
3245,1,F,BAO_0000221,10141.0,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,Cavia porcellus,,Ileum,,
3246,1,F,BAO_0000221,10141.0,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,Cavia porcellus,,Ileum,,
3247,1,F,BAO_0000221,10141.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,,Cavia porcellus,,Ileum,,
3248,1,F,BAO_0000221,10141.0,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,,Cavia porcellus,,Ileum,,
3249,1,F,BAO_0000221,10141.0,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,,Cavia porcellus,,Ileum,,
3250,1,F,BAO_0000221,10141.0,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,,Cavia porcellus,,Ileum,,
3251,1,F,BAO_0000221,10141.0,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,,Cavia porcellus,,Ileum,,
3252,1,F,BAO_0000221,10141.0,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,,Cavia porcellus,,Ileum,,
3253,1,F,BAO_0000221,10141.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,,Cavia porcellus,,Ileum,,
3254,1,F,BAO_0000221,10141.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,,Cavia porcellus,,Ileum,,
3255,1,F,BAO_0000221,10141.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,,Cavia porcellus,,Ileum,,
3256,1,F,BAO_0000221,10141.0,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,,Cavia porcellus,,Ileum,,
3257,1,F,BAO_0000221,10141.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,Cavia porcellus,,Ileum,,
3258,1,F,BAO_0000221,10141.0,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,Cavia porcellus,,Ileum,,
3259,1,B,BAO_0000357,10141.0,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,Cavia porcellus,,,,
3260,1,B,BAO_0000249,10141.0,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Cavia porcellus,,Striatum,,
3261,1,B,BAO_0000249,10141.0,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Cavia porcellus,,Striatum,,
3262,1,B,BAO_0000357,10141.0,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,,Cavia porcellus,,Striatum,,
3263,1,B,BAO_0000357,10141.0,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,Cavia porcellus,,Striatum,,
3264,1,B,BAO_0000357,10141.0,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,Cavia porcellus,,Striatum,,
3265,1,B,BAO_0000357,10141.0,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,Cavia porcellus,,Striatum,,
3266,1,F,BAO_0000221,10141.0,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,,Cavia porcellus,,Ileum,,
3267,1,F,BAO_0000221,10141.0,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,,Cavia porcellus,,Ileum,,
3268,1,F,BAO_0000221,10141.0,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,Cavia porcellus,,Ileum,,
3269,1,B,BAO_0000357,10141.0,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,,Cavia porcellus,,,,
3270,1,B,BAO_0000357,10141.0,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,,Cavia porcellus,,,,
3271,1,F,BAO_0000019,10141.0,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,,,,
3272,1,F,BAO_0000019,10141.0,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,,Cavia porcellus,,,,
3273,1,F,BAO_0000019,10141.0,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,,,,
3274,1,B,BAO_0000357,10141.0,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,,,,
3275,1,B,BAO_0000357,10141.0,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,,Striatum,,
3276,1,B,BAO_0000357,10141.0,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,,Cavia porcellus,,Striatum,,
3277,1,B,BAO_0000249,10141.0,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Cavia porcellus,,Striatum,,
3278,1,B,BAO_0000249,10141.0,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,Cavia porcellus,,Striatum,,
3279,1,B,BAO_0000221,10141.0,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,,Cavia porcellus,,Ileum,,
3280,1,B,BAO_0000357,10141.0,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,,Cavia porcellus,,,,
3281,1,B,BAO_0000357,10141.0,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,Cavia porcellus,,,,
3282,1,B,BAO_0000357,10141.0,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,,Cavia porcellus,,,,
3283,1,B,BAO_0000357,10141.0,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,Cavia porcellus,,,,
3284,1,F,BAO_0000221,10141.0,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,Cavia porcellus,,Ileum,,
3285,1,F,BAO_0000221,10141.0,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,,Cavia porcellus,,Ileum,,
3286,1,F,BAO_0000221,10141.0,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,,Cavia porcellus,,Ileum,,
3287,1,F,BAO_0000221,10141.0,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,,Cavia porcellus,,Ileum,,
3288,1,F,BAO_0000221,10141.0,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,Cavia porcellus,,Ileum,,
3289,1,B,BAO_0000357,10141.0,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,,Cavia porcellus,,,,
3290,1,B,BAO_0000357,10141.0,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,,Cavia porcellus,,,,
3291,1,F,BAO_0000019,10141.0,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,,,,
3292,1,B,BAO_0000357,10141.0,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,,Cavia porcellus,,,,
3293,1,B,BAO_0000019,10141.0,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,,Cavia porcellus,,,,
3294,1,B,BAO_0000219,10141.0,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,,Cavia porcellus,,,HEK293,
3295,1,B,BAO_0000019,10141.0,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,,Cavia porcellus,,,,
3296,1,B,BAO_0000357,10141.0,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,,Cavia porcellus,,,,
3297,1,B,BAO_0000357,10141.0,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,,Cavia porcellus,,,,
3298,1,B,BAO_0000357,10141.0,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,,Cavia porcellus,,Striatum,,
3299,1,B,BAO_0000221,10141.0,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,,Cavia porcellus,,Hippocampus,,
3300,1,B,BAO_0000357,10141.0,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,,Cavia porcellus,,,,
3301,1,B,BAO_0000357,10141.0,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,,Cavia porcellus,,,,
3302,1,F,BAO_0000221,10141.0,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,Cavia porcellus,,Ileum,,
3303,1,B,BAO_0000357,,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,,,,,
3304,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,,,,,
3305,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,,,,,
3306,1,B,BAO_0000219,,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,,,,HeLa,
3307,1,B,BAO_0000357,,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,
3308,1,B,BAO_0000357,,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,,,,,
3309,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,,,,,HeLa,
3310,1,B,BAO_0000357,,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,,,,,
3311,1,B,BAO_0000357,,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,,,,,
3312,1,B,BAO_0000219,,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,,,,,
3313,1,B,BAO_0000357,,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,,,,,
3314,1,F,BAO_0000019,,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,,,Cardiac atrium,,
3315,1,F,BAO_0000019,,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,,,Cardiac atrium,,
3316,1,B,BAO_0000357,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,
3317,1,B,BAO_0000221,,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,,,Hippocampus,,
3318,1,B,BAO_0000221,9823.0,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,,Sus scrofa,,Hippocampus,,
3319,1,B,BAO_0000019,9986.0,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,,Oryctolagus cuniculus,,,,
3320,1,B,BAO_0000357,10116.0,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,,Rattus norvegicus,,,,
3321,1,F,BAO_0000019,,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,,,,
3322,1,B,BAO_0000357,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,,,,,
3323,1,B,BAO_0000357,,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,,,,,
3324,1,F,BAO_0000019,,670,lntrinsic activity relative to 5-HT receptor,,,,,,,
3325,1,F,BAO_0000019,,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,,,,,
3326,1,F,BAO_0000019,,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,,,,,
3327,1,F,BAO_0000019,,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,,,,,
3328,1,F,BAO_0000019,,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,,,,,
3329,1,F,BAO_0000019,,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,,,,,
3330,1,F,BAO_0000019,,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,,,,,
3331,1,B,BAO_0000357,,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,,,,,
3332,1,F,BAO_0000019,,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,,,,,
3333,1,B,BAO_0000357,10116.0,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,,Rattus norvegicus,,,,
3334,1,B,BAO_0000357,,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,,,,
3335,1,B,BAO_0000357,,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,,,,,
3336,1,B,BAO_0000357,,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,,,,,
3337,1,B,BAO_0000019,10116.0,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,,Rattus norvegicus,,,,
3338,1,B,BAO_0000249,,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,,,Striatum,,
3339,1,B,BAO_0000249,,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,,,,,
3340,1,B,BAO_0000249,,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,,,,,
3341,1,B,BAO_0000019,10116.0,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,Rattus norvegicus,,Striatum,,
3342,1,B,BAO_0000019,,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,,,Striatum,,
3343,1,B,BAO_0000249,,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,,,Striatum,,
3344,1,B,BAO_0000019,,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,,,Striatum,,
3345,1,B,BAO_0000249,,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,,,Striatum,,
3346,1,B,BAO_0000249,,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,,,Striatum,,
3347,1,B,BAO_0000249,,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,,,,,
3348,1,F,BAO_0000221,,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,,,Brain,,
3349,1,F,BAO_0000019,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,,,,,
3350,1,F,BAO_0000019,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,,,,,
3351,1,F,BAO_0000019,,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,,,,,
3352,1,F,BAO_0000019,,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,,,,,
3353,1,F,BAO_0000019,,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,,,,,
3354,1,B,BAO_0000357,10116.0,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,,Rattus norvegicus,,,,
3355,1,B,BAO_0000249,,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,,,Striatum,,
3356,1,F,BAO_0000019,10116.0,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,,Rattus norvegicus,,,,
3357,1,F,BAO_0000019,,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,,,,,
3358,1,F,BAO_0000019,,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,,,,
3359,1,F,BAO_0000019,10116.0,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,,Rattus norvegicus,,,,
3360,1,F,BAO_0000019,,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,,,,,
3361,1,F,BAO_0000019,,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,,,,,
3362,1,F,BAO_0000218,,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,,,,,
3363,1,F,BAO_0000019,,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,,,,
3364,1,F,BAO_0000019,10116.0,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,,Rattus norvegicus,,,,
3365,1,F,BAO_0000019,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,,,,,
3366,1,B,BAO_0000357,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,
3367,1,B,BAO_0000357,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,,,,,
3368,1,B,BAO_0000357,,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,,,,,
3369,1,B,BAO_0000357,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,
3370,1,F,BAO_0000019,,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,
3371,1,B,BAO_0000357,,16117,In vitro binding affinity towards 5-HT4 receptor was determined,,,,,,,
3372,1,F,BAO_0000019,,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,
3373,1,F,BAO_0000019,,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,,,,,
3374,1,B,BAO_0000357,,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,,,,,
3375,1,B,BAO_0000357,,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,,,,,
3376,1,B,BAO_0000357,,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,,,,,
3377,1,B,BAO_0000357,,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,,,,,
3378,1,B,BAO_0000357,,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,,,,,
3379,1,B,BAO_0000249,,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,,,,,Brain membranes
3380,1,B,BAO_0000249,,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,,,,,Brain membranes
3381,1,B,BAO_0000249,,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,,,,,Brain membranes
3382,1,B,BAO_0000019,,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,,,,,
3383,1,B,BAO_0000019,10116.0,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3384,1,B,BAO_0000221,,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,,,Hippocampus,,
3385,1,B,BAO_0000019,,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,,,,,
3386,1,B,BAO_0000019,,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,,,,,
3387,1,F,BAO_0000019,,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,,,,,
3388,1,B,BAO_0000223,10116.0,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3389,1,B,BAO_0000223,10116.0,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3390,1,B,BAO_0000019,,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,,,,,
3391,1,B,BAO_0000249,,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,,,,,
3392,1,B,BAO_0000019,10116.0,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,,Rattus norvegicus,,,,
3393,1,B,BAO_0000019,,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,,,,,
3394,1,B,BAO_0000019,,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,,,,,
3395,1,B,BAO_0000019,,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,,,,,
3396,1,B,BAO_0000249,,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,,,,,
3397,1,B,BAO_0000223,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,,,,,
3398,1,B,BAO_0000223,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,,,,,
3399,1,B,BAO_0000223,10116.0,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,,Rattus norvegicus,,,,
3400,1,B,BAO_0000249,,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,,,,,
3401,1,F,BAO_0000221,,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,,,Brain,,
3402,1,F,BAO_0000019,,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,,,,,
3403,1,F,BAO_0000019,,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,,,,,
3404,1,F,BAO_0000218,,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,In vivo,,,,,,
3405,1,B,BAO_0000019,,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,,,,
3406,1,B,BAO_0000357,,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3407,1,B,BAO_0000019,,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,,,,
3408,1,B,BAO_0000019,,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,,,,,
3409,1,B,BAO_0000019,,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,,,,,
3410,1,B,BAO_0000019,,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,,,,
3411,1,B,BAO_0000249,,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,,,,,
3412,1,F,BAO_0000019,10116.0,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,,Rattus norvegicus,,,,
3413,1,B,BAO_0000357,,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3414,1,B,BAO_0000223,,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,,,,,
3415,1,B,BAO_0000019,,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,,,,
3416,1,F,BAO_0000019,,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,,,,,
3417,1,B,BAO_0000223,,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3418,1,B,BAO_0000223,,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3419,1,F,BAO_0000019,10141.0,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,,Cavia porcellus,,,,
3420,1,F,BAO_0000019,10141.0,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,Cavia porcellus,,,,
3421,1,F,BAO_0000019,10141.0,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,,Cavia porcellus,,,,
3422,1,B,BAO_0000223,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3423,1,F,BAO_0000019,,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,,,,,
3424,1,B,BAO_0000223,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,,,,,
3425,1,F,BAO_0000019,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,,,,,
3426,1,F,BAO_0000019,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,,,,,
3427,1,F,BAO_0000019,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,,,,,
3428,1,B,BAO_0000223,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,,,,,
3429,1,F,BAO_0000019,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,,,,,
3430,1,F,BAO_0000019,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,,,,,
3431,1,F,BAO_0000019,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,,,,,
3432,1,B,BAO_0000223,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,,,,,
3433,1,B,BAO_0000223,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,,,,,
3434,1,F,BAO_0000019,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,,,,,
3435,1,B,BAO_0000223,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,,,,,
3436,1,B,BAO_0000223,,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3437,1,B,BAO_0000219,,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,,,,,
3438,1,B,BAO_0000223,,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,,,,,
3439,1,B,BAO_0000219,,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,,,,,NG108-15,
3440,1,B,BAO_0000019,,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,,,,,
3441,1,B,BAO_0000219,,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,,,,,NG108-15,
3442,1,B,BAO_0000223,,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,
3443,1,B,BAO_0000223,,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,
3444,1,B,BAO_0000219,,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,In vitro,,,,,,
3445,1,B,BAO_0000223,,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,,,,
3446,1,F,BAO_0000019,,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,,,,,
3447,1,F,BAO_0000019,10141.0,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,,Cavia porcellus,,,,
3448,1,F,BAO_0000019,10141.0,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,,Cavia porcellus,,,,
3449,1,F,BAO_0000019,10141.0,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,,Cavia porcellus,,,,
3450,1,F,BAO_0000019,10141.0,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,Cavia porcellus,,,,
3451,1,B,BAO_0000223,,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,,,,,
3452,1,B,BAO_0000223,,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3453,1,B,BAO_0000223,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,,,,,
3454,1,B,BAO_0000223,,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,,,,,
3455,1,B,BAO_0000223,,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,,,,,
3456,1,B,BAO_0000223,,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,,,,,
3457,1,B,BAO_0000357,,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,,,,
3458,1,B,BAO_0000223,,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3459,1,B,BAO_0000357,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,,,,,
3460,1,B,BAO_0000357,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3461,1,B,BAO_0000357,,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,,,,,
3462,1,B,BAO_0000223,,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,,,,
3463,1,B,BAO_0000223,,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,,,,,
3464,1,B,BAO_0000223,,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,,,,
3465,1,B,BAO_0000019,,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,,,,
3466,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3467,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,
3468,1,B,BAO_0000357,,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,
3469,1,B,BAO_0000357,,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,,,,
3470,1,B,BAO_0000019,,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,,,,
3471,1,B,BAO_0000357,,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,,,,
3472,1,B,BAO_0000357,,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,,,,,
3473,1,F,BAO_0000019,,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,,,,,
3474,1,B,BAO_0000357,,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,,,,,
3475,1,B,BAO_0000019,,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,,,,,
3476,1,B,BAO_0000019,,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,,,,,
3477,1,B,BAO_0000223,,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,,,,,
3478,1,B,BAO_0000357,,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,,,,
3479,1,F,BAO_0000019,,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,,,,,
3480,1,B,BAO_0000357,,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,,,,
3481,1,F,BAO_0000219,10116.0,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,,Rattus norvegicus,,,Oocytes,
3482,1,F,BAO_0000219,10116.0,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,,Rattus norvegicus,,,Oocytes,
3483,1,F,BAO_0000219,10116.0,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,,Rattus norvegicus,,,Oocytes,
3484,1,F,BAO_0000221,10141.0,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,,Cavia porcellus,,Ileum,,
3485,1,F,BAO_0000221,10141.0,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,,Cavia porcellus,,Ileum,,
3486,1,F,BAO_0000019,10141.0,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,,Cavia porcellus,,,,
3487,1,B,BAO_0000221,10141.0,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,,Cavia porcellus,,Ileum,,
3488,1,B,BAO_0000357,10141.0,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,,Cavia porcellus,,,,
3489,1,B,BAO_0000221,10141.0,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,,Cavia porcellus,,Ileum,,
3490,1,B,BAO_0000221,,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,,,Ileum,,
3491,1,B,BAO_0000357,,3269,Affinity against 5-hydroxytryptamine 7 receptor,,,,,,,
3492,1,B,BAO_0000224,10141.0,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,Cavia porcellus,,,,
3493,1,B,BAO_0000224,10141.0,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,Cavia porcellus,,,,
3494,1,B,BAO_0000221,10141.0,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,,Cavia porcellus,,Ileum,,
3495,1,B,BAO_0000224,10141.0,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,Cavia porcellus,,,,
3496,1,B,BAO_0000224,10141.0,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,Cavia porcellus,,,,
3497,1,F,BAO_0000019,10141.0,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,Cavia porcellus,,,,
3498,1,F,BAO_0000019,10141.0,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,Cavia porcellus,,,,
3499,1,B,BAO_0000219,9606.0,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,,Homo sapiens,,Cardiac atrium,,
3500,1,B,BAO_0000219,9606.0,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,,Homo sapiens,,Cardiac atrium,,
3501,1,F,BAO_0000019,9606.0,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,,Homo sapiens,,,,
3502,1,F,BAO_0000219,9606.0,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,,Homo sapiens,,Cardiac atrium,,
3503,1,B,BAO_0000019,10090.0,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,,Mus musculus,,,,
3504,1,B,BAO_0000019,10090.0,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,,Mus musculus,,,,
3505,1,B,BAO_0000019,,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,,,,,,,
3506,1,B,BAO_0000224,,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,,,,,,,
3507,1,B,BAO_0000019,,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,,,,,
3508,1,B,BAO_0000224,,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,,,,,
3509,1,B,BAO_0000224,,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,,,,,
3510,1,F,BAO_0000019,,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,,,Stomach,,
3511,1,F,BAO_0000019,,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,,,Stomach,,
3512,1,F,BAO_0000019,,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,,,,
3513,1,B,BAO_0000224,,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,,,,,
3514,1,B,BAO_0000224,,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,,,,,
3515,1,B,BAO_0000221,,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,,,Hippocampus,,
3516,1,B,BAO_0000357,,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,,,,,,,
3517,1,B,BAO_0000019,,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,,,,,
3518,1,B,BAO_0000019,10116.0,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,,Rattus norvegicus,,,,
3519,1,B,BAO_0000224,10116.0,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,,Rattus norvegicus,,,,
3520,1,F,BAO_0000019,10116.0,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,,Rattus norvegicus,,Brain,,
3521,1,F,BAO_0000221,10116.0,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,,Rattus norvegicus,,Cerebellum,,
3522,1,B,BAO_0000019,10116.0,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,,Rattus norvegicus,,,,
3523,1,B,BAO_0000224,10116.0,6347,Percent binding affinity against 5-hydroxytryptamine receptor,,,Rattus norvegicus,,,,
3524,1,B,BAO_0000019,,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,,,,,
3525,1,B,BAO_0000224,10116.0,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,,Rattus norvegicus,,,,
3526,1,B,BAO_0000224,10116.0,1579,Affinity against 5-hydroxytryptamine receptor was determined,,,Rattus norvegicus,,,,
3527,1,B,BAO_0000019,10116.0,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,,Rattus norvegicus,,Stomach,,
3528,1,B,BAO_0000219,9606.0,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,,Homo sapiens,,,,
3529,1,B,BAO_0000219,9606.0,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,,Homo sapiens,,,,
3530,1,B,BAO_0000357,,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,,,,,
3531,1,B,BAO_0000357,,15796,Inhibition of 5-hydroxytryptamine reuptake,,,,,,,
3532,1,F,BAO_0000019,,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,,,,,
3533,1,F,BAO_0000019,,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,,,,,
3534,1,F,BAO_0000019,,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,,,,,
3535,1,F,BAO_0000019,,12409,Tested for 5-hydroxytryptamine receptor uptake,,,,,,,
3536,1,B,BAO_0000219,9606.0,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,Homo sapiens,,,CHO,
3537,1,F,BAO_0000019,9606.0,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,,Homo sapiens,,,,
3538,1,B,BAO_0000249,9606.0,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,,Homo sapiens,,,,
3539,1,B,BAO_0000357,,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,,,,,
3540,1,B,BAO_0000249,,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,,,,,
3541,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,,,Striatum,,
3542,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,,,Striatum,,
3543,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,,,Striatum,,
3544,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,,,Striatum,,
3545,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,,,Striatum,,
3546,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,,,Striatum,,
3547,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,,,Striatum,,
3548,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,,,Striatum,,
3549,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,,,Striatum,,
3550,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,,,Striatum,,
3551,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,,,Striatum,,
3552,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,,,Limbic system,,
3553,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,,,Limbic system,,
3554,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,,,Limbic system,,
3555,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,,,Limbic system,,
3556,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,,,Limbic system,,
3557,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,,,Limbic system,,
3558,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,,,Limbic system,,
3559,1,B,BAO_0000357,,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,
3560,1,F,BAO_0000019,,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,
3561,1,B,BAO_0000357,,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,,,,,
3562,1,B,BAO_0000357,,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,,,,,
3563,1,B,BAO_0000357,,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,,,,,
3564,1,B,BAO_0000357,,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,
3565,1,B,BAO_0000357,,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,,,,
3566,1,B,BAO_0000357,,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,,,,
3567,1,B,BAO_0000219,,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,,,,,COS-7,
3568,1,B,BAO_0000219,,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,,,,,COS-7,
3569,1,B,BAO_0000219,,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,,,,,COS-7,
3570,1,B,BAO_0000219,,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,,,,,COS-7,
3571,1,B,BAO_0000219,,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,,,C6,
3572,1,B,BAO_0000219,,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,,,C6,
3573,1,B,BAO_0000219,,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,,,,,C6,
3574,1,B,BAO_0000219,,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,,,,,C6,
3575,1,B,BAO_0000357,,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,,,,,
3576,1,B,BAO_0000357,,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,,,,,
3577,1,B,BAO_0000357,9606.0,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,,,Homo sapiens,,,,
3578,1,B,BAO_0000219,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,,,,,CHO,
3579,1,B,BAO_0000357,9606.0,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,,Homo sapiens,,,,
3580,1,B,BAO_0000357,9606.0,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,,Homo sapiens,,,,
3581,1,B,BAO_0000357,9606.0,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,,Homo sapiens,,,,
3582,1,B,BAO_0000357,9606.0,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,,Homo sapiens,,,,
3583,1,B,BAO_0000357,,6013,Binding affinity towards 5-HT5A receptor,,,,,,,
3584,1,B,BAO_0000357,,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,,,,
3585,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,,,,,
3586,1,B,BAO_0000357,,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,,,,,,,
3587,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,,HEK293,
3588,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,,,HEK293,
3589,1,B,BAO_0000219,,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,,,,,HEK293,
3590,1,B,BAO_0000357,10090.0,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,,Mus musculus,,,,
3591,1,B,BAO_0000357,10090.0,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,Mus musculus,,,,
3592,1,B,BAO_0000357,10090.0,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,,Mus musculus,,,,
3593,1,B,BAO_0000357,10090.0,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,,Mus musculus,,,,
3594,1,B,BAO_0000357,10090.0,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,,Mus musculus,,,,
3595,1,B,BAO_0000357,,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,,,,
3596,1,B,BAO_0000219,,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,,,HEK293,
3597,1,B,BAO_0000219,,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,,,HEK293,
3598,1,B,BAO_0000357,,4820,Binding affinity towards 5-HT5a receptor,,,,,,,
3599,1,B,BAO_0000357,9606.0,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,,,Homo sapiens,,,,
3600,1,B,BAO_0000357,,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,,,,,
3601,1,B,BAO_0000357,,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,,,,,
3602,1,B,BAO_0000357,,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,,,,,,,
3603,1,B,BAO_0000357,,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,,,,,
3604,1,B,BAO_0000357,,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,,,,,
3605,1,F,BAO_0000019,10141.0,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,,Cavia porcellus,,,,
3606,1,B,BAO_0000223,,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,,,,,
3607,1,B,BAO_0000357,9606.0,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,,,Homo sapiens,,,,
3608,1,B,BAO_0000357,9606.0,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,,Homo sapiens,,,,
3609,1,B,BAO_0000357,,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,,,,,,,
3610,1,B,BAO_0000357,9606.0,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,,Homo sapiens,,,,
3611,1,B,BAO_0000219,,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,,,,,HeLa,
3612,1,B,BAO_0000357,9606.0,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,,Homo sapiens,,,,
3613,1,B,BAO_0000357,9606.0,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,Homo sapiens,,,,
3614,1,B,BAO_0000357,9606.0,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,Homo sapiens,,,,
3615,1,B,BAO_0000357,9606.0,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,,Homo sapiens,,,,
3616,1,B,BAO_0000357,9606.0,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,,,Homo sapiens,,,,
3617,1,B,BAO_0000357,,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,
3618,1,B,BAO_0000357,,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,
3619,1,B,BAO_0000219,,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,,,,,HEK293,
3620,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,,,,,
3621,1,B,BAO_0000219,,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,,,,,HEK293,
3622,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,
3623,1,B,BAO_0000219,9606.0,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,Homo sapiens,,,HEK293,
3624,1,B,BAO_0000019,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,,,,,
3625,1,B,BAO_0000019,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,,,,
3626,1,B,BAO_0000219,,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,,,,,COS-7,
3627,1,B,BAO_0000357,9606.0,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,,Homo sapiens,,,,
3628,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,,,,,
3629,1,B,BAO_0000357,,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,,,,,
3630,1,B,BAO_0000219,,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,,,,HEK293,
3631,1,F,BAO_0000019,,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,,,,,
3632,1,B,BAO_0000357,,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,,,,,
3633,1,B,BAO_0000357,,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,,,,
3634,1,B,BAO_0000219,9606.0,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,,Homo sapiens,,,HeLa,
3635,1,B,BAO_0000219,9606.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,,Homo sapiens,,,HeLa,
3636,1,B,BAO_0000219,,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,,,,,HeLa,
3637,1,B,BAO_0000219,,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,,,HeLa,
3638,1,B,BAO_0000219,,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,,,HeLa,
3639,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,,,CHO,
3640,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,,HEK293,
3641,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,,,,,HEK293,
3642,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,,,HEK293,
3643,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,,,,,HeLa,
3644,1,B,BAO_0000357,,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,
3645,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,,,,,HeLa,
3646,1,B,BAO_0000357,,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,,,,,
3647,1,B,BAO_0000357,,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,,,,
3648,1,B,BAO_0000219,,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,,,,,HeLa,
3649,1,B,BAO_0000357,,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,,,,,
3650,1,B,BAO_0000219,,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,,,,,
3651,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,,,,,HeLa,
3652,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,,,,,HeLa,
3653,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,,,,,HeLa,
3654,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,,,,,HeLa,
3655,1,B,BAO_0000219,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,,,,,CHO,
3656,1,B,BAO_0000019,,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,,,,,
3657,1,B,BAO_0000357,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,,,,,
3658,1,B,BAO_0000357,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,,,,,
3659,1,B,BAO_0000219,9606.0,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,,Homo sapiens,,,HeLa,
3660,1,B,BAO_0000357,,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,
3661,1,B,BAO_0000357,,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,,,,,
3662,1,F,BAO_0000019,9606.0,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,Homo sapiens,,,,
3663,1,B,BAO_0000357,,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,,,,,
3664,1,B,BAO_0000357,,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,
3665,1,B,BAO_0000357,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,,,,,
3666,1,B,BAO_0000357,,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,,,,,
3667,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,,,,,
3668,1,F,BAO_0000019,,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,,,,,
3669,1,F,BAO_0000019,,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,,,,,
3670,1,B,BAO_0000357,,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,,,,,
3671,1,B,BAO_0000357,,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,,,,,
3672,1,B,BAO_0000357,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,,,,,
3673,1,B,BAO_0000357,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,,,,,
3674,1,B,BAO_0000357,,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,,,,,,,
3675,1,B,BAO_0000357,,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,,,,,
3676,1,B,BAO_0000357,9606.0,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,,,Homo sapiens,,,,
3677,1,B,BAO_0000357,,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,,,,,
3678,1,B,BAO_0000357,,3269,Affinity against 5-hydroxytryptamine 6 receptor,,,,,,,
3679,1,B,BAO_0000357,,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,,,,,
3680,1,B,BAO_0000357,9606.0,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,,,Homo sapiens,,,,
3681,1,B,BAO_0000219,,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,,,,,HEK293,
3682,1,B,BAO_0000357,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,,,,,
3683,1,B,BAO_0000357,,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,,,,,
3684,1,B,BAO_0000219,,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,,,,,HEK293,
3685,1,B,BAO_0000357,9606.0,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,,Homo sapiens,,,,
3686,1,B,BAO_0000219,,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,,,,,CHO,
3687,1,B,BAO_0000357,9606.0,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,Homo sapiens,,,,
3688,1,B,BAO_0000357,9606.0,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,,Homo sapiens,,,,
3689,1,B,BAO_0000357,9606.0,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,,,Homo sapiens,,,,
3690,1,B,BAO_0000219,,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,,,,,CHO,
3691,1,B,BAO_0000357,,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,,,,,
3692,1,B,BAO_0000357,,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,,,
3693,1,B,BAO_0000357,,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,,,,
3694,1,B,BAO_0000357,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,,,,,
3695,1,B,BAO_0000357,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,,,,
3696,1,B,BAO_0000219,,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,,,,,HEK293,
3697,1,B,BAO_0000019,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,,,,,
3698,1,B,BAO_0000019,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,,,,
3699,1,B,BAO_0000357,9606.0,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,,Homo sapiens,,,,
3700,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,,,,,
3701,1,B,BAO_0000357,,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,,,,,
3702,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,,,,,CHO,
3703,1,B,BAO_0000019,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,,,,,
3704,1,B,BAO_0000357,,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,,,,,
3705,1,B,BAO_0000357,,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,,,,,
3706,1,B,BAO_0000219,9606.0,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,Homo sapiens,,,COS-7,
3707,1,B,BAO_0000219,,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,,,,COS-7,
3708,1,B,BAO_0000219,9606.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,,Homo sapiens,,,HEK293,
3709,1,B,BAO_0000357,,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,,,,,
3710,1,B,BAO_0000219,,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,,,,,HEK293,
3711,1,B,BAO_0000357,,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,,,,,
3712,1,B,BAO_0000357,,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,,,,,
3713,1,B,BAO_0000219,,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,,,,,
3714,1,B,BAO_0000219,,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,,,,,HEK293,
3715,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,,,HEK293,
3716,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,,,HEK293,
3717,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,,,HEK293,
3718,1,B,BAO_0000219,,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,,,,,HEK293,
3719,1,B,BAO_0000219,,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,,,,,CHO,
3720,1,B,BAO_0000219,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,,,,,HEK293,
3721,1,B,BAO_0000219,,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,,,,,HEK293,
3722,1,B,BAO_0000219,,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,,,,,HEK293,
3723,1,B,BAO_0000219,,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,,,,,HEK293,
3724,1,B,BAO_0000357,,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,,,,,
3725,1,B,BAO_0000219,,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,,,,,COS-7,
3726,1,B,BAO_0000219,,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,,,,,HEK293,
3727,1,B,BAO_0000219,,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,,,,,HEK293,
3728,1,B,BAO_0000219,,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,,,,,HEK293,
3729,1,B,BAO_0000219,9606.0,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,,Homo sapiens,,,HEK293,
3730,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,,,,,HEK293,
3731,1,B,BAO_0000219,,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,,,,,HEK293,
3732,1,B,BAO_0000219,,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,,,,,HEK293,
3733,1,B,BAO_0000357,9606.0,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,,Homo sapiens,,,,
3734,1,B,BAO_0000357,10090.0,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,Mus musculus,,,,
3735,1,B,BAO_0000019,9986.0,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,,Oryctolagus cuniculus,,,,
3736,1,B,BAO_0000219,,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,,,,,CHO,
3737,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,,,,,CHO,
3738,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,,,,,CHO,
3739,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,,,,,CHO,
3740,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,,,,,CHO,
3741,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,,,,,CHO,
3742,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,,,,,CHO,
3743,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,,,,,CHO,
3744,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,,,,,CHO,
3745,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,,,,,CHO,
3746,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,,,,,CHO,
3747,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,,,,,CHO,
3748,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,,,,,CHO,
3749,1,B,BAO_0000357,,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,,,,,
3750,1,B,BAO_0000357,10116.0,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,Rattus norvegicus,,,,
3751,1,B,BAO_0000357,,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,,,,,
3752,1,B,BAO_0000019,,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,,,,,
3753,1,B,BAO_0000357,10116.0,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,,Rattus norvegicus,,,,
3754,1,B,BAO_0000357,10116.0,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,,Rattus norvegicus,,,,
3755,1,B,BAO_0000219,10116.0,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,,Rattus norvegicus,,,CHO,
3756,1,B,BAO_0000357,,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,,,,
3757,1,B,BAO_0000357,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,,,,,
3758,1,B,BAO_0000219,,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,,,,,CHO,
3759,1,B,BAO_0000219,,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,,,,,CHO,
3760,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,,,,,CHO,
3761,1,B,BAO_0000219,,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,,,,,CHO,
3762,1,F,BAO_0000221,,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,,,Ileum,,
3763,1,F,BAO_0000221,,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,,,Ileum,,
3764,1,F,BAO_0000221,,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,,,,Ileum,,
3765,1,B,BAO_0000249,10116.0,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,,Rattus norvegicus,,,,Membranes
3766,1,B,BAO_0000357,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,,,,,
3767,1,B,BAO_0000357,,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,,,,,
3768,1,B,BAO_0000019,,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,,,,Hypothalamus,,
3769,1,B,BAO_0000357,,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,,,,,
3770,1,B,BAO_0000249,,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,,,,Hypothalamus,,
3771,1,B,BAO_0000357,,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,,,
3772,1,F,BAO_0000219,10116.0,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,,Rattus norvegicus,,,HEK293,
3773,1,F,BAO_0000219,10116.0,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,,Rattus norvegicus,,,HEK293,
3774,1,F,BAO_0000219,10116.0,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,,Rattus norvegicus,,,HEK293,
3775,1,B,BAO_0000357,,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,,,
3776,1,B,BAO_0000357,,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,,,,,
3777,1,B,BAO_0000357,,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,,,,,
3778,1,B,BAO_0000357,9606.0,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,Homo sapiens,,,,
3779,1,B,BAO_0000357,,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,,,,,
3780,1,B,BAO_0000357,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,,,,,
3781,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,,,,
3782,1,F,BAO_0000019,,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,,,,,
3783,1,B,BAO_0000357,,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,,,,,
3784,1,B,BAO_0000357,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,,,,
3785,1,B,BAO_0000357,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,,,,,
3786,1,B,BAO_0000357,,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,,,,,
3787,1,B,BAO_0000357,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,,,,,
3788,1,B,BAO_0000357,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,,,,,
3789,1,B,BAO_0000357,,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,,,,,,,
3790,1,B,BAO_0000357,,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,,,,,
3791,1,B,BAO_0000357,,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,,,,,
3792,1,B,BAO_0000357,,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,,,,,
3793,1,B,BAO_0000221,,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,,,Ileum,,
3794,1,F,BAO_0000019,,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,,,,,
3795,1,F,BAO_0000019,9606.0,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,,Homo sapiens,,,,
3796,1,B,BAO_0000357,,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,,,,,
3797,1,B,BAO_0000357,,409,In vitro inhibition of human recombinant lipoxygenase enzyme,,,,,,,
3798,1,B,BAO_0000357,,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,,,,,
3799,1,B,BAO_0000357,,11090,Inhibition of 5-lipoxygenase in human whole blood.,,,,,Blood,,
3800,1,B,BAO_0000357,,11090,Inhibition of 5-lipoxygenase in human whole blood.,,,,,Blood,,
3801,1,B,BAO_0000357,,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,,,,,
3802,1,B,BAO_0000357,,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,,,,,
3803,1,F,BAO_0000219,,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,,,,,
3804,1,F,BAO_0000019,,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,,,,Blood,,
3805,1,B,BAO_0000357,,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,,,,,
3806,1,B,BAO_0000357,,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,,,,,
3807,1,B,BAO_0000357,,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,,,,,
3808,1,B,BAO_0000357,,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,,,,,
3809,1,B,BAO_0000357,9606.0,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,,Homo sapiens,,Blood,,
3810,1,B,BAO_0000357,,12703,In vitro potency against human 5-Lipoxygenase,,,,,,,
3811,1,F,BAO_0000019,9606.0,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,,Homo sapiens,,,,
3812,1,F,BAO_0000019,,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,,,,Blood,,
3813,1,F,BAO_0000019,,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,,,,
3814,1,B,BAO_0000219,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,,,,,
3815,1,B,BAO_0000219,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,,,,,
3816,1,B,BAO_0000219,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,,,,,
3817,1,B,BAO_0000219,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,,,,,
3818,1,B,BAO_0000219,,12365,Inhibition of human 5-lipoxygenase in human cells,,,,,,,
3819,1,B,BAO_0000357,,10603,Inhibition of human neutrophil 5-lipoxygenase,,,,,,,
3820,1,B,BAO_0000019,,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,,,,,
3821,1,B,BAO_0000357,,12281,Inhibition of 5-lipoxygenase from human whole blood,,,,,Blood,,
3822,1,B,BAO_0000357,,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,,,,
3823,1,B,BAO_0000219,,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,,,,,
3824,1,B,BAO_0000357,,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,,,,,
3825,1,B,BAO_0000357,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,,,
3826,1,B,BAO_0000357,,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,,,,,
3827,1,B,BAO_0000357,,12780,Tested against 5-lipoxygenase,,,,,,,
3828,1,B,BAO_0000357,,12780,Tested for activity against 5-Lipoxygenase (5-LO),,,,,,,
3829,1,B,BAO_0000357,,12780,Tested for activity against 5-lipoxygenase,,,,,,,
3830,1,B,BAO_0000357,,11966,Tested for inhibition of 5-HPETE production by human 5-LO,,,,,,,
3831,1,F,BAO_0000019,,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,,,,
3832,1,B,BAO_0000357,,13165,Inhibition of Human 5-lipoxygenase,,,,,,,
3833,1,B,BAO_0000019,,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,,,,,
3834,1,B,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,,,,
3835,1,B,BAO_0000219,,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,,,,,
3836,1,B,BAO_0000019,,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,,,,,
3837,1,B,BAO_0000019,,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,,,,,
3838,1,B,BAO_0000357,,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,,,,Blood,,
3839,1,B,BAO_0000357,,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,,,,,
3840,1,B,BAO_0000357,,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,,,
3841,1,B,BAO_0000019,,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,,,,,
3842,1,B,BAO_0000357,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,,,
3843,1,B,BAO_0000219,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,,,,,
3844,1,B,BAO_0000219,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,,,,,
3845,1,B,BAO_0000219,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,,,,,
3846,1,B,BAO_0000219,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,,,,,
3847,1,B,BAO_0000357,,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,,,,,
3848,1,B,BAO_0000357,,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,,,,,
3849,1,B,BAO_0000357,,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,,,,,
3850,1,B,BAO_0000357,,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,,,,
3851,1,B,BAO_0000357,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,,,,,
3852,1,B,BAO_0000357,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,,,
3853,1,B,BAO_0000019,,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,,,,,
3854,1,B,BAO_0000019,,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,,,,,
3855,1,B,BAO_0000357,,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,,,,,
3856,1,B,BAO_0000357,,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,,,,
3857,1,F,BAO_0000019,,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,,,,
3858,1,B,BAO_0000357,,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,,,,,
3859,1,B,BAO_0000357,,10603,Inhibition of lipoxygenase at the concentration of 1 uM,,,,,,,
3860,1,B,BAO_0000357,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,,,,,
3861,1,B,BAO_0000357,9606.0,14580,Inhibition of 5-Lipoxygenase (5-LOX),,,Homo sapiens,,,,
3862,1,B,BAO_0000357,,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,,,,
3863,1,B,BAO_0000357,,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,,,,
3864,1,B,BAO_0000357,,6339,Inhibitory activity against lipoxygenase-2 in mice,,,,,,,
3865,1,B,BAO_0000357,,6339,Inhibitory activity against murine lipoxygenase-2.,,,,,,,
3866,1,B,BAO_0000357,10090.0,12281,Inhibition of 5-lipoxygenase from mouse macrophage,,,Mus musculus,,,,
3867,1,B,BAO_0000357,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,,,,,
3868,1,B,BAO_0000019,9823.0,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,Sus scrofa,,,,
3869,1,B,BAO_0000019,9823.0,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,,Sus scrofa,,,,
3870,1,B,BAO_0000019,9986.0,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,,Oryctolagus cuniculus,,,,
3871,1,B,BAO_0000019,10116.0,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,,Rattus norvegicus,,,,
3872,1,B,BAO_0000019,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,,,,,
3873,1,B,BAO_0000019,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,,,,
3874,1,B,BAO_0000019,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,,,,,
3875,1,B,BAO_0000019,,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,,,,,
3876,1,B,BAO_0000019,,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,,,,,
3877,1,B,BAO_0000019,,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,,,,,
3878,1,B,BAO_0000019,,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,,,,,
3879,1,B,BAO_0000019,,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,,,,,
3880,1,B,BAO_0000219,,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,,,,RBL-1,
3881,1,B,BAO_0000219,,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,,,,RBL-1,
3882,1,B,BAO_0000357,,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,,,,,
3883,1,B,BAO_0000357,,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,,,,,
3884,1,B,BAO_0000357,,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,,,,,
3885,1,B,BAO_0000357,,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,,,,
3886,1,B,BAO_0000019,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,,,,
3887,1,B,BAO_0000019,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,,,,,
3888,1,B,BAO_0000219,10116.0,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,,Rattus norvegicus,,,RBL-2H3,
3889,1,B,BAO_0000357,,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,,,,
3890,1,B,BAO_0000357,,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,,,,,
3891,1,B,BAO_0000219,,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,,,,,RBL-1,
3892,1,B,BAO_0000219,10116.0,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,,Rattus norvegicus,,,RBL-1,
3893,1,B,BAO_0000357,,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,,,,,
3894,1,B,BAO_0000219,,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,,,,,RBL-1,
3895,1,B,BAO_0000219,,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,,,,,RBL-1,
3896,1,B,BAO_0000219,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,,,,RBL-1,
3897,1,B,BAO_0000219,,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,,,,,RBL-1,
3898,1,B,BAO_0000357,,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,,,,,
3899,1,B,BAO_0000357,,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,,,,,
3900,1,B,BAO_0000357,,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,,,,,
3901,1,B,BAO_0000019,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,,,,,
3902,1,B,BAO_0000019,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,,,,,
3903,1,B,BAO_0000019,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,,,,,
3904,1,B,BAO_0000019,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,,,,,
3905,1,F,BAO_0000219,,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,,,,,RBL-1,
3906,1,B,BAO_0000219,,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,,,,,RBL-1,
3907,1,B,BAO_0000219,,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,,,,,RBL-1,
3908,1,B,BAO_0000019,,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,,,,,
3909,1,B,BAO_0000357,10116.0,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,,Rattus norvegicus,,,,
3910,1,B,BAO_0000219,,9295,In vitro inhibitory activity against RBL-1 5-LO,,,,,,RBL-1,
3911,1,B,BAO_0000219,,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,,,,,RBL-1,
3912,1,B,BAO_0000219,,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,,,,,RBL-1,
3913,1,B,BAO_0000218,,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,,,,,
3914,1,B,BAO_0000357,,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,,,,,
3915,1,B,BAO_0000218,,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,,,,,
3916,1,B,BAO_0000219,,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,,,,,RBL-1,
3917,1,B,BAO_0000019,,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,,,,Blood,,
3918,1,B,BAO_0000357,,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,,,,,
3919,1,F,BAO_0000019,,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,,,,,
3920,1,F,BAO_0000219,,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,,,,,
3921,1,B,BAO_0000219,,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,,,,,RBL-1,
3922,1,B,BAO_0000357,,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,,,,,
3923,1,B,BAO_0000219,,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,,,,,RBL-1,
3924,1,B,BAO_0000219,,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,,,,,RBL-1,
3925,1,B,BAO_0000219,,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,,,,,RBL-1,
3926,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase,,,,,,RBL-1,
3927,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,,,,,RBL-1,
3928,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,,,,,RBL-1,
3929,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,,,,,RBL-1,
3930,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,,,,,RBL-1,
3931,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,,,,,RBL-1,
3932,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,,,,,RBL-1,
3933,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,,,,,RBL-1,
3934,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,,,,,RBL-1,
3935,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,,,,,RBL-1,
3936,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,,,,,RBL-1,
3937,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,,,,,RBL-1,
3938,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,,,,,RBL-1,
3939,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,,,,,RBL-1,
3940,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,,,,,RBL-1,
3941,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,,,,,RBL-1,
3942,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,,,,,RBL-1,
3943,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,,,,,RBL-1,
3944,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,,,,,RBL-1,
3945,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,,,,,RBL-1,
3946,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,,,,,RBL-1,
3947,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,,,,,RBL-1,
3948,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,,,,,RBL-1,
3949,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,,,,,RBL-1,
3950,1,B,BAO_0000019,,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,,,,,
3951,1,B,BAO_0000019,,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,,,,,
3952,1,F,BAO_0000219,,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,,,,,RBL-2H3,
3953,1,F,BAO_0000219,,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,,,,,RBL-2H3,
3954,1,B,BAO_0000219,10116.0,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,,Rattus norvegicus,,,RBL-1,
3955,1,B,BAO_0000019,,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,,,,,
3956,1,B,BAO_0000019,,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,,,,,
3957,1,B,BAO_0000219,10116.0,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,Rattus norvegicus,,,RBL-1,
3958,1,B,BAO_0000219,,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,,,,,RBL-1,
3959,1,B,BAO_0000357,,137,In vitro inhibitory activity against 5-lipoxygenase was determined,,,,,,,
3960,1,B,BAO_0000219,,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,,,,,RBL-1,
3961,1,B,BAO_0000219,,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,,,,,RBL-1,
3962,1,F,BAO_0000019,10116.0,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,,Rattus norvegicus,,,,
3963,1,B,BAO_0000219,,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,,,,,RBL-1,
3964,1,B,BAO_0000019,,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,,,,,
3965,1,B,BAO_0000219,,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,,,,,RBL-1,
3966,1,B,BAO_0000357,,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,,,,,
3967,1,B,BAO_0000219,10116.0,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,,Rattus norvegicus,,,RBL-1,
3968,1,B,BAO_0000219,10116.0,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,,Rattus norvegicus,,,RBL-1,
3969,1,B,BAO_0000219,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,,,RBL-1,
3970,1,B,BAO_0000219,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,,,,RBL-1,
3971,1,B,BAO_0000219,10116.0,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,,Rattus norvegicus,,,RBL-1,
3972,1,B,BAO_0000219,,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,,,RBL-1,
3973,1,F,BAO_0000019,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,,,,Limbic system,,
3974,1,F,BAO_0000019,,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,,,Limbic system,,
3975,1,F,BAO_0000019,,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,,,,,
3976,1,B,BAO_0000221,,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,,Hippocampus,,
3977,1,B,BAO_0000221,,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,,Hippocampus,,
3978,1,B,BAO_0000019,,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,,,,
3979,1,F,BAO_0000019,9615.0,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,,Canis lupus familiaris,,Blood,,
3980,1,F,BAO_0000019,,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,,,,Blood,,
3981,1,B,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,,,,
3982,1,B,BAO_0000219,,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,,,,,
3983,1,B,BAO_0000219,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,,,,,
3984,1,B,BAO_0000219,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,,,,,
3985,1,B,BAO_0000219,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,,,,
3986,1,B,BAO_0000219,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,,,,
3987,1,B,BAO_0000357,,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,,,,,
3988,1,B,BAO_0000357,,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,,,,,
3989,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
3990,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
3991,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
3992,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
3993,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
3994,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
3995,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
3996,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
3997,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
3998,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
3999,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4000,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4001,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4002,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4003,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4004,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4005,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4006,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4007,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4008,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4009,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4010,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4011,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4012,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4013,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4014,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4015,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4016,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4017,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4018,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4019,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4020,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4021,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4022,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4023,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4024,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4025,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4026,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4027,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4028,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4029,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4030,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4031,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4032,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4033,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4034,1,F,BAO_0000218,9615.0,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,Canis lupus familiaris,,Blood,,
4035,1,B,BAO_0000218,9615.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,,Canis lupus familiaris,,,,
4036,1,B,BAO_0000218,9615.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,,Canis lupus familiaris,,,,
4037,1,B,BAO_0000218,9615.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,,Canis lupus familiaris,,,,
4038,1,B,BAO_0000218,9615.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,,Canis lupus familiaris,,,,
4039,1,B,BAO_0000218,9615.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,,Canis lupus familiaris,,,,
4040,1,B,BAO_0000218,9615.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,,Canis lupus familiaris,,,,
4041,1,B,BAO_0000218,9615.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,,Canis lupus familiaris,,,,
4042,1,B,BAO_0000218,9615.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,,Canis lupus familiaris,,,,
4043,1,B,BAO_0000357,10141.0,9203,Ability to inhibit 5-lipoxygenase in guinea pig,,,Cavia porcellus,,,,
4044,1,B,BAO_0000357,10141.0,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,,Cavia porcellus,,,,
4045,1,B,BAO_0000357,10141.0,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,,Cavia porcellus,,,,
4046,1,B,BAO_0000218,10141.0,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,,Cavia porcellus,,Blood,,
4047,1,B,BAO_0000357,10141.0,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,,Cavia porcellus,,,,
4048,1,B,BAO_0000357,10141.0,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,,Cavia porcellus,,,,
4049,1,B,BAO_0000019,10141.0,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,,Cavia porcellus,,,,
4050,1,B,BAO_0000019,10141.0,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,Cavia porcellus,,,,
4051,1,B,BAO_0000019,10141.0,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,Cavia porcellus,,,,
4052,1,B,BAO_0000019,10141.0,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,Cavia porcellus,,,,
4053,1,B,BAO_0000357,10141.0,7788,Inhibitory activity against 5-lipoxygenase,,,Cavia porcellus,,,,
4054,1,B,BAO_0000357,10141.0,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,,Cavia porcellus,,,,
4055,1,B,BAO_0000357,10141.0,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,,Cavia porcellus,,,,
4056,1,B,BAO_0000357,10141.0,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,,Cavia porcellus,,,,
4057,1,B,BAO_0000357,10141.0,13243,Inhibitory activity uM,,,Cavia porcellus,,,,
4058,1,B,BAO_0000219,10141.0,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,,Cavia porcellus,,,,
4059,1,B,BAO_0000357,10141.0,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,,,Cavia porcellus,,,,
4060,1,B,BAO_0000357,10141.0,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,Cavia porcellus,,,,
4061,1,B,BAO_0000357,10141.0,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,,Cavia porcellus,,,,
4062,1,B,BAO_0000357,10141.0,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,Cavia porcellus,,,,
4063,1,B,BAO_0000357,10141.0,13243,Inhibitory activity uM,,,Cavia porcellus,,,,
4064,1,B,BAO_0000357,10141.0,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,,Cavia porcellus,,,,
4065,1,B,BAO_0000357,10141.0,13243,Inhibitory activity uM,,,Cavia porcellus,,,,
4066,1,F,BAO_0000019,10141.0,13243,Inhibitory activity uM,,,Cavia porcellus,,,,
4067,1,B,BAO_0000019,10141.0,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,Cavia porcellus,,,,
4068,1,B,BAO_0000357,10141.0,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,Cavia porcellus,,,,
4069,1,F,BAO_0000221,10141.0,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,,Cavia porcellus,,Ileum,,
4070,1,B,BAO_0000357,,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,,,
4071,1,B,BAO_0000357,,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,,,
4072,1,B,BAO_0000357,,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,,,,,
4073,1,B,BAO_0000357,,12780,In vitro inhibition of human 5-Lipoxygenase.,,,,,,,
4074,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,Rattus norvegicus,,Liver,,Microsomes
4075,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,Rattus norvegicus,,Liver,,Microsomes
4076,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,Rattus norvegicus,,Liver,,Microsomes
4077,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,,Rattus norvegicus,,Liver,,Microsomes
4078,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,Rattus norvegicus,,Liver,,Microsomes
4079,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,Rattus norvegicus,,Liver,,Microsomes
4080,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,Rattus norvegicus,,Liver,,Microsomes
4081,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,Rattus norvegicus,,Liver,,Microsomes
4082,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,Rattus norvegicus,,Liver,,Microsomes
4083,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,Rattus norvegicus,,Liver,,Microsomes
4084,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,Rattus norvegicus,,Liver,,Microsomes
4085,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,,Rattus norvegicus,,Liver,,Microsomes
4086,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,Rattus norvegicus,,Liver,,Microsomes
4087,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,Rattus norvegicus,,Liver,,Microsomes
4088,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,Rattus norvegicus,,Liver,,Microsomes
4089,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,,Rattus norvegicus,,Liver,,Microsomes
4090,1,B,BAO_0000251,10116.0,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,Rattus norvegicus,,Liver,,Microsomes
4091,1,B,BAO_0000251,10116.0,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,Rattus norvegicus,,Liver,,Microsomes
4092,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,,Rattus norvegicus,,Liver,,Microsomes
4093,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,,Rattus norvegicus,,Liver,,Microsomes
4094,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,,Rattus norvegicus,,Liver,,Microsomes
4095,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,,Rattus norvegicus,,Liver,,Microsomes
4096,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,,Rattus norvegicus,,Liver,,Microsomes
4097,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,Rattus norvegicus,,Liver,,Microsomes
4098,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,Rattus norvegicus,,Liver,,Microsomes
4099,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,,Rattus norvegicus,,Liver,,Microsomes
4100,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,,Rattus norvegicus,,Liver,,Microsomes
4101,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,Rattus norvegicus,,Liver,,Microsomes
4102,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,Rattus norvegicus,,Liver,,Microsomes
4103,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,Rattus norvegicus,,Liver,,Microsomes
4104,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,Rattus norvegicus,,Liver,,Microsomes
4105,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,Rattus norvegicus,,Liver,,Microsomes
4106,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,Rattus norvegicus,,Liver,,Microsomes
4107,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,Rattus norvegicus,,Liver,,Microsomes
4108,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,Rattus norvegicus,,Liver,,Microsomes
4109,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,Rattus norvegicus,,Liver,,Microsomes
4110,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,Rattus norvegicus,,Liver,,Microsomes
4111,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,Rattus norvegicus,,Liver,,Microsomes
4112,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,Rattus norvegicus,,Liver,,Microsomes
4113,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,Rattus norvegicus,,Liver,,Microsomes
4114,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,Rattus norvegicus,,Liver,,Microsomes
4115,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,Rattus norvegicus,,Liver,,Microsomes
4116,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,,Rattus norvegicus,,Liver,,Microsomes
4117,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,,Rattus norvegicus,,Liver,,Microsomes
4118,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,,Rattus norvegicus,,Liver,,Microsomes
4119,1,B,BAO_0000251,10116.0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,,Rattus norvegicus,,Liver,,Microsomes
4120,1,B,BAO_0000251,10116.0,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,Rattus norvegicus,,Liver,,Microsomes
4121,1,B,BAO_0000251,10116.0,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,,Rattus norvegicus,,,,Microsomes
4122,1,B,BAO_0000251,10116.0,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,Rattus norvegicus,,Liver,,Microsomes
4123,1,B,BAO_0000251,10116.0,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,Rattus norvegicus,,Liver,,Microsomes
4124,1,B,BAO_0000251,10116.0,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,,Rattus norvegicus,,Liver,,Microsomes
4125,1,B,BAO_0000251,10116.0,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,Rattus norvegicus,,Liver,,Microsomes
4126,1,B,BAO_0000251,10116.0,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,Rattus norvegicus,,Liver,,Microsomes
4127,1,F,BAO_0000219,9606.0,10797,In vitro inhibition of 7226/S myeloma cancer cell line,,,Homo sapiens,,,RPMI-8226,
4128,1,F,BAO_0000219,9606.0,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,,Homo sapiens,,,BEL-7404 tumor cell line,
4129,1,F,BAO_0000219,9606.0,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,,Homo sapiens,,,786-0,
4130,1,F,BAO_0000219,9606.0,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,,Homo sapiens,,,786-0,
4131,1,F,BAO_0000219,10029.0,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,,Cricetulus griseus,,,V79,
4132,1,F,BAO_0000219,10029.0,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,,Cricetulus griseus,,,V79,
4133,1,F,BAO_0000219,10116.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,,Rattus norvegicus,,,7800C1 cell line,
4134,1,F,BAO_0000219,10116.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,,Rattus norvegicus,,,7800C1 cell line,
4135,1,F,BAO_0000219,10116.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,,Rattus norvegicus,,,7800C1 cell line,
4136,1,F,BAO_0000219,10116.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,,Rattus norvegicus,,,7800C1 cell line,
4137,1,F,BAO_0000219,10116.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,,Rattus norvegicus,,,7800C1 cell line,
4138,1,F,BAO_0000219,10116.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,,Rattus norvegicus,,,7800C1 cell line,
4139,1,F,BAO_0000219,9606.0,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,,,Homo sapiens,,,786-0,
4140,1,F,BAO_0000219,9606.0,12858,Cytotoxic activity against 786-0 Renal cancer cell line,,,Homo sapiens,,,786-0,
4141,1,F,BAO_0000219,9606.0,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,,Homo sapiens,,,786-0,
4142,1,F,BAO_0000219,9606.0,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,,Homo sapiens,,,786-0,
4143,1,F,BAO_0000219,9606.0,5858,In vitro antitumor activity against human renal 786-0 cell line,,,Homo sapiens,,,786-0,
4144,1,F,BAO_0000219,9606.0,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,,,Homo sapiens,,,786-0,
4145,1,F,BAO_0000219,9606.0,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,,Homo sapiens,,,786-0,
4146,1,F,BAO_0000219,9606.0,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,,Homo sapiens,,,786-0,
4147,1,F,BAO_0000219,9606.0,14696,inhibition of the growth of renal cancer(786-0) cell line,,,Homo sapiens,,,786-0,
4148,1,F,BAO_0000219,9606.0,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,,Homo sapiens,,,786-0,
4149,1,F,BAO_0000219,9606.0,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,,Homo sapiens,,,786-0,
4150,1,F,BAO_0000219,9606.0,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,,,Homo sapiens,,,786-0,
4151,1,F,BAO_0000219,9606.0,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,,Homo sapiens,,,786-0,
4152,1,F,BAO_0000219,9606.0,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,,,Homo sapiens,,,786-0,
4153,1,F,BAO_0000219,9606.0,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,,Homo sapiens,,,786-0,
4154,1,F,BAO_0000219,9606.0,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,,,Homo sapiens,,,786-0,
4155,1,F,BAO_0000219,9606.0,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,,,Homo sapiens,,,786-0,
4156,1,B,BAO_0000219,,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,,,,,RBL-1,
4157,1,B,BAO_0000219,,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,,,,,RBL-1,
4158,1,B,BAO_0000019,,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,,,,,
4159,1,B,BAO_0000219,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,,,RBL-1,
4160,1,B,BAO_0000219,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,,,,RBL-1,
4161,1,B,BAO_0000357,,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,,,,,
4162,1,B,BAO_0000219,,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,,,,,
4163,1,B,BAO_0000219,,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,,,,,RBL-1,
4164,1,B,BAO_0000357,,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,,,,,
4165,1,B,BAO_0000357,,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,,,,,
4166,1,B,BAO_0000357,,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,,,,,
4167,1,B,BAO_0000357,,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,,,,,
4168,1,B,BAO_0000357,,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,,,,,
4169,1,B,BAO_0000019,10116.0,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,,Rattus norvegicus,,,,
4170,1,B,BAO_0000219,,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,,,,,RBL-1,
4171,1,B,BAO_0000357,,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,,,,,
4172,1,B,BAO_0000357,,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,,,,,
4173,1,B,BAO_0000357,,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,,,,,
4174,1,B,BAO_0000019,,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,,,,
4175,1,B,BAO_0000219,,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,,,,,RBL-1,
4176,1,F,BAO_0000019,,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,,,,
4177,1,B,BAO_0000219,,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,,,,,RBL-1,
4178,1,B,BAO_0000357,,414,Tested for its inhibitory activity against 5-lipoxygenase,,,,,,,
4179,1,B,BAO_0000357,,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,,,,,
4180,1,B,BAO_0000019,,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,,,,,
4181,1,B,BAO_0000019,,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,,,,
4182,1,B,BAO_0000219,,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,,,RBL-1,
4183,1,B,BAO_0000219,,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,,,,,RBL-1,
4184,1,B,BAO_0000219,,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,,,RBL-1,
4185,1,B,BAO_0000219,,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,,,RBL-1,
4186,1,B,BAO_0000218,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,,,,,
4187,1,B,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,,,,,RBL-1,
4188,1,B,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,,,,RBL-1,
4189,1,B,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,,,,
4190,1,B,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,,,,,
4191,1,B,BAO_0000218,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),In vivo,,,,,,
4192,1,F,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,,,,,RBL-2H3,
4193,1,F,BAO_0000219,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,,,,,RBL-2H3,
4194,1,B,BAO_0000019,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,,,,,
4195,1,B,BAO_0000019,,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,,,,,
4196,1,B,BAO_0000019,,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,,,,,
4197,1,B,BAO_0000019,,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,,,,,
4198,1,B,BAO_0000019,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,,,,,
4199,1,B,BAO_0000219,,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,,,,,RBL-1,
4200,1,B,BAO_0000357,10116.0,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,,Rattus norvegicus,,,,
4201,1,B,BAO_0000219,,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,,,,,RBL-1,
4202,1,F,BAO_0000219,,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,,,,,RBL-1,
4203,1,B,BAO_0000357,,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,,,,,,,
4204,1,B,BAO_0000219,,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,,,,,RBL-1,
4205,1,B,BAO_0000219,,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,,,,,RBL-1,
4206,1,B,BAO_0000219,,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,,,,,RBL-1,
4207,1,B,BAO_0000219,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,,,,,RBL-1,
4208,1,B,BAO_0000219,10116.0,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,,Rattus norvegicus,,,RBL-1,
4209,1,B,BAO_0000219,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,,,,RBL-1,
4210,1,B,BAO_0000219,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,,,,,RBL-1,
4211,1,B,BAO_0000219,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,,,,,RBL-1,
4212,1,B,BAO_0000219,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,,,,,RBL-1,
4213,1,B,BAO_0000219,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,,,,,RBL-1,
4214,1,B,BAO_0000219,,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,,,,,RBL-1,
4215,1,B,BAO_0000357,10116.0,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,,,Rattus norvegicus,,,,
4216,1,B,BAO_0000357,,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,,,,,
4217,1,B,BAO_0000357,,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,,,,,
4218,1,B,BAO_0000219,,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,,,,,RBL-1,
4219,1,B,BAO_0000219,,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,,,,,RBL-1,
4220,1,B,BAO_0000219,,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,,,,,RBL-1,
4221,1,B,BAO_0000219,,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,,,,,RBL-1,
4222,1,B,BAO_0000219,,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,,,,,RBL-1,
4223,1,B,BAO_0000019,,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,,,,,
4224,1,B,BAO_0000357,,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,,,,
4225,1,B,BAO_0000357,,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,,,,
4226,1,B,BAO_0000219,,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,,,,RBL-1,
4227,1,B,BAO_0000219,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,,,,RBL-1,
4228,1,B,BAO_0000219,,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,,,,,RBL-1,
4229,1,B,BAO_0000219,,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,,,,,RBL-1,
4230,1,B,BAO_0000219,,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,,,,,RBL-1,
4231,1,B,BAO_0000219,,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,,,RBL-1,
4232,1,B,BAO_0000219,10116.0,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,,Rattus norvegicus,,,RBL-1,
4233,1,B,BAO_0000019,,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,,,,,
4234,1,B,BAO_0000219,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,,,,RBL-1,
4235,1,B,BAO_0000219,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,,,RBL-1,
4236,1,B,BAO_0000219,,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,,,RBL-1,
4237,1,B,BAO_0000219,,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,,,RBL-1,
4238,1,B,BAO_0000019,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,,,,
4239,1,B,BAO_0000019,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,,,,
4240,1,B,BAO_0000019,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,,,,
4241,1,B,BAO_0000019,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,,,,,
4242,1,B,BAO_0000357,,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,,,,,
4243,1,B,BAO_0000357,,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,,,,,
4244,1,B,BAO_0000019,,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,,,,
4245,1,B,BAO_0000219,,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,,,,,RBL-1,
4246,1,B,BAO_0000219,,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,,,,,RBL-1,
4247,1,B,BAO_0000219,,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,,,,,RBL-2H3,
4248,1,B,BAO_0000219,,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,,,,RBL-2H3,
4249,1,F,BAO_0000219,,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,,,,RBL-2H3,
4250,1,F,BAO_0000019,,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,,,,,
4251,1,B,BAO_0000357,,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,,,,,,,
4252,1,F,BAO_0000219,,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,,,,,RBL-2H3,
4253,1,B,BAO_0000019,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,,,,,
4254,1,B,BAO_0000019,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,,,,,
4255,1,B,BAO_0000019,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,,,,,
4256,1,B,BAO_0000019,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,,,,
4257,1,B,BAO_0000019,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,,,,
4258,1,B,BAO_0000219,,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,,,,,RBL-1,
4259,1,B,BAO_0000219,,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,,,,,RBL-1,
4260,1,F,BAO_0000219,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,,,,,RBL-1,
4261,1,F,BAO_0000219,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,,,,,RBL-1,
4262,1,F,BAO_0000219,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,,,,,RBL-1,
4263,1,F,BAO_0000219,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,,,,,RBL-1,
4264,1,F,BAO_0000219,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,,,,,RBL-1,
4265,1,F,BAO_0000219,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,,,,,RBL-1,
4266,1,F,BAO_0000219,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,,,,,RBL-1,
4267,1,F,BAO_0000219,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,,,,,RBL-1,
4268,1,F,BAO_0000219,,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,,,,,RBL-1,
4269,1,F,BAO_0000019,10116.0,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,,Rattus norvegicus,,,,
4270,1,B,BAO_0000357,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,,,,,
4271,1,B,BAO_0000357,,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,,,,,
4272,1,B,BAO_0000219,,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,,,,,RBL-1,
4273,1,B,BAO_0000219,,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,,,,RBL-1,
4274,1,B,BAO_0000219,,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,,,,,RBL-1,
4275,1,B,BAO_0000219,,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,,,,,RBL-1,
4276,1,B,BAO_0000219,,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,,,,,RBL-1,
4277,1,B,BAO_0000019,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,,,,
4278,1,B,BAO_0000219,,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,,,,,RBL-1,
4279,1,B,BAO_0000219,,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,,,,,RBL-1,
4280,1,B,BAO_0000219,,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,,,,,RBL-1,
4281,1,B,BAO_0000219,,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,,,,,RBL-1,
4282,1,B,BAO_0000219,,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,,,,,RBL-1,
4283,1,B,BAO_0000219,,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,,,,,
4284,1,B,BAO_0000219,9606.0,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,,Homo sapiens,,,RBL-1,
4285,1,B,BAO_0000219,10116.0,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,,Rattus norvegicus,,,RBL-1,
4286,1,B,BAO_0000219,10116.0,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,,Rattus norvegicus,,,RBL-1,
4287,1,B,BAO_0000019,10116.0,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,Rattus norvegicus,,,,
4288,1,B,BAO_0000357,3847.0,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,,Glycine max,,,,
4289,1,B,BAO_0000019,,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,,,,,
4290,1,B,BAO_0000357,,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,,,,,
4291,1,B,BAO_0000357,,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,,,,,
4292,1,B,BAO_0000357,,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,,,,,
4293,1,B,BAO_0000219,,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,,,,,RBL-1,
4294,1,B,BAO_0000357,,168,Inhibitory activity against 5-lipoxygenase.,,,,,,,
4295,1,B,BAO_0000357,,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,,,,,
4296,1,B,BAO_0000357,,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,,,,,
4297,1,B,BAO_0000357,,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,,,,,
4298,1,F,BAO_0000019,,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,,,,,
4299,1,B,BAO_0000357,,4501,Tested for the inhibitory activity against 5-lipoxygenase,,,,,,,
4300,1,B,BAO_0000357,,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,,,,,
4301,1,B,BAO_0000357,,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,,,,,
4302,1,B,BAO_0000357,,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,,,,,
4303,1,B,BAO_0000357,,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,,,,,
4304,1,B,BAO_0000219,,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,,,,,RBL-1,
4305,1,B,BAO_0000357,,11089,,,,,,,,
4306,1,B,BAO_0000357,,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,,,,,
4307,1,B,BAO_0000019,,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,,,,,
4308,1,B,BAO_0000357,,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,,,,,
4309,1,B,BAO_0000357,,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,,,,,
4310,1,B,BAO_0000357,,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,,,,,
4311,1,B,BAO_0000357,,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,,,,,
4312,1,B,BAO_0000357,,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,,,,,
4313,1,B,BAO_0000357,,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,,,,,
4314,1,B,BAO_0000019,,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,,,,,
4315,1,B,BAO_0000019,,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,,,,,
4316,1,B,BAO_0000019,,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,,,,,
4317,1,B,BAO_0000220,,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,,,,,
4318,1,F,BAO_0000019,9606.0,4349,The dark toxicity against 543 human galactophore carcinoma cells,,,Homo sapiens,,,,
4319,1,F,BAO_0000219,9606.0,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,,Homo sapiens,,,Panel (56 tumour cell lines),
4320,1,F,BAO_0000219,9606.0,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,,Homo sapiens,,,5637,
4321,1,F,BAO_0000219,9606.0,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,,Homo sapiens,,,5637,
4322,1,F,BAO_0000219,9606.0,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,,Homo sapiens,,,5637,
4323,1,F,BAO_0000219,9606.0,17589,Growth inhibition against human 5637 cell lines,,,Homo sapiens,,,5637,
4324,1,F,BAO_0000219,9606.0,16748,Antitumor activity against human bladder carcinoma 5637 cells.,,,Homo sapiens,,,5637,
4325,1,F,BAO_0000219,9606.0,16747,Antitumor activity against human bladder carcinoma 5637 cells,,,Homo sapiens,,,5637,
4326,1,F,BAO_0000219,9606.0,16747,Antitumor activity against human bladder carcinoma 5637 cells,,,Homo sapiens,,,5637,
4327,1,B,BAO_0000357,9913.0,15285,In vitro inhibition of bovine trypsin(Trp).,,,Bos taurus,,,,
4328,1,B,BAO_0000219,9527.0,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,,Cercopithecidae,,,CV-1,
4329,1,B,BAO_0000357,,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,,,,,
4330,1,F,BAO_0000019,,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,,,,,
4331,1,F,BAO_0000218,,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,In vivo,,,,,,
4332,1,B,BAO_0000357,10141.0,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,,Cavia porcellus,,,,
4333,1,A,BAO_0000251,10116.0,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,Rattus norvegicus,,,,Microsomes
4334,1,A,BAO_0000251,10116.0,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,Rattus norvegicus,,,,Microsomes
4335,1,F,BAO_0000019,,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,,,,
4336,1,F,BAO_0000019,,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,,,,
4337,1,B,BAO_0000019,5691.0,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,,Trypanosoma brucei,,,,
4338,1,B,BAO_0000019,5691.0,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,,Trypanosoma brucei,,,,
4339,1,B,BAO_0000019,9940.0,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,,Ovis aries,,,,
4340,1,B,BAO_0000019,9940.0,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,,Ovis aries,,,,
4341,1,B,BAO_0000357,,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,,,,,
4342,1,F,BAO_0000019,9606.0,4337,Average inhibitory concentration against 60 human cell lines was reported,,,Homo sapiens,,,,
4343,1,F,BAO_0000019,9606.0,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,,Homo sapiens,,,,
4344,1,F,BAO_0000219,9606.0,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,,Homo sapiens,,,Panel NCI-60 (60 carcinoma cell lines),
4345,1,F,BAO_0000219,9606.0,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,,Homo sapiens,,,Panel NCI-60 (60 carcinoma cell lines),
4346,1,F,BAO_0000219,,17376,In vitro mean growth inhibitory activity against 60-cell panel,,,,,,Panel NCI-60 (60 carcinoma cell lines),
4347,1,F,BAO_0000219,,17376,In vitro mean growth lethal concentration against 60-cell panel,,,,,,Panel NCI-60 (60 carcinoma cell lines),
4348,1,F,BAO_0000219,,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,,,,,Panel NCI-60 (60 carcinoma cell lines),
4349,1,F,BAO_0000219,,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,,,,,Panel NCI-60 (60 carcinoma cell lines),
4350,1,F,BAO_0000019,,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,,,,
4351,1,F,BAO_0000019,,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,,,,
4352,1,B,BAO_0000357,,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,,,,,
4353,1,F,BAO_0000218,5833.0,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,,Plasmodium falciparum,,,,
4354,1,F,BAO_0000218,5833.0,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,,Plasmodium falciparum,,,,
4355,1,F,BAO_0000218,5833.0,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,,Plasmodium falciparum,,,,
4356,1,F,BAO_0000218,5833.0,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,,Plasmodium falciparum,,,,
4357,1,F,BAO_0000218,5833.0,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,,Plasmodium falciparum,,,,
4358,1,F,BAO_0000218,10090.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,Mus musculus,,,6C3HED,
4359,1,F,BAO_0000218,10090.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,Mus musculus,,,6C3HED,
4360,1,F,BAO_0000218,10090.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,,Mus musculus,,,6C3HED,
4361,1,F,BAO_0000218,10090.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,Mus musculus,,,6C3HED,
4362,1,F,BAO_0000218,10090.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,Mus musculus,,,6C3HED,
4363,1,F,BAO_0000218,10090.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,,Mus musculus,,,6C3HED,
4364,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,In vivo,,Mus musculus,,,,
4365,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,In vivo,,Mus musculus,,,,
4366,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),In vivo,,Mus musculus,,,,
4367,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,In vivo,,Mus musculus,,,,
4368,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,In vivo,,Mus musculus,,,,
4369,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,In vivo,,Mus musculus,,,,
4370,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,In vivo,,Mus musculus,,,,
4371,1,F,BAO_0000218,10090.0,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",In vivo,,Mus musculus,,,,
4372,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),In vivo,,Mus musculus,,,,
4373,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),In vivo,,Mus musculus,,,,
4374,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,In vivo,,Mus musculus,,,,
4375,1,F,BAO_0000218,10090.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,Mus musculus,,,,
4376,1,F,BAO_0000218,10090.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,Mus musculus,,,,
4377,1,F,BAO_0000218,10090.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,Mus musculus,,,,
4378,1,F,BAO_0000218,10090.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,Mus musculus,,,,
4379,1,F,BAO_0000218,10090.0,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,,Mus musculus,,,,
4380,1,F,BAO_0000218,10090.0,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,,Mus musculus,,,,
4381,1,F,BAO_0000218,10090.0,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,,Mus musculus,,,,
4382,1,F,BAO_0000218,10090.0,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,,Mus musculus,,,,
4383,1,A,BAO_0000218,10090.0,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,,Mus musculus,,,,
4384,1,A,BAO_0000218,10090.0,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,,Mus musculus,,,,
4385,1,A,BAO_0000218,10090.0,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,,Mus musculus,,,,
4386,1,A,BAO_0000218,10090.0,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,,Mus musculus,,,,
4387,1,F,BAO_0000218,10090.0,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,,Mus musculus,,,6C3HED,
4388,1,F,BAO_0000218,,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,In vivo,,,,,,
4389,1,A,BAO_0000218,10090.0,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,,Mus musculus,,,,
4390,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,In vivo,,Mus musculus,,,6C3HED,
4391,1,F,BAO_0000218,10090.0,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,In vivo,,Mus musculus,,,6C3HED,
4392,1,F,BAO_0000218,10090.0,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,,Mus musculus,,,6C3HED,
4393,1,F,BAO_0000218,10090.0,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,,Mus musculus,,,6C3HED,
4394,1,F,BAO_0000218,10090.0,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,,Mus musculus,,,6C3HED,
4395,1,B,BAO_0000019,1280.0,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,,Staphylococcus aureus,,,,
4396,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,,Rattus norvegicus,,Liver,,Microsomes
4397,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,Rattus norvegicus,,Liver,,Microsomes
4398,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,,Rattus norvegicus,,Liver,,Microsomes
4399,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,,Rattus norvegicus,,Liver,,Microsomes
4400,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,,Rattus norvegicus,,Liver,,Microsomes
4401,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,,Rattus norvegicus,,Liver,,Microsomes
4402,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,,Rattus norvegicus,,Liver,,Microsomes
4403,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,,Rattus norvegicus,,Liver,,Microsomes
4404,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,Rattus norvegicus,,Liver,,Microsomes
4405,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,Rattus norvegicus,,Liver,,Microsomes
4406,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,Rattus norvegicus,,Liver,,Microsomes
4407,1,B,BAO_0000251,10116.0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,Rattus norvegicus,,Liver,,Microsomes
4408,1,A,BAO_0000218,9527.0,347,The apparent total plasma clearance in monkey,In vivo,,Cercopithecidae,,Plasma,,
4409,1,A,BAO_0000218,9527.0,3341,Compound was evaluated for Hepatic clearance in monkey,In vivo,,Cercopithecidae,,,,
4410,1,A,BAO_0000218,9527.0,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,In vivo,,Cercopithecidae,,,,
4411,1,A,BAO_0000218,9527.0,4514,Plasma clearance in rhesus monkey,In vivo,,Cercopithecidae,,,,
4412,1,A,BAO_0000218,9527.0,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,In vivo,,Cercopithecidae,,,,
4413,1,A,BAO_0000218,9527.0,6821,Plasma clearance of compound was determined in monkey,In vivo,,Cercopithecidae,,,,
4414,1,A,BAO_0000218,9527.0,6057,Plasma clearance was calculated in rhesus monkey,In vivo,,Cercopithecidae,,,,
4415,1,A,BAO_0000218,9527.0,5145,Plasma clearance in rhesus monkey,In vivo,,Cercopithecidae,,,,
4416,1,A,BAO_0000218,9527.0,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Cercopithecidae,,,,
4417,1,A,BAO_0000218,9527.0,5472,Plasma clearance was evaluated in rhesus,In vivo,,Cercopithecidae,,,,
4418,1,A,BAO_0000218,9527.0,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,In vivo,,Cercopithecidae,,,,
4419,1,A,BAO_0000218,9527.0,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,,Cercopithecidae,,,,
4420,1,A,BAO_0000218,9527.0,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,,,,
4421,1,A,BAO_0000218,9527.0,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,,,,
4422,1,A,BAO_0000218,9527.0,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,In vivo,,Cercopithecidae,,,,
4423,1,A,BAO_0000218,9527.0,6535,Cmax in monkey after administration of 1 mg/kg iv,In vivo,,Cercopithecidae,,,,
4424,1,A,BAO_0000218,9527.0,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,In vivo,,Cercopithecidae,,,,
4425,1,A,BAO_0000218,9527.0,5922,Cmax in cynomolgus monkey by iv administration,In vivo,,Cercopithecidae,,,,
4426,1,A,BAO_0000218,9527.0,5922,Cmax in cynomolgus monkey by po administration,In vivo,,Cercopithecidae,,,,
4427,1,A,BAO_0000218,9527.0,6078,Cmax value evaluated in monkey,In vivo,,Cercopithecidae,,,,
4428,1,A,BAO_0000218,9527.0,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,,,,
4429,1,A,BAO_0000218,9527.0,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,In vivo,,Cercopithecidae,,Plasma,,
4430,1,A,BAO_0000218,9527.0,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,In vivo,,Cercopithecidae,,Plasma,,
4431,1,A,BAO_0000218,9527.0,5553,Maximal plasma concentration in squirrel monkeys,In vivo,,Cercopithecidae,,Plasma,,
4432,1,A,BAO_0000218,9527.0,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,Cercopithecidae,,,,
4433,1,A,BAO_0000218,9527.0,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,In vivo,,Cercopithecidae,,Plasma,,
4434,1,A,BAO_0000218,9527.0,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,Cercopithecidae,,,,
4435,1,A,BAO_0000218,9527.0,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,,Cercopithecidae,,,,
4436,1,A,BAO_0000218,9527.0,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,,Cercopithecidae,,,,
4437,1,A,BAO_0000218,9527.0,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,In vivo,,Cercopithecidae,,,,
4438,1,A,BAO_0000218,9527.0,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,In vivo,,Cercopithecidae,,,,
4439,1,A,BAO_0000218,9527.0,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,In vivo,,Cercopithecidae,,Plasma,,
4440,1,A,BAO_0000218,9527.0,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,,Cercopithecidae,,,,
4441,1,A,BAO_0000218,9527.0,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,,Cercopithecidae,,,,
4442,1,A,BAO_0000218,9443.0,4257,Absolute bioavailability was evaluated in monkey,In vivo,,monkey,,,,
4443,1,A,BAO_0000218,9443.0,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,monkey,,,,
4444,1,A,BAO_0000218,9443.0,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,In vivo,,monkey,,,,
4445,1,A,BAO_0000218,9544.0,17267,Bioavailability of compound was determined in rhesus monkey,In vivo,,Macaca mulatta,,,,
4446,1,A,BAO_0000218,38020.0,4256,Bioavailability determined after oral administration in marmoset,In vivo,,marmosets,,,,
4447,1,A,BAO_0000218,9541.0,4256,Oral bioavailability in cynomolgus monkey,In vivo,,Macaca fascicularis,,,,
4448,1,A,BAO_0000218,9443.0,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,In vivo,,monkey,,,,
4449,1,A,BAO_0000218,9443.0,16365,Bioavailability was evaluated after oral administration in monkey,In vivo,,monkey,,,,
4450,1,A,BAO_0000218,9541.0,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,Macaca fascicularis,,,,
4451,1,A,BAO_0000218,9544.0,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,Macaca mulatta,,,,
4452,1,A,BAO_0000218,9544.0,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,Macaca mulatta,,,,
4453,1,A,BAO_0000218,9443.0,17592,Bioavailability of the compound was determined in monkey,In vivo,,monkey,,,,
4454,1,A,BAO_0000218,9521.0,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),In vivo,,Saimiri sciureus,,,,
4455,1,A,BAO_0000218,9443.0,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,monkey,,,,
4456,1,A,BAO_0000218,9443.0,3341,Oral bioavailability in monkey,In vivo,,monkey,,,,
4457,1,A,BAO_0000218,9521.0,64,Compound was tested for bioavailability in squirrel monkey,In vivo,,Saimiri sciureus,,,,
4458,1,A,BAO_0000218,9544.0,5005,Oral bioavailability in Rhesus monkey,In vivo,,Macaca mulatta,,,,
4459,1,A,BAO_0000218,9544.0,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),In vivo,,Macaca mulatta,,,,
4460,1,A,BAO_0000218,9541.0,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,In vivo,,Macaca fascicularis,,,,
4461,1,A,BAO_0000218,9541.0,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,In vivo,,Macaca fascicularis,,,,
4462,1,A,BAO_0000218,9443.0,5302,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,,monkey,,,,
4463,1,A,BAO_0000218,9443.0,17667,Oral bioavailability of compound at 5 mg/kg in monkey,In vivo,,monkey,,,,
4464,1,A,BAO_0000218,9615.0,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,,Canis lupus familiaris,,,,
4465,1,A,BAO_0000218,9615.0,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,,Canis lupus familiaris,,,,
4466,1,A,BAO_0000218,9615.0,3854,Plasma half life determined,,,Canis lupus familiaris,,Plasma,,
4467,1,A,BAO_0000218,9615.0,993,Plasma half life in dog,,,Canis lupus familiaris,,Plasma,,
4468,1,A,BAO_0000218,9615.0,4514,Plasma half-life in Beagle dogs,,,Canis lupus familiaris,,Plasma,,
4469,1,A,BAO_0000218,9615.0,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,,Canis lupus familiaris,,Plasma,,
4470,1,A,BAO_0000218,9615.0,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),In vivo,,Canis lupus familiaris,,Plasma,,
4471,1,A,BAO_0000218,9615.0,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,,,,
4472,1,A,BAO_0000218,9615.0,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,,,,
4473,1,A,BAO_0000218,9615.0,5313,Tested for the half life period in dog,,,Canis lupus familiaris,,,,
4474,1,A,BAO_0000218,9615.0,5313,Tested for the half life period in dog at dosage of 10 mpk,In vivo,,Canis lupus familiaris,,,,
4475,1,A,BAO_0000218,9615.0,3880,The compound was tested for half life in dog,,,Canis lupus familiaris,,,,
4476,1,A,BAO_0000218,9615.0,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,,Canis lupus familiaris,,Plasma,,
4477,1,A,BAO_0000218,9615.0,3880,The half life was determined,,,Canis lupus familiaris,,,,
4478,1,A,BAO_0000218,9615.0,3918,The plasma half-life in dogs,,,Canis lupus familiaris,,Plasma,,
4479,1,A,BAO_0000218,9615.0,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,,Canis lupus familiaris,,Plasma,,
4480,1,A,BAO_0000218,9615.0,17796,Half life in dog,,,Canis lupus familiaris,,,,
4481,1,A,BAO_0000218,9615.0,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,,Canis lupus familiaris,,,,
4482,1,A,BAO_0000218,9615.0,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,,,,
4483,1,A,BAO_0000218,9615.0,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,,,,
4484,1,A,BAO_0000218,9669.0,6113,Cmax in ferrets after 30 mg/kg oral dose,In vivo,,Mustela putorius furo,,,,
4485,1,F,BAO_0000218,9669.0,6113,Emesis in ferrets at 30 mg/kg oral dose,In vivo,,Mustela putorius furo,,,,
4486,1,A,BAO_0000218,9541.0,17796,Bioavailability in cynomolgus monkey,In vivo,,Macaca fascicularis,,,,
4487,1,A,BAO_0000218,9541.0,17796,Volume of distribution in cynomolgus,In vivo,,Macaca fascicularis,,,,
4488,1,A,BAO_0000218,10141.0,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,,Cavia porcellus,,Plasma,,
4489,1,A,BAO_0000218,10141.0,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,Cavia porcellus,,,,
4490,1,A,BAO_0000218,10141.0,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,,Cavia porcellus,,,,
4491,1,A,BAO_0000218,10141.0,4878,AUC in guinea pig after 3mg/kg oral dose,In vivo,,Cavia porcellus,,Plasma,,
4492,1,A,BAO_0000218,10141.0,5308,Bioavailability in guinea pig was tested,In vivo,,Cavia porcellus,,,,
4493,1,A,BAO_0000218,10141.0,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,In vivo,,Cavia porcellus,,,,
4494,1,A,BAO_0000218,10141.0,4876,Tested for the oral bioavailability of the compound,In vivo,,Cavia porcellus,,,,
4495,1,A,BAO_0000218,10141.0,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,In vivo,,Cavia porcellus,,,,
4496,1,A,BAO_0000218,10141.0,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,In vivo,,Cavia porcellus,,,,
4497,1,A,BAO_0000218,10141.0,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,In vivo,,Cavia porcellus,,Lung,,
4498,1,A,BAO_0000218,10141.0,4878,Cmax in guinea pig after 3mg/kg oral dose,In vivo,,Cavia porcellus,,,,
4499,1,A,BAO_0000019,10141.0,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,,Blood,,
4500,1,A,BAO_0000019,10141.0,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,,Brain,,
4501,1,A,BAO_0000019,10141.0,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,,,,
4502,1,A,BAO_0000019,10141.0,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,,Intestine,,
4503,1,A,BAO_0000019,10141.0,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,,Kidney,,
4504,1,A,BAO_0000019,10141.0,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,,Liver,,
4505,1,A,BAO_0000019,10141.0,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,,,,
4506,1,A,BAO_0000019,10141.0,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,,Cavia porcellus,,Spleen,,
4507,1,A,BAO_0000218,10141.0,14465,Elimination T1/2 in Guinea pig (PO dose),In vivo,,Cavia porcellus,,,,
4508,1,A,BAO_0000019,10141.0,5689,Partition coefficient was measured as -log (counts per min ),,,Cavia porcellus,,,,
4509,1,A,BAO_0000218,10141.0,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,,Cavia porcellus,,,,
4510,1,A,BAO_0000218,10141.0,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,,Cavia porcellus,,,,
4511,1,A,BAO_0000218,10141.0,14465,Elimination T1/2 in Guinea pig (PO dose),In vivo,,Cavia porcellus,,,,
4512,1,A,BAO_0000218,10141.0,4876,"Tested for the half life period of the compound, intravenously",In vivo,,Cavia porcellus,,,,
4513,1,A,BAO_0000019,10141.0,5689,Half-life was measured,,,Cavia porcellus,,,,
4514,1,A,BAO_0000019,10141.0,7515,The time required for onset of inotropy after addition of a single dose of delta F75,,,Cavia porcellus,,,,
4515,1,A,BAO_0000218,10141.0,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,In vivo,,Cavia porcellus,,,,
4516,1,A,BAO_0000218,10141.0,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,In vivo,,Cavia porcellus,,,,
4517,1,A,BAO_0000218,10029.0,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,,Cricetulus griseus,,,,
4518,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,,,
4519,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,,,,
4520,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,,,
4521,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,,,
4522,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,In vivo,,Mus musculus,,,,
4523,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,,,
4524,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,,,
4525,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Blood,,
4526,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Blood,,
4527,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Blood,,
4528,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Bone,,
4529,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Bone,,
4530,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Bone,,
4531,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Brain,,
4532,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Brain,,
4533,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Brain,,
4534,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Heart,,
4535,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Heart,,
4536,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Heart,,
4537,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Intestine,,
4538,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Intestine,,
4539,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Intestine,,
4540,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Kidney,,
4541,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Kidney,,
4542,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Kidney,,
4543,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Liver,,
4544,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Liver,,
4545,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Liver,,
4546,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Lung,,
4547,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Lung,,
4548,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Lung,,
4549,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Muscle tissue,,
4550,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Muscle tissue,,
4551,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Muscle tissue,,
4552,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Spleen,,
4553,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Spleen,,
4554,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Spleen,,
4555,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,In vivo,,Mus musculus,,Stomach,,
4556,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,In vivo,,Mus musculus,,Stomach,,
4557,1,A,BAO_0000218,10090.0,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,In vivo,,Mus musculus,,Stomach,,
4558,1,A,BAO_0000218,10090.0,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,,Mus musculus,,,,
4559,1,F,BAO_0000218,10090.0,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,,Mus musculus,,,,
4560,1,A,BAO_0000218,10090.0,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,,,,
4561,1,A,BAO_0000218,10090.0,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,In vivo,,Mus musculus,,,,
4562,1,A,BAO_0000218,10090.0,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,In vivo,,Mus musculus,,,,
4563,1,F,BAO_0000218,10090.0,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,In vivo,,Mus musculus,,,,
4564,1,F,BAO_0000219,9606.0,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,,Homo sapiens,,,A2780,
4565,1,F,BAO_0000219,9606.0,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,,Homo sapiens,,,A2780,
4566,1,F,BAO_0000219,9606.0,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,,,Homo sapiens,,,A2780,
4567,1,F,BAO_0000219,9606.0,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,,Homo sapiens,,,A2780,
4568,1,F,BAO_0000219,9606.0,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,,Homo sapiens,,,A2780,
4569,1,F,BAO_0000219,9606.0,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,,Homo sapiens,,,A2780,
4570,1,F,BAO_0000219,9606.0,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,,Homo sapiens,,,A2780,
4571,1,F,BAO_0000219,9606.0,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,,Homo sapiens,,,A2780,
4572,1,F,BAO_0000219,9606.0,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,,Homo sapiens,,,A2780,
4573,1,F,BAO_0000219,9606.0,2859,Compound was evaluated for cytotoxicity against A2780 cell line,,,Homo sapiens,,,A2780,
4574,1,F,BAO_0000219,9606.0,5618,In vitro inhibitory activity against human tumor cell line A2780,,,Homo sapiens,,,A2780,
4575,1,F,BAO_0000219,9606.0,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,,Homo sapiens,,,A2780,
4576,1,F,BAO_0000219,9606.0,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,,Homo sapiens,,,A2780,
4577,1,F,BAO_0000219,9606.0,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,,Homo sapiens,,,A2780,
4578,1,F,BAO_0000219,9606.0,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,,Homo sapiens,,,A2780,
4579,1,F,BAO_0000219,9606.0,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,,Homo sapiens,,,A2780,
4580,1,F,BAO_0000219,9606.0,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,,Homo sapiens,,,A2780,
4581,1,F,BAO_0000219,9606.0,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,,Homo sapiens,,,A2780,
4582,1,F,BAO_0000218,9606.0,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,Homo sapiens,,,A2780,
4583,1,F,BAO_0000219,9606.0,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,,Homo sapiens,,,A2780,
4584,1,F,BAO_0000219,9606.0,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,,Homo sapiens,,,A2780,
4585,1,F,BAO_0000219,9606.0,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,,Homo sapiens,,,A2780,
4586,1,F,BAO_0000219,9606.0,2040,Relative resistance factor in A2780 cisplatin-resistant line,,,Homo sapiens,,,A2780,
4587,1,F,BAO_0000219,9606.0,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,,Homo sapiens,,,A2780,
4588,1,F,BAO_0000219,9606.0,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,,Homo sapiens,,,A2780,
4589,1,F,BAO_0000218,9606.0,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,Homo sapiens,,,A2780,
4590,1,F,BAO_0000218,9606.0,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,Homo sapiens,,,A2780,
4591,1,F,BAO_0000219,9606.0,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,,Homo sapiens,,,A2780,
4592,1,F,BAO_0000219,9606.0,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,,Homo sapiens,,,A2780,
4593,1,F,BAO_0000219,9606.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,,Homo sapiens,,,A2780,
4594,1,F,BAO_0000219,9606.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,,Homo sapiens,,,A2780,
4595,1,F,BAO_0000219,9606.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,,Homo sapiens,,,A2780,
4596,1,F,BAO_0000219,9606.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,,Homo sapiens,,,A2780,
4597,1,F,BAO_0000219,9606.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,,Homo sapiens,,,A2780,
4598,1,F,BAO_0000219,9606.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,,Homo sapiens,,,A2780,
4599,1,F,BAO_0000219,9606.0,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,,Homo sapiens,,,A2780,
4600,1,F,BAO_0000219,9606.0,17420,Antiproliferative effect of compound on A2780/DX cell line,,,Homo sapiens,,,A2780,
4601,1,F,BAO_0000219,9606.0,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,,Homo sapiens,,,A2780,
4602,1,F,BAO_0000219,9606.0,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,,Homo sapiens,,,A2780,
4603,1,F,BAO_0000219,9606.0,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,,Homo sapiens,,,A2780,
4604,1,F,BAO_0000219,9606.0,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,,Homo sapiens,,,A2780,
4605,1,F,BAO_0000219,9606.0,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,,Homo sapiens,,,A2780,
4606,1,F,BAO_0000219,9606.0,17270,In vitro cytotoxicity against A2780ADR cell line,,,Homo sapiens,,,A2780,
4607,1,F,BAO_0000219,9606.0,17270,In vitro cytotoxicity against A2780CIS cell line,,,Homo sapiens,,,A2780,
4608,1,F,BAO_0000219,9606.0,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,,Homo sapiens,,,A2780,
4609,1,F,BAO_0000219,9606.0,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,,Homo sapiens,,,A2780,
4610,1,F,BAO_0000219,9606.0,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,,Homo sapiens,,,A2780,
4611,1,F,BAO_0000219,9606.0,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,,Homo sapiens,,,A2780,
4612,1,A,BAO_0000218,9544.0,17839,Oral bioavailability of compound in rhesus macaques,In vivo,,Macaca mulatta,,,,
4613,1,A,BAO_0000218,9443.0,6821,Oral bioavailability in monkey,In vivo,,monkey,,,,
4614,1,A,BAO_0000218,9443.0,6078,Oral bioavailability evaluated in monkey,In vivo,,monkey,,,,
4615,1,A,BAO_0000218,9443.0,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),In vivo,,monkey,,,,
4616,1,A,BAO_0000218,9544.0,4449,Oral bioavailability in Rhesus monkey,In vivo,,Macaca mulatta,,,,
4617,1,A,BAO_0000218,9544.0,6057,Oral bioavailability was calculated in rhesus monkey,In vivo,,Macaca mulatta,,,,
4618,1,A,BAO_0000218,9541.0,5922,Oral bioavailability in cynomolgus monkey,In vivo,,Macaca fascicularis,,,,
4619,1,A,BAO_0000218,9443.0,5940,Oral bioavailability in monkey,In vivo,,monkey,,,,
4620,1,A,BAO_0000218,9443.0,6265,Oral bioavailability in monkey,In vivo,,monkey,,,,
4621,1,A,BAO_0000218,9443.0,6265,Oral bioavailability in monkey (dose 1 mg/kg),In vivo,,monkey,,,,
4622,1,A,BAO_0000218,9443.0,6265,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,,monkey,,,,
4623,1,A,BAO_0000218,9443.0,5940,Oral bioavailability in monkey,In vivo,,monkey,,,,
4624,1,A,BAO_0000218,9443.0,5940,Oral bioavailability in monkey,In vivo,,monkey,,,,
4625,1,A,BAO_0000218,9544.0,4514,Oral bioavailability in rhesus monkey,In vivo,,Macaca mulatta,,,,
4626,1,A,BAO_0000218,9544.0,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,In vivo,,Macaca mulatta,,,,
4627,1,A,BAO_0000218,9521.0,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,In vivo,,Saimiri sciureus,,,,
4628,1,A,BAO_0000218,9443.0,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,monkey,,,,
4629,1,A,BAO_0000218,9544.0,5472,Oral bioavailability in Rhesus monkey,In vivo,,Macaca mulatta,,,,
4630,1,A,BAO_0000218,9544.0,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),In vivo,,Macaca mulatta,,,,
4631,1,A,BAO_0000218,9443.0,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,In vivo,,monkey,,,,
4632,1,A,BAO_0000218,9544.0,5145,Bioavailability in Rhesus monkey,In vivo,,Macaca mulatta,,,,
4633,1,A,BAO_0000218,9527.0,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,,,,
4634,1,A,BAO_0000218,9527.0,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,,,,
4635,1,A,BAO_0000218,9527.0,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,In vivo,,Cercopithecidae,,,,
4636,1,A,BAO_0000218,9527.0,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,In vivo,,Cercopithecidae,,,,
4637,1,A,BAO_0000218,9527.0,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,In vivo,,Cercopithecidae,,,,
4638,1,A,BAO_0000218,9527.0,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,,Cercopithecidae,,,,
4639,1,A,BAO_0000218,9527.0,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,,Cercopithecidae,,,,
4640,1,A,BAO_0000218,9527.0,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,Cercopithecidae,,,,
4641,1,A,BAO_0000218,9527.0,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,Cercopithecidae,,,,
4642,1,A,BAO_0000251,9527.0,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,,Cercopithecidae,,,,Microsomes
4643,1,A,BAO_0000251,9527.0,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,,Cercopithecidae,,,,Microsomes
4644,1,A,BAO_0000251,9527.0,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,,Cercopithecidae,,,,Microsomes
4645,1,A,BAO_0000251,9527.0,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,,Cercopithecidae,,,,Microsomes
4646,1,A,BAO_0000218,9527.0,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,Cercopithecidae,,,,
4647,1,A,BAO_0000218,9527.0,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,Cercopithecidae,,,,
4648,1,A,BAO_0000019,9527.0,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,,Cercopithecidae,,,,
4649,1,A,BAO_0000218,9527.0,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,,,,
4650,1,A,BAO_0000218,9527.0,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,,,,
4651,1,A,BAO_0000019,9527.0,6821,Elimination Half-life of compound was determined in monkey,,,Cercopithecidae,,,,
4652,1,A,BAO_0000019,9527.0,17267,Half life of compound was determined in rhesus monkey,,,Cercopithecidae,,,,
4653,1,A,BAO_0000366,9527.0,5819,Half life in monkey plasma,,,Cercopithecidae,,Plasma,,
4654,1,A,BAO_0000366,9527.0,5819,Half life in monkey plasma; Not detected,,,Cercopithecidae,,Plasma,,
4655,1,A,BAO_0000218,9527.0,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,Cercopithecidae,,,,
4656,1,A,BAO_0000218,9527.0,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,In vivo,,Cercopithecidae,,,,
4657,1,A,BAO_0000019,9527.0,1399,Terminal half life of the compound.,,,Cercopithecidae,,,,
4658,1,A,BAO_0000218,9527.0,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,Cercopithecidae,,,,
4659,1,A,BAO_0000218,9527.0,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,Cercopithecidae,,,,
4660,1,A,BAO_0000218,9527.0,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,Cercopithecidae,,,,
4661,1,A,BAO_0000218,9527.0,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,,Urine,,
4662,1,A,BAO_0000218,9527.0,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,,Urine,,
4663,1,A,BAO_0000218,9527.0,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,In vivo,,Cercopithecidae,,,,
4664,1,A,BAO_0000218,9527.0,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,Cercopithecidae,,,,
4665,1,A,BAO_0000218,9527.0,5472,Volume of distribution was evaluated in rhesus,In vivo,,Cercopithecidae,,,,
4666,1,A,BAO_0000218,10029.0,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,,Cricetulus griseus,,,,
4667,1,A,BAO_0000218,10029.0,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,In vivo,,Cricetulus griseus,,,,
4668,1,A,BAO_0000218,10029.0,4727,Bioavailability in hamster was determined,In vivo,,Cricetulus griseus,,,,
4669,1,A,BAO_0000218,10029.0,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,In vivo,,Cricetulus griseus,,,,
4670,1,A,BAO_0000218,10029.0,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,In vivo,,Cricetulus griseus,,,,
4671,1,A,BAO_0000221,10029.0,4727,Half life of compound was determined in hamster blood,,,Cricetulus griseus,,Blood,,
4672,1,A,BAO_0000019,9823.0,1452,Michaelis-Menten constant of the compound.,,,Sus scrofa,,,,
4673,1,A,BAO_0000019,9823.0,1452,Vmax value was measured at 0 uM concentration of silyl ether.,,,Sus scrofa,,,,
4674,1,A,BAO_0000019,9823.0,1452,Vmax value was measured at 10 uM concentration of silyl ether.,,,Sus scrofa,,,,
4675,1,A,BAO_0000019,9823.0,1452,Vmax value was measured at 5 uM concentration of silyl ether.,,,Sus scrofa,,,,
4676,1,B,BAO_0000357,9606.0,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,,Homo sapiens,,,,
4677,1,A,BAO_0000218,9606.0,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,,Homo sapiens,,,,
4678,1,A,BAO_0000019,9606.0,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,Homo sapiens,,,,
4679,1,A,BAO_0000019,9606.0,7766,Active metabolite of ifosfamide determined in humans; A-Active,,,Homo sapiens,,,,
4680,1,A,BAO_0000019,9606.0,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,,Homo sapiens,,,,
4681,1,A,BAO_0000019,9606.0,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,,Homo sapiens,,,,
4682,1,A,BAO_0000019,9606.0,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,,Homo sapiens,,,,
4683,1,A,BAO_0000019,9606.0,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,,Homo sapiens,,,,
4684,1,A,BAO_0000218,9606.0,17791,Compound was evaluated for oral bioavailability in human,,,Homo sapiens,,,,
4685,1,A,BAO_0000019,9606.0,7766,Metabolite of ifosfamide determined in urine; NF-Not found,,,Homo sapiens,,Urine,,
4686,1,A,BAO_0000019,9606.0,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,,Homo sapiens,,,,
4687,1,A,BAO_0000019,9606.0,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,,Homo sapiens,,,,
4688,1,A,BAO_0000019,9606.0,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,,Homo sapiens,,,,
4689,1,A,BAO_0000019,9606.0,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,,Homo sapiens,,,,
4690,1,A,BAO_0000019,9606.0,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,,Homo sapiens,,,,
4691,1,A,BAO_0000019,9606.0,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,,Homo sapiens,,,,
4692,1,A,BAO_0000019,9606.0,6852,Percent of compound in healthy individuals (Group D),,,Homo sapiens,,,,
4693,1,A,BAO_0000251,9606.0,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,Homo sapiens,,Liver,,Microsomes
4694,1,A,BAO_0000019,9606.0,17409,Binding towards human plasma protein at 10 uM,,,Homo sapiens,,,,
4695,1,A,BAO_0000019,9606.0,17409,Binding towards human plasma protein at 100 uM,,,Homo sapiens,,,,
4696,1,A,BAO_0000019,9606.0,17176,Human plasma protein binding activity was determined,,,Homo sapiens,,,,
4697,1,A,BAO_0000019,9606.0,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,Homo sapiens,,,,
4698,1,A,BAO_0000019,9606.0,17267,Percent binding of compound towards human plasma protein was determined,,,Homo sapiens,,,,
4699,1,A,BAO_0000251,9606.0,5944,Plasma clearance in human liver microsomes,In vitro,,Homo sapiens,,Liver,,Microsomes
4700,1,A,BAO_0000251,9606.0,5668,In vitro intrinsic clearance in human liver microsome,In vitro,,Homo sapiens,,Liver,,Microsomes
4701,1,A,BAO_0000251,9606.0,5669,In vitro intrinsic clearance in human liver microsome,In vitro,,Homo sapiens,,Liver,,Microsomes
4702,1,A,BAO_0000251,9606.0,5041,In vitro microsome metabolism clearance in human was determined,In vitro,,Homo sapiens,,,,Microsomes
4703,1,A,BAO_0000251,9606.0,5041,In vitro microsome metabolism clearance in human was determined; High,In vitro,,Homo sapiens,,,,Microsomes
4704,1,A,BAO_0000251,9606.0,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,In vitro,,Homo sapiens,,,,Microsomes
4705,1,A,BAO_0000251,9606.0,5676,Pharmacokinetic property (clearance) in human liver microsome,In vitro,,Homo sapiens,,Liver,,Microsomes
4706,1,A,BAO_0000251,9606.0,5944,Plasma clearance in human liver microsomes,In vitro,,Homo sapiens,,Liver,,Microsomes
4707,1,A,BAO_0000251,9606.0,17538,In vitro clearance in human liver microsomes,In vitro,,Homo sapiens,,Liver,,Microsomes
4708,1,A,BAO_0000251,9606.0,6331,Intrinsic clearance in human liver microsomes was determined,In vitro,,Homo sapiens,,Liver,,Microsomes
4709,1,A,BAO_0000251,9606.0,5948,Intrinsic clearance in human liver microsomes was determined,In vitro,,Homo sapiens,,Liver,,Microsomes
4710,1,A,BAO_0000218,9606.0,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,In vivo,,Homo sapiens,,,,
4711,1,A,BAO_0000218,9606.0,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,,Homo sapiens,,,,
4712,1,A,BAO_0000218,9606.0,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,,Homo sapiens,,,,
4713,1,A,BAO_0000019,9606.0,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,,,Homo sapiens,,,,
4714,1,A,BAO_0000019,9606.0,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,,,Homo sapiens,,,,
4715,1,A,BAO_0000019,9606.0,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,,Urine,,
4716,1,A,BAO_0000019,9606.0,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,,Urine,,
4717,1,A,BAO_0000019,9606.0,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,,Urine,,
4718,1,A,BAO_0000019,9606.0,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,,Urine,,
4719,1,F,BAO_0000218,10090.0,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,In vivo,,Mus musculus,,,,
4720,1,F,BAO_0000218,10090.0,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,In vivo,,Mus musculus,,,,
4721,1,F,BAO_0000218,10090.0,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,In vivo,,Mus musculus,,,,
4722,1,F,BAO_0000218,10090.0,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,In vivo,,Mus musculus,,,,
4723,1,A,BAO_0000218,10090.0,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,,Mus musculus,,,,
4724,1,A,BAO_0000218,10090.0,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,,Mus musculus,,,,
4725,1,A,BAO_0000218,10090.0,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,,Mus musculus,,,,
4726,1,A,BAO_0000218,10090.0,6251,In vitro metabolic potential in mouse liver microsomes,,,Mus musculus,,Liver,,
4727,1,A,BAO_0000218,10090.0,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,,,Mus musculus,,,,
4728,1,A,BAO_0000218,10090.0,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,,Mus musculus,,Adrenal gland,,
4729,1,A,BAO_0000218,10090.0,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,,Mus musculus,,Brain,,
4730,1,A,BAO_0000218,10090.0,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,,Mus musculus,,Brain,,
4731,1,A,BAO_0000218,10090.0,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,,Mus musculus,,,,
4732,1,A,BAO_0000218,10090.0,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,,Mus musculus,,Kidney,,
4733,1,A,BAO_0000218,10090.0,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,,Mus musculus,,,,
4734,1,A,BAO_0000218,10090.0,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,,Mus musculus,,,,
4735,1,A,BAO_0000218,10090.0,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,,Mus musculus,,Serum,,
4736,1,A,BAO_0000218,10090.0,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,,Mus musculus,,Serum,,
4737,1,A,BAO_0000218,10090.0,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,,Mus musculus,,Serum,,
4738,1,A,BAO_0000218,10090.0,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,In vivo,,Mus musculus,,Plasma,,
4739,1,A,BAO_0000218,10090.0,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,In vivo,,Mus musculus,,Plasma,,
4740,1,A,BAO_0000218,10090.0,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,In vivo,,Mus musculus,,Plasma,,
4741,1,F,BAO_0000218,10090.0,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,In vivo,,Mus musculus,,,,
4742,1,F,BAO_0000218,10090.0,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,In vivo,,Mus musculus,,,,
4743,1,F,BAO_0000218,10090.0,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,In vivo,,Mus musculus,,,,
4744,1,F,BAO_0000218,10090.0,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,In vivo,,Mus musculus,,,,
4745,1,F,BAO_0000218,10090.0,17764,Half life after intravenous administration in mice at 23 uM/kg,In vivo,,Mus musculus,,,,
4746,1,A,BAO_0000218,10090.0,17764,Half life after intravenous administration in mice at 24 uM/kg,In vivo,,Mus musculus,,,,
4747,1,A,BAO_0000218,10090.0,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,,Mus musculus,,,,
4748,1,A,BAO_0000218,10090.0,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,In vivo,,Mus musculus,,,,
4749,1,A,BAO_0000218,10090.0,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,In vivo,,Mus musculus,,,,
4750,1,A,BAO_0000218,10090.0,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),In vivo,,Mus musculus,,,,
4751,1,A,BAO_0000218,10090.0,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",In vivo,,Mus musculus,,,,
4752,1,A,BAO_0000218,10090.0,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,In vivo,,Mus musculus,,,,
4753,1,A,BAO_0000218,10090.0,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,,Mus musculus,,Blood,,
4754,1,A,BAO_0000218,10090.0,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,,,,
4755,1,A,BAO_0000218,10090.0,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,In vivo,,Mus musculus,,,,
4756,1,A,BAO_0000218,10090.0,6619,Half life in ob/ob mice,,,Mus musculus,,,,
4757,1,A,BAO_0000218,10090.0,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,In vivo,,Mus musculus,,,,
4758,1,A,BAO_0000218,10090.0,4239,Half-life was measured in mouse,,,Mus musculus,,,,
4759,1,A,BAO_0000218,10090.0,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,In vivo,,Mus musculus,,,,
4760,1,A,BAO_0000218,10090.0,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,,Mus musculus,,,,
4761,1,A,BAO_0000218,10090.0,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,,Mus musculus,,,,
4762,1,A,BAO_0000218,10090.0,17641,T2 in brain of mice at the oral dose of 50 mg/kg,,,Mus musculus,,Brain,,
4763,1,A,BAO_0000218,10090.0,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,,,Mus musculus,,Kidney,,
4764,1,A,BAO_0000218,10090.0,17641,T2 in liver of mice at the oral dose of 50 mg/kg,,,Mus musculus,,Liver,,
4765,1,A,BAO_0000218,10090.0,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,,,Mus musculus,,Lung,,
4766,1,A,BAO_0000218,10090.0,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,,,Mus musculus,,Spleen,,
4767,1,A,BAO_0000218,10090.0,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,,Mus musculus,,,,
4768,1,A,BAO_0000218,10090.0,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",In vivo,,Mus musculus,,,,
4769,1,A,BAO_0000218,10090.0,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,In vivo,,Mus musculus,,,,
4770,1,A,BAO_0000218,10090.0,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,In vivo,,Mus musculus,,,,
4771,1,A,BAO_0000218,10090.0,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,In vivo,,Mus musculus,,,,
4772,1,F,BAO_0000219,9606.0,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,,Homo sapiens,,,A2780,
4773,1,F,BAO_0000219,9606.0,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,,Homo sapiens,,,A2780,
4774,1,F,BAO_0000219,9606.0,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,Homo sapiens,,,A2780,
4775,1,F,BAO_0000219,9606.0,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,Homo sapiens,,,A2780,
4776,1,F,BAO_0000219,9606.0,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,Homo sapiens,,,A2780,
4777,1,F,BAO_0000219,9606.0,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,Homo sapiens,,,A2780,
4778,1,F,BAO_0000219,9606.0,17270,In vitro cytotoxicity against A2780TAX cell line,,,Homo sapiens,,,A2780,
4779,1,F,BAO_0000219,9606.0,5618,In vitro inhibitory activity against human tumor cell line A2780cis,,,Homo sapiens,,,A2780cisR,
4780,1,F,BAO_0000219,9606.0,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,,Homo sapiens,,,A2780,
4781,1,F,BAO_0000219,9606.0,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,,Homo sapiens,,,A2780cisR,
4782,1,F,BAO_0000219,9606.0,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,Homo sapiens,,,A2780cisR,
4783,1,F,BAO_0000219,9606.0,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,,Homo sapiens,,,A2780,
4784,1,F,BAO_0000219,9606.0,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,,Homo sapiens,,,A2780,
4785,1,F,BAO_0000219,9606.0,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,,Homo sapiens,,,A2780,
4786,1,F,BAO_0000219,9606.0,12989,In vitro antitumor activity against A2780cisR cell line.,,,Homo sapiens,,,A2780,
4787,1,F,BAO_0000219,9606.0,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,,Homo sapiens,,,A2780,
4788,1,F,BAO_0000219,9606.0,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,,Homo sapiens,,,A2780,
4789,1,F,BAO_0000219,9606.0,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,,Homo sapiens,,,A2780cisR,
4790,1,F,BAO_0000219,9606.0,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,,Homo sapiens,,,A2780,
4791,1,B,BAO_0000019,10116.0,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,,Rattus norvegicus,,,,
4792,1,F,BAO_0000019,,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,,,,,
4793,1,F,BAO_0000019,10116.0,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,Rattus norvegicus,,,,
4794,1,F,BAO_0000219,9606.0,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,,Homo sapiens,,,HEK293,
4795,1,F,BAO_0000219,9606.0,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,,Homo sapiens,,,HEK293,
4796,1,B,BAO_0000019,10090.0,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,,Mus musculus,,,,
4797,1,F,BAO_0000019,,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,,,,,
4798,1,F,BAO_0000019,10090.0,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,Mus musculus,,,,
4799,1,B,BAO_0000357,,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,,,,,
4800,1,F,BAO_0000219,9606.0,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,,Homo sapiens,,,T-cells,
4801,1,F,BAO_0000219,9606.0,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,,Homo sapiens,,,T-cells,
4802,1,F,BAO_0000219,9606.0,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,,Homo sapiens,,,A-375,
4803,1,F,BAO_0000219,9606.0,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,,Homo sapiens,,,A-375,
4804,1,F,BAO_0000219,9606.0,2683,In vitro antitumor activity against A375cell line extracted form melanoma,,,Homo sapiens,,,A-375,
4805,1,F,BAO_0000219,9606.0,15313,Inhibition of cell growth in (A375) melan cell line,,,Homo sapiens,,,A-375,
4806,1,F,BAO_0000219,9606.0,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,,Homo sapiens,,,A-375,
4807,1,F,BAO_0000219,9606.0,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,,Homo sapiens,,,A-375,
4808,1,F,BAO_0000219,9606.0,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,,Homo sapiens,,,A-375,
4809,1,F,BAO_0000219,9606.0,14777,Antiproliferative activity measured against A427 human lung carcinoma,,,Homo sapiens,,,A-427,
4810,1,F,BAO_0000219,9606.0,14777,Antiproliferative activity measured against A427 human lung carcinoma,,,Homo sapiens,,,A-427,
4811,1,F,BAO_0000219,9606.0,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,,,Homo sapiens,,,A-427,
4812,1,F,BAO_0000219,9606.0,14368,Inhibition of large cell lung carcinoma (A427),,,Homo sapiens,,,A-427,
4813,1,F,BAO_0000219,9606.0,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,,Homo sapiens,,,A-427,
4814,1,F,BAO_0000219,9606.0,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,,Homo sapiens,,,A-427,
4815,1,F,BAO_0000219,9606.0,2545,Inhibitory concentration in human lung carcinoma A427 cell line,,,Homo sapiens,,,A-427,
4816,1,F,BAO_0000219,9606.0,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,,Homo sapiens,,,A-427,
4817,1,A,BAO_0000218,9527.0,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,,Cercopithecidae,,,,
4818,1,A,BAO_0000218,9527.0,4578,Tested for volume of distribution upon iv administration to african green monkey,In vivo,,Cercopithecidae,,,,
4819,1,A,BAO_0000218,9527.0,17592,Volume of distribution in monkey,In vivo,,Cercopithecidae,,,,
4820,1,A,BAO_0000218,9544.0,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,Macaca mulatta,,,,
4821,1,A,BAO_0000218,9544.0,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,In vivo,,Macaca mulatta,,,,
4822,1,A,BAO_0000218,9527.0,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,In vivo,,Cercopithecidae,,,,
4823,1,A,BAO_0000218,9527.0,5355,The distribution volume after intravenous administration in cynomolgus monkeys,In vivo,,Cercopithecidae,,,,
4824,1,A,BAO_0000218,9527.0,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,,Cercopithecidae,,,,
4825,1,A,BAO_0000218,9527.0,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,,Cercopithecidae,,,,
4826,1,A,BAO_0000218,9527.0,6057,Volume displacement was calculated in rhesus monkey,In vivo,,Cercopithecidae,,,,
4827,1,A,BAO_0000218,9527.0,5145,Volume of distribution in steady state was determined in rhesus monkey,In vivo,,Cercopithecidae,,,,
4828,1,A,BAO_0000218,9527.0,6821,Volume of distribution of compound was determined in monkey,In vivo,,Cercopithecidae,,,,
4829,1,A,BAO_0000218,9527.0,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,,,,
4830,1,A,BAO_0000218,9527.0,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,,,,
4831,1,A,BAO_0000218,9527.0,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Cercopithecidae,,,,
4832,1,A,BAO_0000218,9527.0,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,,,,
4833,1,A,BAO_0000218,9527.0,6535,Volume distribution in monkey after administration of 1 mg/kg iv,In vivo,,Cercopithecidae,,,,
4834,1,A,BAO_0000218,9527.0,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,Cercopithecidae,,,,
4835,1,A,BAO_0000218,9527.0,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,,Cercopithecidae,,,,
4836,1,A,BAO_0000218,9527.0,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,Cercopithecidae,,,,
4837,1,A,BAO_0000218,9527.0,4578,Oral systemic bioavailability upon iv administration to african green monkey,In vivo,,Cercopithecidae,,,,
4838,1,A,BAO_0000218,9527.0,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,Cercopithecidae,,,,
4839,1,A,BAO_0000019,9527.0,11271,Baboon plasma free fraction. ,,,Cercopithecidae,,,,
4840,1,A,BAO_0000218,9527.0,6057,Area under the curve was calculated in rhesus monkey after iv administration,,,Cercopithecidae,,,,
4841,1,A,BAO_0000019,9527.0,6057,Area under the curve was calculated in rhesus monkey after peroral administration,,,Cercopithecidae,,,,
4842,1,A,BAO_0000019,9527.0,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,,Cercopithecidae,,,,
4843,1,A,BAO_0000218,9527.0,5302,Half life period in monkey after 5 mg/kg dose,In vivo,,Cercopithecidae,,,,
4844,1,A,BAO_0000218,9527.0,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,In vivo,,Cercopithecidae,,,,
4845,1,A,BAO_0000218,9527.0,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,In vivo,,Cercopithecidae,,,,
4846,1,A,BAO_0000218,9527.0,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,,Cercopithecidae,,Plasma,,
4847,1,A,BAO_0000218,9527.0,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,In vivo,,Cercopithecidae,,,,
4848,1,A,BAO_0000218,9527.0,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,,,,
4849,1,A,BAO_0000019,9527.0,3341,Compound was evaluated for terminal half life in monkey,,,Cercopithecidae,,,,
4850,1,A,BAO_0000218,9527.0,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,In vivo,,Cercopithecidae,,,,
4851,1,A,BAO_0000218,9544.0,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,Macaca mulatta,,Plasma,,
4852,1,A,BAO_0000019,9527.0,4847,Half life of compound was determined in squirrel monkey,,,Cercopithecidae,,,,
4853,1,A,BAO_0000218,9541.0,4256,Half life after iv administration in cynomolgus monkey,In vivo,,Macaca fascicularis,,,,
4854,1,A,BAO_0000218,9527.0,6535,Half life in monkey plasma after administration of 1 mg/kg iv,In vivo,,Cercopithecidae,,Plasma,,
4855,1,A,BAO_0000019,9527.0,6057,Half life was calculated in rhesus monkey,,,Cercopithecidae,,,,
4856,1,A,BAO_0000019,9527.0,17592,Half life in monkey,,,Cercopithecidae,,,,
4857,1,A,BAO_0000218,9527.0,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Cercopithecidae,,,,
4858,1,A,BAO_0000019,9527.0,5472,Half life was evaluated in rhesus,,,Cercopithecidae,,,,
4859,1,A,BAO_0000218,9527.0,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,Cercopithecidae,,,,
4860,1,A,BAO_0000218,9527.0,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,In vivo,,Cercopithecidae,,,,
4861,1,A,BAO_0000218,9527.0,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,Cercopithecidae,,,,
4862,1,A,BAO_0000218,9527.0,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,,Cercopithecidae,,,,
4863,1,A,BAO_0000218,9527.0,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,In vivo,,Cercopithecidae,,,,
4864,1,A,BAO_0000019,9527.0,6078,Half-life was calculated in monkey,,,Cercopithecidae,,,,
4865,1,A,BAO_0000019,9527.0,5147,Half-life in Squirrel monkey,,,Cercopithecidae,,,,
4866,1,A,BAO_0000019,9527.0,5145,Half-life in rhesus monkey,,,Cercopithecidae,,,,
4867,1,A,BAO_0000218,9527.0,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,In vivo,,Cercopithecidae,,,,
4868,1,A,BAO_0000218,9527.0,5355,Half-life period after intravenous administration in cynomolgus monkeys,In vivo,,Cercopithecidae,,,,
4869,1,A,BAO_0000218,9527.0,5355,Half-life period after oral administration in cynomolgus monkeys,In vivo,,Cercopithecidae,,,,
4870,1,A,BAO_0000218,9527.0,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,In vivo,,Cercopithecidae,,,,
4871,1,A,BAO_0000019,9606.0,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,,Urine,,
4872,1,A,BAO_0000019,9606.0,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,,Urine,,
4873,1,A,BAO_0000019,9606.0,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,,Urine,,
4874,1,A,BAO_0000019,9606.0,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,Homo sapiens,,Urine,,
4875,1,A,BAO_0000019,9606.0,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,Homo sapiens,,Urine,,
4876,1,A,BAO_0000019,9606.0,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,Homo sapiens,,Urine,,
4877,1,A,BAO_0000019,9606.0,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,Homo sapiens,,Urine,,
4878,1,A,BAO_0000019,9606.0,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,Homo sapiens,,Urine,,
4879,1,A,BAO_0000218,9606.0,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,In vivo,,Homo sapiens,,,,
4880,1,A,BAO_0000218,9606.0,16643,Oral bioavailability in human,In vivo,,Homo sapiens,,,,
4881,1,A,BAO_0000019,9606.0,17248,Compound was tested for human plasma protein binding,,,Homo sapiens,,,,
4882,1,A,BAO_0000019,9606.0,17248,Compound was tested for human plasma protein binding; Not determined,,,Homo sapiens,,,,
4883,1,A,BAO_0000019,9606.0,6241,Protein binding activity of compound in human plasma; % Free,,,Homo sapiens,,,,
4884,1,A,BAO_0000019,9606.0,17716,Unbound fraction (plasma),,,Homo sapiens,,,,
4885,1,A,BAO_0000366,9606.0,17605,Half life for the hydrolysis of compound in human blood serum,,,Homo sapiens,,Plasma,,
4886,1,A,BAO_0000366,9606.0,17625,Half life period in human plasma using phosphate buffer (0.08 M),,,Homo sapiens,,Plasma,,
4887,1,A,BAO_0000366,9606.0,17625,Half life period in human plasma using phosphate buffer (0.1 M),,,Homo sapiens,,Plasma,,
4888,1,A,BAO_0000366,9606.0,17747,Half-life in human plasma was determined,,,Homo sapiens,,Plasma,,
4889,1,A,BAO_0000019,9606.0,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,,Homo sapiens,,,,
4890,1,A,BAO_0000019,9606.0,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,,Homo sapiens,,,,
4891,1,A,BAO_0000019,9606.0,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,Homo sapiens,,,,
4892,1,A,BAO_0000019,9606.0,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,Homo sapiens,,,,
4893,1,A,BAO_0000019,9606.0,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,Homo sapiens,,,,
4894,1,A,BAO_0000019,9606.0,17599,Partition coefficient (logP),,,Homo sapiens,,,,
4895,1,A,BAO_0000019,9606.0,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,,Homo sapiens,,,,
4896,1,A,BAO_0000251,9606.0,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,,Homo sapiens,,,,Microsomes
4897,1,A,BAO_0000019,9606.0,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,,Homo sapiens,,,,
4898,1,A,BAO_0000019,9606.0,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,,Homo sapiens,,,,
4899,1,A,BAO_0000019,9606.0,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,,Homo sapiens,,,,
4900,1,A,BAO_0000251,9606.0,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,,Homo sapiens,,,,Microsomes
4901,1,A,BAO_0000251,9606.0,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,,Homo sapiens,,,,Microsomes
4902,1,A,BAO_0000251,9606.0,14294,Metabolism of compound in human microsomes; Trace,,,Homo sapiens,,,,Microsomes
4903,1,A,BAO_0000251,9606.0,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,,Homo sapiens,,Liver,,Microsomes
4904,1,A,BAO_0000251,9606.0,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,,Homo sapiens,,,,Microsomes
4905,1,A,BAO_0000251,9606.0,6251,In vitro metabolic potential in human liver microsomes,,,Homo sapiens,,Liver,,Microsomes
4906,1,A,BAO_0000019,9606.0,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,,Homo sapiens,,,,
4907,1,A,BAO_0000019,9606.0,17313,Tested for human plasma protein binding of the compound; Not tested,,,Homo sapiens,,,,
4908,1,A,BAO_0000019,9606.0,6227,Compound was tested for percent protein binding (PB) in human,,,Homo sapiens,,,,
4909,1,A,BAO_0000019,9606.0,5530,Protein binding in human plasma,,,Homo sapiens,,Plasma,,
4910,1,A,BAO_0000019,9606.0,6108,Permeability coefficient (B to A) in Caco-2 cell,,,Homo sapiens,,,,
4911,1,A,BAO_0000019,9606.0,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,,Homo sapiens,,,,
4912,1,A,BAO_0000019,9606.0,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,,Homo sapiens,,,,
4913,1,A,BAO_0000019,9606.0,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,,,Homo sapiens,,,,
4914,1,A,BAO_0000219,9606.0,17582,Cellular permeability of compound was determined in Caco-2 cells; High,,,Homo sapiens,,,Caco-2,
4915,1,A,BAO_0000219,9606.0,6838,Permeability in Caco-2 cells of compound,,,Homo sapiens,,,Caco-2,
4916,1,A,BAO_0000019,9606.0,6108,Permeability coefficient (A to B) in Caco-2 cell,,,Homo sapiens,,,,
4917,1,A,BAO_0000019,9606.0,6108,Permeability coefficient (B to A) in Caco-2 cell,,,Homo sapiens,,,,
4918,1,A,BAO_0000019,9606.0,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),,,Homo sapiens,,,,
4919,1,A,BAO_0000019,9606.0,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,,Homo sapiens,,,,
4920,1,A,BAO_0000019,9606.0,4514,Compound was tested for protein binding in human plasma,,,Homo sapiens,,,,
4921,1,A,BAO_0000019,9606.0,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,,Homo sapiens,,,,
4922,1,A,BAO_0000019,9606.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,,Homo sapiens,,Urine,,
4923,1,A,BAO_0000218,10090.0,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,In vivo,,Mus musculus,,,,
4924,1,A,BAO_0000218,10090.0,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,,Mus musculus,,,,
4925,1,A,BAO_0000218,10090.0,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,,Mus musculus,,,,
4926,1,A,BAO_0000218,10090.0,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,In vivo,,Mus musculus,,Plasma,,
4927,1,A,BAO_0000218,10090.0,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,,Plasma,,
4928,1,F,BAO_0000218,10090.0,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,In vivo,,Mus musculus,,,,
4929,1,A,BAO_0000218,10090.0,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,In vivo,,Mus musculus,,,,
4930,1,A,BAO_0000218,10090.0,17764,Tmax after peroral administration in mice at 2.4 uM/kg,In vivo,,Mus musculus,,,,
4931,1,A,BAO_0000218,10090.0,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,In vivo,,Mus musculus,,,,
4932,1,A,BAO_0000218,10090.0,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,,Brain,,
4933,1,A,BAO_0000218,10090.0,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,,Kidney,,
4934,1,A,BAO_0000218,10090.0,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,,Liver,,
4935,1,A,BAO_0000218,10090.0,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,,Lung,,
4936,1,F,BAO_0000218,10090.0,17764,Tmax in mice at 18 uM/kg i.p. administration,In vivo,,Mus musculus,,,,
4937,1,F,BAO_0000218,10090.0,17764,Tmax in mice at 23 uM/kg i.v. administration,In vivo,,Mus musculus,,,,
4938,1,F,BAO_0000218,10090.0,17764,Tmax in mice at 25 uM/kg i.p. administration,In vivo,,Mus musculus,,,,
4939,1,F,BAO_0000218,10090.0,17764,Tmax in mice at 26 uM/kg i.p. administration,In vivo,,Mus musculus,,,,
4940,1,A,BAO_0000218,10090.0,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,,Spleen,,
4941,1,A,BAO_0000218,10090.0,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,,,,
4942,1,A,BAO_0000218,10090.0,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,,Mus musculus,,,,
4943,1,A,BAO_0000218,10090.0,5951,Tmax value in IRC mice,,,Mus musculus,,,,
4944,1,A,BAO_0000218,10090.0,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,,Mus musculus,,,,
4945,1,A,BAO_0000218,10090.0,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,,Mus musculus,,,,
4946,1,A,BAO_0000218,10090.0,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,,Mus musculus,,Urine,,
4947,1,A,BAO_0000218,10090.0,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,,Mus musculus,,Urine,,
4948,1,A,BAO_0000218,10090.0,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,,Mus musculus,,Urine,,
4949,1,A,BAO_0000218,10090.0,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,Mus musculus,,,,
4950,1,A,BAO_0000218,10090.0,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,Mus musculus,,,,
4951,1,A,BAO_0000218,10090.0,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,,Mus musculus,,,,
4952,1,A,BAO_0000218,10090.0,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,In vivo,,Mus musculus,,,,
4953,1,A,BAO_0000218,10090.0,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,In vivo,,Mus musculus,,,,
4954,1,A,BAO_0000218,10090.0,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,,Mus musculus,,,,
4955,1,A,BAO_0000218,10090.0,5980,Vd in mice,In vivo,,Mus musculus,,,,
4956,1,A,BAO_0000218,10090.0,17592,Volume of distribution in mouse,In vivo,,Mus musculus,,,,
4957,1,A,BAO_0000218,10090.0,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,,,,
4958,1,A,BAO_0000218,10090.0,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,In vivo,,Mus musculus,,,,
4959,1,A,BAO_0000218,10090.0,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,In vivo,,Mus musculus,,,,
4960,1,A,BAO_0000218,10090.0,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,In vivo,,Mus musculus,,,,
4961,1,A,BAO_0000218,10090.0,4239,Pharmacokinetic property (vdss) was measured in mouse,In vivo,,Mus musculus,,,,
4962,1,A,BAO_0000218,10090.0,2862,Value distribution upon iv administration in mouse,In vivo,,Mus musculus,,,,
4963,1,A,BAO_0000218,10090.0,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,In vivo,,Mus musculus,,,,
4964,1,A,BAO_0000218,10090.0,2675,Volume of distribution was evaluated in mice after intravenous administration,In vivo,,Mus musculus,,,,
4965,1,A,BAO_0000218,10090.0,2675,Volume of distribution was evaluated in mice after oral administration,In vivo,,Mus musculus,,,,
4966,1,A,BAO_0000218,10090.0,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,,Mus musculus,,,,
4967,1,A,BAO_0000218,10090.0,5727,Steady state volume of distribution was determined in mice,In vivo,,Mus musculus,,,,
4968,1,A,BAO_0000218,10090.0,17852,Volume distribution (steady state) of compound was determined in mouse,In vivo,,Mus musculus,,,,
4969,1,A,BAO_0000218,10090.0,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,In vivo,,Mus musculus,,,,
4970,1,A,BAO_0000218,10090.0,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,,,,
4971,1,A,BAO_0000218,10090.0,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,,Mus musculus,,,,
4972,1,A,BAO_0000218,10090.0,16438,Biodistribution of compound (oxidized form) in in kidney tissue,In vivo,,Mus musculus,,Kidney,,
4973,1,A,BAO_0000218,10090.0,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,,Mus musculus,,Blood,,
4974,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,,Mus musculus,,Blood,,
4975,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Blood,,
4976,1,F,BAO_0000219,9606.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,,Homo sapiens,,,A-427,
4977,1,F,BAO_0000219,9606.0,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,,,Homo sapiens,,,A-431,
4978,1,F,BAO_0000219,9606.0,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,,Homo sapiens,,,A-431,
4979,1,F,BAO_0000219,9606.0,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,,Homo sapiens,,,A-431,
4980,1,F,BAO_0000219,9606.0,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,,Homo sapiens,,,A-431,
4981,1,F,BAO_0000219,9606.0,6700,Inhibition of A431 human carcinoma cell proliferation,,,Homo sapiens,,,A-431,
4982,1,F,BAO_0000219,9606.0,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,,Homo sapiens,,,A-431,
4983,1,F,BAO_0000219,9606.0,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,,Homo sapiens,,,A-431,
4984,1,F,BAO_0000219,9606.0,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,,,Homo sapiens,,,A-431,
4985,1,F,BAO_0000218,9606.0,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,,Homo sapiens,,,A-431,
4986,1,F,BAO_0000219,9606.0,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,,,Homo sapiens,,,A-431,
4987,1,F,BAO_0000219,9606.0,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,,Homo sapiens,,,A-431,
4988,1,F,BAO_0000219,9606.0,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,,Homo sapiens,,,A-431,
4989,1,F,BAO_0000219,,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,,,,,A-431,
4990,1,F,BAO_0000219,9606.0,6333,Tested for antiproliferative activity against human A431 cells,,,Homo sapiens,,,A-431,
4991,1,F,BAO_0000219,9606.0,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,,Homo sapiens,,,A-431,
4992,1,F,BAO_0000219,9606.0,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,,Homo sapiens,,,A-431,
4993,1,F,BAO_0000219,9606.0,5126,Inhibition of A431 cell proliferation,,,Homo sapiens,,,A-431,
4994,1,F,BAO_0000219,9606.0,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,,,Homo sapiens,,,A-431,
4995,1,F,BAO_0000219,9606.0,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,,Homo sapiens,,,A-431,
4996,1,F,BAO_0000219,9606.0,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,,Homo sapiens,,,A-431,
4997,1,F,BAO_0000219,9606.0,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,,Homo sapiens,,,A-431,
4998,1,F,BAO_0000219,9606.0,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,,Homo sapiens,,,A-431,
4999,1,F,BAO_0000219,9606.0,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,,Homo sapiens,,,A-431,
5000,1,F,BAO_0000219,,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,,,,,A-431,
5001,1,F,BAO_0000218,9606.0,17824,In vivo antiproliferative activity against A431 cell line,,,Homo sapiens,,,A-431,
5002,1,F,BAO_0000219,9606.0,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,,Homo sapiens,,,A-431,
5003,1,F,BAO_0000219,9606.0,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,,,Homo sapiens,,,A-431,
5004,1,F,BAO_0000219,9606.0,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,,Homo sapiens,,,A-431,
5005,1,F,BAO_0000219,9606.0,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,,Homo sapiens,,,A-431,
5006,1,F,BAO_0000219,9606.0,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,,Homo sapiens,,,A-431,
5007,1,F,BAO_0000219,9606.0,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,,Homo sapiens,,,A-431,
5008,1,F,BAO_0000019,9606.0,5296,Inhibition of EGFR overexpressing A431 cell proliferation,,,Homo sapiens,,,,
5009,1,F,BAO_0000219,9606.0,12624,Inhibition of A431 cell proliferation,,,Homo sapiens,,,A-431,
5010,1,F,BAO_0000219,9606.0,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,,Homo sapiens,,,A-431,
5011,1,F,BAO_0000219,9606.0,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,,Homo sapiens,,,A-431,
5012,1,F,BAO_0000219,,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,,,,,A-431,
5013,1,F,BAO_0000219,9606.0,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,,Homo sapiens,,,A-431,
5014,1,F,BAO_0000219,9606.0,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,,Homo sapiens,,,A-431,
5015,1,F,BAO_0000219,9606.0,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,,Homo sapiens,,,A-431,
5016,1,F,BAO_0000219,9606.0,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,,Homo sapiens,,,A-431,
5017,1,F,BAO_0000219,9606.0,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,,Homo sapiens,,,A-431,
5018,1,F,BAO_0000219,9606.0,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,,Homo sapiens,,,A-431,
5019,1,F,BAO_0000219,9606.0,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,,Homo sapiens,,,A-431,
5020,1,A,BAO_0000019,9527.0,5922,Half-life period in cynomolgus monkey,,,Cercopithecidae,,,,
5021,1,A,BAO_0000366,9527.0,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",In vitro,,Cercopithecidae,,Plasma,,
5022,1,A,BAO_0000218,9527.0,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,In vivo,,Cercopithecidae,,,,
5023,1,A,BAO_0000366,9527.0,993,Plasma half life in monkey,,,Cercopithecidae,,Plasma,,
5024,1,A,BAO_0000366,9527.0,4514,Plasma half-life in rhesus monkey,,,Cercopithecidae,,Plasma,,
5025,1,A,BAO_0000218,9527.0,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,,Plasma,,
5026,1,A,BAO_0000218,9527.0,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,Cercopithecidae,,Plasma,,
5027,1,A,BAO_0000218,9527.0,4578,Tested for half life upon iv administration to african green monkey,In vivo,,Cercopithecidae,,,,
5028,1,A,BAO_0000218,9527.0,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,,,,
5029,1,A,BAO_0000218,9527.0,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,,Cercopithecidae,,,,
5030,1,A,BAO_0000218,9527.0,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,,Cercopithecidae,,,,
5031,1,A,BAO_0000218,9527.0,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,In vivo,,Cercopithecidae,,,,
5032,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,,Cercopithecidae,,,,
5033,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,,Cercopithecidae,,,,
5034,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,,Cercopithecidae,,,,
5035,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,,Cercopithecidae,,,,
5036,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,,Cercopithecidae,,,,
5037,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,,Cercopithecidae,,,,
5038,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,,Cercopithecidae,,,,
5039,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,,Cercopithecidae,,,,
5040,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,,Cercopithecidae,,,,
5041,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,,Cercopithecidae,,,,
5042,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,,Cercopithecidae,,,,
5043,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,,Cercopithecidae,,,,
5044,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,,Cercopithecidae,,,,
5045,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,,Cercopithecidae,,,,
5046,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,,Cercopithecidae,,,,
5047,1,A,BAO_0000019,9527.0,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,,Cercopithecidae,,,,
5048,1,A,BAO_0000218,10116.0,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),In vivo,,Rattus norvegicus,,,,
5049,1,A,BAO_0000218,10116.0,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,,Rattus norvegicus,,Plasma,,
5050,1,A,BAO_0000218,10116.0,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,,,Rattus norvegicus,,Plasma,,
5051,1,A,BAO_0000218,10116.0,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,,,Rattus norvegicus,,Plasma,,
5052,1,A,BAO_0000218,10116.0,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,,,,
5053,1,A,BAO_0000218,10116.0,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,,,,
5054,1,A,BAO_0000218,10116.0,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,,,,
5055,1,A,BAO_0000218,10116.0,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,,,Rattus norvegicus,,,,
5056,1,A,BAO_0000218,10116.0,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,,,,
5057,1,A,BAO_0000019,9557.0,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,Papio hamadryas,,,,
5058,1,A,BAO_0000019,9557.0,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,,Papio hamadryas,,,,
5059,1,A,BAO_0000019,9557.0,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,,Papio hamadryas,,,,
5060,1,A,BAO_0000019,9557.0,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,,Papio hamadryas,,,,
5061,1,A,BAO_0000019,9557.0,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,,Papio hamadryas,,,,
5062,1,A,BAO_0000019,9557.0,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,,Papio hamadryas,,,,
5063,1,A,BAO_0000019,9557.0,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,,Papio hamadryas,,,,
5064,1,A,BAO_0000019,9557.0,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,Papio hamadryas,,,,
5065,1,A,BAO_0000019,9615.0,3510,Area under curve after 1 mpk peroral administration to beagles,,,beagle,,,,
5066,1,A,BAO_0000019,9615.0,3510,Area under curve after 2 mpk peroral administration to beagles,,,beagle,,,,
5067,1,A,BAO_0000218,9615.0,3510,Cmax value after 1 mpk peroral administration to beagles,In vivo,,beagle,,,,
5068,1,A,BAO_0000019,9606.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,,Homo sapiens,,Urine,,
5069,1,A,BAO_0000019,9606.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,,Homo sapiens,,Urine,,
5070,1,A,BAO_0000019,9606.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,,Homo sapiens,,Urine,,
5071,1,A,BAO_0000019,9606.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,,Homo sapiens,,Urine,,
5072,1,A,BAO_0000019,9606.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,,Homo sapiens,,Urine,,
5073,1,A,BAO_0000019,9606.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,,Homo sapiens,,Urine,,
5074,1,A,BAO_0000019,9606.0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,,Homo sapiens,,Urine,,
5075,1,A,BAO_0000251,9606.0,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,,,Homo sapiens,,Liver,,Microsomes
5076,1,A,BAO_0000019,9606.0,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,,Homo sapiens,,,,
5077,1,A,BAO_0000019,9606.0,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,,Homo sapiens,,,,
5078,1,A,BAO_0000019,9606.0,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,,Homo sapiens,,,,
5079,1,A,BAO_0000251,9606.0,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,,Homo sapiens,,Liver,,Microsomes
5080,1,A,BAO_0000019,9606.0,6570,Metabolic stability (% remaining at 30 mins) in human S9.,,,Homo sapiens,,,,
5081,1,A,BAO_0000019,9606.0,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,,Homo sapiens,,,,
5082,1,A,BAO_0000251,9606.0,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,,,Homo sapiens,,Liver,,Microsomes
5083,1,A,BAO_0000251,9606.0,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,,Homo sapiens,,Liver,,Microsomes
5084,1,A,BAO_0000251,9606.0,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,,Homo sapiens,,Liver,,Microsomes
5085,1,A,BAO_0000218,9606.0,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,,Homo sapiens,,,,
5086,1,A,BAO_0000019,9606.0,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,,Homo sapiens,,,,
5087,1,A,BAO_0000019,9606.0,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,,,Homo sapiens,,,,
5088,1,A,BAO_0000019,9606.0,3956,The percent remaining in human plasma after 30 min was determined,,,Homo sapiens,,,,
5089,1,A,BAO_0000366,9606.0,5074,Conversion rate of the prodrug in human plasma,,,Homo sapiens,,Plasma,,
5090,1,A,BAO_0000366,9606.0,5074,Conversion rate of the prodrug in human plasma; ND means no data,,,Homo sapiens,,Plasma,,
5091,1,A,BAO_0000221,9606.0,4727,Half life of compound was determined in human blood,,,Homo sapiens,,Blood,,
5092,1,A,BAO_0000019,9606.0,5965,Half life of compound was determined in man with once daily dosing,,,Homo sapiens,,,,
5093,1,A,BAO_0000251,9606.0,5732,Half life in human microsomes,In vitro,,Homo sapiens,,,,Microsomes
5094,1,A,BAO_0000366,9606.0,5819,Half life in human plasma,,,Homo sapiens,,Plasma,,
5095,1,A,BAO_0000366,9606.0,5819,Half life in human plasma; Not detected,,,Homo sapiens,,Plasma,,
5096,1,A,BAO_0000218,9606.0,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,,Homo sapiens,,,,
5097,1,A,BAO_0000251,9606.0,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,In vitro,,Homo sapiens,,Liver,,Microsomes
5098,1,A,BAO_0000366,9606.0,5229,Half-life in human plasma,,,Homo sapiens,,Plasma,,
5099,1,A,BAO_0000366,9606.0,5229,Half-life of the parent prodrug in plasma,,,Homo sapiens,,Plasma,,
5100,1,A,BAO_0000366,9606.0,2192,In vitro half life in human plasma was determined,In vitro,,Homo sapiens,,Plasma,,
5101,1,A,BAO_0000251,9606.0,3032,The compound was tested In Vitro for half life in human liver microsomes.,In vitro,,Homo sapiens,,Liver,,Microsomes
5102,1,A,BAO_0000218,9606.0,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,,Homo sapiens,,,,
5103,1,A,BAO_0000218,9606.0,17716,Observed volume of distribution,In vivo,,Homo sapiens,,,,
5104,1,A,BAO_0000218,9606.0,15778,Oral bioavailability in human,In vivo,,Homo sapiens,,,,
5105,1,A,BAO_0000019,9606.0,17313,Tested for human plasma protein binding of the compound,,,Homo sapiens,,,,
5106,1,A,BAO_0000019,9606.0,4231,"First order rate constant, k was determined in human plasma",,,Homo sapiens,,,,
5107,1,A,BAO_0000019,9606.0,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,Homo sapiens,,,,
5108,1,A,BAO_0000019,9606.0,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,Homo sapiens,,,,
5109,1,A,BAO_0000251,9606.0,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,Homo sapiens,,Liver,,Microsomes
5110,1,A,BAO_0000019,9606.0,10839,The compound was tested for the plasma binding in human,,,Homo sapiens,,,,
5111,1,A,BAO_0000019,9606.0,10839,Plasma protein binding (human),,,Homo sapiens,,,,
5112,1,A,BAO_0000251,9606.0,3199,Compound was evaluated for half-life in human liver microsomes,In vitro,,Homo sapiens,,Liver,,Microsomes
5113,1,A,BAO_0000221,9606.0,1345,Half life measured in vitro for its stability in human blood,In vitro,,Homo sapiens,,Blood,,
5114,1,A,BAO_0000019,9606.0,4297,Half life in human serum,,,Homo sapiens,,Serum,,
5115,1,A,BAO_0000019,9606.0,4297,Half life in human serum; ND=not determined,,,Homo sapiens,,Serum,,
5116,1,A,BAO_0000019,9606.0,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,,,Homo sapiens,,,,
5117,1,A,BAO_0000019,9606.0,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,,,Homo sapiens,,,,
5118,1,A,BAO_0000366,9606.0,4231,Half life of the in human plasma,,,Homo sapiens,,Plasma,,
5119,1,A,BAO_0000220,9606.0,5633,Half life period in human hepatic S9 fraction was determined,In vitro,,Homo sapiens,,,,S9
5120,1,A,BAO_0000251,9606.0,5633,Half life period in human liver microsome was determined,In vitro,,Homo sapiens,,Liver,,Microsomes
5121,1,A,BAO_0000019,9606.0,17791,Half life period was determined; 6-7,,,Homo sapiens,,,,
5122,1,A,BAO_0000019,9606.0,17791,Half life period was evaluated in human,,,Homo sapiens,,,,
5123,1,A,BAO_0000366,9606.0,3160,Half life time in human plasma,,,Homo sapiens,,Plasma,,
5124,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Brain,,
5125,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Heart,,
5126,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Heart,,
5127,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Kidney,,
5128,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,,Mus musculus,,Kidney,,
5129,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Kidney,,
5130,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Liver,,
5131,1,A,BAO_0000218,10090.0,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,,Mus musculus,,Liver,,
5132,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Liver,,
5133,1,A,BAO_0000218,10090.0,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,,Mus musculus,,Spleen,,
5134,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,,Mus musculus,,Spleen,,
5135,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Spleen,,
5136,1,A,BAO_0000218,10090.0,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,,Brain,,
5137,1,A,BAO_0000218,10090.0,16438,Biodistribution of compound (oxidized form) in blood tissue,In vivo,,Mus musculus,,Blood,,
5138,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Blood,,
5139,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,,Blood,,
5140,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,,Blood,,
5141,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Blood,,
5142,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,,Blood,,
5143,1,A,BAO_0000218,10090.0,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,In vivo,,Mus musculus,,Brain,,
5144,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Brain,,
5145,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,,Brain,,
5146,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Brain,,
5147,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,,Brain,,
5148,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,,Brain,,
5149,1,A,BAO_0000218,10090.0,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,In vivo,,Mus musculus,,Heart,,
5150,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Heart,,
5151,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Heart,,
5152,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,,Heart,,
5153,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Heart,,
5154,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,,Heart,,
5155,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Kidney,,
5156,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,,Kidney,,
5157,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,,Kidney,,
5158,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Kidney,,
5159,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,Mus musculus,,Kidney,,
5160,1,A,BAO_0000218,10090.0,16438,Biodistribution of compound (oxidized form) in liver tissue,In vivo,,Mus musculus,,Liver,,
5161,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,Mus musculus,,Liver,,
5162,1,A,BAO_0000218,10090.0,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,Mus musculus,,Liver,,
5163,1,F,BAO_0000219,9606.0,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,,Homo sapiens,,,A-431,
5164,1,F,BAO_0000219,9606.0,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,,Homo sapiens,,,A-431,
5165,1,F,BAO_0000218,,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,,,,,A-431,
5166,1,F,BAO_0000218,,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,,,,,A-431,
5167,1,F,BAO_0000219,9606.0,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,,Homo sapiens,,,A-431,
5168,1,F,BAO_0000219,9606.0,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,,Homo sapiens,,,A-431,
5169,1,F,BAO_0000219,9606.0,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,,Homo sapiens,,,A-431,
5170,1,F,BAO_0000219,9606.0,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,,Homo sapiens,,,A-431,
5171,1,F,BAO_0000219,9606.0,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,,Homo sapiens,,,A-431,
5172,1,F,BAO_0000218,,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,,,,,A-431,
5173,1,F,BAO_0000218,,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,,,,A-431,
5174,1,F,BAO_0000218,,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,,,,A-431,
5175,1,F,BAO_0000218,,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,,,,,A-431,
5176,1,F,BAO_0000218,,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,,,,,A-431,
5177,1,F,BAO_0000219,9606.0,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,,Homo sapiens,,,A-431,
5178,1,F,BAO_0000219,,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,,,,,A-431,
5179,1,F,BAO_0000218,,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,,,,,A-431,
5180,1,F,BAO_0000218,,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,,,,A-431,
5181,1,F,BAO_0000218,,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,,,,A-431,
5182,1,F,BAO_0000218,10090.0,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,,Mus musculus,,,A-431,
5183,1,F,BAO_0000218,10090.0,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,,Mus musculus,,,A-431,
5184,1,F,BAO_0000218,10090.0,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,,Mus musculus,,,A-431,
5185,1,F,BAO_0000218,10090.0,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,,Mus musculus,,,A-431,
5186,1,F,BAO_0000219,9606.0,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,,Homo sapiens,,,A-431,
5187,1,F,BAO_0000219,9606.0,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,,Homo sapiens,,,A-431,
5188,1,F,BAO_0000219,9606.0,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,,Homo sapiens,,,A-431,
5189,1,F,BAO_0000219,9606.0,3558,Dose giving a 50% decrease in the living cell number (A437 cells),,,Homo sapiens,,,A-431,
5190,1,F,BAO_0000219,9606.0,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,,,Homo sapiens,,,A549,
5191,1,F,BAO_0000219,9606.0,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,,Homo sapiens,,,A549,
5192,1,F,BAO_0000219,9606.0,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,,Homo sapiens,,,A549,
5193,1,F,BAO_0000219,9606.0,17229,In vitro antitumor activity against renal A498 tumor cell lines,,,Homo sapiens,,,A498,
5194,1,F,BAO_0000219,9606.0,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,,Homo sapiens,,,A498,
5195,1,F,BAO_0000219,9606.0,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,,Homo sapiens,,,A498,
5196,1,F,BAO_0000219,9606.0,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,,Homo sapiens,,,A498,
5197,1,F,BAO_0000219,9606.0,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,,Homo sapiens,,,A498,
5198,1,F,BAO_0000219,9606.0,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,,Homo sapiens,,,A498,
5199,1,F,BAO_0000219,9606.0,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,,,Homo sapiens,,,A498,
5200,1,F,BAO_0000219,9606.0,15403,Compound was evaluated against Human cell line renal A498,,,Homo sapiens,,,A498,
5201,1,F,BAO_0000219,9606.0,1009,Compound was tested for inhibition of A498 human renal cancer cell line,,,Homo sapiens,,,A498,
5202,1,F,BAO_0000219,9606.0,1043,Growth inhibitory activity against A498 human cancer cell line,,,Homo sapiens,,,A498,
5203,1,F,BAO_0000219,9606.0,5858,In vitro antitumor activity against human renal A498 cell line,,,Homo sapiens,,,A498,
5204,1,F,BAO_0000219,9606.0,5958,In vitro cytotoxic activity against renal (A498) cell line,,,Homo sapiens,,,A498,
5205,1,F,BAO_0000219,9606.0,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,,,Homo sapiens,,,A498,
5206,1,F,BAO_0000219,9606.0,12781,Tested for cytostatic activity against renal A498 cell line,,,Homo sapiens,,,A498,
5207,1,F,BAO_0000219,9606.0,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,,Homo sapiens,,,A498,
5208,1,F,BAO_0000219,9606.0,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,,Homo sapiens,,,A498,
5209,1,A,BAO_0000218,9615.0,3510,Cmax value after 2 mpk peroral administration to beagles,In vivo,,beagle,,,,
5210,1,A,BAO_0000218,9615.0,3510,Bioavailability,In vivo,,Canis lupus familiaris,beagle,,,
5211,1,A,BAO_0000218,9615.0,3510,Bioavailability after 1 mpk peroral administration to beagles,In vivo,,Canis lupus familiaris,beagle,,,
5212,1,A,BAO_0000218,9615.0,3510,Bioavailability after 2 mpk peroral administration to beagles,In vivo,,Canis lupus familiaris,beagle,,,
5213,1,A,BAO_0000019,9913.0,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,,Bos taurus,,,,
5214,1,A,BAO_0000019,9913.0,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,,Bos taurus,,,,
5215,1,A,BAO_0000019,9913.0,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,,Bos taurus,,,,
5216,1,A,BAO_0000019,9913.0,9372,Solubility against bovine alpha-chymotrypsin,,,Bos taurus,,,,
5217,1,A,BAO_0000019,9913.0,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,Bos taurus,,,,
5218,1,A,BAO_0000019,9913.0,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,Bos taurus,,,,
5219,1,A,BAO_0000221,9913.0,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,,Bos taurus,,Spleen,,
5220,1,A,BAO_0000019,9913.0,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,,Bos taurus,,,,
5221,1,A,BAO_0000019,9913.0,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,,Bos taurus,,,,
5222,1,A,BAO_0000019,9913.0,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,,Bos taurus,,,,
5223,1,A,BAO_0000221,9913.0,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,,Bos taurus,,Spleen,,
5224,1,A,BAO_0000019,9913.0,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,,,Bos taurus,,,,
5225,1,A,BAO_0000019,9913.0,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,,Bos taurus,,,,
5226,1,A,BAO_0000019,9913.0,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,,Bos taurus,,,,
5227,1,A,BAO_0000019,9913.0,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,,Bos taurus,,,,
5228,1,A,BAO_0000019,9913.0,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,,Bos taurus,,,,
5229,1,A,BAO_0000218,9615.0,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,,Canis lupus familiaris,,Plasma,,
5230,1,A,BAO_0000218,9615.0,17594,AUC after administration at 100 mg/kg/day in dogs,,,Canis lupus familiaris,,Plasma,,
5231,1,A,BAO_0000218,9615.0,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,,Canis lupus familiaris,,Plasma,,
5232,1,A,BAO_0000218,9615.0,16907,AUC value after 15 mg/kg iv dose in Dogs,,,Canis lupus familiaris,,Plasma,,
5233,1,A,BAO_0000218,9615.0,16907,AUC value after 30 mg/kg po dose in Dogs,,,Canis lupus familiaris,,Plasma,,
5234,1,A,BAO_0000218,9615.0,2959,AUC value after administration of 4 mg/Kg oral dose in dog,,,Canis lupus familiaris,,Plasma,,
5235,1,A,BAO_0000218,9615.0,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,,Canis lupus familiaris,,Plasma,,
5236,1,A,BAO_0000218,9615.0,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,,Canis lupus familiaris,,,,
5237,1,A,BAO_0000218,9615.0,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,,Canis lupus familiaris,,,,
5238,1,A,BAO_0000218,9615.0,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,,Canis lupus familiaris,,,,
5239,1,A,BAO_0000218,9615.0,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,,Canis lupus familiaris,,,,
5240,1,A,BAO_0000218,9615.0,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,,Canis lupus familiaris,,,,
5241,1,A,BAO_0000218,9615.0,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,,,Canis lupus familiaris,,,,
5242,1,A,BAO_0000218,9615.0,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,Canis lupus familiaris,,,,
5243,1,A,BAO_0000218,9615.0,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,,Canis lupus familiaris,,,,
5244,1,A,BAO_0000218,9615.0,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,,Canis lupus familiaris,,,,
5245,1,A,BAO_0000218,9615.0,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,Canis lupus familiaris,,,,
5246,1,A,BAO_0000218,9615.0,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,,Canis lupus familiaris,,,,
5247,1,A,BAO_0000218,9615.0,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,Canis lupus familiaris,,,,
5248,1,A,BAO_0000218,9615.0,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,,Canis lupus familiaris,,,,
5249,1,A,BAO_0000218,9615.0,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,,Canis lupus familiaris,,,,
5250,1,A,BAO_0000218,9615.0,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,Canis lupus familiaris,,,,
5251,1,A,BAO_0000218,9615.0,5668,Area under curve was determine after peroral administration at 10 mpk in dog,,,Canis lupus familiaris,,,,
5252,1,A,BAO_0000218,9615.0,5668,Area under curve was determine after peroral administration at 5 mpk in dog,,,Canis lupus familiaris,,,,
5253,1,A,BAO_0000218,9615.0,5006,Area under curve was determined,,,Canis lupus familiaris,,,,
5254,1,A,BAO_0000218,9615.0,5006,Area under curve in dogs,,,Canis lupus familiaris,,,,
5255,1,A,BAO_0000218,9615.0,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,,,Canis lupus familiaris,,,,
5256,1,A,BAO_0000218,9615.0,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,,Canis lupus familiaris,,,,
5257,1,A,BAO_0000218,9615.0,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,,Canis lupus familiaris,,,,
5258,1,A,BAO_0000218,9615.0,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,Canis lupus familiaris,,,,
5259,1,A,BAO_0000218,9615.0,5302,Area under curve value in dog at a dose of 5 mg/kg,,,Canis lupus familiaris,,,,
5260,1,A,BAO_0000218,9615.0,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,,,Canis lupus familiaris,,,,
5261,1,A,BAO_0000218,9615.0,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,,,Canis lupus familiaris,,,,
5262,1,A,BAO_0000218,9615.0,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,,Canis lupus familiaris,,,,
5263,1,A,BAO_0000218,9615.0,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,,Canis lupus familiaris,,,,
5264,1,A,BAO_0000019,9606.0,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,,Homo sapiens,,,,
5265,1,A,BAO_0000019,9606.0,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,Homo sapiens,,,,
5266,1,A,BAO_0000019,9606.0,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,,Homo sapiens,,,,
5267,1,A,BAO_0000019,9606.0,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,,Homo sapiens,,,,
5268,1,A,BAO_0000221,9606.0,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,,,Homo sapiens,,Blood,,
5269,1,A,BAO_0000366,9606.0,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,Homo sapiens,,Plasma,,
5270,1,A,BAO_0000366,9606.0,6787,Half life in human plasma,,,Homo sapiens,,Plasma,,
5271,1,A,BAO_0000366,9606.0,4898,Half life in human plasma was reported,,,Homo sapiens,,Plasma,,
5272,1,A,BAO_0000019,9606.0,6072,Half life in human serum,,,Homo sapiens,,Serum,,
5273,1,A,BAO_0000366,9606.0,16907,Half life upon exposure to human plasma,,,Homo sapiens,,Plasma,,
5274,1,A,BAO_0000251,9606.0,5656,t1/2 in human microsomes,In vitro,,Homo sapiens,,,,Microsomes
5275,1,A,BAO_0000366,9606.0,4755,Half life period in 80% human plasma at 37 degree Centigrade,,,Homo sapiens,,Plasma,,
5276,1,A,BAO_0000221,9606.0,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,,Homo sapiens,,Zone of skin,,
5277,1,A,BAO_0000366,9606.0,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,In vitro,,Homo sapiens,,Plasma,,
5278,1,A,BAO_0000019,9606.0,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,,Homo sapiens,,,,
5279,1,A,BAO_0000251,9606.0,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,In vitro,,Homo sapiens,,Liver,,Microsomes
5280,1,A,BAO_0000366,9606.0,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,Homo sapiens,,Plasma,,
5281,1,A,BAO_0000366,9606.0,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,Homo sapiens,,Plasma,,
5282,1,A,BAO_0000366,9606.0,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,Homo sapiens,,Plasma,,
5283,1,A,BAO_0000019,9606.0,1540,Half-life in the CEM cell extracts,,,Homo sapiens,,,,
5284,1,A,BAO_0000366,9606.0,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,,Homo sapiens,,Plasma,,
5285,1,A,BAO_0000366,9606.0,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,,Homo sapiens,,Plasma,,
5286,1,A,BAO_0000019,9606.0,5523,Half-life was determined,,,Homo sapiens,,,,
5287,1,A,BAO_0000221,9606.0,1499,Half-life (human blood stability),,,Homo sapiens,,Blood,,
5288,1,A,BAO_0000221,9606.0,1499,Half-life (human blood stability); no data,,,Homo sapiens,,Blood,,
5289,1,A,BAO_0000366,9606.0,17065,Half-life in human plasma,,,Homo sapiens,,Plasma,,
5290,1,A,BAO_0000019,9606.0,6861,CYP3A4 metabolism half-life (t1/2),,,Homo sapiens,,,,
5291,1,A,BAO_0000221,9606.0,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,,Homo sapiens,,Blood,,
5292,1,A,BAO_0000366,9606.0,530,In vitro half life in human plasma,In vitro,,Homo sapiens,,Plasma,,
5293,1,A,BAO_0000366,9606.0,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",In vitro,,Homo sapiens,,Plasma,,
5294,1,A,BAO_0000366,9606.0,6695,In vitro hydrolysis in human plasma,In vitro,,Homo sapiens,,Plasma,,
5295,1,A,BAO_0000366,9606.0,6695,In vitro hydrolysis in human plasma; no data,In vitro,,Homo sapiens,,Plasma,,
5296,1,A,BAO_0000251,9606.0,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,In vitro,,Homo sapiens,,Liver,,Microsomes
5297,1,A,BAO_0000366,9606.0,993,Plasma half life in human,,,Homo sapiens,,Plasma,,
5298,1,A,BAO_0000366,9606.0,15429,Stability after incubation with human plasma (at 37 degree C),,,Homo sapiens,,Plasma,,
5299,1,A,BAO_0000366,9606.0,1675,T1/2 was evaluated in human plasma,,,Homo sapiens,,Plasma,,
5300,1,A,BAO_0000366,9606.0,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,Homo sapiens,,Plasma,,
5301,1,A,BAO_0000366,9606.0,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,,Homo sapiens,,Plasma,,
5302,1,A,BAO_0000019,9606.0,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,Homo sapiens,,,,
5303,1,A,BAO_0000019,9606.0,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,In vitro,,Homo sapiens,,,,
5304,1,A,BAO_0000019,9606.0,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,In vitro,,Homo sapiens,,,,
5305,1,A,BAO_0000366,9606.0,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,,Homo sapiens,,Plasma,,
5306,1,A,BAO_0000366,9606.0,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,,Homo sapiens,,Plasma,,
5307,1,A,BAO_0000019,9606.0,5495,Time taken for 50% to be consumed by serum PON1 was determined,,,Homo sapiens,,,,
5308,1,A,BAO_0000019,9606.0,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,,Homo sapiens,,,,
5309,1,A,BAO_0000251,9606.0,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,Homo sapiens,,Liver,,Microsomes
5310,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,,,,
5311,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,,,,
5312,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,,,,
5313,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,,,,
5314,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,,,,
5315,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Mus sp.,,,,
5316,1,F,BAO_0000219,9606.0,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,,,Homo sapiens,,,786-0,
5317,1,F,BAO_0000219,9606.0,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,,Homo sapiens,,,786-0,
5318,1,F,BAO_0000219,9606.0,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,,Homo sapiens,,,786-0,
5319,1,F,BAO_0000219,9606.0,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,,Homo sapiens,,,786-0,
5320,1,F,BAO_0000219,9606.0,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,,Homo sapiens,,,786-0,
5321,1,F,BAO_0000219,9606.0,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,,Homo sapiens,,,786-0,
5322,1,F,BAO_0000219,9606.0,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,,Homo sapiens,,,786-0,
5323,1,F,BAO_0000219,9606.0,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,,Homo sapiens,,,786-0,
5324,1,F,BAO_0000219,9606.0,12888,Cytotoxic effect on renal cancer line 786-0,,,Homo sapiens,,,786-0,
5325,1,F,BAO_0000219,9606.0,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,,Homo sapiens,,,786-0,
5326,1,F,BAO_0000219,9606.0,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,,Homo sapiens,,,786-0,
5327,1,F,BAO_0000219,9606.0,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,,Homo sapiens,,,786-0,
5328,1,F,BAO_0000219,9606.0,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,,Homo sapiens,,,786-0,
5329,1,F,BAO_0000219,9606.0,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,,Homo sapiens,,,786-0,
5330,1,F,BAO_0000219,9606.0,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,,Homo sapiens,,,786-0,
5331,1,F,BAO_0000219,9606.0,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,,Homo sapiens,,,786-0,
5332,1,F,BAO_0000219,9606.0,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,,Homo sapiens,,,786-0,
5333,1,F,BAO_0000219,9606.0,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,,Homo sapiens,,,786-0,
5334,1,F,BAO_0000219,9606.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,,Homo sapiens,,,791T cell line,
5335,1,F,BAO_0000219,9606.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,,Homo sapiens,,,791T cell line,
5336,1,F,BAO_0000219,9606.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,,Homo sapiens,,,791T cell line,
5337,1,F,BAO_0000219,9606.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,,Homo sapiens,,,791T cell line,
5338,1,F,BAO_0000219,9606.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,,Homo sapiens,,,791T cell line,
5339,1,F,BAO_0000219,9606.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,,Homo sapiens,,,791T cell line,
5340,1,F,BAO_0000219,9606.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,,Homo sapiens,,,791T cell line,
5341,1,F,BAO_0000219,9606.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,,Homo sapiens,,,791T cell line,
5342,1,F,BAO_0000219,9606.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,,Homo sapiens,,,791T cell line,
5343,1,F,BAO_0000219,9606.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,,Homo sapiens,,,791T cell line,
5344,1,F,BAO_0000219,9606.0,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,,Homo sapiens,,,786-0,
5345,1,F,BAO_0000019,,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,,,,,
5346,1,F,BAO_0000219,9606.0,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,,Homo sapiens,,,RPMI-8226,
5347,1,F,BAO_0000219,9606.0,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,,Homo sapiens,,,RPMI-8226,
5348,1,F,BAO_0000219,9606.0,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,,Homo sapiens,,,RPMI-8226,
5349,1,F,BAO_0000219,9606.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,Homo sapiens,,,RPMI-8226,
5350,1,F,BAO_0000219,9606.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,Homo sapiens,,,RPMI-8226,
5351,1,F,BAO_0000219,9606.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,Homo sapiens,,,RPMI-8226,
5352,1,F,BAO_0000219,9606.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,Homo sapiens,,,RPMI-8226,
5353,1,F,BAO_0000219,9606.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,Homo sapiens,,,RPMI-8226,
5354,1,F,BAO_0000219,9606.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,Homo sapiens,,,RPMI-8226,
5355,1,F,BAO_0000219,9606.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,Homo sapiens,,,RPMI-8226,
5356,1,F,BAO_0000219,9606.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,Homo sapiens,,,RPMI-8226,
5357,1,F,BAO_0000219,9606.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,Homo sapiens,,,RPMI-8226,
5358,1,F,BAO_0000219,9606.0,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,,Homo sapiens,,,A498,
5359,1,F,BAO_0000219,9606.0,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,,,Homo sapiens,,,A498,
5360,1,F,BAO_0000219,9606.0,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,,Homo sapiens,,,A498,
5361,1,F,BAO_0000219,9606.0,4337,In vitro inhibitory concentration against renal cancer cell line A498,,,Homo sapiens,,,A498,
5362,1,F,BAO_0000219,9606.0,15277,Cytotoxicity against A 498 tumor cell line,,,Homo sapiens,,,A498,
5363,1,F,BAO_0000219,9606.0,4812,In vitro antitumor activity against A498 human cancer cell line,,,Homo sapiens,,,A498,
5364,1,F,BAO_0000219,9606.0,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,,Homo sapiens,,,A498,
5365,1,F,BAO_0000219,9606.0,4995,Inhibitory dose required against A498 human tumor cell lines,,,Homo sapiens,,,A498,
5366,1,F,BAO_0000219,9606.0,5847,Anticancer activity against one renal cancer (A498 cell line),,,Homo sapiens,,,A498,
5367,1,F,BAO_0000219,9606.0,6557,In vitro cytotoxicity against melanoma A498 cell line,,,Homo sapiens,,,A498,
5368,1,F,BAO_0000219,9606.0,2597,Compound was tested for growth inhibitory activity against A498 cell line,,,Homo sapiens,,,A498,
5369,1,F,BAO_0000219,9606.0,6058,Compound tested for growth inhibition of renal cancer cell line A498,,,Homo sapiens,,,A498,
5370,1,F,BAO_0000219,9606.0,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,,Homo sapiens,,,A498,
5371,1,F,BAO_0000219,9606.0,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,,Homo sapiens,,,A498,
5372,1,F,BAO_0000219,9606.0,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,,Homo sapiens,,,A498,
5373,1,F,BAO_0000219,9606.0,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,,,Homo sapiens,,,A498,
5374,1,F,BAO_0000219,9606.0,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,,Homo sapiens,,,A498,
5375,1,F,BAO_0000219,9606.0,12888,Cytotoxic effect on renal cancer lines A498,,,Homo sapiens,,,A498,
5376,1,F,BAO_0000219,9606.0,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,,Homo sapiens,,,A498,
5377,1,F,BAO_0000219,9606.0,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,,Homo sapiens,,,A498,
5378,1,F,BAO_0000219,9606.0,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,,Homo sapiens,,,A498,
5379,1,F,BAO_0000219,9606.0,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,,Homo sapiens,,,A498,
5380,1,F,BAO_0000219,9606.0,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,,Homo sapiens,,,A498,
5381,1,F,BAO_0000219,9606.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,,Homo sapiens,,,A498,
5382,1,F,BAO_0000219,9606.0,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,,Homo sapiens,,,A549,
5383,1,F,BAO_0000219,9606.0,10196,Antitumor activity against A549 human lung carcinoma cell line,,,Homo sapiens,,,A549,
5384,1,F,BAO_0000219,9606.0,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,,Homo sapiens,,,A549,
5385,1,F,BAO_0000219,9606.0,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,,Homo sapiens,,,A549,
5386,1,F,BAO_0000219,9606.0,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,,Homo sapiens,,,A549,
5387,1,F,BAO_0000219,9606.0,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,,Homo sapiens,,,A549,
5388,1,F,BAO_0000219,9606.0,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,,,A549,
5389,1,F,BAO_0000219,9606.0,16470,In vitro cytotoxic activity against human lung A549 cell line,,,Homo sapiens,,,A549,
5390,1,F,BAO_0000219,9606.0,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,,Homo sapiens,,,A549,
5391,1,F,BAO_0000219,9606.0,16470,In vitro cytotoxic activity against human lung A549 cell line),,,Homo sapiens,,,A549,
5392,1,F,BAO_0000219,9606.0,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,,Homo sapiens,,,A549,
5393,1,F,BAO_0000219,9606.0,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,,Homo sapiens,,,A549,
5394,1,F,BAO_0000219,9606.0,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,,Homo sapiens,,,A549,
5395,1,F,BAO_0000219,9606.0,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,,Homo sapiens,,,A549,
5396,1,F,BAO_0000219,9606.0,16597,Inhibition of A549 human lung carcinoma cell proliferation,,,Homo sapiens,,,A549,
5397,1,F,BAO_0000219,9606.0,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,,,Homo sapiens,,,A549,
5398,1,F,BAO_0000219,9606.0,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,,Homo sapiens,,,A549,
5399,1,F,BAO_0000219,9606.0,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,,Homo sapiens,,,A549,
5400,1,F,BAO_0000219,9606.0,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,,Homo sapiens,,,A549,
5401,1,F,BAO_0000219,9606.0,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,,,A549,
5402,1,F,BAO_0000219,9606.0,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,,Homo sapiens,,,A549,
5403,1,F,BAO_0000219,9606.0,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,,Homo sapiens,,,A549,
5404,1,F,BAO_0000219,9606.0,4090,Inhibition of A549 cancer cell proliferation,,,Homo sapiens,,,A549,
5405,1,F,BAO_0000219,9606.0,4090,Inhibition of A549 cancer cell proliferation (Not tested),,,Homo sapiens,,,A549,
5406,1,F,BAO_0000219,9606.0,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,,Homo sapiens,,,A549,
5407,1,F,BAO_0000219,9606.0,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,,Homo sapiens,,,A549,
5408,1,F,BAO_0000219,9606.0,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,,,Homo sapiens,,,A549,
5409,1,F,BAO_0000219,9606.0,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,,Homo sapiens,,,A549,
5410,1,F,BAO_0000219,9606.0,5194,Cytotoxicity against Renal cell lines A549 was determined,,,Homo sapiens,,,A549,
5411,1,A,BAO_0000218,9615.0,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,,,Canis lupus familiaris,,,,
5412,1,A,BAO_0000218,9615.0,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,,,Canis lupus familiaris,,,,
5413,1,A,BAO_0000218,9615.0,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,Canis lupus familiaris,,,,
5414,1,A,BAO_0000218,9615.0,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,Canis lupus familiaris,,,,
5415,1,A,BAO_0000218,9615.0,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,,Canis lupus familiaris,,,,
5416,1,A,BAO_0000218,9615.0,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,,Canis lupus familiaris,,,,
5417,1,A,BAO_0000218,9615.0,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,,Canis lupus familiaris,,,,
5418,1,A,BAO_0000218,9615.0,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,,Canis lupus familiaris,,,,
5419,1,A,BAO_0000218,9615.0,17657,Area under plasma concentration time curve in dog upon oral administration,,,Canis lupus familiaris,,Plasma,,
5420,1,A,BAO_0000218,9615.0,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,,Canis lupus familiaris,,Plasma,,
5421,1,A,BAO_0000218,9615.0,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,,Canis lupus familiaris,,,,
5422,1,A,BAO_0000218,9615.0,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,,Canis lupus familiaris,,,,
5423,1,A,BAO_0000218,9615.0,3132,Area under the curve for the compound was obtained when tested in dog,,,Canis lupus familiaris,,,,
5424,1,A,BAO_0000218,9615.0,5473,Area under the curve at a dose of 1 mg/kg,,,Canis lupus familiaris,,,,
5425,1,A,BAO_0000218,9615.0,5474,Area under the curve at a dose of 1 mg/kg (oral),,,Canis lupus familiaris,,,,
5426,1,A,BAO_0000218,9615.0,5474,Area under the curve at i.v. dose of 0.2 mg/kg,,,Canis lupus familiaris,,,,
5427,1,A,BAO_0000218,9615.0,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,,Canis lupus familiaris,,,,
5428,1,A,BAO_0000218,9615.0,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,,Canis lupus familiaris,,,,
5429,1,A,BAO_0000218,9615.0,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,,Canis lupus familiaris,,,,
5430,1,A,BAO_0000218,9615.0,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,,Canis lupus familiaris,,,,
5431,1,A,BAO_0000218,9615.0,2877,Compound was evaluated for area under the curve in dog blood.,,,Canis lupus familiaris,,,,
5432,1,A,BAO_0000218,9615.0,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,,Canis lupus familiaris,,,,
5433,1,A,BAO_0000218,9615.0,5130,AUC in dog after oral dose (1 mg/kg),,,Canis lupus familiaris,,Plasma,,
5434,1,A,BAO_0000218,9615.0,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,,Canis lupus familiaris,,,,
5435,1,A,BAO_0000218,9615.0,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,,Canis lupus familiaris,,,,
5436,1,A,BAO_0000218,9615.0,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,,,Canis lupus familiaris,,,,
5437,1,A,BAO_0000218,9615.0,16367,Pharmacokinetic parameter AUC after oral administration to dogs,,,Canis lupus familiaris,,,,
5438,1,A,BAO_0000218,9615.0,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,,Canis lupus familiaris,,,,
5439,1,A,BAO_0000218,9615.0,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,,Canis lupus familiaris,,,,
5440,1,A,BAO_0000218,9615.0,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,,Canis lupus familiaris,,,,
5441,1,A,BAO_0000218,9615.0,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,,Canis lupus familiaris,,,,
5442,1,A,BAO_0000218,9615.0,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,,Canis lupus familiaris,,,,
5443,1,A,BAO_0000218,9615.0,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,,Canis lupus familiaris,,,,
5444,1,A,BAO_0000218,9615.0,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,Canis lupus familiaris,,,,
5445,1,A,BAO_0000218,9615.0,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,Canis lupus familiaris,,,,
5446,1,A,BAO_0000218,9615.0,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,Canis lupus familiaris,,,,
5447,1,A,BAO_0000218,9615.0,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,Canis lupus familiaris,,,,
5448,1,A,BAO_0000218,9615.0,17791,Compound was evaluated for oral bioavailability in dog; 90-100,,,Canis lupus familiaris,,,,
5449,1,A,BAO_0000218,9615.0,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,,Canis lupus familiaris,,,,
5450,1,A,BAO_0000218,9615.0,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,,Canis lupus familiaris,,,,
5451,1,A,BAO_0000218,9615.0,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,,,Canis lupus familiaris,,,,
5452,1,A,BAO_0000218,9615.0,3880,Oral bioavailability in dog,,,Canis lupus familiaris,,,,
5453,1,A,BAO_0000218,9615.0,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,,Canis lupus familiaris,,,,
5454,1,A,BAO_0000218,9615.0,17409,Plasma protein binding towards dog plasma at 10 uM,,,Canis lupus familiaris,,Plasma,,
5455,1,A,BAO_0000218,9615.0,17409,Plasma protein binding towards dog plasma at 100 uM,,,Canis lupus familiaris,,Plasma,,
5456,1,A,BAO_0000218,9615.0,2959,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,,Canis lupus familiaris,,,,
5457,1,A,BAO_0000218,9615.0,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,In vivo,,Canis lupus familiaris,,,,
5458,1,A,BAO_0000218,9615.0,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
5459,1,A,BAO_0000218,9615.0,15145,Bioavailability in dogs,In vivo,,Canis lupus familiaris,,,,
5460,1,A,BAO_0000218,9615.0,4219,Bioavailability,In vivo,,Canis lupus familiaris,,,,
5461,1,A,BAO_0000218,9615.0,17538,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,,,,
5462,1,A,BAO_0000218,9615.0,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,In vivo,,Canis lupus familiaris,,,,
5463,1,A,BAO_0000218,9615.0,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),In vivo,,Canis lupus familiaris,,,,
5464,1,A,BAO_0000218,9615.0,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,In vivo,,Canis lupus familiaris,,,,
5465,1,A,BAO_0000218,9615.0,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,In vivo,,Canis lupus familiaris,,,,
5466,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,,,,
5467,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,,Liver,,
5468,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Mus sp.,,Liver,,
5469,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,,Liver,,
5470,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,,,,
5471,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,,,,
5472,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,,Muscle tissue,,
5473,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Mus sp.,,Muscle tissue,,
5474,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,,Muscle tissue,,
5475,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,,Spleen,,
5476,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,,Spleen,,
5477,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,Mus sp.,,,,
5478,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Mus sp.,,,,
5479,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,,,,
5480,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,Mus sp.,,,,
5481,1,A,BAO_0000218,10095.0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,Mus sp.,,,,
5482,1,A,BAO_0000019,9527.0,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,Cercopithecidae,,,,
5483,1,A,BAO_0000019,9527.0,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,Cercopithecidae,,Cerebellum,,
5484,1,A,BAO_0000019,9527.0,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,Cercopithecidae,,Frontal cortex,,
5485,1,A,BAO_0000019,9527.0,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,,Cercopithecidae,,,,
5486,1,A,BAO_0000019,9527.0,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,,Cercopithecidae,,Striatum,,
5487,1,A,BAO_0000019,9527.0,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,Cercopithecidae,,,,
5488,1,A,BAO_0000019,9527.0,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,Cercopithecidae,,Cerebellum,,
5489,1,A,BAO_0000019,9527.0,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,Cercopithecidae,,Frontal cortex,,
5490,1,A,BAO_0000019,9527.0,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,,Cercopithecidae,,,,
5491,1,A,BAO_0000019,9527.0,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,,Cercopithecidae,,Striatum,,
5492,1,A,BAO_0000218,9527.0,17791,Compound was evaluated for oral bioavailability in rats,,,Cercopithecidae,,,,
5493,1,A,BAO_0000218,9527.0,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,In vivo,,Cercopithecidae,,Plasma,,
5494,1,A,BAO_0000019,9527.0,17791,Half life period was evaluated in monkey,,,Cercopithecidae,,,,
5495,1,A,BAO_0000218,9527.0,110,Half-life in rhesus monkeys by intravenous administration of dose,In vivo,,Cercopithecidae,,,,
5496,1,A,BAO_0000218,10090.0,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,,Mus musculus,,Plasma,,
5497,1,A,BAO_0000218,10090.0,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,,,Mus musculus,,Plasma,,
5498,1,A,BAO_0000218,10090.0,17718,AUC value was determined after oral administration,,,Mus musculus,,Plasma,,
5499,1,A,BAO_0000218,10090.0,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,Mus musculus,,,,
5500,1,A,BAO_0000218,10090.0,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,Mus musculus,,,,
5501,1,A,BAO_0000218,10090.0,2862,Area under curve by ioral administration in mouse,,,Mus musculus,,,,
5502,1,A,BAO_0000218,10090.0,2862,Area under curve by iv administration in mouse,,,Mus musculus,,,,
5503,1,A,BAO_0000218,10090.0,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,,,Mus musculus,,,,
5504,1,A,BAO_0000218,10090.0,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,,Mus musculus,,,,
5505,1,A,BAO_0000218,10090.0,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,,Mus musculus,,,,
5506,1,A,BAO_0000218,10090.0,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,,Mus musculus,,,,
5507,1,A,BAO_0000218,10090.0,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,,Mus musculus,,,,
5508,1,F,BAO_0000219,9606.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,Homo sapiens,,,RPMI-8226,
5509,1,F,BAO_0000219,9606.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,Homo sapiens,,,RPMI-8226,
5510,1,F,BAO_0000219,9606.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,Homo sapiens,,,RPMI-8226,
5511,1,F,BAO_0000219,9606.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,Homo sapiens,,,RPMI-8226,
5512,1,F,BAO_0000219,9606.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,Homo sapiens,,,RPMI-8226,
5513,1,F,BAO_0000219,9606.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,Homo sapiens,,,RPMI-8226,
5514,1,F,BAO_0000219,9606.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,Homo sapiens,,,RPMI-8226,
5515,1,F,BAO_0000219,9606.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,Homo sapiens,,,RPMI-8226,
5516,1,F,BAO_0000219,9606.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,Homo sapiens,,,RPMI-8226,
5517,1,F,BAO_0000219,9606.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,Homo sapiens,,,RPMI-8226,
5518,1,F,BAO_0000219,9606.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,Homo sapiens,,,RPMI-8226,
5519,1,F,BAO_0000219,9606.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,Homo sapiens,,,RPMI-8226,
5520,1,F,BAO_0000219,9606.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,Homo sapiens,,,RPMI-8226,
5521,1,F,BAO_0000219,9606.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,Homo sapiens,,,RPMI-8226,
5522,1,F,BAO_0000219,9606.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,Homo sapiens,,,RPMI-8226,
5523,1,F,BAO_0000219,9606.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,Homo sapiens,,,RPMI-8226,
5524,1,F,BAO_0000219,9606.0,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,,Homo sapiens,,,RPMI-8226,
5525,1,F,BAO_0000219,9606.0,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,,Homo sapiens,,,RPMI-8226,
5526,1,F,BAO_0000219,9606.0,17378,Cytotoxicity of compound against 8226/DOX1V cells,,,Homo sapiens,,,RPMI-8226,
5527,1,F,BAO_0000219,9606.0,17378,Cytotoxicity of compound against 8226/S cells,,,Homo sapiens,,,RPMI-8226,
5528,1,F,BAO_0000219,9606.0,17079,Inhibitory concentration against 8226 myeloma cancer cell line,,,Homo sapiens,,,RPMI-8226,
5529,1,F,BAO_0000219,9606.0,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,,Homo sapiens,,,RPMI-8226,
5530,1,F,BAO_0000219,9606.0,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,,Homo sapiens,,,833K,
5531,1,F,BAO_0000219,9606.0,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,,Homo sapiens,,,833K,
5532,1,F,BAO_0000219,9606.0,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,,Homo sapiens,,,833K,
5533,1,F,BAO_0000219,9606.0,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,,Homo sapiens,,,833K,
5534,1,B,BAO_0000019,,6608,Inhibitory activity against caspase-1,,,,,,,
5535,1,B,BAO_0000357,1351.0,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,,Enterococcus faecalis,,,,
5536,1,F,BAO_0000219,9606.0,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,,Homo sapiens,,,8701-BC,
5537,1,F,BAO_0000219,9606.0,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,,Homo sapiens,,,8701-BC,
5538,1,F,BAO_0000019,,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,,,,,
5539,1,F,BAO_0000019,,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,,,,,
5540,1,F,BAO_0000019,,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,,,,,
5541,1,B,BAO_0000019,,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,,,,,
5542,1,F,BAO_0000019,1314.0,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,Streptococcus pyogenes,,,,
5543,1,F,BAO_0000019,1314.0,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,Streptococcus pyogenes,,,,
5544,1,B,BAO_0000357,,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,,,,,
5545,1,F,BAO_0000219,9606.0,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,,,Homo sapiens,,,KB ,
5546,1,A,BAO_0000219,9606.0,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,,,Homo sapiens,,,KB ,
5547,1,F,BAO_0000219,9606.0,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,,,Homo sapiens,,,,
5548,1,F,BAO_0000219,10116.0,12446,Cytotoxic concentration against 9L cells was determined on day 3,,,Rattus norvegicus,,,9L,
5549,1,F,BAO_0000219,10116.0,15345,Tested in vitro for anticancer activity against 9L cells,,,Rattus norvegicus,,,9L,
5550,1,F,BAO_0000219,10116.0,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,,,Rattus norvegicus,,,9L,
5551,1,F,BAO_0000219,9606.0,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,,Homo sapiens,,,A549,
5552,1,F,BAO_0000219,9606.0,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,,Homo sapiens,,,A549,
5553,1,F,BAO_0000219,9606.0,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,,Homo sapiens,,,A549,
5554,1,F,BAO_0000219,9606.0,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,,Homo sapiens,,,A549,
5555,1,F,BAO_0000219,9606.0,13330,Cytotoxicity against human lung carcinoma A549 cell line,,,Homo sapiens,,,A549,
5556,1,F,BAO_0000219,9606.0,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,,Homo sapiens,,,A549,
5557,1,F,BAO_0000219,9606.0,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,,Homo sapiens,,,A549,
5558,1,F,BAO_0000219,9606.0,14425,"In vitro growth inhibition of A549, lung carcinoma",,,Homo sapiens,,,A549,
5559,1,F,BAO_0000219,9606.0,14425,"In vitro growth inhibition of A549, lung carcinoma.",,,Homo sapiens,,,A549,
5560,1,F,BAO_0000219,9606.0,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,Homo sapiens,,,A549,
5561,1,F,BAO_0000219,9606.0,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,,,Homo sapiens,,,A549,
5562,1,F,BAO_0000219,9606.0,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,,Homo sapiens,,,A549,
5563,1,F,BAO_0000219,9606.0,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,,Homo sapiens,,,A549,
5564,1,F,BAO_0000219,9606.0,5677,Cytotoxicity in A549 (human carcinoma) cell line.,,,Homo sapiens,,,A549,
5565,1,F,BAO_0000219,9606.0,13788,Cytotoxicity on lung carcinoma (A-549) cell line,,,Homo sapiens,,,A549,
5566,1,F,BAO_0000219,9606.0,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,,Homo sapiens,,,A549,
5567,1,F,BAO_0000219,9606.0,6726,Effective dose of compound against replication of A549 cell line was evaluated,,,Homo sapiens,,,A549,
5568,1,F,BAO_0000219,9606.0,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,,Homo sapiens,,,A549,
5569,1,F,BAO_0000219,9606.0,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,,Homo sapiens,,,A549,
5570,1,F,BAO_0000219,9606.0,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,,Homo sapiens,,,A549,
5571,1,F,BAO_0000219,9606.0,3936,The compound was evaluated for antiproliferative activity against A549 cell line,,,Homo sapiens,,,A549,
5572,1,F,BAO_0000219,9606.0,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,,Homo sapiens,,,A549,
5573,1,F,BAO_0000219,9606.0,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,,,Homo sapiens,,,A549,
5574,1,F,BAO_0000219,9606.0,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,,Homo sapiens,,,A549,
5575,1,F,BAO_0000219,9606.0,6776,Growth inhibition against A549 cell line was evaluated,,,Homo sapiens,,,A549,
5576,1,F,BAO_0000219,9606.0,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,,Homo sapiens,,,A549,
5577,1,F,BAO_0000219,9606.0,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,,Homo sapiens,,,A549,
5578,1,F,BAO_0000219,9606.0,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,,Homo sapiens,,,A549,
5579,1,F,BAO_0000219,9606.0,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,,,Homo sapiens,,,A549,
5580,1,F,BAO_0000219,9606.0,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,,Homo sapiens,,,A549,
5581,1,F,BAO_0000219,9606.0,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,,Homo sapiens,,,A549,
5582,1,F,BAO_0000219,9606.0,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,,Homo sapiens,,,A549,
5583,1,F,BAO_0000219,9606.0,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,,Homo sapiens,,,A549,
5584,1,F,BAO_0000219,9606.0,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,,Homo sapiens,,,A549,
5585,1,F,BAO_0000219,9606.0,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,,Homo sapiens,,,A549,
5586,1,F,BAO_0000219,9606.0,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,,Homo sapiens,,,A549,
5587,1,F,BAO_0000219,9606.0,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,,Homo sapiens,,,A549,
5588,1,F,BAO_0000219,9606.0,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,,Homo sapiens,,,A549,
5589,1,F,BAO_0000219,9606.0,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,,Homo sapiens,,,A549,
5590,1,F,BAO_0000219,9606.0,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,,Homo sapiens,,,A549,
5591,1,F,BAO_0000219,9606.0,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,,Homo sapiens,,,A549,
5592,1,F,BAO_0000219,9606.0,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,,Homo sapiens,,,A549,
5593,1,F,BAO_0000219,9606.0,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,,Homo sapiens,,,A549,
5594,1,F,BAO_0000219,9606.0,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,,Homo sapiens,,,A549,
5595,1,F,BAO_0000219,9606.0,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,,Homo sapiens,,,A549,
5596,1,F,BAO_0000219,9606.0,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,,,Homo sapiens,,,A549,
5597,1,F,BAO_0000219,9606.0,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,,Homo sapiens,,,A549,
5598,1,F,BAO_0000219,9606.0,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,,Homo sapiens,,,A549,
5599,1,A,BAO_0000218,9615.0,3043,Oral bioavailability in dog (conscious),In vivo,,Canis lupus familiaris,,,,
5600,1,A,BAO_0000218,9615.0,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,In vivo,,Canis lupus familiaris,,,,
5601,1,A,BAO_0000218,9615.0,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,In vivo,,Canis lupus familiaris,,,,
5602,1,A,BAO_0000218,9615.0,4453,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
5603,1,A,BAO_0000218,9615.0,1696,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
5604,1,A,BAO_0000218,9615.0,5045,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
5605,1,A,BAO_0000218,9615.0,5356,Oral bioavailability in dog (fasted),In vivo,,Canis lupus familiaris,,,,
5606,1,A,BAO_0000218,9615.0,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,In vivo,,Canis lupus familiaris,,,,
5607,1,A,BAO_0000218,9615.0,6448,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
5608,1,A,BAO_0000218,9615.0,1475,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
5609,1,A,BAO_0000218,9615.0,3788,Percent bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
5610,1,A,BAO_0000218,9615.0,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,In vivo,,Canis lupus familiaris,,,,
5611,1,A,BAO_0000218,9615.0,13397,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
5612,1,A,BAO_0000218,9615.0,2137,The compound was evaluated for bioavailability in dogs; 34-44,In vivo,,Canis lupus familiaris,,,,
5613,1,A,BAO_0000218,9615.0,2959,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,,Canis lupus familiaris,,,,
5614,1,A,BAO_0000218,9615.0,6448,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
5615,1,A,BAO_0000218,9615.0,6084,8 hour trough Blood level in dog was measured after administration of compound,,,Canis lupus familiaris,,,,
5616,1,A,BAO_0000218,9615.0,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,In vivo,,Canis lupus familiaris,,Plasma,,
5617,1,A,BAO_0000218,9615.0,6316,C24 after oral administration at 5 mg/kg,,,Canis lupus familiaris,,,,
5618,1,A,BAO_0000218,9615.0,5238,Clearance after oral and iv dosing in dogs,,,Canis lupus familiaris,,,,
5619,1,A,BAO_0000218,9615.0,17796,Clearance of the drug was measured in the plasma of dog,,,Canis lupus familiaris,,Plasma,,
5620,1,A,BAO_0000218,9615.0,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,,Canis lupus familiaris,,,,
5621,1,A,BAO_0000218,9615.0,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
5622,1,A,BAO_0000218,9615.0,6621,Clearance of compound was determined in dogs,In vivo,,Canis lupus familiaris,,,,
5623,1,A,BAO_0000218,9615.0,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,In vivo,,Canis lupus familiaris,,,,
5624,1,A,BAO_0000218,9615.0,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,,Canis lupus familiaris,,,,
5625,1,A,BAO_0000218,9615.0,17267,Plasma clearance in dog was determined,In vivo,,Canis lupus familiaris,,,,
5626,1,A,BAO_0000218,9615.0,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,Canis lupus familiaris,,,,
5627,1,A,BAO_0000218,9615.0,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,In vivo,,Canis lupus familiaris,,,,
5628,1,A,BAO_0000218,9615.0,6535,Plasma clearance in dog after administration of 1 mg/kg iv,In vivo,,Canis lupus familiaris,,,,
5629,1,A,BAO_0000218,9615.0,6535,Plasma clearance in dogs,In vivo,,Canis lupus familiaris,,,,
5630,1,A,BAO_0000218,9615.0,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,In vivo,,Canis lupus familiaris,,,,
5631,1,A,BAO_0000218,9615.0,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,,Canis lupus familiaris,,,,
5632,1,A,BAO_0000218,9615.0,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,In vivo,,Canis lupus familiaris,,,,
5633,1,A,BAO_0000218,9615.0,16907,Plasma clearance after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,,,,
5634,1,A,BAO_0000218,9615.0,16367,Plasma administration to dogs,In vivo,,Canis lupus familiaris,,,,
5635,1,A,BAO_0000218,9615.0,5505,Plasma clearance was determined,In vivo,,Canis lupus familiaris,,,,
5636,1,A,BAO_0000218,9615.0,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,,,,
5637,1,A,BAO_0000218,9615.0,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,,,,
5638,1,A,BAO_0000251,9606.0,5007,Intrinsic clearance in human liver microsomes,In vitro,,Homo sapiens,,Liver,,Microsomes
5639,1,A,BAO_0000251,9606.0,5007,Intrinsic clearance in human liver microsomes,In vitro,,Homo sapiens,,Liver,,Microsomes
5640,1,A,BAO_0000218,9615.0,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,,Canis lupus familiaris,,,,
5641,1,A,BAO_0000218,9615.0,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,,Canis lupus familiaris,,,,
5642,1,A,BAO_0000218,9615.0,16452,Clearance in dog (dose 1 mg/kg i.v.),In vivo,,Canis lupus familiaris,,,,
5643,1,A,BAO_0000218,9615.0,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,In vivo,,Canis lupus familiaris,,,,
5644,1,A,BAO_0000218,9615.0,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,,Canis lupus familiaris,,,,
5645,1,A,BAO_0000218,9615.0,5668,Plasma clearance after peroral administration at 10 mpk in dog,In vivo,,Canis lupus familiaris,,,,
5646,1,A,BAO_0000218,9615.0,5668,Plasma clearance after peroral administration at 5 mpk in dog,In vivo,,Canis lupus familiaris,,,,
5647,1,A,BAO_0000218,9615.0,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
5648,1,A,BAO_0000218,9615.0,15660,Plasma clearance was measured in dog,In vivo,,Canis lupus familiaris,,,,
5649,1,A,BAO_0000218,9615.0,15660,Plasma clearance was measured in dog,In vivo,,Canis lupus familiaris,,,,
5650,1,A,BAO_0000218,9615.0,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,,Canis lupus familiaris,,,,
5651,1,A,BAO_0000218,9615.0,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,In vivo,,Canis lupus familiaris,,,,
5652,1,A,BAO_0000218,9615.0,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,,Canis lupus familiaris,,,,
5653,1,A,BAO_0000218,9615.0,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
5654,1,A,BAO_0000218,9615.0,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
5655,1,A,BAO_0000218,9615.0,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
5656,1,A,BAO_0000218,9615.0,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
5657,1,A,BAO_0000218,9615.0,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
5658,1,A,BAO_0000218,9615.0,1918,Clearance value was evaluated in dog plasma,In vivo,,Canis lupus familiaris,,Plasma,,
5659,1,A,BAO_0000218,9615.0,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
5660,1,A,BAO_0000218,9615.0,4839,Compound was tested for plasma clearance in dog,In vivo,,Canis lupus familiaris,,Plasma,,
5661,1,A,BAO_0000218,9615.0,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,In vivo,,Canis lupus familiaris,,,,
5662,1,A,BAO_0000218,10090.0,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,,Mus musculus,,,,
5663,1,A,BAO_0000218,10090.0,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,,Mus musculus,,,,
5664,1,A,BAO_0000218,10090.0,5302,Area under curve value in mouse at a dose of 10 mg/kg,,,Mus musculus,,,,
5665,1,A,BAO_0000218,10090.0,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,,Mus musculus,,,,
5666,1,A,BAO_0000218,10090.0,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,,Mus musculus,,,,
5667,1,F,BAO_0000218,10090.0,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,Mus musculus,,,,
5668,1,F,BAO_0000218,10090.0,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,Mus musculus,,,,
5669,1,F,BAO_0000218,10090.0,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,Mus musculus,,,,
5670,1,F,BAO_0000218,10090.0,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,Mus musculus,,,,
5671,1,A,BAO_0000218,10090.0,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,,Mus musculus,,,,
5672,1,A,BAO_0000218,10090.0,17753,Area under curve was determined for the compound at 24 mg/Kg,,,Mus musculus,,,,
5673,1,A,BAO_0000218,10090.0,17753,Area under curve was determined for the compound at 40 mg/Kg,,,Mus musculus,,,,
5674,1,A,BAO_0000218,10090.0,17753,Area under curve was determined for the compound at 5 mg/Kg,,,Mus musculus,,,,
5675,1,A,BAO_0000218,10090.0,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,,,Mus musculus,,,,
5676,1,A,BAO_0000218,10090.0,3132,Area under the curve for the compound was obtained when tested in mouse,,,Mus musculus,,,,
5677,1,A,BAO_0000218,10090.0,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,,Mus musculus,,,,
5678,1,A,BAO_0000218,10090.0,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,,Mus musculus,,,,
5679,1,A,BAO_0000218,10090.0,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,,Mus musculus,,,,
5680,1,A,BAO_0000218,10090.0,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,,Mus musculus,,,,
5681,1,A,BAO_0000218,10090.0,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,Mus musculus,,,,
5682,1,A,BAO_0000218,10090.0,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,Mus musculus,,,,
5683,1,A,BAO_0000218,10090.0,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,Mus musculus,,,,
5684,1,A,BAO_0000218,10090.0,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,,Mus musculus,,,,
5685,1,A,BAO_0000218,10090.0,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,,Mus musculus,,,,
5686,1,A,BAO_0000218,10090.0,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,,Mus musculus,,,,
5687,1,A,BAO_0000218,10090.0,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,,Mus musculus,,,,
5688,1,A,BAO_0000218,10090.0,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,,Mus musculus,,,,
5689,1,A,BAO_0000218,10090.0,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,Mus musculus,,,,
5690,1,A,BAO_0000218,10090.0,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,,Mus musculus,,,,
5691,1,A,BAO_0000218,10090.0,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,,Mus musculus,,,,
5692,1,A,BAO_0000218,10090.0,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,,Mus musculus,,,,
5693,1,A,BAO_0000218,10090.0,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,,Mus musculus,,,,
5694,1,A,BAO_0000218,10090.0,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,,Mus musculus,,,,
5695,1,A,BAO_0000218,10090.0,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,,Mus musculus,,,,
5696,1,A,BAO_0000218,10090.0,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,Mus musculus,,,,
5697,1,A,BAO_0000218,10090.0,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,Mus musculus,,,,
5698,1,A,BAO_0000218,10090.0,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,,Mus musculus,,,,
5699,1,A,BAO_0000218,10090.0,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,,Mus musculus,,,,
5700,1,A,BAO_0000218,10090.0,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,,Mus musculus,,,,
5701,1,A,BAO_0000218,10090.0,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,,Mus musculus,,,,
5702,1,A,BAO_0000218,10090.0,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,,Mus musculus,,,,
5703,1,A,BAO_0000218,10090.0,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,,Mus musculus,,,,
5704,1,A,BAO_0000218,10090.0,2675,Area under the curve was evaluated in mice after intravenous administration,,,Mus musculus,,,,
5705,1,A,BAO_0000218,10090.0,2675,Area under the curve was evaluated in mice after oral administration,,,Mus musculus,,,,
5706,1,A,BAO_0000218,10090.0,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,,Mus musculus,,Plasma,,
5707,1,A,BAO_0000218,10090.0,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,,Mus musculus,,Plasma,,
5708,1,A,BAO_0000218,10090.0,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,Mus musculus,,,,
5709,1,A,BAO_0000218,10090.0,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,,,Mus musculus,,,,
5710,1,A,BAO_0000218,10090.0,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Blood,,
5711,1,F,BAO_0000219,,15345,The compound was tested in vitro for anticancer activity against 9L cells,,,,,,9L,
5712,1,F,BAO_0000019,10116.0,2181,Anti proliferation activity determined; Weak effect,,,Rattus norvegicus,,,,
5713,1,F,BAO_0000219,10116.0,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,,Rattus norvegicus,,,,
5714,1,F,BAO_0000219,10116.0,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,,Rattus norvegicus,,,,
5715,1,F,BAO_0000219,10116.0,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,,Rattus norvegicus,,,,
5716,1,F,BAO_0000019,10090.0,10486,The cytotoxic activity was in vitro tested by 9PS assay method,,,Mus musculus,,,,
5717,1,F,BAO_0000019,10090.0,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,,,Mus musculus,,,,
5718,1,A,BAO_0000019,,15508,Partition coefficient (logD6.5),,,,,,,
5719,1,F,BAO_0000219,9606.0,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,,Homo sapiens,,,A2780,
5720,1,F,BAO_0000219,9606.0,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,,Homo sapiens,,,A-375,
5721,1,F,BAO_0000219,9606.0,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,,Homo sapiens,,,A-431,
5722,1,F,BAO_0000219,9606.0,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,,Homo sapiens,,,A-431,
5723,1,F,BAO_0000219,9606.0,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,,Homo sapiens,,,A498,
5724,1,F,BAO_0000219,9606.0,2596,in vitro cytotoxicity against A 498 cancer cell line,,,Homo sapiens,,,A498,
5725,1,F,BAO_0000219,9606.0,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,,Homo sapiens,,,A498,
5726,1,F,BAO_0000219,9606.0,1847,Cytotoxic activity against A 498 renal cancer cell lines.,,,Homo sapiens,,,A498,
5727,1,F,BAO_0000219,9606.0,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,,Homo sapiens,,,A498,
5728,1,F,BAO_0000019,1280.0,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,Staphylococcus aureus,,,,
5729,1,F,BAO_0000019,1280.0,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,Staphylococcus aureus,,,,
5730,1,F,BAO_0000019,1280.0,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,Staphylococcus aureus,,,,
5731,1,F,BAO_0000019,1280.0,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,Staphylococcus aureus,,,,
5732,1,F,BAO_0000219,9606.0,4782,Inhibitory concentration required against A 549 lung cancer cell line,,,Homo sapiens,,,A549,
5733,1,F,BAO_0000219,9606.0,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,,Homo sapiens,,,A549,
5734,1,F,BAO_0000219,9606.0,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,,Homo sapiens,,,A549,
5735,1,F,BAO_0000219,9606.0,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,,,Homo sapiens,,,A549,
5736,1,F,BAO_0000219,9606.0,4594,Compound was tested for its cytotoxicity against A 549 cell line,,,Homo sapiens,,,A549,
5737,1,F,BAO_0000219,9606.0,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,,Homo sapiens,,,A549,
5738,1,F,BAO_0000219,9606.0,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,,Homo sapiens,,,A549,
5739,1,F,BAO_0000219,9606.0,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,,Homo sapiens,,,A549,
5740,1,F,BAO_0000219,9606.0,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,,Homo sapiens,,,A549,
5741,1,F,BAO_0000219,9606.0,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,,,Homo sapiens,,,A549,
5742,1,F,BAO_0000219,9606.0,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,,Homo sapiens,,,A549,
5743,1,F,BAO_0000219,9606.0,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,,Homo sapiens,,,A549,
5744,1,F,BAO_0000219,9606.0,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,,Homo sapiens,,,A549,
5745,1,F,BAO_0000218,,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,,,,,
5746,1,F,BAO_0000218,,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,In vivo,,,,,,
5747,1,F,BAO_0000218,,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,In vivo,,,,,,
5748,1,F,BAO_0000218,,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,In vivo,,,,,,
5749,1,F,BAO_0000218,,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,In vivo,,,,,,
5750,1,F,BAO_0000218,,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,In vivo,,,,,,
5751,1,F,BAO_0000219,9606.0,3600,Inhibition of A-498 human Renal cell proliferation,,,Homo sapiens,,,A498,
5752,1,F,BAO_0000019,10116.0,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,,Rattus norvegicus,,,,
5753,1,F,BAO_0000019,10116.0,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,,Rattus norvegicus,,,,
5754,1,F,BAO_0000019,10116.0,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,,Rattus norvegicus,,,,
5755,1,F,BAO_0000219,9606.0,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,,Homo sapiens,,,A 172,
5756,1,F,BAO_0000219,9606.0,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,,,A 172,
5757,1,F,BAO_0000219,9606.0,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,,,A 172,
5758,1,F,BAO_0000219,9606.0,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,,Homo sapiens,,,A549,
5759,1,F,BAO_0000219,9606.0,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,,Homo sapiens,,,A549,
5760,1,F,BAO_0000219,9606.0,13799,Cytotoxic activity evaluated against A549 tumor cells,,,Homo sapiens,,,A549,
5761,1,F,BAO_0000219,9606.0,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,,Homo sapiens,,,A549,
5762,1,F,BAO_0000219,9606.0,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,,Homo sapiens,,,A549,
5763,1,F,BAO_0000219,9606.0,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,,Homo sapiens,,,A549,
5764,1,F,BAO_0000219,9606.0,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,,Homo sapiens,,,A549,
5765,1,F,BAO_0000219,9606.0,6851,Cytotoxicity of compound against A549 cell line,,,Homo sapiens,,,A549,
5766,1,F,BAO_0000219,9606.0,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,,,Homo sapiens,,,A549,
5767,1,F,BAO_0000219,9606.0,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,,Homo sapiens,,,A549,
5768,1,F,BAO_0000219,9606.0,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,,Homo sapiens,,,A549,
5769,1,F,BAO_0000219,9606.0,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,,Homo sapiens,,,A549,
5770,1,F,BAO_0000219,9606.0,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,,Homo sapiens,,,A549,
5771,1,F,BAO_0000219,9606.0,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,,Homo sapiens,,,A549,
5772,1,F,BAO_0000219,9606.0,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,,Homo sapiens,,,A549,
5773,1,F,BAO_0000219,9606.0,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,Homo sapiens,,,A549,
5774,1,F,BAO_0000219,9606.0,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,,Homo sapiens,,,A549,
5775,1,F,BAO_0000219,9606.0,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,,Homo sapiens,,,A549,
5776,1,F,BAO_0000219,9606.0,5895,In vitro cytotoxicity against A549 (human lung cancer),,,Homo sapiens,,,A549,
5777,1,F,BAO_0000219,9606.0,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,,Homo sapiens,,,A549,
5778,1,F,BAO_0000218,9606.0,17824,In vivo antiproliferative activity against A549 cell line,,,Homo sapiens,,,A549,
5779,1,F,BAO_0000219,9606.0,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),,,Homo sapiens,,,A549,
5780,1,F,BAO_0000219,9606.0,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,,Homo sapiens,,,A549,
5781,1,F,BAO_0000219,9606.0,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,,Homo sapiens,,,A549,
5782,1,F,BAO_0000219,9606.0,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,,Homo sapiens,,,A549,
5783,1,F,BAO_0000219,9606.0,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,,Homo sapiens,,,A549,
5784,1,F,BAO_0000219,9606.0,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,,Homo sapiens,,,A549,
5785,1,F,BAO_0000219,9606.0,4862,Inhibitory activity against A549 lung cancer cell line,,,Homo sapiens,,,A549,
5786,1,F,BAO_0000219,9606.0,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,,Homo sapiens,,,A549,
5787,1,F,BAO_0000219,9606.0,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,,Homo sapiens,,,A549,
5788,1,F,BAO_0000219,9606.0,15970,Inhibitory concentration against A549 (lung cancer) cell line,,,Homo sapiens,,,A549,
5789,1,F,BAO_0000219,9606.0,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,,Homo sapiens,,,A549,
5790,1,F,BAO_0000219,9606.0,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,,Homo sapiens,,,A549,
5791,1,F,BAO_0000219,9606.0,13736,Activity against A549 cancer cell line.,,,Homo sapiens,,,A549,
5792,1,F,BAO_0000219,9606.0,4312,The compound was evaluated for cytotoxicity against A549 cell line,,,Homo sapiens,,,A549,
5793,1,F,BAO_0000219,9606.0,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,,Homo sapiens,,,A549,
5794,1,F,BAO_0000219,9606.0,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,,Homo sapiens,,,A549,
5795,1,F,BAO_0000219,9606.0,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,,,Homo sapiens,,,A549,
5796,1,F,BAO_0000219,9606.0,4634,Inhibitory activity against A549 lung cancer cell line,,,Homo sapiens,,,A549,
5797,1,F,BAO_0000219,9606.0,1149,Inhibitory activity against A549 cell line; inactive,,,Homo sapiens,,,A549,
5798,1,F,BAO_0000219,9606.0,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,,Homo sapiens,,,A549,
5799,1,F,BAO_0000219,9606.0,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,,Homo sapiens,,,A549,
5800,1,F,BAO_0000219,9606.0,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,,Homo sapiens,,,A549,
5801,1,F,BAO_0000219,9606.0,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,,Homo sapiens,,,A549,
5802,1,F,BAO_0000219,9606.0,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,,Homo sapiens,,,A549,
5803,1,F,BAO_0000219,9606.0,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,,Homo sapiens,,,A549,
5804,1,F,BAO_0000219,9606.0,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,,Homo sapiens,,,A549,
5805,1,F,BAO_0000219,9606.0,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,,Homo sapiens,,,A549,
5806,1,F,BAO_0000219,9606.0,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,,Homo sapiens,,,A549,
5807,1,A,BAO_0000218,9615.0,17800,Plasma clearance (in vivo) in mongrel dogs was determined,In vivo,,Canis lupus familiaris,,,,
5808,1,A,BAO_0000218,9615.0,5985,Plasma clearance was measured in dog,In vivo,,Canis lupus familiaris,,,,
5809,1,A,BAO_0000218,9615.0,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,,Canis lupus familiaris,,,,
5810,1,A,BAO_0000218,9615.0,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
5811,1,A,BAO_0000218,9615.0,4839,Tested for plasma clearance in dog,In vivo,,Canis lupus familiaris,,Plasma,,
5812,1,A,BAO_0000218,9615.0,3639,The compound was tested for clearance in dog plasma.,In vivo,,Canis lupus familiaris,,,,
5813,1,A,BAO_0000218,9615.0,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",In vivo,,Canis lupus familiaris,,,,
5814,1,A,BAO_0000218,9615.0,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,In vivo,,Canis lupus familiaris,,,,
5815,1,A,BAO_0000218,9615.0,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,,Canis lupus familiaris,,Plasma,,
5816,1,A,BAO_0000218,9615.0,17538,In vitro clearance in dog liver microsomes,In vitro,,Canis lupus familiaris,,Liver,,Microsomes
5817,1,A,BAO_0000218,9615.0,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,,Canis lupus familiaris,,,,
5818,1,A,BAO_0000218,9615.0,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,,Canis lupus familiaris,,,,
5819,1,A,BAO_0000218,9615.0,1696,Plasma clearance in dog,In vivo,,Canis lupus familiaris,,,,
5820,1,A,BAO_0000218,9615.0,6762,Clearance rate in dog,In vivo,,Canis lupus familiaris,,,,
5821,1,A,BAO_0000218,9615.0,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,In vivo,,Canis lupus familiaris,,Plasma,,
5822,1,A,BAO_0000218,9615.0,6305,Clearance in dogs,In vivo,,Canis lupus familiaris,,,,
5823,1,A,BAO_0000218,9615.0,4942,Plasma clearance in dogs,In vivo,,Canis lupus familiaris,,,,
5824,1,A,BAO_0000218,9615.0,4219,Plasma clearance was determined,In vivo,,Canis lupus familiaris,,,,
5825,1,A,BAO_0000218,9615.0,17853,Lower clearance in dog (i.v.) at 0.5 mpk,In vivo,,Canis lupus familiaris,,,,
5826,1,A,BAO_0000218,9615.0,4514,Plasma clearance in Beagle dogs,In vivo,,Canis lupus familiaris,,,,
5827,1,A,BAO_0000218,9615.0,6448,Plasma clearance (Clp) in dog,In vivo,,Canis lupus familiaris,,,,
5828,1,A,BAO_0000218,9615.0,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
5829,1,A,BAO_0000218,9615.0,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,In vivo,,Canis lupus familiaris,,,,
5830,1,A,BAO_0000218,9615.0,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
5831,1,A,BAO_0000218,9615.0,6821,Plasma clearance of compound was determined in dog,In vivo,,Canis lupus familiaris,,,,
5832,1,A,BAO_0000218,9615.0,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
5833,1,A,BAO_0000218,9615.0,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,,Canis lupus familiaris,,,,
5834,1,A,BAO_0000218,9615.0,5374,Plasma clearance in dog was determined,In vivo,,Canis lupus familiaris,,,,
5835,1,A,BAO_0000218,9615.0,6057,Plasma clearance was calculated in dog,In vivo,,Canis lupus familiaris,,,,
5836,1,A,BAO_0000218,9615.0,4727,Plasma clearance at the dose of 2 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
5837,1,A,BAO_0000218,9615.0,5145,Plasma clearance in dog,In vivo,,Canis lupus familiaris,,,,
5838,1,A,BAO_0000218,9615.0,17657,Plasma clearance in dog,In vivo,,Canis lupus familiaris,,,,
5839,1,A,BAO_0000218,9615.0,17657,Plasma clearance in dog; Unable to calculate,In vivo,,Canis lupus familiaris,,,,
5840,1,A,BAO_0000218,9615.0,5145,Plasma clearance in rhesus monkey,In vivo,,Canis lupus familiaris,,,,
5841,1,A,BAO_0000218,9615.0,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,,Canis lupus familiaris,,,,
5842,1,A,BAO_0000218,9615.0,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,,,,
5843,1,A,BAO_0000218,9615.0,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,,,,
5844,1,A,BAO_0000218,9615.0,5472,Plasma clearance was evaluated in dog,In vivo,,Canis lupus familiaris,,,,
5845,1,A,BAO_0000218,9615.0,5472,Plasma clearance was evaluated in dog; Not tested,In vivo,,Canis lupus familiaris,,,,
5846,1,A,BAO_0000218,9615.0,5472,Plasma clearance was evaluated in rhesus,In vivo,,Canis lupus familiaris,,,,
5847,1,A,BAO_0000218,9615.0,5472,Plasma clearance was evaluated in rhesus; Not tested,In vivo,,Canis lupus familiaris,,,,
5848,1,A,BAO_0000218,9615.0,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,In vivo,,Canis lupus familiaris,,,,
5849,1,A,BAO_0000218,9615.0,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Canis lupus familiaris,,,,
5850,1,A,BAO_0000218,9615.0,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,,Canis lupus familiaris,,,,
5851,1,A,BAO_0000218,9615.0,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,,,,
5852,1,A,BAO_0000218,9615.0,5474,Clearance value at a dose of 0.2 mg/kg i.v.,In vivo,,Canis lupus familiaris,,,,
5853,1,A,BAO_0000218,9615.0,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
5854,1,A,BAO_0000218,9615.0,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,In vivo,,Canis lupus familiaris,,,,
5855,1,A,BAO_0000218,9615.0,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,In vivo,,Canis lupus familiaris,,,,
5856,1,A,BAO_0000218,9615.0,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,,Canis lupus familiaris,,,,
5857,1,A,BAO_0000218,9615.0,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,,Canis lupus familiaris,,,,
5858,1,A,BAO_0000218,9615.0,6535,Cmax in dog after administration of 1 mg/kg iv,In vivo,,Canis lupus familiaris,,,,
5859,1,A,BAO_0000218,9615.0,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,,Plasma,,
5860,1,A,BAO_0000218,9615.0,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,In vivo,,Canis lupus familiaris,,,,
5861,1,A,BAO_0000218,9615.0,5668,Cmax was determine after peroral administration at 10 mpk in dog,In vivo,,Canis lupus familiaris,,,,
5862,1,A,BAO_0000218,9615.0,5668,Cmax was determine after peroral administration at 5 mpk in dog,In vivo,,Canis lupus familiaris,,,,
5863,1,A,BAO_0000218,9615.0,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
5864,1,A,BAO_0000218,9615.0,5600,Cmax after 0.3 mg/kg po administration in dog,In vivo,,Canis lupus familiaris,,,,
5865,1,A,BAO_0000218,9615.0,17764,Cmax after peroral administration in dogs at 2.4 uM/kg,In vivo,,Canis lupus familiaris,,,,
5866,1,A,BAO_0000218,9615.0,6123,Cmax in dog after oral administration at 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
5867,1,A,BAO_0000218,9615.0,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,In vivo,,Canis lupus familiaris,,,,
5868,1,A,BAO_0000218,9615.0,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,In vivo,,Canis lupus familiaris,,,,
5869,1,A,BAO_0000218,9615.0,16907,Cmax value after 15 mg/kg iv dose in Dogs,In vivo,,Canis lupus familiaris,,,,
5870,1,A,BAO_0000218,10090.0,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Blood,,
5871,1,A,BAO_0000218,10090.0,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Blood,,
5872,1,A,BAO_0000218,10090.0,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Bone,,
5873,1,A,BAO_0000218,10090.0,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Bone,,
5874,1,A,BAO_0000218,10090.0,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Bone,,
5875,1,A,BAO_0000218,10090.0,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,,,
5876,1,A,BAO_0000218,10090.0,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,,,
5877,1,A,BAO_0000218,10090.0,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,,,
5878,1,A,BAO_0000218,10090.0,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Heart,,
5879,1,A,BAO_0000218,10090.0,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Heart,,
5880,1,A,BAO_0000218,10090.0,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Heart,,
5881,1,A,BAO_0000218,10090.0,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Kidney,,
5882,1,A,BAO_0000218,10090.0,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Kidney,,
5883,1,A,BAO_0000218,10090.0,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Kidney,,
5884,1,A,BAO_0000218,10090.0,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Intestine,,
5885,1,A,BAO_0000218,10090.0,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Intestine,,
5886,1,A,BAO_0000218,10090.0,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Intestine,,
5887,1,A,BAO_0000218,10090.0,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Liver,,
5888,1,A,BAO_0000218,10090.0,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Liver,,
5889,1,A,BAO_0000218,10090.0,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Liver,,
5890,1,A,BAO_0000218,10090.0,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Lung,,
5891,1,A,BAO_0000218,10090.0,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Lung,,
5892,1,A,BAO_0000218,10090.0,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Lung,,
5893,1,A,BAO_0000218,10090.0,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Muscle tissue,,
5894,1,A,BAO_0000218,10090.0,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Muscle tissue,,
5895,1,A,BAO_0000218,10090.0,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Muscle tissue,,
5896,1,A,BAO_0000218,10090.0,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,,,
5897,1,A,BAO_0000218,10090.0,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,,,
5898,1,A,BAO_0000218,10090.0,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,,,
5899,1,A,BAO_0000218,10090.0,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Intestine,,
5900,1,A,BAO_0000218,10090.0,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Intestine,,
5901,1,A,BAO_0000218,10090.0,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Intestine,,
5902,1,A,BAO_0000218,10090.0,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Spleen,,
5903,1,A,BAO_0000218,10090.0,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Spleen,,
5904,1,A,BAO_0000218,10090.0,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Spleen,,
5905,1,A,BAO_0000218,10090.0,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Stomach,,
5906,1,A,BAO_0000218,10090.0,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Stomach,,
5907,1,F,BAO_0000219,9606.0,2036,Cytotoxicity against A-172 human tumor cell lines,,,Homo sapiens,,,A 172,
5908,1,F,BAO_0000219,9606.0,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,,Homo sapiens,,,A 172,
5909,1,F,BAO_0000219,9606.0,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,,Homo sapiens,,,A204,
5910,1,F,BAO_0000219,9606.0,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,,,Homo sapiens,,,A2780,
5911,1,F,BAO_0000219,9606.0,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,,Homo sapiens,,,A-375,
5912,1,F,BAO_0000219,9606.0,12152,Tested in vitro against A-375 cell line human melanoma,,,Homo sapiens,,,A-375,
5913,1,F,BAO_0000219,9606.0,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,,Homo sapiens,,,A-427,
5914,1,F,BAO_0000219,9606.0,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,,,A-427,
5915,1,F,BAO_0000219,9606.0,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,,Homo sapiens,,,A-427,
5916,1,F,BAO_0000219,9606.0,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,Homo sapiens,,,A-427,
5917,1,F,BAO_0000219,9606.0,10413,Antitumor activity on A-427 lung carcinoma cell lines,,,Homo sapiens,,,A-427,
5918,1,F,BAO_0000219,9606.0,6418,Cytotoxic activity against human A-427 lung tumor cell line,,,Homo sapiens,,,A-427,
5919,1,F,BAO_0000219,9606.0,17134,In vitro antitumor effects against human A-427 cell lines.,,,Homo sapiens,,,A-427,
5920,1,F,BAO_0000219,9606.0,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,,,Homo sapiens,,,A-427,
5921,1,F,BAO_0000219,9606.0,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,,Homo sapiens,,,A-427,
5922,1,F,BAO_0000219,9606.0,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,,,Homo sapiens,,,A-427,
5923,1,F,BAO_0000219,9606.0,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,,Homo sapiens,,,A-431,
5924,1,F,BAO_0000219,9606.0,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,,Homo sapiens,,,A498,
5925,1,F,BAO_0000219,9606.0,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,,Homo sapiens,,,A498,
5926,1,F,BAO_0000219,9606.0,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,,,Homo sapiens,,,A498,
5927,1,F,BAO_0000219,9606.0,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,,Homo sapiens,,,A498,
5928,1,F,BAO_0000219,9606.0,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,,Homo sapiens,,,A498,
5929,1,F,BAO_0000219,9606.0,4461,Antitumor cytotoxic activity against A-498 cell line was determined,,,Homo sapiens,,,A498,
5930,1,F,BAO_0000219,9606.0,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,,Homo sapiens,,,A498,
5931,1,F,BAO_0000219,9606.0,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,,Homo sapiens,,,A498,
5932,1,F,BAO_0000219,9606.0,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,,Homo sapiens,,,A498,
5933,1,F,BAO_0000219,9606.0,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,,Homo sapiens,,,A498,
5934,1,F,BAO_0000219,9606.0,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,,Homo sapiens,,,A498,
5935,1,F,BAO_0000219,9606.0,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,,Homo sapiens,,,A549,
5936,1,F,BAO_0000219,9606.0,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,,Homo sapiens,,,A549,
5937,1,F,BAO_0000219,9606.0,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,,,Homo sapiens,,,A549,
5938,1,F,BAO_0000219,9606.0,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,,Homo sapiens,,,A549,
5939,1,F,BAO_0000219,9606.0,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,,Homo sapiens,,,A549,
5940,1,F,BAO_0000219,9606.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,,Homo sapiens,,,A549,
5941,1,F,BAO_0000219,9606.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,,Homo sapiens,,,A549,
5942,1,F,BAO_0000219,9606.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,,Homo sapiens,,,A549,
5943,1,F,BAO_0000219,9606.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,,Homo sapiens,,,A549,
5944,1,F,BAO_0000219,9606.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,,Homo sapiens,,,A549,
5945,1,F,BAO_0000219,9606.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,,Homo sapiens,,,A549,
5946,1,F,BAO_0000219,9606.0,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,,Homo sapiens,,,A549,
5947,1,F,BAO_0000219,9606.0,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,,Homo sapiens,,,A549,
5948,1,F,BAO_0000219,9606.0,6513,Cytotoxic activity against A-549 cell line,,,Homo sapiens,,,A549,
5949,1,F,BAO_0000219,9606.0,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,,Homo sapiens,,,A549,
5950,1,F,BAO_0000219,9606.0,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,,Homo sapiens,,,A549,
5951,1,F,BAO_0000219,9606.0,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,,Homo sapiens,,,A549,
5952,1,F,BAO_0000219,9606.0,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,,Homo sapiens,,,A549,
5953,1,F,BAO_0000219,9606.0,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,,Homo sapiens,,,A549,
5954,1,F,BAO_0000219,9606.0,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,,,Homo sapiens,,,A549,
5955,1,F,BAO_0000219,9606.0,5771,Cytotoxic activity towards A-549 cells,,,Homo sapiens,,,A549,
5956,1,F,BAO_0000219,9606.0,14425,"In vitro percent inhibition of A549, lung carcinoma.",,,Homo sapiens,,,A549,
5957,1,F,BAO_0000219,9606.0,14425,"In vitro percent inhibition of A549, lung carcinoma",,,Homo sapiens,,,A549,
5958,1,F,BAO_0000219,9606.0,14425,"In vitro percent inhibition of A549, lung carcinoma.",,,Homo sapiens,,,A549,
5959,1,F,BAO_0000219,9606.0,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,,Homo sapiens,,,A549,
5960,1,F,BAO_0000219,9606.0,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,,Homo sapiens,,,A549,
5961,1,F,BAO_0000219,9606.0,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,,Homo sapiens,,,A549,
5962,1,F,BAO_0000219,9606.0,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,,Homo sapiens,,,A549,
5963,1,F,BAO_0000218,9606.0,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,Homo sapiens,,,A549,
5964,1,F,BAO_0000218,9606.0,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,Homo sapiens,,,A549,
5965,1,F,BAO_0000218,9606.0,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,Homo sapiens,,,A549,
5966,1,F,BAO_0000218,9606.0,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,Homo sapiens,,,A549,
5967,1,F,BAO_0000218,9606.0,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,Homo sapiens,,,A549,
5968,1,F,BAO_0000219,9606.0,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,,Homo sapiens,,,A549,
5969,1,F,BAO_0000218,9606.0,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,,Homo sapiens,,,A549,
5970,1,F,BAO_0000219,9606.0,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,,Homo sapiens,,,A549,
5971,1,F,BAO_0000219,9606.0,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,,Homo sapiens,,,A549,
5972,1,F,BAO_0000219,9606.0,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,,Homo sapiens,,,A549,
5973,1,F,BAO_0000219,9606.0,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,,Homo sapiens,,,A549,
5974,1,F,BAO_0000219,9606.0,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,,Homo sapiens,,,A549,
5975,1,F,BAO_0000219,9606.0,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,,Homo sapiens,,,A549,
5976,1,F,BAO_0000219,9606.0,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,,Homo sapiens,,,A549,
5977,1,F,BAO_0000219,9606.0,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,,Homo sapiens,,,A549,
5978,1,F,BAO_0000219,9606.0,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,,Homo sapiens,,,A549,
5979,1,F,BAO_0000219,9606.0,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,,Homo sapiens,,,A549,
5980,1,F,BAO_0000219,9606.0,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,,Homo sapiens,,,A549,
5981,1,F,BAO_0000219,9606.0,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,,Homo sapiens,,,A549,
5982,1,F,BAO_0000219,9606.0,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,,Homo sapiens,,,A549,
5983,1,F,BAO_0000219,9606.0,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,,Homo sapiens,,,A549,
5984,1,F,BAO_0000219,9606.0,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,,Homo sapiens,,,A549,
5985,1,F,BAO_0000219,9606.0,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,,Homo sapiens,,,A549,
5986,1,F,BAO_0000219,9606.0,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,,Homo sapiens,,,A549,
5987,1,F,BAO_0000219,10090.0,17737,In vitro antiproliferative activity against A549 cell line,,,Mus musculus,,,A549,
5988,1,F,BAO_0000219,,6630,Synergism with indomethacin in A549 cells,,,,,,A549,
5989,1,F,BAO_0000219,,6630,Synergism with tolmetin in A549 cells,,,,,,A549,
5990,1,F,BAO_0000219,,6630,Synergism with sulindac in A549 cells,,,,,,A549,
5991,1,F,BAO_0000219,,6630,Antagonism of indomethacin in A549 cells,,,,,,A549,
5992,1,F,BAO_0000219,,6630,Antagonism of sulindac in A549 cells,,,,,,A549,
5993,1,F,BAO_0000219,,6630,Antagonism of tolmetin in A549 cells,,,,,,A549,
5994,1,F,BAO_0000219,,6630,Synergism with indomethacin in A549 cells,,,,,,A549,
5995,1,F,BAO_0000219,,6630,Synergism with sulindac in A549 cells,,,,,,A549,
5996,1,F,BAO_0000219,,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,,,,,A549,
5997,1,A,BAO_0000218,9615.0,16907,Cmax value after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,,,,
5998,1,A,BAO_0000218,9615.0,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,,Canis lupus familiaris,,,,
5999,1,A,BAO_0000218,9615.0,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,In vivo,,Canis lupus familiaris,,,,
6000,1,A,BAO_0000218,9615.0,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,,Canis lupus familiaris,,,,
6001,1,A,BAO_0000218,9615.0,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,In vivo,,Canis lupus familiaris,,,,
6002,1,A,BAO_0000218,9615.0,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,In vivo,,Canis lupus familiaris,,,,
6003,1,A,BAO_0000218,9615.0,6241,Cmax value in dog,In vivo,,Canis lupus familiaris,,,,
6004,1,A,BAO_0000218,9615.0,6241,Cmax value in dogs after oral administration at 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
6005,1,A,BAO_0000218,9615.0,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,In vivo,,Canis lupus familiaris,,,,
6006,1,A,BAO_0000218,9615.0,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,,Canis lupus familiaris,,Plasma,,
6007,1,A,BAO_0000218,9615.0,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,,Canis lupus familiaris,,Plasma,,
6008,1,A,BAO_0000218,9615.0,1021,Concentration maxima after oral dosing in dogs,In vivo,,Canis lupus familiaris,,,,
6009,1,A,BAO_0000218,9615.0,1021,Concentration maxima after oral dosing in dogs; not available,In vivo,,Canis lupus familiaris,,,,
6010,1,A,BAO_0000218,9615.0,1021,Concentration maxima after oral dosing in dogs; not available,In vivo,,Canis lupus familiaris,,,,
6011,1,A,BAO_0000218,9615.0,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,In vivo,,Canis lupus familiaris,,,,
6012,1,A,BAO_0000218,9615.0,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,In vivo,,Canis lupus familiaris,,,,
6013,1,A,BAO_0000218,9615.0,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
6014,1,A,BAO_0000218,9615.0,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,In vivo,,Canis lupus familiaris,,,,
6015,1,A,BAO_0000218,9615.0,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,In vivo,,Canis lupus familiaris,,,,
6016,1,A,BAO_0000218,9615.0,5130,Cmax in dog plasma after oral dose (1 mg/kg),In vivo,,Canis lupus familiaris,,Plasma,,
6017,1,A,BAO_0000218,9615.0,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6018,1,A,BAO_0000218,9615.0,5473,Maximal plasma concentration at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6019,1,A,BAO_0000218,9615.0,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),In vivo,,Canis lupus familiaris,,Plasma,,
6020,1,A,BAO_0000218,9615.0,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,In vivo,,Canis lupus familiaris,,Plasma,,
6021,1,A,BAO_0000218,9615.0,3031,Maximum concentration of compound in dog was evaluated.,In vivo,,Canis lupus familiaris,,,,
6022,1,A,BAO_0000218,9615.0,4527,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
6023,1,A,BAO_0000218,9615.0,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,In vivo,,Canis lupus familiaris,,,,
6024,1,A,BAO_0000218,9615.0,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,,Canis lupus familiaris,,,,
6025,1,A,BAO_0000218,9615.0,3132,Maximum concentration obtained in dog plasma was determined,In vivo,,Canis lupus familiaris,,Plasma,,
6026,1,A,BAO_0000218,9615.0,5006,Maximum concentration was determined,In vivo,,Canis lupus familiaris,,,,
6027,1,A,BAO_0000218,9615.0,4727,Maximum concentration at the dose of 2 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
6028,1,A,BAO_0000218,9615.0,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,Canis lupus familiaris,,,,
6029,1,A,BAO_0000218,9615.0,1918,Maximum concentration was evaluated in dog plasma,In vivo,,Canis lupus familiaris,,Plasma,,
6030,1,A,BAO_0000218,9615.0,3045,Maximum concentration was evaluated after 75 min after administration in dog,In vivo,,Canis lupus familiaris,,,,
6031,1,A,BAO_0000218,9615.0,9579,Maximum plasma concentration determined in dog after oral administration of 17b,In vivo,,Canis lupus familiaris,,Plasma,,
6032,1,A,BAO_0000218,9615.0,9579,Maximum plasma concentration determined in dog after oral administration of 2b,In vivo,,Canis lupus familiaris,,Plasma,,
6033,1,A,BAO_0000218,9615.0,933,Maximum plasma concentration in dog,In vivo,,Canis lupus familiaris,,Plasma,,
6034,1,A,BAO_0000218,9615.0,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6035,1,A,BAO_0000218,9615.0,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6036,1,A,BAO_0000218,9615.0,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6037,1,A,BAO_0000218,9615.0,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6038,1,A,BAO_0000218,9615.0,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,,Plasma,,
6039,1,A,BAO_0000218,9615.0,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6040,1,A,BAO_0000218,9615.0,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,,Plasma,,
6041,1,A,BAO_0000218,9615.0,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,,Plasma,,
6042,1,A,BAO_0000218,9615.0,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,,Canis lupus familiaris,,Plasma,,
6043,1,A,BAO_0000218,9615.0,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6044,1,A,BAO_0000218,9615.0,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,,Plasma,,
6045,1,A,BAO_0000218,9615.0,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,In vivo,,Canis lupus familiaris,,Plasma,,
6046,1,A,BAO_0000218,9615.0,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,In vivo,,Canis lupus familiaris,,Plasma,,
6047,1,A,BAO_0000218,9615.0,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6048,1,A,BAO_0000218,9615.0,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6049,1,A,BAO_0000218,9615.0,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6050,1,A,BAO_0000218,9615.0,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6051,1,A,BAO_0000218,9615.0,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6052,1,A,BAO_0000218,9615.0,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
6053,1,A,BAO_0000218,9615.0,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
6054,1,A,BAO_0000218,10090.0,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Stomach,,
6055,1,A,BAO_0000218,10090.0,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,Mus musculus,,Urine,,
6056,1,A,BAO_0000218,10090.0,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,,Mus musculus,,Urine,,
6057,1,A,BAO_0000218,10090.0,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,,Mus musculus,,Urine,,
6058,1,A,BAO_0000218,10090.0,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,,Mus musculus,,,,
6059,1,A,BAO_0000218,10090.0,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,,Mus musculus,,,,
6060,1,A,BAO_0000218,10090.0,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,,Mus musculus,,,,
6061,1,A,BAO_0000218,10090.0,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,Mus musculus,,Blood,,
6062,1,A,BAO_0000218,10090.0,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,,Mus musculus,,,,
6063,1,A,BAO_0000218,10090.0,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,,Mus musculus,,,,
6064,1,A,BAO_0000218,10090.0,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,,Mus musculus,,,,
6065,1,A,BAO_0000218,10090.0,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,Mus musculus,,Blood,,
6066,1,A,BAO_0000218,10090.0,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,,Mus musculus,,Blood,,
6067,1,A,BAO_0000218,10090.0,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),,,Mus musculus,,,,
6068,1,A,BAO_0000218,10090.0,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,,Mus musculus,,,,
6069,1,A,BAO_0000218,10090.0,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,Mus musculus,,,,
6070,1,A,BAO_0000218,10090.0,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,Mus musculus,,,,
6071,1,A,BAO_0000218,10090.0,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,Mus musculus,,,,
6072,1,A,BAO_0000218,10090.0,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,,Mus musculus,,,,
6073,1,A,BAO_0000218,10090.0,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,,Mus musculus,,,,
6074,1,A,BAO_0000218,10090.0,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,,Mus musculus,,,,
6075,1,A,BAO_0000218,10090.0,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,,Mus musculus,,,,
6076,1,A,BAO_0000218,10090.0,17827,Time at maximum activity in mice (Radiolabeled compound),,,Mus musculus,,,,
6077,1,A,BAO_0000218,10090.0,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,,Mus musculus,,,,
6078,1,A,BAO_0000218,10090.0,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,,Mus musculus,,,,
6079,1,A,BAO_0000218,10090.0,17409,Binding towards mouse plasma protein at 10 uM,,,Mus musculus,,,,
6080,1,A,BAO_0000218,10090.0,17409,Binding towards mouse plasma protein at 100 uM,,,Mus musculus,,,,
6081,1,A,BAO_0000218,10090.0,2675,Bioavailability was evaluated in mice after intravenous administration,In vivo,,Mus musculus,,,,
6082,1,A,BAO_0000218,10090.0,2675,Bioavailability was evaluated in mice after oral administration,In vivo,,Mus musculus,,,,
6083,1,A,BAO_0000218,10090.0,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,In vivo,,Mus musculus,,,,
6084,1,A,BAO_0000218,10090.0,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,In vivo,,Mus musculus,,,,
6085,1,A,BAO_0000218,10090.0,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,In vivo,,Mus musculus,,,,
6086,1,A,BAO_0000218,10090.0,2862,Oral bioavailability in mouse,In vivo,,Mus musculus,,,,
6087,1,A,BAO_0000218,10090.0,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,In vivo,,Mus musculus,,,,
6088,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Brain,,
6089,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Brain,,
6090,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Brain,,
6091,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Brain,,
6092,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Brain,,
6093,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Brain,,
6094,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Heart,,
6095,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Heart,,
6096,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Heart,,
6097,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Heart,,
6098,1,F,BAO_0000219,9606.0,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,,Homo sapiens,,,A549,
6099,1,F,BAO_0000219,9606.0,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,,Homo sapiens,,,A549,
6100,1,F,BAO_0000219,9606.0,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,,,Homo sapiens,,,A549,
6101,1,F,BAO_0000219,9606.0,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,,Homo sapiens,,,A549,
6102,1,F,BAO_0000219,9606.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,,,Homo sapiens,,,A549,
6103,1,F,BAO_0000219,9606.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,,Homo sapiens,,,A549,
6104,1,F,BAO_0000219,9606.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,,Homo sapiens,,,A549,
6105,1,F,BAO_0000219,9606.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,,Homo sapiens,,,A549,
6106,1,F,BAO_0000219,9606.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,,Homo sapiens,,,A549,
6107,1,F,BAO_0000219,9606.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,,Homo sapiens,,,A549,
6108,1,F,BAO_0000219,9606.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,,Homo sapiens,,,A549,
6109,1,F,BAO_0000219,9606.0,15167,In vitro cytotoxicity against A-549 human lung cancer cells,,,Homo sapiens,,,A549,
6110,1,F,BAO_0000219,9606.0,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,,Homo sapiens,,,A549,
6111,1,F,BAO_0000219,9606.0,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,,Homo sapiens,,,A549,
6112,1,F,BAO_0000219,9606.0,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,,Homo sapiens,,,A549,
6113,1,F,BAO_0000219,9606.0,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,,Homo sapiens,,,A549,
6114,1,F,BAO_0000219,9606.0,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,,Homo sapiens,,,A549,
6115,1,F,BAO_0000219,9606.0,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,,Homo sapiens,,,A549,
6116,1,F,BAO_0000219,9606.0,4461,Antitumor cytotoxic activity against A-549 cell line was determined,,,Homo sapiens,,,A549,
6117,1,F,BAO_0000219,9606.0,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,,Homo sapiens,,,A549,
6118,1,F,BAO_0000219,9606.0,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,,Homo sapiens,,,A549,
6119,1,F,BAO_0000219,9606.0,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,,Homo sapiens,,,A549,
6120,1,F,BAO_0000219,9606.0,3265,Antitumoral activity was assayed against A-549 cell line,,,Homo sapiens,,,A549,
6121,1,F,BAO_0000219,9606.0,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,,Homo sapiens,,,A549,
6122,1,F,BAO_0000219,9606.0,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,,Homo sapiens,,,A549,
6123,1,F,BAO_0000219,9606.0,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,Homo sapiens,,,A549,
6124,1,F,BAO_0000219,9606.0,1481,Compound was tested for inhibition of cell growth of A-549 cells,,,Homo sapiens,,,A549,
6125,1,F,BAO_0000219,9606.0,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,,Homo sapiens,,,A549,
6126,1,F,BAO_0000219,9606.0,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,,Homo sapiens,,,A549,
6127,1,F,BAO_0000219,9606.0,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,,,Homo sapiens,,,A549,
6128,1,F,BAO_0000219,9606.0,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,,Homo sapiens,,,A549,
6129,1,F,BAO_0000219,9606.0,1847,Cytotoxic activity against A-549 cell lines.,,,Homo sapiens,,,A549,
6130,1,F,BAO_0000219,9606.0,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,,Homo sapiens,,,A549,
6131,1,F,BAO_0000219,9606.0,1003,Cytotoxicity against human A549 non small cell lung cell lines,,,Homo sapiens,,,A549,
6132,1,F,BAO_0000219,9606.0,15313,Inhibition of cell growth in (A-549) lung cell line,,,Homo sapiens,,,A549,
6133,1,F,BAO_0000219,9606.0,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,,Homo sapiens,,,A549,
6134,1,F,BAO_0000219,9606.0,16049,In vitro antitumor activity against A-549 tumor cells.,,,Homo sapiens,,,A549,
6135,1,F,BAO_0000219,9606.0,17134,In vitro antitumor effects against human A-549 cell lines.,,,Homo sapiens,,,A549,
6136,1,F,BAO_0000219,9606.0,6406,In vitro cytotoxic activity of compound against A-549 cell line,,,Homo sapiens,,,A549,
6137,1,F,BAO_0000219,9606.0,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,,Homo sapiens,,,A549,
6138,1,F,BAO_0000219,9606.0,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,,Homo sapiens,,,A549,
6139,1,F,BAO_0000219,9606.0,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,,Homo sapiens,,,A549,
6140,1,F,BAO_0000219,9606.0,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,,Homo sapiens,,,A549,
6141,1,F,BAO_0000219,9606.0,6663,Inhibitory concentration of compound against A-549 cell line,,,Homo sapiens,,,A549,
6142,1,F,BAO_0000219,9606.0,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,,Homo sapiens,,,A549,
6143,1,F,BAO_0000219,9606.0,14709,cytotoxic activity against leukemia (A-549) cancer cell line,,,Homo sapiens,,,A549,
6144,1,F,BAO_0000219,9606.0,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,,Homo sapiens,,,A549,
6145,1,F,BAO_0000219,9606.0,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,,Homo sapiens,,,A549,
6146,1,F,BAO_0000219,9606.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,,Homo sapiens,,,A549,
6147,1,F,BAO_0000219,9606.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,,Homo sapiens,,,A549,
6148,1,F,BAO_0000219,9606.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,,Homo sapiens,,,A549,
6149,1,F,BAO_0000219,9606.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,,Homo sapiens,,,A549,
6150,1,F,BAO_0000219,,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,,,,,A549,
6151,1,F,BAO_0000219,9606.0,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,,Homo sapiens,,,A549,
6152,1,F,BAO_0000219,9606.0,17846,Cytotoxicity against A549 cells; No cytotoxicity,,,Homo sapiens,,,A549,
6153,1,F,BAO_0000219,9606.0,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,,,Homo sapiens,,,A549,
6154,1,F,BAO_0000219,9606.0,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,,Homo sapiens,,,A549,
6155,1,F,BAO_0000219,9606.0,5609,In vitro anticancer activity against human lung (A549) cell line,,,Homo sapiens,,,A549,
6156,1,F,BAO_0000219,9606.0,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,,Homo sapiens,,,A549,
6157,1,F,BAO_0000219,9606.0,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6158,1,F,BAO_0000219,9606.0,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6159,1,F,BAO_0000219,9606.0,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6160,1,F,BAO_0000219,9606.0,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6161,1,F,BAO_0000219,9606.0,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6162,1,F,BAO_0000219,9606.0,16295,Inhibition of A549 human lung tumor cell proliferation,,,Homo sapiens,,,A549,
6163,1,F,BAO_0000219,9606.0,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,,Homo sapiens,,,A549,
6164,1,F,BAO_0000219,9606.0,3439,In vitro cytotoxicity against human tumor cell line A549,,,Homo sapiens,,,A549,
6165,1,F,BAO_0000219,9606.0,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,,Homo sapiens,,,A549,
6166,1,F,BAO_0000219,9606.0,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,,Homo sapiens,,,A549,
6167,1,F,BAO_0000219,9606.0,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,,Homo sapiens,,,A549,
6168,1,F,BAO_0000219,9606.0,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,,Homo sapiens,,,A549,
6169,1,F,BAO_0000219,9606.0,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,,Homo sapiens,,,A549,
6170,1,F,BAO_0000219,9606.0,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,,Homo sapiens,,,A549,
6171,1,F,BAO_0000219,9606.0,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,,Homo sapiens,,,A549,
6172,1,F,BAO_0000219,9606.0,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,,Homo sapiens,,,A549,
6173,1,F,BAO_0000219,9606.0,5609,In vitro anticancer activity against human lung (A549) cell line,,,Homo sapiens,,,A549,
6174,1,F,BAO_0000219,9606.0,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,,Homo sapiens,,,A549,
6175,1,F,BAO_0000219,9606.0,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,,Homo sapiens,,,A549,
6176,1,F,BAO_0000219,9606.0,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,,Homo sapiens,,,A549,
6177,1,F,BAO_0000219,9606.0,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,,Homo sapiens,,,A549,
6178,1,F,BAO_0000219,9606.0,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,,Homo sapiens,,,A549,
6179,1,F,BAO_0000219,9606.0,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,,,Homo sapiens,,,A549,
6180,1,F,BAO_0000219,9606.0,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,,Homo sapiens,,,A549,
6181,1,F,BAO_0000219,9606.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,,Homo sapiens,,,A549,
6182,1,F,BAO_0000219,9606.0,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,,Homo sapiens,,,A549,
6183,1,F,BAO_0000219,9606.0,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,,Homo sapiens,,,A549,
6184,1,F,BAO_0000219,9606.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,,Homo sapiens,,,A549,
6185,1,F,BAO_0000219,9606.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,,Homo sapiens,,,A549,
6186,1,F,BAO_0000219,9606.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,,Homo sapiens,,,A549,
6187,1,F,BAO_0000219,9606.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,,Homo sapiens,,,A549,
6188,1,F,BAO_0000219,9606.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,,Homo sapiens,,,A549,
6189,1,F,BAO_0000219,9606.0,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,,Homo sapiens,,,A549,
6190,1,F,BAO_0000219,9606.0,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,,Homo sapiens,,,A549,
6191,1,F,BAO_0000219,9606.0,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,,Homo sapiens,,,A549,
6192,1,F,BAO_0000219,9606.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6193,1,F,BAO_0000219,9606.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6194,1,F,BAO_0000219,9606.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6195,1,F,BAO_0000219,9606.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6196,1,A,BAO_0000218,9615.0,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,,,,
6197,1,A,BAO_0000218,9615.0,6084,Pharmacokinetic activity (Cmax) in dog,In vivo,,Canis lupus familiaris,,,,
6198,1,A,BAO_0000218,9615.0,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,,Canis lupus familiaris,,,,
6199,1,A,BAO_0000218,9615.0,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,In vivo,,Canis lupus familiaris,,,,
6200,1,A,BAO_0000218,9615.0,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,In vivo,,Canis lupus familiaris,,,,
6201,1,A,BAO_0000218,9615.0,5932,Cmax in dog plasma after 30mg/kg oral dose,In vivo,,Canis lupus familiaris,,Plasma,,
6202,1,A,BAO_0000218,9615.0,4273,Tested for the peak blood level in dog,In vivo,,Canis lupus familiaris,,Blood,,
6203,1,A,BAO_0000218,9615.0,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",In vivo,,Canis lupus familiaris,,,,
6204,1,A,BAO_0000218,9615.0,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",In vivo,,Canis lupus familiaris,,,,
6205,1,A,BAO_0000218,9615.0,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,In vivo,,Canis lupus familiaris,,Blood,,
6206,1,A,BAO_0000218,9615.0,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,,Canis lupus familiaris,,,,
6207,1,A,BAO_0000218,9615.0,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,,Canis lupus familiaris,,,,
6208,1,A,BAO_0000218,9615.0,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,,,Canis lupus familiaris,,Plasma,,
6209,1,A,BAO_0000218,9615.0,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,,Canis lupus familiaris,,,,
6210,1,A,BAO_0000218,9615.0,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,,Canis lupus familiaris,,,,
6211,1,A,BAO_0000218,9615.0,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,,Canis lupus familiaris,,,,
6212,1,A,BAO_0000218,9615.0,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,,Canis lupus familiaris,,,,
6213,1,A,BAO_0000218,9615.0,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,,Canis lupus familiaris,,Urine,,
6214,1,A,BAO_0000218,9615.0,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,,Canis lupus familiaris,,Urine,,
6215,1,A,BAO_0000218,9615.0,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,,Canis lupus familiaris,,Urine,,
6216,1,A,BAO_0000218,9615.0,4257,Absolute bioavailability was evaluated in dog,In vivo,,Canis lupus familiaris,,,,
6217,1,A,BAO_0000218,9615.0,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,In vivo,,Canis lupus familiaris,,,,
6218,1,A,BAO_0000218,9615.0,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,,,,
6219,1,A,BAO_0000218,9615.0,17267,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6220,1,A,BAO_0000218,9615.0,6621,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6221,1,A,BAO_0000218,9615.0,3854,Bioavailability after intravenous administration in dogs,In vivo,,Canis lupus familiaris,,,,
6222,1,A,BAO_0000218,9615.0,3854,Bioavailability after peroral administration in dogs,In vivo,,Canis lupus familiaris,,,,
6223,1,A,BAO_0000218,9615.0,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,,Canis lupus familiaris,,,,
6224,1,A,BAO_0000218,9615.0,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,In vivo,,Canis lupus familiaris,,,,
6225,1,A,BAO_0000218,9615.0,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,In vivo,,Canis lupus familiaris,,Plasma,,
6226,1,A,BAO_0000218,9615.0,5006,Bioavailability,In vivo,,Canis lupus familiaris,,,,
6227,1,A,BAO_0000218,9615.0,5199,Bioavailability,In vivo,,Canis lupus familiaris,,,,
6228,1,A,BAO_0000218,9615.0,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
6229,1,A,BAO_0000218,9615.0,3771,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6230,1,A,BAO_0000218,9615.0,4953,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6231,1,A,BAO_0000218,9615.0,5064,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6232,1,A,BAO_0000218,9615.0,17657,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6233,1,A,BAO_0000218,9615.0,17796,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6234,1,A,BAO_0000218,9615.0,17853,Bioavailability in dog (p.o.) at 2.0 mpk,In vivo,,Canis lupus familiaris,,,,
6235,1,A,BAO_0000218,9615.0,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),In vivo,,Canis lupus familiaris,,,,
6236,1,A,BAO_0000218,9615.0,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,Canis lupus familiaris,,,,
6237,1,A,BAO_0000218,9615.0,5006,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6238,1,A,BAO_0000218,9615.0,16365,Bioavailability was evaluated after oral administration in dog,In vivo,,Canis lupus familiaris,,,,
6239,1,A,BAO_0000218,9615.0,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,Canis lupus familiaris,,,,
6240,1,A,BAO_0000218,9615.0,1918,Bioavailability was evaluated in dog,In vivo,,Canis lupus familiaris,,,,
6241,1,A,BAO_0000218,9615.0,4239,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6242,1,A,BAO_0000218,9615.0,6505,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6243,1,A,BAO_0000218,9615.0,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,,Canis lupus familiaris,,,,
6244,1,A,BAO_0000218,9615.0,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,,Canis lupus familiaris,,,,
6245,1,A,BAO_0000218,9615.0,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,,Canis lupus familiaris,,,,
6246,1,A,BAO_0000218,9615.0,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,,,,
6247,1,A,BAO_0000218,9615.0,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
6248,1,A,BAO_0000218,9615.0,17804,Bioavailability of compound in dog was determined after peroral administration,In vivo,,Canis lupus familiaris,,,,
6249,1,A,BAO_0000218,9615.0,3184,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6250,1,A,BAO_0000218,9615.0,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,,Canis lupus familiaris,,,,
6251,1,A,BAO_0000218,9615.0,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,,Canis lupus familiaris,,,,
6252,1,A,BAO_0000218,9615.0,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,In vivo,,Canis lupus familiaris,,,,
6253,1,A,BAO_0000218,9615.0,4839,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6254,1,A,BAO_0000218,9615.0,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),In vivo,,Canis lupus familiaris,,,,
6255,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Heart,,
6256,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Heart,,
6257,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Kidney,,
6258,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Kidney,,
6259,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Kidney,,
6260,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Kidney,,
6261,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Kidney,,
6262,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Kidney,,
6263,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Liver,,
6264,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Liver,,
6265,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Liver,,
6266,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Liver,,
6267,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Liver,,
6268,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Liver,,
6269,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Lung,,
6270,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Lung,,
6271,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Lung,,
6272,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Lung,,
6273,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Lung,,
6274,1,A,BAO_0000218,10090.0,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,Mus musculus,,Lung,,
6275,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,,Mus musculus,,,CCRF S-180,
6276,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,,Mus musculus,,,CCRF S-180,
6277,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,,CCRF S-180,
6278,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,,Mus musculus,,,CCRF S-180,
6279,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,,Mus musculus,,,CCRF S-180,
6280,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,,Mus musculus,,Brain,CCRF S-180,
6281,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,,Mus musculus,,Brain,CCRF S-180,
6282,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,Brain,CCRF S-180,
6283,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,,Mus musculus,,Brain,CCRF S-180,
6284,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,,Mus musculus,,Brain,CCRF S-180,
6285,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,,Mus musculus,,Heart,CCRF S-180,
6286,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,,Mus musculus,,Heart,CCRF S-180,
6287,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,Heart,CCRF S-180,
6288,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,,Mus musculus,,Heart,CCRF S-180,
6289,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,,Mus musculus,,Heart,CCRF S-180,
6290,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,,Mus musculus,,Kidney,CCRF S-180,
6291,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,,Mus musculus,,Kidney,CCRF S-180,
6292,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,Kidney,CCRF S-180,
6293,1,F,BAO_0000219,9606.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,,Homo sapiens,,,A549,
6294,1,F,BAO_0000219,9606.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,,Homo sapiens,,,A549,
6295,1,F,BAO_0000219,9606.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,,Homo sapiens,,,A549,
6296,1,F,BAO_0000219,9606.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,,Homo sapiens,,,A549,
6297,1,F,BAO_0000219,9606.0,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,,Homo sapiens,,,A549,
6298,1,F,BAO_0000219,9606.0,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,,Homo sapiens,,,A549,
6299,1,F,BAO_0000219,9606.0,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,,Homo sapiens,,,A549,
6300,1,F,BAO_0000219,9606.0,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,,Homo sapiens,,,A549,
6301,1,F,BAO_0000219,9606.0,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,,Homo sapiens,,,A549,
6302,1,F,BAO_0000219,9606.0,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,,Homo sapiens,,,A549,
6303,1,F,BAO_0000219,9606.0,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,,Homo sapiens,,,A549,
6304,1,F,BAO_0000219,9606.0,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,,Homo sapiens,,,A549,
6305,1,F,BAO_0000219,9606.0,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,,Homo sapiens,,,A549,
6306,1,F,BAO_0000219,9606.0,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,,Homo sapiens,,,A549,
6307,1,F,BAO_0000219,9606.0,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,,Homo sapiens,,,A549,
6308,1,F,BAO_0000219,9606.0,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,,,Homo sapiens,,,A549,
6309,1,F,BAO_0000219,9606.0,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,,Homo sapiens,,,A549,
6310,1,F,BAO_0000219,9606.0,5076,Cytotoxic activity of compound against A-549 tumor cell line.,,,Homo sapiens,,,A549,
6311,1,F,BAO_0000219,9606.0,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,,Homo sapiens,,,A549,
6312,1,F,BAO_0000219,9606.0,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,,Homo sapiens,,,A549,
6313,1,F,BAO_0000219,9606.0,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,,Homo sapiens,,,A549,
6314,1,F,BAO_0000219,9606.0,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,,Homo sapiens,,,A549,
6315,1,F,BAO_0000219,9606.0,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,,Homo sapiens,,,A549,
6316,1,F,BAO_0000219,9606.0,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,,Homo sapiens,,,A549,
6317,1,F,BAO_0000219,9606.0,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,,Homo sapiens,,,A549,
6318,1,F,BAO_0000219,9606.0,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,,Homo sapiens,,,A549,
6319,1,F,BAO_0000219,9606.0,11333,Cytotoxic concentration against A-549 tumor cells.,,,Homo sapiens,,,A549,
6320,1,F,BAO_0000219,9606.0,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,,Homo sapiens,,,A549,
6321,1,F,BAO_0000219,9606.0,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,,Homo sapiens,,,A549,
6322,1,F,BAO_0000218,470.0,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,,Acinetobacter baumannii,,,,
6323,1,F,BAO_0000218,471.0,10624,Activity against Acinetobacter calcoaceticus (AC54),,,Acinetobacter calcoaceticus,,,,
6324,1,F,BAO_0000218,5059.0,16717,In vitro antifungal activity against Aspergillus flavus CM74,,,Aspergillus flavus,,,,
6325,1,F,BAO_0000218,5059.0,16717,In vitro antifungal activity against Aspergillus flavus CM74,,,Aspergillus flavus,,,,
6326,1,F,BAO_0000218,746128.0,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,,Aspergillus fumigatus,,,,
6327,1,F,BAO_0000218,746128.0,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,,Aspergillus fumigatus,,,,
6328,1,F,BAO_0000218,746128.0,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),,,Aspergillus fumigatus,,,,
6329,1,F,BAO_0000218,746128.0,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),,,Aspergillus fumigatus,,,,
6330,1,F,BAO_0000218,746128.0,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,,Aspergillus fumigatus,,,,
6331,1,F,BAO_0000218,746128.0,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,Aspergillus fumigatus,,,,
6332,1,F,BAO_0000218,746128.0,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,Aspergillus fumigatus,,,,
6333,1,F,BAO_0000218,1655.0,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,,Actinomyces naeslundii,,,,
6334,1,F,BAO_0000218,1656.0,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,,Actinomyces viscosus,,,,
6335,1,F,BAO_0000218,6277.0,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,Acanthocheilonema viteae,,,,
6336,1,F,BAO_0000218,6277.0,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,Acanthocheilonema viteae,,,,
6337,1,F,BAO_0000218,714.0,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,,Aggregatibacter actinomycetemcomitans,,,,
6338,1,F,BAO_0000218,714.0,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,,Aggregatibacter actinomycetemcomitans,,,,
6339,1,F,BAO_0000218,714.0,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,,Aggregatibacter actinomycetemcomitans,,,,
6340,1,F,BAO_0000219,9606.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6341,1,F,BAO_0000219,9606.0,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6342,1,F,BAO_0000219,9606.0,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,,Homo sapiens,,,A549,
6343,1,F,BAO_0000219,9606.0,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,,Homo sapiens,,,A549,
6344,1,F,BAO_0000219,9606.0,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,,Homo sapiens,,,A549,
6345,1,F,BAO_0000219,9606.0,16381,GI values against A549 cells (lung cancer),,,Homo sapiens,,,A549,
6346,1,F,BAO_0000219,9606.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,,Homo sapiens,,,A549,
6347,1,F,BAO_0000219,9606.0,16325,Inhibitory activity against A549 human adenocarcinoma,,,Homo sapiens,,,A549,
6348,1,F,BAO_0000218,9606.0,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,,Homo sapiens,,,A549,
6349,1,F,BAO_0000218,9606.0,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,,Homo sapiens,,,A549,
6350,1,F,BAO_0000219,9606.0,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,,,Homo sapiens,,,A549,
6351,1,F,BAO_0000219,9606.0,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,,Homo sapiens,,,A549,
6352,1,F,BAO_0000219,9606.0,17488,Cytotoxicity against human A549 lung cells,,,Homo sapiens,,,A549,
6353,1,F,BAO_0000218,9606.0,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,,Homo sapiens,,,A549,
6354,1,F,BAO_0000219,9606.0,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,,,Homo sapiens,,,A549,
6355,1,F,BAO_0000219,9606.0,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,,,Homo sapiens,,,A549,
6356,1,F,BAO_0000219,9606.0,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,,Homo sapiens,,,A549,
6357,1,F,BAO_0000219,9606.0,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,,Homo sapiens,,,A549,
6358,1,F,BAO_0000219,9606.0,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,,Homo sapiens,,,A549,
6359,1,F,BAO_0000219,9606.0,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,,Homo sapiens,,,A549,
6360,1,F,BAO_0000219,9606.0,2525,In vitro inhibitory activity against A549 tumor cell culture,,,Homo sapiens,,,A549,
6361,1,F,BAO_0000219,9606.0,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,,Homo sapiens,,,A549,
6362,1,F,BAO_0000219,9606.0,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,,Homo sapiens,,,A549,
6363,1,F,BAO_0000219,9606.0,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,,Homo sapiens,,,A549,
6364,1,F,BAO_0000219,9606.0,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,,Homo sapiens,,,A549,
6365,1,F,BAO_0000219,9606.0,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,,Homo sapiens,,,A549,
6366,1,F,BAO_0000219,9606.0,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,,Homo sapiens,,,A549,
6367,1,F,BAO_0000219,9606.0,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,,Homo sapiens,,,A549,
6368,1,F,BAO_0000219,9606.0,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,,Homo sapiens,,,A549,
6369,1,F,BAO_0000219,9606.0,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,,Homo sapiens,,,A549,
6370,1,F,BAO_0000219,9606.0,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,,Homo sapiens,,,A549,
6371,1,F,BAO_0000219,9606.0,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,,Homo sapiens,,,A549,
6372,1,F,BAO_0000219,9606.0,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,,Homo sapiens,,,A549,
6373,1,F,BAO_0000219,9606.0,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,,Homo sapiens,,,A549,
6374,1,F,BAO_0000219,9606.0,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,,Homo sapiens,,,A549,
6375,1,F,BAO_0000219,9606.0,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,,Homo sapiens,,,A549,
6376,1,F,BAO_0000219,9606.0,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,,Homo sapiens,,,A549,
6377,1,F,BAO_0000219,9606.0,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,,Homo sapiens,,,A549,
6378,1,F,BAO_0000219,9606.0,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,,Homo sapiens,,,A549,
6379,1,F,BAO_0000219,9606.0,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,,Homo sapiens,,,A549,
6380,1,F,BAO_0000219,9606.0,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,,Homo sapiens,,,A549,
6381,1,F,BAO_0000219,9606.0,12301,Antitumor activity against A549/ATCC cell line,,,Homo sapiens,,,A549,
6382,1,F,BAO_0000219,9606.0,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,,Homo sapiens,,,A549,
6383,1,F,BAO_0000219,9606.0,11818,In vitro cytotoxicity against A549/ATCC cell line.,,,Homo sapiens,,,A549,
6384,1,F,BAO_0000219,9606.0,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,,Homo sapiens,,,A549,
6385,1,F,BAO_0000219,9606.0,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,,Homo sapiens,,,A549,
6386,1,F,BAO_0000219,9606.0,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,,Homo sapiens,,,A549,
6387,1,F,BAO_0000219,9606.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,,Homo sapiens,,,A549,
6388,1,F,BAO_0000219,9606.0,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,,Homo sapiens,,,,
6389,1,A,BAO_0000218,9615.0,5005,Compound was tested for oral bioavailability in dogs,In vivo,,Canis lupus familiaris,,,,
6390,1,A,BAO_0000218,9615.0,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,In vivo,,Canis lupus familiaris,,,,
6391,1,A,BAO_0000218,9615.0,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,In vivo,,Canis lupus familiaris,,,,
6392,1,A,BAO_0000218,9615.0,5374,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6393,1,A,BAO_0000218,9615.0,5374,Compound was tested for the oral bioavailability in dog; No availability,In vivo,,Canis lupus familiaris,,,,
6394,1,A,BAO_0000218,9615.0,6265,Oral bioavailability in dog (dose 5 mg/kg),In vivo,,Canis lupus familiaris,,,,
6395,1,A,BAO_0000218,9615.0,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,,Canis lupus familiaris,,,,
6396,1,A,BAO_0000218,9615.0,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,,Canis lupus familiaris,,,,
6397,1,A,BAO_0000218,9615.0,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),In vivo,,Canis lupus familiaris,,,,
6398,1,A,BAO_0000218,9615.0,5302,Oral bioavailability in dog (dose 5 mg/kg),In vivo,,Canis lupus familiaris,,,,
6399,1,A,BAO_0000218,9615.0,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),In vivo,,Canis lupus familiaris,,,,
6400,1,A,BAO_0000218,9615.0,16452,Oral bioavailability of active FTIs in dogs,In vivo,,Canis lupus familiaris,,,,
6401,1,A,BAO_0000218,9615.0,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,,Canis lupus familiaris,,,,
6402,1,A,BAO_0000218,9615.0,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,,,,
6403,1,A,BAO_0000218,9615.0,17839,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6404,1,A,BAO_0000218,9615.0,6762,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6405,1,A,BAO_0000218,9615.0,6821,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6406,1,A,BAO_0000218,9615.0,6821,Oral bioavailability of compound was determined in dog; Not tested,In vivo,,Canis lupus familiaris,,,,
6407,1,A,BAO_0000218,9615.0,5210,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6408,1,A,BAO_0000218,9615.0,6227,Oral bioavailability (10 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,,,,
6409,1,A,BAO_0000218,9615.0,761,Oral bioavailability,In vivo,,Canis lupus familiaris,,,,
6410,1,A,BAO_0000218,9615.0,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),In vivo,,Canis lupus familiaris,,,,
6411,1,A,BAO_0000218,9615.0,761,Oral bioavailability administered in solution in rats,In vivo,,Canis lupus familiaris,,,,
6412,1,A,BAO_0000218,9615.0,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,,,,
6413,1,A,BAO_0000218,9615.0,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,In vivo,,Canis lupus familiaris,,,,
6414,1,A,BAO_0000218,9615.0,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),In vivo,,Canis lupus familiaris,,,,
6415,1,A,BAO_0000218,9615.0,6535,Oral bioavailability in Dog; ND = not determined,In vivo,,Canis lupus familiaris,,,,
6416,1,A,BAO_0000218,9615.0,3352,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6417,1,A,BAO_0000218,9615.0,6168,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6418,1,A,BAO_0000218,9615.0,5988,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6419,1,A,BAO_0000218,9615.0,4942,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6420,1,A,BAO_0000218,9615.0,4942,Oral bioavailability in dogs; No data,In vivo,,Canis lupus familiaris,,,,
6421,1,A,BAO_0000218,9615.0,14541,Oral bioavailability measured in dogs,In vivo,,Canis lupus familiaris,,,,
6422,1,A,BAO_0000218,9615.0,4449,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6423,1,A,BAO_0000218,9615.0,6057,Oral bioavailability was calculated in dog,In vivo,,Canis lupus familiaris,,,,
6424,1,A,BAO_0000218,9615.0,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,In vivo,,Canis lupus familiaris,,,,
6425,1,A,BAO_0000218,9615.0,5542,Oral bioavailability in dog (i.v. dosing),In vivo,,Canis lupus familiaris,,,,
6426,1,A,BAO_0000218,9615.0,5542,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6427,1,A,BAO_0000218,9615.0,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,In vivo,,Canis lupus familiaris,,,,
6428,1,A,BAO_0000218,9615.0,4514,Oral bioavailability in Beagle dogs,In vivo,,Canis lupus familiaris,,,,
6429,1,A,BAO_0000218,9615.0,3624,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6430,1,A,BAO_0000218,9615.0,3854,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6431,1,A,BAO_0000218,9615.0,5836,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6432,1,A,BAO_0000218,9615.0,5940,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6433,1,A,BAO_0000218,9615.0,6168,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6434,1,A,BAO_0000218,9615.0,6227,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6435,1,A,BAO_0000218,9615.0,6251,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6436,1,A,BAO_0000218,9615.0,6448,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6437,1,A,BAO_0000218,9615.0,6647,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6438,1,A,BAO_0000218,9615.0,5940,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6439,1,A,BAO_0000218,9615.0,933,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6440,1,A,BAO_0000218,9615.0,5210,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6441,1,A,BAO_0000218,9615.0,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),In vivo,,Canis lupus familiaris,,,,
6442,1,A,BAO_0000218,9615.0,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,,Canis lupus familiaris,,,,
6443,1,A,BAO_0000218,9615.0,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,,Canis lupus familiaris,,,,
6444,1,A,BAO_0000218,9615.0,5472,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6445,1,A,BAO_0000218,9615.0,5985,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6446,1,A,BAO_0000218,9615.0,15660,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6447,1,A,BAO_0000218,9615.0,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),In vivo,,Canis lupus familiaris,,,,
6448,1,A,BAO_0000218,9615.0,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,Canis lupus familiaris,,,,
6449,1,A,BAO_0000218,9615.0,6305,Oral bioavailability (F) in dogs,In vivo,,Canis lupus familiaris,,,,
6450,1,A,BAO_0000218,9615.0,5210,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6451,1,A,BAO_0000218,9615.0,5238,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6452,1,A,BAO_0000218,9615.0,5668,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,,,,
6453,1,A,BAO_0000218,9615.0,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,In vivo,,Canis lupus familiaris,,,,
6454,1,A,BAO_0000218,9615.0,5668,Oral bioavailability in dog (dose 5 mg/kg),In vivo,,Canis lupus familiaris,,,,
6455,1,A,BAO_0000218,9615.0,6084,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,,,,
6456,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,,Mus musculus,,Kidney,CCRF S-180,
6457,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,,Mus musculus,,Kidney,CCRF S-180,
6458,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,,Mus musculus,,Liver,CCRF S-180,
6459,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,,Mus musculus,,Liver,CCRF S-180,
6460,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,Liver,CCRF S-180,
6461,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,,Mus musculus,,Liver,CCRF S-180,
6462,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,,Mus musculus,,Liver,CCRF S-180,
6463,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,,Mus musculus,,Lung,CCRF S-180,
6464,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,,Mus musculus,,Lung,CCRF S-180,
6465,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,Lung,CCRF S-180,
6466,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,,Mus musculus,,Lung,CCRF S-180,
6467,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,,Mus musculus,,Lung,CCRF S-180,
6468,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,,Mus musculus,,,CCRF S-180,
6469,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,,Mus musculus,,,CCRF S-180,
6470,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,,CCRF S-180,
6471,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,,Mus musculus,,,CCRF S-180,
6472,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,,Mus musculus,,,CCRF S-180,
6473,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,,Mus musculus,,Spleen,CCRF S-180,
6474,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,,Mus musculus,,Spleen,CCRF S-180,
6475,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,Spleen,CCRF S-180,
6476,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,,Mus musculus,,Spleen,CCRF S-180,
6477,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,,Mus musculus,,Spleen,CCRF S-180,
6478,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,,Mus musculus,,,CCRF S-180,
6479,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,,Mus musculus,,,CCRF S-180,
6480,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,,CCRF S-180,
6481,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,,Mus musculus,,,CCRF S-180,
6482,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,,Mus musculus,,,CCRF S-180,
6483,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,,Mus musculus,,,CCRF S-180,
6484,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,,Mus musculus,,,CCRF S-180,
6485,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,,CCRF S-180,
6486,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,,Mus musculus,,,CCRF S-180,
6487,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,,Mus musculus,,,CCRF S-180,
6488,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,,Mus musculus,,Heart,CCRF S-180,
6489,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,,Mus musculus,,Heart,CCRF S-180,
6490,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,Heart,CCRF S-180,
6491,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,,Mus musculus,,Heart,CCRF S-180,
6492,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,,Mus musculus,,Heart,CCRF S-180,
6493,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,,Mus musculus,,Liver,CCRF S-180,
6494,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,,Mus musculus,,Liver,CCRF S-180,
6495,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,Liver,CCRF S-180,
6496,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,,Mus musculus,,Liver,CCRF S-180,
6497,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,,Mus musculus,,Liver,CCRF S-180,
6498,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,,Mus musculus,,Lung,CCRF S-180,
6499,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,,Mus musculus,,Lung,CCRF S-180,
6500,1,F,BAO_0000218,107673.0,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,aeinetobacter anitrotap,,,,
6501,1,F,BAO_0000218,107673.0,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,Acinetobacter calcoaceticus subsp. anitratus,,,,
6502,1,F,BAO_0000218,107673.0,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,Acinetobacter calcoaceticus subsp. anitratus,,,,
6503,1,F,BAO_0000218,107673.0,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,aeinetobacter anitrotap,,,,
6504,1,F,BAO_0000218,471.0,10624,Activity against Acinetobacter calcoaceticus (AC54),,,Acinetobacter calcoaceticus,,,,
6505,1,F,BAO_0000218,28377.0,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,,Anolis carolinensis,,,,
6506,1,F,BAO_0000218,28377.0,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,,Anolis carolinensis,,,,
6507,1,F,BAO_0000218,1655.0,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,,,Actinomyces naeslundii,,,,
6508,1,F,BAO_0000218,1655.0,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,,,Actinomyces naeslundii,,,,
6509,1,F,BAO_0000218,1655.0,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,,Actinomyces naeslundii,,,,
6510,1,F,BAO_0000218,1655.0,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,,Actinomyces naeslundii,,,,
6511,1,F,BAO_0000218,1655.0,9560,Plaque bactericidal index against Actinomyces naeslundii 631,,,Actinomyces naeslundii,,,,
6512,1,F,BAO_0000218,1655.0,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,,,Actinomyces naeslundii,,,,
6513,1,F,BAO_0000218,1655.0,9560,Plaque bactericidal index against Actinomyces naeslundii B74,,,Actinomyces naeslundii,,,,
6514,1,F,BAO_0000218,1655.0,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,,,Actinomyces naeslundii,,,,
6515,1,F,BAO_0000218,85549.0,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,,Artemia salina,,,,
6516,1,F,BAO_0000218,85549.0,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,,Artemia salina,,,,
6517,1,F,BAO_0000218,6253.0,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,Ascaris suum,,,,
6518,1,F,BAO_0000218,6253.0,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,Ascaris suum,,,,
6519,1,F,BAO_0000218,6253.0,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,Ascaris suum,,,,
6520,1,F,BAO_0000218,6253.0,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,Ascaris suum,,,,
6521,1,F,BAO_0000218,6253.0,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,Ascaris suum,,,,
6522,1,F,BAO_0000218,6253.0,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,,Ascaris suum,,,,
6523,1,F,BAO_0000218,6253.0,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,Ascaris suum,,,,
6524,1,F,BAO_0000218,6253.0,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,Ascaris suum,,,,
6525,1,F,BAO_0000218,6253.0,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,Ascaris suum,,,,
6526,1,F,BAO_0000218,6253.0,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,Ascaris suum,,,,
6527,1,F,BAO_0000218,6253.0,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,Ascaris suum,,,,
6528,1,F,BAO_0000218,6253.0,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,,Ascaris suum,,,,
6529,1,F,BAO_0000218,1656.0,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,Actinomyces viscosus,,,,
6530,1,F,BAO_0000218,1656.0,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,Actinomyces viscosus,,,,
6531,1,F,BAO_0000218,1656.0,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,,Actinomyces viscosus,,,,
6532,1,F,BAO_0000218,1656.0,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,,,Actinomyces viscosus,,,,
6533,1,F,BAO_0000218,1656.0,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,,,Actinomyces viscosus,,,,
6534,1,F,BAO_0000218,1656.0,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,,,Actinomyces viscosus,,,,
6535,1,F,BAO_0000218,1656.0,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,,,Actinomyces viscosus,,,,
6536,1,F,BAO_0000218,1656.0,9560,Plaque bactericidal index against Actinomyces viscosus M-100,,,Actinomyces viscosus,,,,
6537,1,F,BAO_0000218,1656.0,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,,Actinomyces viscosus,,,,
6538,1,F,BAO_0000218,1656.0,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,Actinomyces viscosus,,,,
6539,1,F,BAO_0000218,1656.0,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,Actinomyces viscosus,,,,
6540,1,F,BAO_0000218,1656.0,9560,Plaque bactericidal index against Actinomyces viscosus 626,,,Actinomyces viscosus,,,,
6541,1,F,BAO_0000218,1656.0,9560,Plaque bactericidal index against Actinomyces viscosus T14V,,,Actinomyces viscosus,,,,
6542,1,F,BAO_0000218,6277.0,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,,,,
6543,1,F,BAO_0000218,6277.0,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,,,,
6544,1,F,BAO_0000218,6277.0,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,,,,
6545,1,F,BAO_0000218,6277.0,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,,,,
6546,1,F,BAO_0000218,6277.0,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,,,,
6547,1,F,BAO_0000219,9606.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,,Homo sapiens,,,A673,
6548,1,F,BAO_0000219,9606.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,,Homo sapiens,,,A704,
6549,1,F,BAO_0000219,10116.0,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,,Rattus norvegicus,,,,
6550,1,F,BAO_0000219,10090.0,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,,Mus musculus,,,A9,
6551,1,F,BAO_0000219,10090.0,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,,Mus musculus,,,A9,
6552,1,F,BAO_0000219,9606.0,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,,Homo sapiens,,,A9,
6553,1,F,BAO_0000219,9606.0,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,,Homo sapiens,,,A9,
6554,1,F,BAO_0000219,9606.0,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,,Homo sapiens,,,Human ovarian carcinoma cell line,
6555,1,F,BAO_0000219,10090.0,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,,Mus musculus,,,A9,
6556,1,F,BAO_0000219,10090.0,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,,Mus musculus,,,A9,
6557,1,F,BAO_0000219,10090.0,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,,Mus musculus,,,A9,
6558,1,F,BAO_0000219,10090.0,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,,Mus musculus,,,A9,
6559,1,F,BAO_0000219,10090.0,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,,Mus musculus,,,A9,
6560,1,F,BAO_0000019,,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,,,,,
6561,1,F,BAO_0000219,10090.0,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,,Mus musculus,,,A9,
6562,1,F,BAO_0000219,10090.0,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,,Mus musculus,,,A9,
6563,1,F,BAO_0000219,10029.0,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,,Cricetulus griseus,,,AA6,
6564,1,F,BAO_0000219,9606.0,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,,Homo sapiens,,,,
6565,1,F,BAO_0000219,9606.0,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,,Homo sapiens,,,,
6566,1,F,BAO_0000219,9606.0,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,,Homo sapiens,,,AA5,
6567,1,F,BAO_0000219,9606.0,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),,,Homo sapiens,,,AA5,
6568,1,F,BAO_0000219,9606.0,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,,Homo sapiens,,,AA5,
6569,1,F,BAO_0000219,9606.0,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,,Homo sapiens,,,U-937,
6570,1,F,BAO_0000219,10029.0,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,,Cricetulus griseus,,,UV4,
6571,1,F,BAO_0000219,10029.0,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,Cricetulus griseus,,,CHO-AA8,
6572,1,F,BAO_0000219,10029.0,12687,Average intracellular compound concentration when the hypoxic SER=1.6,,,Cricetulus griseus,,,CHO-AA8,
6573,1,F,BAO_0000219,10029.0,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,,,Cricetulus griseus,,,CHO-AA8,
6574,1,F,BAO_0000219,10029.0,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,,Cricetulus griseus,,,CHO-AA8,
6575,1,F,BAO_0000219,10029.0,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,,Cricetulus griseus,,,CHO-AA8,
6576,1,F,BAO_0000219,10029.0,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,,Cricetulus griseus,,,CHO-AA8,
6577,1,F,BAO_0000219,10029.0,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,,Cricetulus griseus,,,CHO-AA8,
6578,1,F,BAO_0000219,10029.0,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,,Cricetulus griseus,,,CHO-AA8,
6579,1,F,BAO_0000219,10029.0,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,,Cricetulus griseus,,,CHO-AA8,
6580,1,F,BAO_0000219,10029.0,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,,Cricetulus griseus,,,CHO-AA8,
6581,1,A,BAO_0000219,10029.0,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,,Cricetulus griseus,,,CHO-AA8,
6582,1,A,BAO_0000219,10029.0,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,,Cricetulus griseus,,,CHO-AA8,
6583,1,A,BAO_0000219,10029.0,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,,Cricetulus griseus,,,CHO-AA8,
6584,1,A,BAO_0000219,10029.0,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,,Cricetulus griseus,,,CHO-AA8,
6585,1,F,BAO_0000219,10029.0,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,,Cricetulus griseus,,,CHO-AA8,
6586,1,F,BAO_0000219,10029.0,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,,Cricetulus griseus,,,CHO-AA8,
6587,1,F,BAO_0000219,36483.0,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,,hampster,,,CHO-AA8,
6588,1,F,BAO_0000219,10029.0,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,,,Cricetulus griseus,,,CHO-AA8,
6589,1,F,BAO_0000219,10029.0,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,,Cricetulus griseus,,,CHO-AA8,
6590,1,F,BAO_0000219,10029.0,13436,Inhibition of growth under aerobic conditions in AA8 cells,,,Cricetulus griseus,,,CHO-AA8,
6591,1,A,BAO_0000218,9615.0,6084,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,,,,
6592,1,A,BAO_0000218,9615.0,5711,Oral bioavailability in dog at 10 mg/kg of the compound,In vivo,,Canis lupus familiaris,,,,
6593,1,A,BAO_0000218,9615.0,4353,Oral bioavailability in dog (dose 5 uM/kg),In vivo,,Canis lupus familiaris,,,,
6594,1,A,BAO_0000218,9615.0,4353,Oral bioavailability in dog (dose 5 uM/kg),In vivo,,Canis lupus familiaris,,,,
6595,1,A,BAO_0000218,9615.0,17800,Oral bioavailability in dog (mongrel),In vivo,,Canis lupus familiaris,,,,
6596,1,A,BAO_0000218,9615.0,3994,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,,,,
6597,1,F,BAO_0000218,9615.0,3994,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,Canis lupus familiaris,,,,
6598,1,A,BAO_0000218,9615.0,5145,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6599,1,A,BAO_0000218,9615.0,16452,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,Canis lupus familiaris,,,,
6600,1,A,BAO_0000218,9615.0,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),In vivo,,Canis lupus familiaris,,,,
6601,1,A,BAO_0000218,9615.0,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,In vivo,,Canis lupus familiaris,,,,
6602,1,A,BAO_0000218,9615.0,4273,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6603,1,A,BAO_0000218,9615.0,12500,Bioavailability in dog (dose 3-10 mg/kg),In vivo,,Canis lupus familiaris,,,,
6604,1,A,BAO_0000218,9615.0,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,In vivo,,Canis lupus familiaris,,Plasma,,
6605,1,A,BAO_0000218,9615.0,3639,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6606,1,A,BAO_0000218,9615.0,3880,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6607,1,A,BAO_0000218,9615.0,4838,Bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6608,1,A,BAO_0000218,9615.0,15600,oral bioavailability was measured in dogs,In vivo,,Canis lupus familiaris,,,,
6609,1,A,BAO_0000218,9615.0,17248,Compound was tested for plasma protein binding in dog; Not determined,,,Canis lupus familiaris,,,,
6610,1,A,BAO_0000218,9615.0,17248,Compound was tested for plasma protein binding of dog,,,Canis lupus familiaris,,,,
6611,1,A,BAO_0000218,9615.0,17248,Compound was tested for plasma protein binding of dog; Not determined,,,Canis lupus familiaris,,,,
6612,1,A,BAO_0000218,9615.0,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,,Canis lupus familiaris,,,,
6613,1,A,BAO_0000218,9615.0,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,In vivo,,Canis lupus familiaris,,,,
6614,1,A,BAO_0000218,9615.0,3749,Half life was determined,,,Canis lupus familiaris,,,,
6615,1,A,BAO_0000218,9615.0,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,,,,
6616,1,A,BAO_0000218,9615.0,3022,Half life was evaluated in dog,,,Canis lupus familiaris,,,,
6617,1,A,BAO_0000218,9615.0,3749,Half life was determined,,,Canis lupus familiaris,,,,
6618,1,A,BAO_0000218,9615.0,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,,,,
6619,1,A,BAO_0000218,9615.0,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,,Heart,,
6620,1,A,BAO_0000218,9615.0,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,,Kidney,,
6621,1,A,BAO_0000218,9615.0,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,,Liver,,
6622,1,A,BAO_0000218,9615.0,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,,Lung,,
6623,1,A,BAO_0000218,9615.0,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,Canis lupus familiaris,,Spleen,,
6624,1,A,BAO_0000218,9615.0,3639,LogP in dog,,,Canis lupus familiaris,,,,
6625,1,A,BAO_0000218,9615.0,6227,Partition coefficient (logP),,,Canis lupus familiaris,,,,
6626,1,A,BAO_0000218,9615.0,6227,Partition coefficient in dog,,,Canis lupus familiaris,,,,
6627,1,A,BAO_0000218,9615.0,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,,Canis lupus familiaris,,,,
6628,1,A,BAO_0000218,9615.0,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),In vivo,,Canis lupus familiaris,,,,
6629,1,A,BAO_0000218,9615.0,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,,Canis lupus familiaris,,,,
6630,1,A,BAO_0000218,9615.0,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,,Canis lupus familiaris,,,,
6631,1,A,BAO_0000218,9615.0,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,,Canis lupus familiaris,,,,
6632,1,A,BAO_0000218,9615.0,14294,Metabolism of compound in dog S9 microsomes; Trace,,,Canis lupus familiaris,,,,
6633,1,A,BAO_0000218,9615.0,6251,In vitro metabolic potential in dog liver microsomes,,,Canis lupus familiaris,,Liver,,
6634,1,A,BAO_0000218,9615.0,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,In vivo,,Canis lupus familiaris,,,,
6635,1,A,BAO_0000218,9615.0,2713,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6636,1,A,BAO_0000218,9615.0,6512,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6637,1,A,BAO_0000218,9615.0,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Canis lupus familiaris,,,,
6638,1,A,BAO_0000218,9615.0,3749,The compound was tested for bioavailability in dogs,In vivo,,Canis lupus familiaris,,,,
6639,1,A,BAO_0000218,9615.0,3749,The compound was tested for oral bioavailability in dogs,In vivo,,Canis lupus familiaris,,,,
6640,1,A,BAO_0000218,9615.0,6742,Oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
6641,1,A,BAO_0000218,9615.0,6227,Compound was tested for percent protein binding (PB) in dog,,,Canis lupus familiaris,,,,
6642,1,A,BAO_0000218,9615.0,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,,Canis lupus familiaris,,,,
6643,1,A,BAO_0000218,9615.0,2877,Compound was evaluated for plasma clearance.,In vivo,,Canis lupus familiaris,,Plasma,,
6644,1,A,BAO_0000218,9615.0,12500,The compound was tested for plasma clearance in dog,In vivo,,Canis lupus familiaris,,Plasma,,
6645,1,A,BAO_0000218,9615.0,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,In vivo,,Canis lupus familiaris,,Plasma,,
6646,1,A,BAO_0000218,9615.0,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,,Canis lupus familiaris,,,,
6647,1,A,BAO_0000218,9615.0,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,,,Canis lupus familiaris,,Liver,,
6648,1,A,BAO_0000218,9615.0,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,In vivo,,Canis lupus familiaris,,,,
6649,1,A,BAO_0000218,9615.0,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,,Canis lupus familiaris,,,,
6650,1,A,BAO_0000218,9615.0,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,In vivo,,Canis lupus familiaris,,,,
6651,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,Lung,CCRF S-180,
6652,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,,Mus musculus,,Lung,CCRF S-180,
6653,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,,Mus musculus,,Lung,CCRF S-180,
6654,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,,Mus musculus,,,CCRF S-180,
6655,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,,Mus musculus,,,CCRF S-180,
6656,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,,Mus musculus,,,CCRF S-180,
6657,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,,Mus musculus,,,CCRF S-180,
6658,1,A,BAO_0000218,10090.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,,Mus musculus,,,CCRF S-180,
6659,1,A,BAO_0000218,10090.0,17641,C2 in brain of mice at the oral dose of 50 mg/kg,,,Mus musculus,,Brain,,
6660,1,A,BAO_0000218,10090.0,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,,,Mus musculus,,Kidney,,
6661,1,A,BAO_0000218,10090.0,17641,C2 in liver of mice at the oral dose of 50 mg/kg,,,Mus musculus,,Liver,,
6662,1,A,BAO_0000218,10090.0,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,,,Mus musculus,,Lung,,
6663,1,A,BAO_0000218,10090.0,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,,,Mus musculus,,Spleen,,
6664,1,A,BAO_0000218,10090.0,17852,Plasma clearance in mouse,In vivo,,Mus musculus,,,,
6665,1,A,BAO_0000218,10090.0,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,In vivo,,Mus musculus,,,,
6666,1,A,BAO_0000218,10090.0,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,In vivo,,Mus musculus,,,,
6667,1,A,BAO_0000218,10090.0,2675,Clearance was evaluated in mice after intravenous administration,In vivo,,Mus musculus,,,,
6668,1,A,BAO_0000218,10090.0,2675,Clearance was evaluated in mice after oral administration,In vivo,,Mus musculus,,,,
6669,1,A,BAO_0000218,10090.0,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,In vivo,,Mus musculus,,,,
6670,1,A,BAO_0000218,10090.0,17753,Plasma clearance of compound was determined at 40 mg/Kg,In vivo,,Mus musculus,,,,
6671,1,A,BAO_0000218,10090.0,17753,Plasma clearance of at 24 mg/Kg,In vivo,,Mus musculus,,,,
6672,1,A,BAO_0000218,10090.0,17753,Plasma clearance at 24 mg/Kg,In vivo,,Mus musculus,,,,
6673,1,A,BAO_0000218,10090.0,17753,Plasma clearance at 5 mg/Kg,In vivo,,Mus musculus,,,,
6674,1,A,BAO_0000218,10090.0,5727,Plasma clearance in mice,In vivo,,Mus musculus,,,,
6675,1,A,BAO_0000218,10090.0,2862,Plasma clearance value upon iv administration in mouse,In vivo,,Mus musculus,,,,
6676,1,A,BAO_0000218,10090.0,5980,Total plasma clearance in mice,In vivo,,Mus musculus,,Plasma,,
6677,1,A,BAO_0000218,10090.0,17592,Clearance in mouse,In vivo,,Mus musculus,,,,
6678,1,A,BAO_0000218,10090.0,17718,Clearance value was determined,In vivo,,Mus musculus,,,,
6679,1,A,BAO_0000218,10090.0,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,,,,
6680,1,P,BAO_0000100,,17384,Calculated partition coefficient (clogP),,,,,,,
6681,1,A,BAO_0000218,10090.0,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,In vivo,,Mus musculus,,,,
6682,1,A,BAO_0000218,10090.0,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,In vivo,,Mus musculus,,,,
6683,1,A,BAO_0000218,10090.0,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,,,,
6684,1,A,BAO_0000218,10090.0,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,In vivo,,Mus musculus,,,,
6685,1,A,BAO_0000218,10090.0,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,In vivo,,Mus musculus,,,,
6686,1,A,BAO_0000218,10090.0,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,,Mus musculus,,,,
6687,1,A,BAO_0000218,10090.0,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,In vivo,,Mus musculus,,,,
6688,1,A,BAO_0000218,10090.0,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,In vivo,,Mus musculus,,,,
6689,1,A,BAO_0000218,10090.0,17764,Cmax after peroral administration in mice at 2.4 uM/kg,In vivo,,Mus musculus,,,,
6690,1,A,BAO_0000218,10090.0,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,,Brain,,
6691,1,A,BAO_0000218,10090.0,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,,Kidney,,
6692,1,A,BAO_0000218,10090.0,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,,Liver,,
6693,1,A,BAO_0000218,10090.0,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,,Lung,,
6694,1,F,BAO_0000218,10090.0,17764,Cmax in mice at 18 uM/kg i.p. administration,In vivo,,Mus musculus,,,,
6695,1,F,BAO_0000218,10090.0,17764,Cmax in mice at 23 uM/kg i.v. administration,In vivo,,Mus musculus,,,,
6696,1,F,BAO_0000218,10090.0,17764,Cmax in mice at 24 uM/kg i.p. administration,In vivo,,Mus musculus,,,,
6697,1,F,BAO_0000218,10090.0,17764,Cmax in mice at 25 uM/kg i.p. administration,In vivo,,Mus musculus,,,,
6698,1,F,BAO_0000218,10090.0,17764,Cmax in mice at 26 uM/kg i.p. administration,In vivo,,Mus musculus,,,,
6699,1,A,BAO_0000218,10090.0,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,,Mus musculus,,Spleen,,
6700,1,A,BAO_0000218,10090.0,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,Mus musculus,,,,
6701,1,A,BAO_0000218,10090.0,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,,Mus musculus,,,,
6702,1,A,BAO_0000218,10090.0,5727,Cmax value was determined,In vivo,,Mus musculus,,,,
6703,1,A,BAO_0000218,10090.0,5951,Cmax value in IRC mice,In vivo,,Mus musculus,,,,
6704,1,A,BAO_0000218,10090.0,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,,Mus musculus,,,,
6705,1,A,BAO_0000218,10090.0,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,,Mus musculus,,,,
6706,1,A,BAO_0000218,10090.0,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,In vivo,,Mus musculus,,Plasma,,
6707,1,A,BAO_0000218,10090.0,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",In vivo,,Mus musculus,,Plasma,,
6708,1,A,BAO_0000218,10090.0,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,In vivo,,Mus musculus,,,,
6709,1,F,BAO_0000218,6277.0,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,,,,
6710,1,F,BAO_0000218,6277.0,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,,,,
6711,1,F,BAO_0000218,6277.0,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,,Acanthocheilonema viteae,,,,
6712,1,F,BAO_0000219,9606.0,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,,,Homo sapiens,,,A-375,
6713,1,B,BAO_0000249,10116.0,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,,Rattus norvegicus,,,,Brain membranes
6714,1,F,BAO_0000019,9606.0,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,,,Homo sapiens,,,,
6715,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,,,,,CHO,
6716,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,,,,CHO,
6717,1,F,BAO_0000219,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,,,,,CHO,
6718,1,F,BAO_0000219,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,,,,,CHO,
6719,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,,,,,CHO,
6720,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,,,,,CHO,
6721,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,,,,,CHO,
6722,1,F,BAO_0000219,9606.0,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,Homo sapiens,,,CHO,
6723,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,,,,,CHO,
6724,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,,,,,CHO,
6725,1,F,BAO_0000219,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,,,,,CHO,
6726,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,,,,,CHO,
6727,1,F,BAO_0000219,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,,,,,CHO,
6728,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,,,,,CHO,
6729,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,,,,CHO,
6730,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,,,,,CHO,
6731,1,F,BAO_0000219,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,,,,,CHO,
6732,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,,,,,CHO,
6733,1,F,BAO_0000219,,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,,,,,CHO,
6734,1,F,BAO_0000219,,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,,,,CHO,
6735,1,F,BAO_0000219,9986.0,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,,Oryctolagus cuniculus,,,A10,
6736,1,F,BAO_0000219,10116.0,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,,Rattus norvegicus,,,A10,
6737,1,F,BAO_0000219,10116.0,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,,Rattus norvegicus,,,A10,
6738,1,F,BAO_0000219,10116.0,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,,Rattus norvegicus,,,A10,
6739,1,F,BAO_0000219,10116.0,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,,Rattus norvegicus,,,A10,
6740,1,F,BAO_0000219,10116.0,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,,Rattus norvegicus,,,A10,
6741,1,F,BAO_0000219,10029.0,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,,Cricetulus griseus,,,CHO-AA8,
6742,1,F,BAO_0000219,10029.0,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,,Cricetulus griseus,,,CHO-AA8,
6743,1,F,BAO_0000219,10029.0,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,,Cricetulus griseus,,,CHO-AA8,
6744,1,F,BAO_0000219,10029.0,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,,Cricetulus griseus,,,CHO-AA8,
6745,1,F,BAO_0000219,10029.0,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,Cricetulus griseus,,,CHO-AA8,
6746,1,F,BAO_0000219,10029.0,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,,Cricetulus griseus,,,CHO-AA8,
6747,1,F,BAO_0000219,10029.0,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,,Cricetulus griseus,,,CHO-AA8,
6748,1,F,BAO_0000219,10029.0,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,,Cricetulus griseus,,,CHO-AA8,
6749,1,F,BAO_0000219,10029.0,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,,Cricetulus griseus,,,CHO-AA8,
6750,1,F,BAO_0000219,10029.0,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,,Cricetulus griseus,,,CHO-AA8,
6751,1,F,BAO_0000219,10029.0,13435,Inhibitory activity against aerobic growth of AA8 cells.,,,Cricetulus griseus,,,CHO-AA8,
6752,1,A,BAO_0000219,10029.0,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,Cricetulus griseus,,,CHO-AA8,
6753,1,F,BAO_0000219,10029.0,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,Cricetulus griseus,,,CHO-AA8,
6754,1,F,BAO_0000219,10029.0,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,Cricetulus griseus,,,CHO-AA8,
6755,1,F,BAO_0000219,10029.0,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,,Cricetulus griseus,,,CHO-AA8,
6756,1,F,BAO_0000219,10029.0,10368,Cytotoxicity against AA8 cell line,,,Cricetulus griseus,,,CHO-AA8,
6757,1,F,BAO_0000219,10029.0,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,,Cricetulus griseus,,,CHO-AA8,
6758,1,A,BAO_0000219,10029.0,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,Cricetulus griseus,,,CHO-AA8,
6759,1,F,BAO_0000219,10029.0,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,Cricetulus griseus,,,CHO-AA8,
6760,1,A,BAO_0000219,10029.0,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,Cricetulus griseus,,,CHO-AA8,
6761,1,F,BAO_0000219,10029.0,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,,Cricetulus griseus,,,CHO-AA8,
6762,1,F,BAO_0000219,10029.0,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,,Cricetulus griseus,,,CHO-AA8,
6763,1,F,BAO_0000219,10029.0,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,,Cricetulus griseus,,,CHO-AA8,
6764,1,F,BAO_0000218,10029.0,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,,Cricetulus griseus,,,,
6765,1,F,BAO_0000219,10029.0,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,,Cricetulus griseus,,,CHO-AA8,
6766,1,F,BAO_0000219,10029.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,,Cricetulus griseus,,,CHO-AA8,
6767,1,F,BAO_0000219,10029.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,,Cricetulus griseus,,,CHO-AA8,
6768,1,F,BAO_0000219,10029.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,,Cricetulus griseus,,,CHO-AA8,
6769,1,F,BAO_0000219,10029.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,,Cricetulus griseus,,,CHO-AA8,
6770,1,F,BAO_0000219,10029.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,,Cricetulus griseus,,,CHO-AA8,
6771,1,F,BAO_0000219,10029.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,,Cricetulus griseus,,,CHO-AA8,
6772,1,F,BAO_0000219,10029.0,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,,Cricetulus griseus,,,CHO-AA8,
6773,1,F,BAO_0000219,10029.0,11616,Concentration required to reduce AA8 cell survival by 10%,,,Cricetulus griseus,,,CHO-AA8,
6774,1,F,BAO_0000219,10029.0,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,,Cricetulus griseus,,,CHO-AA8,
6775,1,F,BAO_0000219,10029.0,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,,Cricetulus griseus,,,CHO-AA8,
6776,1,F,BAO_0000219,10029.0,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,,Cricetulus griseus,,,CHO-AA8,
6777,1,F,BAO_0000219,10029.0,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,,Cricetulus griseus,,,CHO-AA8,
6778,1,F,BAO_0000219,10029.0,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,,Cricetulus griseus,,,CHO-AA8,
6779,1,F,BAO_0000219,10029.0,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,,Cricetulus griseus,,,CHO-AA8,
6780,1,F,BAO_0000219,10029.0,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,,Cricetulus griseus,,,CHO-AA8,
6781,1,F,BAO_0000019,10029.0,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,Cricetulus griseus,,,,
6782,1,F,BAO_0000219,10029.0,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,,Cricetulus griseus,,,CHO-AA8,
6783,1,F,BAO_0000219,10029.0,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,,Cricetulus griseus,,,CHO-AA8,
6784,1,A,BAO_0000218,9615.0,16907,Half life period after 15 mg/kg iv dose in Dogs,In vivo,,Canis lupus familiaris,,,,
6785,1,A,BAO_0000218,9615.0,16907,Half life period after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,,,,
6786,1,A,BAO_0000218,9615.0,9579,Half life was measured after oral 2b administration (tested in 6 dogs),In vivo,,Canis lupus familiaris,,,,
6787,1,A,BAO_0000218,9615.0,9579,Half life was measured in dog after oral 17b administration,In vivo,,Canis lupus familiaris,,,,
6788,1,A,BAO_0000218,9615.0,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,In vivo,,Canis lupus familiaris,,,,
6789,1,A,BAO_0000218,9615.0,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,In vivo,,Canis lupus familiaris,,,,
6790,1,A,BAO_0000218,9615.0,16907,Tmax value after 15 mg/kg iv dose in Dogs,In vivo,,Canis lupus familiaris,,,,
6791,1,A,BAO_0000218,9615.0,16907,Tmax value after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,,,,
6792,1,A,BAO_0000218,9615.0,3184,Compound was evaluated for its half life when administered intravenously in dog,In vivo,,Canis lupus familiaris,,,,
6793,1,A,BAO_0000218,9615.0,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,,Canis lupus familiaris,,Plasma,,
6794,1,A,BAO_0000218,9615.0,6821,Elimination Half-life of compound was determined in dog,,,Canis lupus familiaris,,,,
6795,1,A,BAO_0000218,9615.0,17839,Half life of compound in dog following oral administration,In vivo,,Canis lupus familiaris,,,,
6796,1,A,BAO_0000218,9615.0,17267,Half life of compound was determined in dog,,,Canis lupus familiaris,,,,
6797,1,A,BAO_0000218,9615.0,4727,Half life of compound was determined in dog blood,,,Canis lupus familiaris,,Blood,,
6798,1,A,BAO_0000218,9615.0,5238,Half life after oral and iv dosing in dogs,In vivo,,Canis lupus familiaris,,,,
6799,1,A,BAO_0000218,9615.0,4942,Half life in dogs in hours,,,Canis lupus familiaris,,,,
6800,1,A,BAO_0000218,9615.0,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,In vivo,,Canis lupus familiaris,,,,
6801,1,A,BAO_0000218,9615.0,5130,t1/2 in dog after oral dose (1 mg/kg),In vivo,,Canis lupus familiaris,,,,
6802,1,A,BAO_0000218,9615.0,1475,Half life was evaluated in dog,,,Canis lupus familiaris,,,,
6803,1,A,BAO_0000218,9615.0,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,In vivo,,Canis lupus familiaris,,,,
6804,1,A,BAO_0000218,9615.0,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,In vivo,,Canis lupus familiaris,,,,
6805,1,A,BAO_0000218,9615.0,6084,Half life period (10 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,,,,
6806,1,A,BAO_0000218,9615.0,6084,Half life period (10 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,,,,
6807,1,A,BAO_0000218,9615.0,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,In vivo,,Canis lupus familiaris,,,,
6808,1,A,BAO_0000218,9615.0,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,In vivo,,Canis lupus familiaris,,,,
6809,1,A,BAO_0000218,9615.0,6084,Half life period in dog,,,Canis lupus familiaris,,,,
6810,1,A,BAO_0000218,9615.0,6241,Half life period in dogs after oral administration at 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
6811,1,A,BAO_0000218,9615.0,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,Canis lupus familiaris,,,,
6812,1,A,BAO_0000218,9615.0,6621,Half-life of compound was determined in dogs,,,Canis lupus familiaris,,,,
6813,1,A,BAO_0000218,9615.0,1696,Half-life in dog plasma,,,Canis lupus familiaris,,Plasma,,
6814,1,A,BAO_0000218,9615.0,17800,Half-life in mongrel dogs was determined,,,Canis lupus familiaris,,,,
6815,1,A,BAO_0000218,9615.0,17657,Half-life in dog upon oral administration,In vivo,,Canis lupus familiaris,,,,
6816,1,A,BAO_0000218,9615.0,17657,Half-life in dog upon oral administration; Unable to calculate,In vivo,,Canis lupus familiaris,,,,
6817,1,A,BAO_0000218,9615.0,4239,Half-life was measured in dog,,,Canis lupus familiaris,,,,
6818,1,A,BAO_0000218,9615.0,5985,Half-life was measured in dog,,,Canis lupus familiaris,,,,
6819,1,A,BAO_0000218,9615.0,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,,Canis lupus familiaris,,,,
6820,1,A,BAO_0000218,9615.0,5199,Oral half life was determined,In vivo,,Canis lupus familiaris,,,,
6821,1,A,BAO_0000218,9615.0,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,In vivo,,Canis lupus familiaris,,Plasma,,
6822,1,A,BAO_0000218,9615.0,1475,Plasma half life was evaluated,,,Canis lupus familiaris,,Plasma,,
6823,1,A,BAO_0000218,9615.0,1475,Plasma half life was evaluated in Dog,,,Canis lupus familiaris,,Plasma,,
6824,1,A,BAO_0000218,9615.0,1475,Plasma half life was evaluated in dog,,,Canis lupus familiaris,,Plasma,,
6825,1,A,BAO_0000218,9615.0,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,In vivo,,Canis lupus familiaris,,,,
6826,1,A,BAO_0000218,9615.0,4883,Tested for the half life value in dog,,,Canis lupus familiaris,,,,
6827,1,A,BAO_0000218,9615.0,4727,Maximum time at the dose of 2 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
6828,1,A,BAO_0000218,9615.0,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,Canis lupus familiaris,,,,
6829,1,A,BAO_0000218,9615.0,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,,Blood,,
6830,1,A,BAO_0000218,9615.0,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,,Blood,,
6831,1,A,BAO_0000218,9615.0,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
6832,1,A,BAO_0000218,9615.0,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,,Canis lupus familiaris,,,,
6833,1,A,BAO_0000218,9615.0,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,In vivo,,Canis lupus familiaris,,,,
6834,1,A,BAO_0000218,9615.0,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,,Canis lupus familiaris,,,,
6835,1,A,BAO_0000218,9615.0,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",In vivo,,Canis lupus familiaris,,,,
6836,1,A,BAO_0000218,9615.0,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,,Canis lupus familiaris,,Plasma,,
6837,1,A,BAO_0000218,9615.0,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,,Canis lupus familiaris,,Plasma,,
6838,1,A,BAO_0000218,9615.0,933,Time taken for maximum plasma concentration in dog,,,Canis lupus familiaris,,Plasma,,
6839,1,A,BAO_0000218,9615.0,16367,Time to reach Cmax after oral administration to dogs,In vivo,,Canis lupus familiaris,,,,
6840,1,A,BAO_0000218,9615.0,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,,Plasma,,
6841,1,A,BAO_0000218,9615.0,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,In vivo,,Canis lupus familiaris,,,,
6842,1,A,BAO_0000218,9615.0,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,,,,
6843,1,A,BAO_0000218,9615.0,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,,,,
6844,1,A,BAO_0000218,9615.0,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
6845,1,A,BAO_0000218,9615.0,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,In vivo,,Canis lupus familiaris,,,,
6846,1,A,BAO_0000218,10090.0,5969,In vivo Cmax in mice at dose of 100 mg/kg,In vivo,,Mus musculus,,,,
6847,1,A,BAO_0000218,10090.0,5969,In vivo Cmax in mice at dose of 50 mg/kg,In vivo,,Mus musculus,,,,
6848,1,A,BAO_0000218,10090.0,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,In vivo,,Mus musculus,,,,
6849,1,A,BAO_0000218,10090.0,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,,Mus musculus,,Plasma,,
6850,1,A,BAO_0000218,10090.0,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,In vivo,,Mus musculus,,Plasma,,
6851,1,A,BAO_0000218,10090.0,3132,Maximum concentration obtained in mouse plasma was determined,In vivo,,Mus musculus,,Plasma,,
6852,1,A,BAO_0000218,10090.0,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,In vivo,,Mus musculus,,Plasma,,
6853,1,A,BAO_0000218,10090.0,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,,Plasma,,
6854,1,A,BAO_0000218,10090.0,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,In vivo,,Mus musculus,,Plasma,,
6855,1,A,BAO_0000218,10090.0,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,In vivo,,Mus musculus,,Plasma,,
6856,1,A,BAO_0000218,10090.0,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,In vivo,,Mus musculus,,Plasma,,
6857,1,A,BAO_0000218,10090.0,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,In vivo,,Mus musculus,,Plasma,,
6858,1,A,BAO_0000218,10090.0,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,In vivo,,Mus musculus,,Plasma,,
6859,1,A,BAO_0000218,10090.0,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,In vivo,,Mus musculus,,Plasma,,
6860,1,A,BAO_0000218,10090.0,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,In vivo,,Mus musculus,,,,
6861,1,A,BAO_0000218,10090.0,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,In vivo,,Mus musculus,,,,
6862,1,A,BAO_0000218,10090.0,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,In vivo,,Mus musculus,,,,
6863,1,A,BAO_0000218,10090.0,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,In vivo,,Mus musculus,,,,
6864,1,A,BAO_0000218,10090.0,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,In vivo,,Mus musculus,,,,
6865,1,A,BAO_0000218,10090.0,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,In vivo,,Mus musculus,,,,
6866,1,A,BAO_0000218,10090.0,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,In vivo,,Mus musculus,,,,
6868,1,A,BAO_0000218,10090.0,5961,Cmax in male mice after 2 mg/kg oral dose,In vivo,,Mus musculus,,,,
6869,1,A,BAO_0000218,10090.0,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,In vivo,,Mus musculus,,,,
6870,1,A,BAO_0000218,10090.0,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,,Mus musculus,,,,
6871,1,A,BAO_0000218,10090.0,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,,Mus musculus,,,,
6872,1,A,BAO_0000218,10090.0,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,,Mus musculus,,,,
6873,1,A,BAO_0000218,10090.0,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,,Mus musculus,,,,
6874,1,A,BAO_0000218,10090.0,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,,Mus musculus,,,,
6875,1,A,BAO_0000218,10090.0,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,,Mus musculus,,,,
6876,1,A,BAO_0000218,10090.0,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,,Mus musculus,,,,
6877,1,A,BAO_0000218,10090.0,2862,Maximum concentration in plasma upon oral administration in mouse,,,Mus musculus,,Plasma,,
6878,1,A,BAO_0000218,10090.0,2675,Maximum plasma concentration was evaluated in mice after oral administration,,,Mus musculus,,Plasma,,
6879,1,A,BAO_0000218,10090.0,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,In vivo,,Mus musculus,,Plasma,,
6880,1,A,BAO_0000218,10090.0,5399,Dose at which the compound induced fecal excretion in mice,,,Mus musculus,,,,
6893,1,F,BAO_0000219,10116.0,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,,Rattus norvegicus,,,A10,
6894,1,F,BAO_0000219,10116.0,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,,Rattus norvegicus,,,A10,
6895,1,F,BAO_0000219,10116.0,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,,Rattus norvegicus,,,A10,
6896,1,F,BAO_0000219,10116.0,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,,Rattus norvegicus,,,A10,
6897,1,F,BAO_0000219,10116.0,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,,Rattus norvegicus,,,A10,
6898,1,F,BAO_0000219,9606.0,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,,Homo sapiens,,,A121,
6899,1,F,BAO_0000219,9606.0,10404,Anticancer activity against human ovarian carcinoma A121 cells,,,Homo sapiens,,,A121,
6900,1,F,BAO_0000219,9606.0,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,,Homo sapiens,,,A121,
6901,1,F,BAO_0000219,9606.0,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,,Homo sapiens,,,A121,
6902,1,F,BAO_0000219,9606.0,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,,,Homo sapiens,,,A121,
6903,1,F,BAO_0000219,9606.0,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,,Homo sapiens,,,A121,
6904,1,F,BAO_0000219,9606.0,1003,Cytotoxicity against human A121 ovarian cells,,,Homo sapiens,,,A121,
6905,1,F,BAO_0000219,9606.0,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,,Homo sapiens,,,A121,
6906,1,F,BAO_0000219,9606.0,12307,In vitro cytotoxicity against human ovarian carcinoma A21,,,Homo sapiens,,,A121,
6907,1,F,BAO_0000219,9606.0,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,,Homo sapiens,,,A121,
6908,1,F,BAO_0000219,9606.0,13370,Inhibitory activity of compound against human A121 ovarian cell line.,,,Homo sapiens,,,A121,
6909,1,F,BAO_0000219,9606.0,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,,Homo sapiens,,,A121,
6910,1,F,BAO_0000219,9606.0,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,,Homo sapiens,,,A121,
6911,1,F,BAO_0000219,9606.0,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,,Homo sapiens,,,A 172,
6912,1,F,BAO_0000219,9606.0,2037,In vitro cytotoxicity against A172 human tumor cell lines.,,,Homo sapiens,,,A 172,
6913,1,F,BAO_0000219,9606.0,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,,Homo sapiens,,,A 172,
6914,1,F,BAO_0000219,9606.0,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,,Homo sapiens,,,A 172,
6915,1,F,BAO_0000219,9606.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,,Homo sapiens,,,A 172,
6916,1,B,BAO_0000224,9615.0,8975,Association constant against A2 adenosine receptor,,,Canis lupus familiaris,,,,
6917,1,F,BAO_0000219,,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,,fish,,,A2,
6918,1,B,BAO_0000224,10116.0,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,,,Rattus norvegicus,,,,
6919,1,F,BAO_0000219,9606.0,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,,Homo sapiens,,,A204,
6920,1,F,BAO_0000219,9606.0,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,,Homo sapiens,,,A204,
6921,1,F,BAO_0000219,9606.0,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,,Homo sapiens,,,A2058,
6922,1,F,BAO_0000219,9606.0,13160,Growth inhibition against Human squamous cell line(A 253),,,Homo sapiens,,,A253 cell line,
6923,1,F,BAO_0000219,9606.0,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,,Homo sapiens,,,A253 cell line,
6924,1,F,BAO_0000219,9606.0,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,,Homo sapiens,,,A253 cell line,
6925,1,F,BAO_0000219,9606.0,15984,Growth inhibition of A253 cell lines.,,,Homo sapiens,,,A253 cell line,
6926,1,F,BAO_0000219,9606.0,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,,Homo sapiens,,,A253 cell line,
6927,1,F,BAO_0000219,9606.0,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,,Homo sapiens,,,A253 cell line,
6928,1,F,BAO_0000219,9606.0,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,,Homo sapiens,,,A253 cell line,
6929,1,F,BAO_0000219,9606.0,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,,Homo sapiens,,,A2780,
6930,1,F,BAO_0000219,9606.0,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,,Homo sapiens,,,A2780,
6931,1,F,BAO_0000219,9606.0,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,,Homo sapiens,,,A2780,
6932,1,F,BAO_0000219,9606.0,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),,,Homo sapiens,,,A2780,
6933,1,F,BAO_0000219,9606.0,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,,Homo sapiens,,,A2780,
6934,1,F,BAO_0000219,9606.0,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,,Homo sapiens,,,A2780,
6935,1,F,BAO_0000219,9606.0,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,,Homo sapiens,,,A2780,
6936,1,F,BAO_0000219,9606.0,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,,Homo sapiens,,,A2780,
6937,1,F,BAO_0000219,9606.0,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,,Homo sapiens,,,A2780,
6938,1,F,BAO_0000219,9606.0,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,,Homo sapiens,,,A2780,
6939,1,F,BAO_0000219,9606.0,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,,Homo sapiens,,,A2780,
6940,1,F,BAO_0000219,9606.0,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,,Homo sapiens,,,A2780,
6941,1,F,BAO_0000219,9606.0,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,,Homo sapiens,,,A2780,
6942,1,F,BAO_0000019,10029.0,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,Cricetulus griseus,,,,
6943,1,A,BAO_0000219,10029.0,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,,Cricetulus griseus,,,CHO-AA8,
6944,1,F,BAO_0000219,10029.0,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,,Cricetulus griseus,,,CHO-AA8,
6945,1,F,BAO_0000219,10029.0,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,,Cricetulus griseus,,,CHO-AA8,
6946,1,F,BAO_0000219,10029.0,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,,Cricetulus griseus,,,CHO-AA8,
6947,1,F,BAO_0000019,10029.0,11858,Growth inhibition against CHO-derived cell line AA8,,,Cricetulus griseus,,,,
6948,1,F,BAO_0000219,10029.0,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,,Cricetulus griseus,,,CHO-AA8,
6949,1,F,BAO_0000219,36483.0,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,,hampster,,,CHO-AA8,
6950,1,F,BAO_0000219,10029.0,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,,Cricetulus griseus,,,CHO-AA8,
6951,1,F,BAO_0000219,10029.0,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,,Cricetulus griseus,,,CHO-AA8,
6952,1,F,BAO_0000219,10029.0,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,,Cricetulus griseus,,,CHO-AA8,
6953,1,F,BAO_0000219,10029.0,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,,Cricetulus griseus,,,CHO-AA8,
6954,1,F,BAO_0000219,10029.0,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,,Cricetulus griseus,,,CHO-AA8,
6955,1,F,BAO_0000019,,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,,,,,
6956,1,F,BAO_0000019,,14837,Number of binding sites (n) of isolated serum protein AAG,,,,,,,
6957,1,B,BAO_0000225,,16037,Association constant for binding to AATT duplex,,,,,,,
6958,1,F,BAO_0000219,9606.0,16597,Inhibition of ABAE human fibroblast cell proliferation,,,Homo sapiens,,,ABAE,
6959,1,F,BAO_0000218,10090.0,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,,Mus musculus,,,AC755,
6960,1,F,BAO_0000218,9986.0,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,,Oryctolagus cuniculus,,,,
6961,1,F,BAO_0000218,9986.0,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,In vivo,,Oryctolagus cuniculus,,,,
6962,1,B,BAO_0000357,,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,,,,,
6963,1,B,BAO_0000357,,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,,,,,
6964,1,F,BAO_0000219,9606.0,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,,Homo sapiens,,,ACH-2 cell line,
6965,1,F,BAO_0000219,9606.0,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,,Homo sapiens,,,ACH-2 cell line,
6966,1,F,BAO_0000219,11676.0,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,,Human immunodeficiency virus 1,,,T cell line,
6967,1,F,BAO_0000219,11676.0,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,,Human immunodeficiency virus 1,,,T cell line,
6968,1,F,BAO_0000219,11676.0,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,,Human immunodeficiency virus 1,,,T cell line,
6969,1,F,BAO_0000219,9606.0,11843,Inhibition of growth of renal cancer ACHN cell line,,,Homo sapiens,,,ACHN,
6970,1,F,BAO_0000219,9606.0,16939,Inhibition of growth of ACHN renal cancer cell line,,,Homo sapiens,,,ACHN,
6971,1,F,BAO_0000219,9606.0,4782,Inhibitory concentration required against ACHN renal cancer cell line,,,Homo sapiens,,,ACHN,
6972,1,F,BAO_0000219,9606.0,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,,,Homo sapiens,,,ACHN,
6973,1,F,BAO_0000219,9606.0,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,,Homo sapiens,,,ACHN,
6974,1,F,BAO_0000219,9606.0,12858,Cytotoxic activity against ACHN Renal cancer cell line,,,Homo sapiens,,,ACHN,
6975,1,F,BAO_0000219,9606.0,17380,Cytotoxicity evaluation against ACHN renal cancer cells,,,Homo sapiens,,,ACHN,
6976,1,F,BAO_0000219,9606.0,5858,In vitro antitumor activity against human renal ACHN cell line,,,Homo sapiens,,,ACHN,
6977,1,F,BAO_0000219,9606.0,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,,Homo sapiens,,,ACHN,
6978,1,F,BAO_0000219,9606.0,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,,Homo sapiens,,,ACHN,
6979,1,F,BAO_0000219,9606.0,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,,Homo sapiens,,,ACHN,
6980,1,F,BAO_0000219,9606.0,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,,Homo sapiens,,,ACHN,
6981,1,F,BAO_0000219,9606.0,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,,Homo sapiens,,,ACHN,
6982,1,F,BAO_0000219,9606.0,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,,Homo sapiens,,,ACHN,
6983,1,F,BAO_0000219,9606.0,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,,Homo sapiens,,,ACHN,
6984,1,F,BAO_0000219,9606.0,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,,Homo sapiens,,,ACHN,
6985,1,F,BAO_0000219,9606.0,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,,Homo sapiens,,,ACHN,
6986,1,F,BAO_0000219,9606.0,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,,Homo sapiens,,,ACHN,
6987,1,F,BAO_0000219,9606.0,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,,Homo sapiens,,,ACHN,
6988,1,F,BAO_0000219,9606.0,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,,Homo sapiens,,,ACHN,
6989,1,F,BAO_0000219,9606.0,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,,Homo sapiens,,,ACHN,
6990,1,F,BAO_0000219,9606.0,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,,Homo sapiens,,,ACHN,
6991,1,A,BAO_0000218,9615.0,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,In vivo,,Canis lupus familiaris,,,,
6992,1,A,BAO_0000218,9615.0,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,,Canis lupus familiaris,,,,
6993,1,A,BAO_0000218,9615.0,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,Canis lupus familiaris,,,,
6994,1,A,BAO_0000218,9615.0,16907,Volume distribution after 15 mg/kg iv dose in Dogs,In vivo,,Canis lupus familiaris,,,,
6995,1,A,BAO_0000218,9615.0,16907,Volume distribution after 30 mg/kg po dose in Dogs,In vivo,,Canis lupus familiaris,,,,
6996,1,A,BAO_0000218,9615.0,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,In vivo,,Canis lupus familiaris,,,,
6997,1,A,BAO_0000218,9615.0,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
6998,1,A,BAO_0000218,9615.0,5472,Volume of distribution was evaluated in dog,In vivo,,Canis lupus familiaris,,,,
6999,1,A,BAO_0000218,9615.0,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
7000,1,A,BAO_0000218,9615.0,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,,Canis lupus familiaris,,,,
7001,1,A,BAO_0000218,9615.0,12500,The compound was tested for volume of distribution in dog,In vivo,,Canis lupus familiaris,,,,
7002,1,A,BAO_0000218,9615.0,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,In vivo,,Canis lupus familiaris,,,,
7003,1,A,BAO_0000218,9615.0,6227,Vd (1 mg/kg) was determined in dog (in vivo),In vivo,,Canis lupus familiaris,,,,
7004,1,A,BAO_0000218,9615.0,6227,Vd in dog,In vivo,,Canis lupus familiaris,,,,
7005,1,A,BAO_0000218,9615.0,4219,Volume distribution was determined,In vivo,,Canis lupus familiaris,,,,
7006,1,A,BAO_0000218,9615.0,1696,Volume of distribution in dog,In vivo,,Canis lupus familiaris,,,,
7007,1,A,BAO_0000218,9615.0,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,In vivo,,Canis lupus familiaris,,,,
7008,1,A,BAO_0000218,9615.0,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,,Canis lupus familiaris,,,,
7009,1,A,BAO_0000218,9615.0,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,,,,
7010,1,A,BAO_0000218,9615.0,4727,Volume distribution at the dose of 2 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
7011,1,A,BAO_0000218,9615.0,16367,Steady state volume of distribution was determined,In vivo,,Canis lupus familiaris,,,,
7012,1,A,BAO_0000218,9615.0,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,In vivo,,Canis lupus familiaris,,,,
7013,1,A,BAO_0000218,9615.0,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,,Canis lupus familiaris,,,,
7014,1,A,BAO_0000218,9615.0,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,,Canis lupus familiaris,,,,
7015,1,A,BAO_0000218,9615.0,16452,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,Canis lupus familiaris,,,,
7016,1,A,BAO_0000218,9615.0,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,,Canis lupus familiaris,,,,
7017,1,A,BAO_0000218,9615.0,4239,Pharmacokinetic property (vdss) was measured in dog,In vivo,,Canis lupus familiaris,,,,
7018,1,A,BAO_0000218,9615.0,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
7019,1,A,BAO_0000218,9615.0,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,In vivo,,Canis lupus familiaris,,,,
7020,1,A,BAO_0000218,9615.0,6057,Volume displacement was calculated in dog,In vivo,,Canis lupus familiaris,,,,
7021,1,A,BAO_0000218,9615.0,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
7022,1,A,BAO_0000218,9615.0,5505,Volume distribution constant was determined,In vivo,,Canis lupus familiaris,,,,
7023,1,A,BAO_0000218,9615.0,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
7024,1,A,BAO_0000218,9615.0,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,,Canis lupus familiaris,,,,
7025,1,A,BAO_0000218,9615.0,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,Canis lupus familiaris,,,,
7026,1,A,BAO_0000218,9615.0,15660,Volume distribution (Vdss) was measured in dog,In vivo,,Canis lupus familiaris,,,,
7027,1,A,BAO_0000218,9615.0,15660,Volume distribution (Vdss) was measured in dog,In vivo,,Canis lupus familiaris,,,,
7028,1,A,BAO_0000218,9615.0,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Canis lupus familiaris,,,,
7029,1,A,BAO_0000218,9615.0,5145,Volume of distribution in steady state was determined in dog,In vivo,,Canis lupus familiaris,,,,
7030,1,A,BAO_0000218,9615.0,6821,Volume of distribution of compound was determined in dog,In vivo,,Canis lupus familiaris,,,,
7031,1,A,BAO_0000218,9615.0,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,In vivo,,Canis lupus familiaris,,,,
7032,1,A,BAO_0000218,9615.0,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,,Canis lupus familiaris,,,,
7033,1,A,BAO_0000218,9615.0,15660,Volume of distribution (Vdss) was measured in dog,In vivo,,Canis lupus familiaris,,,,
7034,1,A,BAO_0000218,9615.0,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,,Canis lupus familiaris,,,,
7035,1,A,BAO_0000218,9615.0,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,,,,
7036,1,A,BAO_0000218,9615.0,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,,,,
7037,1,A,BAO_0000218,9615.0,11659,Maximum rate of depolarization of the upstroke of the action potential,,,Canis lupus familiaris,,,,
7038,1,A,BAO_0000218,9615.0,6448,Steady state volume distribution in dog,In vivo,,Canis lupus familiaris,,,,
7039,1,A,BAO_0000218,9615.0,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,In vivo,,Canis lupus familiaris,,,,
7040,1,A,BAO_0000218,9615.0,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,,Canis lupus familiaris,,,,
7041,1,A,BAO_0000218,9615.0,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,,Canis lupus familiaris,,,,
7042,1,A,BAO_0000218,9615.0,6535,Volume distribution in dog after administration of 1 mg/kg iv,In vivo,,Canis lupus familiaris,,,,
7043,1,A,BAO_0000218,9615.0,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,In vivo,,Canis lupus familiaris,,,,
7044,1,A,BAO_0000218,9615.0,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,,,,
7045,1,A,BAO_0000218,9615.0,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,In vivo,,Canis lupus familiaris,,,,
7046,1,A,BAO_0000218,9615.0,3639,Vss was determined,,,Canis lupus familiaris,,,,
7047,1,A,BAO_0000218,9615.0,3639,Vss in dog,,,Canis lupus familiaris,,,,
7048,1,A,BAO_0000218,9615.0,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
7049,1,A,BAO_0000218,9615.0,4942,Volume distribution in dogs,In vivo,,Canis lupus familiaris,,,,
7050,1,A,BAO_0000218,9615.0,17796,Volume of distribution in dog,In vivo,,Canis lupus familiaris,,,,
7051,1,A,BAO_0000218,9615.0,4883,Tested for the oral bioavailability in dog,In vivo,,Canis lupus familiaris,,,,
7060,1,A,BAO_0000218,10090.0,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,In vivo,,Mus musculus,,,,
7061,1,A,BAO_0000218,10090.0,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,In vivo,,Mus musculus,,,,
7062,1,A,BAO_0000218,10090.0,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,In vivo,,Mus musculus,,,,
7063,1,A,BAO_0000218,10090.0,4239,Bioavailability was measured in mouse,In vivo,,Mus musculus,,,,
7064,1,A,BAO_0000218,10090.0,17592,Bioavailability in mouse,In vivo,,Mus musculus,,,,
7065,1,A,BAO_0000218,10090.0,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,Mus musculus,,,,
7066,1,A,BAO_0000218,10090.0,2801,Bioavailability in mouse,In vivo,,Mus musculus,,,,
7067,1,A,BAO_0000218,10090.0,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,In vivo,,Mus musculus,,,,
7068,1,A,BAO_0000218,10090.0,17718,Oral bioavailability in mouse,In vivo,,Mus musculus,,,,
7069,1,A,BAO_0000218,10090.0,5727,Oral availability at 50 mg/kg po in male mice,In vivo,,Mus musculus,,,,
7070,1,A,BAO_0000218,10090.0,5302,Oral bioavailability in mouse (dose 10 mg/kg),In vivo,,Mus musculus,,,,
7071,1,A,BAO_0000218,10090.0,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,In vivo,,Mus musculus,,,,
7072,1,A,BAO_0000218,10090.0,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",In vivo,,Mus musculus,,,,
7074,1,A,BAO_0000218,10090.0,6091,Oral bioavailability in mouse,In vivo,,Mus musculus,,,,
7075,1,A,BAO_0000218,10090.0,6091,Oral bioavailability in vivo in mice;ND=Not determined,In vivo,,Mus musculus,,,,
7076,1,A,BAO_0000218,10090.0,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,In vivo,,Mus musculus,,,,
7077,1,A,BAO_0000218,10090.0,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),In vivo,,Mus musculus,,,,
7078,1,A,BAO_0000218,10090.0,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),In vivo,,Mus musculus,,,,
7079,1,A,BAO_0000218,10090.0,3802,Tested for bioavailability of the compound,In vivo,,Mus musculus,,,,
7080,1,A,BAO_0000218,10090.0,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,In vivo,,Mus musculus,,,,
7081,1,A,BAO_0000218,10090.0,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,,Mus musculus,,Plasma,,
7082,1,A,BAO_0000218,10090.0,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,,,Mus musculus,,Plasma,,
7083,1,A,BAO_0000218,10090.0,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,,Mus musculus,,Plasma,,
7084,1,A,BAO_0000218,10090.0,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,,Mus musculus,,Plasma,,
7085,1,A,BAO_0000218,10090.0,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,,Mus musculus,,Plasma,,
7086,1,F,BAO_0000218,10090.0,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,,Mus musculus,,,,
7087,1,A,BAO_0000218,10090.0,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,,Mus musculus,,,,
7088,1,A,BAO_0000218,10090.0,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,,Mus musculus,,,,
7089,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Blood,,
7090,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,,Blood,,
7091,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Blood,,
7092,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Blood,,
7093,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Blood,,
7094,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Blood,,
7095,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Blood,,
7096,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Bone,,
7097,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,Mus musculus,,Bone,,
7098,1,F,BAO_0000219,9606.0,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,,Homo sapiens,,,A2780,
7099,1,F,BAO_0000219,9606.0,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,,Homo sapiens,,,A2780,
7100,1,F,BAO_0000219,9606.0,2859,Compound was evaluated for cytotoxicity against A2780 cell line,,,Homo sapiens,,,A2780,
7101,1,F,BAO_0000219,9606.0,15688,Inhibition of A2780 cell clonogenic assay,,,Homo sapiens,,,A2780,
7102,1,F,BAO_0000219,9606.0,5642,Cytotoxic effect on ovarian cancer cell line (A2780),,,Homo sapiens,,,A2780,
7103,1,F,BAO_0000219,9606.0,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,,Homo sapiens,,,A2780,
7104,1,F,BAO_0000219,9606.0,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,,Homo sapiens,,,A2780,
7105,1,F,BAO_0000219,9606.0,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,,Homo sapiens,,,A2780,
7106,1,F,BAO_0000219,9606.0,17582,Antiproliferative activity against human A2780 cells,,,Homo sapiens,,,A2780,
7107,1,F,BAO_0000219,9606.0,17764,Inhibition of human A2780 cell proliferation,,,Homo sapiens,,,A2780,
7108,1,F,BAO_0000219,9606.0,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,,Homo sapiens,,,A2780,
7109,1,F,BAO_0000219,9606.0,17764,Inhibition of human A2780 cell proliferation (No data),,,Homo sapiens,,,A2780,
7110,1,F,BAO_0000219,9606.0,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,,Homo sapiens,,,A2780,
7111,1,F,BAO_0000219,9606.0,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,,,Homo sapiens,,,A2780,
7112,1,F,BAO_0000219,9606.0,17777,Growth inhibition against A2780 wild-type ovarian cell lines,,,Homo sapiens,,,A2780,
7113,1,F,BAO_0000219,9606.0,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,,Homo sapiens,,,A2780,
7114,1,F,BAO_0000019,9606.0,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,,Homo sapiens,,,,
7115,1,F,BAO_0000219,9606.0,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,,Homo sapiens,,,A2780,
7116,1,F,BAO_0000219,9606.0,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,,Homo sapiens,,,A2780,
7117,1,F,BAO_0000219,9606.0,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,,Homo sapiens,,,A2780,
7118,1,F,BAO_0000219,9606.0,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,,Homo sapiens,,,A2780,
7119,1,F,BAO_0000219,9606.0,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,,Homo sapiens,,,A2780,
7120,1,F,BAO_0000219,9606.0,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,,Homo sapiens,,,A2780,
7121,1,F,BAO_0000219,9606.0,15069,In vitro inhibition of human ovarian cell line A2780,,,Homo sapiens,,,A2780,
7122,1,F,BAO_0000219,9606.0,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,,Homo sapiens,,,A2780,
7123,1,F,BAO_0000219,9606.0,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,,Homo sapiens,,,A2780,
7124,1,F,BAO_0000219,9606.0,14553,Concentration required to inhibit A2780-cell growth by 50%,,,Homo sapiens,,,A2780,
7125,1,F,BAO_0000219,9606.0,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,,Homo sapiens,,,A2780,
7126,1,F,BAO_0000219,9606.0,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,,,Homo sapiens,,,A2780,
7127,1,F,BAO_0000219,9606.0,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,,Homo sapiens,,,A2780,
7128,1,F,BAO_0000219,9606.0,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,,Homo sapiens,,,A2780,
7129,1,F,BAO_0000219,9606.0,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,,Homo sapiens,,,A2780,
7130,1,F,BAO_0000219,9606.0,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,,Homo sapiens,,,A2780,
7131,1,F,BAO_0000219,9606.0,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,,,Homo sapiens,,,A2780,
7132,1,F,BAO_0000219,9606.0,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,,Homo sapiens,,,A2780,
7133,1,F,BAO_0000219,9606.0,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,,Homo sapiens,,,A2780,
7134,1,F,BAO_0000219,9606.0,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,,Homo sapiens,,,A2780,
7135,1,F,BAO_0000219,9606.0,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,,Homo sapiens,,,A2780,
7136,1,F,BAO_0000219,9606.0,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,,Homo sapiens,,,A2780,
7137,1,F,BAO_0000219,9606.0,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,,Homo sapiens,,,A2780,
7138,1,F,BAO_0000219,9606.0,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,,Homo sapiens,,,A2780,
7139,1,F,BAO_0000219,9606.0,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,,Homo sapiens,,,A2780,
7140,1,F,BAO_0000219,9606.0,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,,Homo sapiens,,,A2780,
7141,1,F,BAO_0000219,9606.0,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,,Homo sapiens,,,A2780,
7142,1,F,BAO_0000219,9606.0,12989,In vitro antitumor activity against A2780 cell line.,,,Homo sapiens,,,A2780,
7143,1,F,BAO_0000219,9606.0,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,,Homo sapiens,,,A2780,
7144,1,F,BAO_0000219,9606.0,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,,Homo sapiens,,,A2780,
7145,1,F,BAO_0000219,9606.0,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,,Homo sapiens,,,ACHN,
7146,1,F,BAO_0000219,9606.0,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,,,Homo sapiens,,,ACHN,
7147,1,F,BAO_0000219,9606.0,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,,Homo sapiens,,,ACHN,
7148,1,F,BAO_0000219,9606.0,17376,In vitro lethal concentration against most sensitive ACHN cell line,,,Homo sapiens,,,ACHN,
7149,1,F,BAO_0000219,9606.0,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,,,Homo sapiens,,,ACHN,
7150,1,F,BAO_0000219,9606.0,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,,,Homo sapiens,,,ACHN,
7151,1,F,BAO_0000219,9606.0,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,,Homo sapiens,,,ACHN,
7152,1,F,BAO_0000219,9606.0,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,,Homo sapiens,,,ACHN,
7153,1,F,BAO_0000219,9606.0,2806,In vitro anticancer activity against ACHN renal cancer cell line,,,Homo sapiens,,,ACHN,
7154,1,F,BAO_0000219,9606.0,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,,Homo sapiens,,,ACHN,
7155,1,F,BAO_0000219,9606.0,16364,Percent selectivity was evaluated in renal ACHN cell lines,,,Homo sapiens,,,ACHN,
7156,1,F,BAO_0000219,9606.0,13859,In vitro inhibitory activity against renal ACHN cancer cell line,,,Homo sapiens,,,ACHN,
7157,1,F,BAO_0000219,9606.0,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,,,Homo sapiens,,,ACHN,
7158,1,F,BAO_0000219,9606.0,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,,Homo sapiens,,,ACHN,
7159,1,F,BAO_0000219,9606.0,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,,Homo sapiens,,,ACHN,
7160,1,F,BAO_0000219,9606.0,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,,Homo sapiens,,,ACHN,
7161,1,F,BAO_0000219,9606.0,12888,Cytotoxic effect on renal cancer line ACHN,,,Homo sapiens,,,ACHN,
7162,1,F,BAO_0000219,9606.0,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,,Homo sapiens,,,ACHN,
7163,1,F,BAO_0000219,9606.0,3381,In vitro inhibition of Renal Cancer ACHN cell lines,,,Homo sapiens,,,ACHN,
7164,1,F,BAO_0000219,9606.0,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,,,Homo sapiens,,,ACHN,
7165,1,F,BAO_0000219,9606.0,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,,,Homo sapiens,,,ACHN,
7166,1,F,BAO_0000219,9606.0,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,,Homo sapiens,,,ACHN,
7167,1,F,BAO_0000219,9606.0,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,,Homo sapiens,,,ACHN,
7168,1,F,BAO_0000219,9606.0,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,,Homo sapiens,,,ACHN,
7169,1,F,BAO_0000219,9606.0,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,,Homo sapiens,,,ACHN,
7170,1,F,BAO_0000219,9606.0,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,,Homo sapiens,,,ACHN,
7171,1,F,BAO_0000219,9606.0,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,,Homo sapiens,,,ACHN,
7172,1,F,BAO_0000219,9606.0,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,,Homo sapiens,,,ACHN,
7173,1,A,BAO_0000019,,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,
7174,1,F,BAO_0000019,,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,,,,,
7175,1,F,BAO_0000218,10358.0,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,,Cytomegalovirus,,,HEL,
7176,1,F,BAO_0000218,10358.0,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,,Cytomegalovirus,,,,
7177,1,B,BAO_0000357,,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,,,,,
7178,1,B,BAO_0000357,,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,,,,,
7179,1,F,BAO_0000219,9913.0,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,,Bos taurus,,,ADDP cell line,
7180,1,F,BAO_0000219,10090.0,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,,Mus musculus,,,ADJ/PC6,
7181,1,F,BAO_0000219,10090.0,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,,Mus musculus,,,ADJ/PC6,
7182,1,F,BAO_0000219,10090.0,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,,Mus musculus,,,ADJ/PC6,
7183,1,F,BAO_0000219,10090.0,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,,Mus musculus,,,ADJ/PC6,
7184,1,A,BAO_0000219,10090.0,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,,Mus musculus,,,ADJ/PC6,
7185,1,F,BAO_0000219,10090.0,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,,Mus musculus,,,ADJ/PC6,
7186,1,F,BAO_0000019,10090.0,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,,Mus musculus,,,,
7187,1,F,BAO_0000019,10090.0,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,,Mus musculus,,,,
7188,1,F,BAO_0000019,10090.0,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,,Mus musculus,,,,
7189,1,A,BAO_0000218,1423.0,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),In vivo,,Bacillus subtilis,,,,
7190,1,A,BAO_0000218,9615.0,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,,,Canis lupus familiaris,,Plasma,,
7191,1,A,BAO_0000218,9615.0,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,,,Canis lupus familiaris,,Plasma,,
7192,1,A,BAO_0000218,9615.0,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,,,,
7193,1,A,BAO_0000218,9615.0,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,,,,
7194,1,A,BAO_0000218,9615.0,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,,,,
7195,1,A,BAO_0000218,9615.0,3184,Compound was evaluated for its clearance when administered intravenously in dog,In vivo,,Canis lupus familiaris,,,,
7196,1,A,BAO_0000218,9615.0,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,,,,
7197,1,A,BAO_0000218,9615.0,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,,Canis lupus familiaris,,,,
7198,1,P,BAO_0000100,,4219,Calculated partition coefficient (clogP),,,,,,,
7199,1,A,BAO_0000218,9615.0,3748,Half life in dog,,,Canis lupus familiaris,,,,
7200,1,A,BAO_0000218,9615.0,3132,Time taken for EC90 was determined when tested in dog,,,Canis lupus familiaris,,,,
7201,1,A,BAO_0000218,9615.0,4219,Half life (iv) was determined,,,Canis lupus familiaris,,,,
7202,1,A,BAO_0000218,9615.0,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,Canis lupus familiaris,,Liver,,
7203,1,A,BAO_0000218,9615.0,6057,Area under the curve was calculated in dog after iv administration,,,Canis lupus familiaris,,,,
7204,1,A,BAO_0000218,9615.0,6057,Area under the curve was calculated in dog after peroral administration,,,Canis lupus familiaris,,,,
7205,1,A,BAO_0000218,9615.0,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,,Canis lupus familiaris,,,,
7206,1,A,BAO_0000218,9615.0,3639,pKa was evaluated in dog,,,Canis lupus familiaris,,,,
7207,1,A,BAO_0000218,9615.0,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,,Canis lupus familiaris,,,,
7208,1,A,BAO_0000218,9615.0,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,,,,
7209,1,A,BAO_0000218,9615.0,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,Canis lupus familiaris,,,,
7210,1,A,BAO_0000218,9615.0,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,,Canis lupus familiaris,,,,
7211,1,A,BAO_0000218,9615.0,3624,Compound was evaluated for the half-life (t 1/2) in hours,,,Canis lupus familiaris,,,,
7212,1,A,BAO_0000218,9615.0,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,,Blood,,
7213,1,A,BAO_0000218,9615.0,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,,Canis lupus familiaris,,Blood,,
7214,1,A,BAO_0000218,9615.0,4709,Half life after intravenous administration of 1 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
7215,1,A,BAO_0000218,9615.0,15660,Half life was measured in dog,,,Canis lupus familiaris,,,,
7216,1,A,BAO_0000218,9615.0,5302,Half life period in dog after 5 mg/kg dose,In vivo,,Canis lupus familiaris,,,,
7217,1,A,BAO_0000218,9615.0,17791,Half life period was evaluated in dog; 4-4.8,,,Canis lupus familiaris,,,,
7218,1,A,BAO_0000218,9615.0,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,Canis lupus familiaris,,,,
7219,1,A,BAO_0000218,9615.0,4257,Half-life was determined in dog after a3 mg/kg of iv dose,In vivo,,Canis lupus familiaris,,,,
7220,1,A,BAO_0000218,9615.0,3771,Half-life was determined,,,Canis lupus familiaris,,,,
7221,1,A,BAO_0000218,9615.0,6305,Half life in dogs,,,Canis lupus familiaris,,,,
7222,1,A,BAO_0000218,9615.0,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,In vivo,,Canis lupus familiaris,,Plasma,,
7223,1,A,BAO_0000218,9615.0,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,In vivo,,Canis lupus familiaris,,,,
7224,1,A,BAO_0000218,9615.0,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,In vivo,,Canis lupus familiaris,,,,
7225,1,A,BAO_0000218,9615.0,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,In vivo,,Canis lupus familiaris,,,,
7226,1,A,BAO_0000218,9615.0,4839,Compound was tested for half life in dog,,,Canis lupus familiaris,,,,
7227,1,A,BAO_0000218,9615.0,4839,Compound was tested for its half life in dog,,,Canis lupus familiaris,,,,
7228,1,A,BAO_0000218,9615.0,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,,Canis lupus familiaris,,,,
7229,1,A,BAO_0000218,9615.0,17839,Half life of compound in dog was determined,,,Canis lupus familiaris,,,,
7230,1,A,BAO_0000218,9615.0,4219,Half life (iv) was determined,In vivo,,Canis lupus familiaris,,,,
7231,1,A,BAO_0000218,9615.0,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,,Canis lupus familiaris,,Blood,,
7232,1,A,BAO_0000218,9615.0,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,,Canis lupus familiaris,,Plasma,,
7233,1,F,BAO_0000218,9615.0,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,,Canis lupus familiaris,,Plasma,,
7234,1,A,BAO_0000218,9615.0,4453,Half life in dog,,,Canis lupus familiaris,,,,
7235,1,A,BAO_0000218,9615.0,6535,Half life in dog plasma,,,Canis lupus familiaris,,Plasma,,
7236,1,A,BAO_0000218,9615.0,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,In vivo,,Canis lupus familiaris,,Plasma,,
7237,1,A,BAO_0000218,9615.0,6535,Half life in dog plasma after administration of 1 mg/kg iv,In vivo,,Canis lupus familiaris,,Plasma,,
7238,1,A,BAO_0000218,9615.0,3132,Half life in dog plasma was determined at dose 10 mg/kg,In vivo,,Canis lupus familiaris,,Plasma,,
7239,1,A,BAO_0000218,9615.0,5374,Half life in dog was determined,,,Canis lupus familiaris,,,,
7240,1,A,BAO_0000218,9615.0,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,,Canis lupus familiaris,,,,
7241,1,A,BAO_0000218,9615.0,16907,Half life upon exposure to human plasma,,,Canis lupus familiaris,,Plasma,,
7242,1,A,BAO_0000218,9615.0,6057,Half life was calculated in dog,,,Canis lupus familiaris,,,,
7243,1,A,BAO_0000218,9615.0,5006,Half life was determined,,,Canis lupus familiaris,,,,
7244,1,A,BAO_0000218,9615.0,5473,Half life was determined,,,Canis lupus familiaris,,,,
7245,1,A,BAO_0000218,9615.0,4368,Half life by intravenous administration of 1.2 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
7246,1,A,BAO_0000218,9615.0,6448,Half life in dog,,,Canis lupus familiaris,,,,
7247,1,A,BAO_0000218,9615.0,4353,Half life in dog after intra venous administration of the compound,,,Canis lupus familiaris,,,,
7248,1,A,BAO_0000218,9615.0,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,,,Canis lupus familiaris,,,,
7249,1,A,BAO_0000218,9615.0,4353,Half life in dog after po administration of the compound,In vivo,,Canis lupus familiaris,,,,
7250,1,A,BAO_0000218,9615.0,4353,Half life in dog after po administration of the compound; ND means Not determined,In vivo,,Canis lupus familiaris,,,,
7251,1,A,BAO_0000218,9615.0,6265,Half life in dog at the single oral dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
7252,1,A,BAO_0000218,9615.0,5006,Half life in dogs,,,Canis lupus familiaris,,,,
7253,1,A,BAO_0000218,9615.0,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,In vivo,,Canis lupus familiaris,,,,
7254,1,A,BAO_0000218,9615.0,405,Half life in rat,,,Canis lupus familiaris,,,,
7255,1,A,BAO_0000218,9615.0,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,,Canis lupus familiaris,,,,
7256,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Bone,,
7257,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Bone,,
7258,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Bone,,
7259,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Bone,,
7260,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Bone,,
7261,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Gut,,
7262,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,,Gut,,
7263,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Gut,,
7264,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Gut,,
7265,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Gut,,
7266,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Gut,,
7267,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Gut,,
7268,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Heart,,
7269,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,,Heart,,
7270,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Heart,,
7271,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Heart,,
7272,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Heart,,
7273,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Heart,,
7274,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Heart,,
7275,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Kidney,,
7276,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,Mus musculus,,Kidney,,
7277,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Kidney,,
7278,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Kidney,,
7279,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Kidney,,
7280,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Kidney,,
7281,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Kidney,,
7282,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Liver,,
7283,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,,Liver,,
7284,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Liver,,
7285,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Liver,,
7286,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Liver,,
7287,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Liver,,
7288,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Liver,,
7289,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Lung,,
7290,1,F,BAO_0000219,9606.0,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),,,Homo sapiens,,,A2780,
7291,1,F,BAO_0000219,9606.0,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,,Homo sapiens,,,A2780,
7292,1,F,BAO_0000219,9606.0,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,,Homo sapiens,,,A2780,
7293,1,F,BAO_0000219,9606.0,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,,Homo sapiens,,,A2780,
7294,1,F,BAO_0000219,9606.0,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,,Homo sapiens,,,A2780,
7295,1,F,BAO_0000219,9606.0,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,,Homo sapiens,,,A2780,
7296,1,F,BAO_0000219,9606.0,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,,Homo sapiens,,,A2780,
7297,1,F,BAO_0000219,9606.0,17270,In vitro cytotoxicity against A2780 cell line,,,Homo sapiens,,,A2780,
7298,1,F,BAO_0000219,9606.0,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,,Homo sapiens,,,A2780,
7299,1,F,BAO_0000219,9606.0,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,,Homo sapiens,,,A2780,
7300,1,F,BAO_0000218,9606.0,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,,Homo sapiens,,,A2780,
7301,1,F,BAO_0000219,9606.0,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,,Homo sapiens,,,A2780,
7302,1,F,BAO_0000219,9606.0,16936,Inhibition of tubulin polymerization in analogy of ca.,,,Homo sapiens,,,A2780,
7303,1,F,BAO_0000219,9606.0,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,,Homo sapiens,,,A2780,
7304,1,F,BAO_0000219,9606.0,6181,Cytotoxic effect in ovarian cancer cell line (A2780),,,Homo sapiens,,,A2780,
7305,1,F,BAO_0000219,9606.0,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,,Homo sapiens,,,A2780,
7306,1,F,BAO_0000219,9606.0,4840,Tested for the cytotoxicity in A2780 ovarian cell line,,,Homo sapiens,,,A2780,
7307,1,F,BAO_0000219,9606.0,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,,Homo sapiens,,,A2780,
7308,1,F,BAO_0000219,9606.0,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,,Homo sapiens,,,A2780,
7309,1,F,BAO_0000219,,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,,,,,A2780cisR,
7310,1,F,BAO_0000219,,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,,,,A2780cisR,
7311,1,F,BAO_0000219,,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,,,,,A2780cisR,
7312,1,F,BAO_0000219,,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,,,,,A2780cisR,
7313,1,F,BAO_0000218,9606.0,17753,In vivo log of cells killed after administration of compound in A2780 cell line,,,Homo sapiens,,,A2780,
7314,1,F,BAO_0000218,9606.0,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,In vivo,,Homo sapiens,,,A2780,
7315,1,F,BAO_0000219,9606.0,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,,Homo sapiens,,,A2780,
7316,1,F,BAO_0000219,9606.0,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,,Homo sapiens,,,A2780,
7317,1,F,BAO_0000219,9606.0,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,,Homo sapiens,,,A2780,
7318,1,F,BAO_0000219,9606.0,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,,Homo sapiens,,,A2780,
7319,1,F,BAO_0000218,9606.0,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,,Homo sapiens,,,A2780,
7320,1,F,BAO_0000219,9606.0,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,,Homo sapiens,,,A2780,
7321,1,F,BAO_0000219,9606.0,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,,Homo sapiens,,,A2780,
7322,1,F,BAO_0000219,9606.0,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,,Homo sapiens,,,A2780,
7323,1,F,BAO_0000219,9606.0,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,,Homo sapiens,,,A2780,
7324,1,F,BAO_0000219,9606.0,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,,Homo sapiens,,,A2780,
7325,1,F,BAO_0000219,9606.0,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,,Homo sapiens,,,A2780,
7326,1,F,BAO_0000219,9606.0,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,,Homo sapiens,,,A2780,
7327,1,F,BAO_0000219,9606.0,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,,Homo sapiens,,,A2780,
7328,1,F,BAO_0000219,9606.0,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,,Homo sapiens,,,A2780,
7329,1,F,BAO_0000219,9606.0,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,Homo sapiens,,,A2780,
7330,1,F,BAO_0000219,9606.0,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,Homo sapiens,,,A2780,
7331,1,F,BAO_0000219,9606.0,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,Homo sapiens,,,A2780,
7332,1,F,BAO_0000219,10090.0,17737,In vitro antiproliferative activity against A2780 cell line,,,Mus musculus,,,A2780,
7333,1,F,BAO_0000219,10090.0,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,,Mus musculus,,,A2780,
7334,1,F,BAO_0000219,9606.0,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,,Homo sapiens,,,A2780,
7335,1,F,BAO_0000219,9606.0,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,,Homo sapiens,,,A2780,
7336,1,A,BAO_0000218,9615.0,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,,,Canis lupus familiaris,,,,
7337,1,A,BAO_0000218,9615.0,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,In vivo,,Canis lupus familiaris,,,,
7338,1,A,BAO_0000019,9527.0,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,Cercopithecidae,,,,
7339,1,A,BAO_0000218,9527.0,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,,Plasma,,
7340,1,A,BAO_0000218,9527.0,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,Cercopithecidae,,Plasma,,
7341,1,A,BAO_0000218,9541.0,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,,Macaca fascicularis,,,,
7342,1,A,BAO_0000218,9541.0,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,In vivo,,Macaca fascicularis,,,,
7343,1,A,BAO_0000218,9541.0,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,,Macaca fascicularis,,,,
7344,1,A,BAO_0000218,10116.0,4256,Oral Bioavailability in rat,In vivo,,Rattus norvegicus,,,,
7345,1,A,BAO_0000218,9527.0,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,Cercopithecidae,,,,
7346,1,A,BAO_0000218,9527.0,5302,Area under curve value in monkey at a dose of 5 mg/kg,,,Cercopithecidae,,,,
7347,1,A,BAO_0000218,9527.0,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,,Cercopithecidae,,,,
7348,1,A,BAO_0000019,9527.0,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,,Cercopithecidae,,,,
7349,1,A,BAO_0000019,9527.0,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,,Cercopithecidae,,,,
7350,1,A,BAO_0000019,9527.0,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,,Cercopithecidae,,,,
7351,1,A,BAO_0000218,9527.0,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,,Cercopithecidae,,,,
7352,1,A,BAO_0000218,9527.0,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,,Cercopithecidae,,,,
7353,1,A,BAO_0000218,9527.0,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,,Cercopithecidae,,,,
7354,1,A,BAO_0000218,9527.0,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,Cercopithecidae,,,,
7355,1,A,BAO_0000019,9527.0,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,Cercopithecidae,,,,
7356,1,A,BAO_0000218,9527.0,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,,Cercopithecidae,,,,
7357,1,A,BAO_0000218,9527.0,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,,Cercopithecidae,,,,
7358,1,A,BAO_0000218,9527.0,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,,Cercopithecidae,,,,
7359,1,A,BAO_0000218,9527.0,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,,Cercopithecidae,,,,
7360,1,A,BAO_0000218,9527.0,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),In vivo,,Cercopithecidae,,,,
7361,1,A,BAO_0000218,9527.0,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,,Cercopithecidae,,,,
7362,1,A,BAO_0000218,9527.0,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,Cercopithecidae,,,,
7363,1,A,BAO_0000218,9527.0,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,Cercopithecidae,,,,
7364,1,A,BAO_0000019,9527.0,17409,Binding towards monkey plasma protein at 10 uM,,,Cercopithecidae,,,,
7365,1,A,BAO_0000019,9527.0,17409,Binding towards monkey plasma protein at 100 uM,,,Cercopithecidae,,,,
7366,1,A,BAO_0000218,9527.0,1052,Apparent bioavailability in squirrel monkey was determined,In vivo,,Cercopithecidae,,,,
7367,1,A,BAO_0000218,9527.0,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,,Cercopithecidae,,,,
7368,1,A,BAO_0000218,9443.0,17509,Bioavailability in monkey (dose 2 mg/kg),In vivo,,monkey,,,,
7369,1,A,BAO_0000218,9527.0,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,In vivo,,Cercopithecidae,,,,
7370,1,A,BAO_0000218,9527.0,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,,,,
7371,1,A,BAO_0000218,9443.0,11219,Bioavailability in monkey (i.d. dosing),In vivo,,monkey,,,,
7372,1,A,BAO_0000218,9527.0,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,In vivo,,Cercopithecidae,,,,
7373,1,A,BAO_0000019,9527.0,17796,Clearance of the drug was measured in cynomolgus,,,Cercopithecidae,,,,
7374,1,A,BAO_0000218,9527.0,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,In vivo,,Cercopithecidae,,,,
7375,1,A,BAO_0000218,9527.0,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,,Cercopithecidae,,,,
7376,1,A,BAO_0000218,9544.0,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,Macaca mulatta,,Plasma,,
7377,1,A,BAO_0000218,9527.0,17267,Plasma clearance in rhesus monkey was determined,In vivo,,Cercopithecidae,,,,
7378,1,A,BAO_0000218,9527.0,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,In vivo,,Cercopithecidae,,,,
7379,1,A,BAO_0000218,9527.0,5922,Plasma clearance in cynomolgus monkey,In vivo,,Cercopithecidae,,,,
7380,1,A,BAO_0000218,9527.0,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,Cercopithecidae,,,,
7381,1,A,BAO_0000218,9527.0,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,In vivo,,Cercopithecidae,,,,
7382,1,A,BAO_0000218,9527.0,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,In vivo,,Cercopithecidae,,,,
7383,1,A,BAO_0000218,9527.0,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,,Cercopithecidae,,,,
7384,1,A,BAO_0000218,9527.0,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,,Cercopithecidae,,,,
7385,1,A,BAO_0000218,9527.0,4578,Tested for Clearance upon iv administration to african green monkey,In vivo,,Cercopithecidae,,,,
7386,1,A,BAO_0000218,9527.0,17592,Clearance in monkey,In vivo,,Cercopithecidae,,,,
7387,1,A,BAO_0000218,9615.0,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,,,,
7388,1,A,BAO_0000218,9615.0,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,Canis lupus familiaris,,,,
7389,1,A,BAO_0000218,9615.0,16367,Half life was evaluated after intravenous administration to dogs,In vivo,,Canis lupus familiaris,,,,
7390,1,A,BAO_0000218,9615.0,5472,Half life was evaluated in dog,,,Canis lupus familiaris,,,,
7391,1,A,BAO_0000218,9615.0,5474,Half life was evaluated in dog,,,Canis lupus familiaris,,,,
7392,1,A,BAO_0000218,9615.0,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
7393,1,A,BAO_0000218,9615.0,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),In vivo,,Canis lupus familiaris,,,,
7394,1,A,BAO_0000218,9615.0,6227,Half life period after intravenous administration in dog,In vivo,,Canis lupus familiaris,,,,
7395,1,A,BAO_0000218,9615.0,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,In vivo,,Canis lupus familiaris,,,,
7396,1,A,BAO_0000218,9615.0,4527,Half life period at a dose of 1 uM/kg in dog was determined,,,Canis lupus familiaris,,,,
7397,1,A,BAO_0000218,9615.0,5668,Half life period was determine after peroral administration at 10 mpk in dog,In vivo,,Canis lupus familiaris,,,,
7398,1,A,BAO_0000218,9615.0,5668,Half life period was determine after peroral administration at 5 mpk in dog,In vivo,,Canis lupus familiaris,,,,
7399,1,A,BAO_0000218,9615.0,3854,Half life period was determined,,,Canis lupus familiaris,,,,
7400,1,A,BAO_0000218,9615.0,5505,Half life period was determined,,,Canis lupus familiaris,,,,
7401,1,A,BAO_0000218,9615.0,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,In vivo,,Canis lupus familiaris,,,,
7402,1,A,BAO_0000218,9615.0,1918,Half life period was evaluated in dog,,,Canis lupus familiaris,,,,
7403,1,A,BAO_0000218,9615.0,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,,Canis lupus familiaris,,,,
7404,1,A,BAO_0000218,9615.0,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,,Canis lupus familiaris,,,,
7405,1,A,BAO_0000218,9615.0,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,,Canis lupus familiaris,,,,
7406,1,A,BAO_0000218,9615.0,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
7407,1,A,BAO_0000218,9615.0,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,In vivo,,Canis lupus familiaris,,,,
7408,1,A,BAO_0000218,9615.0,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,,Canis lupus familiaris,,,,
7409,1,A,BAO_0000218,9615.0,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,,Canis lupus familiaris,,,,
7410,1,A,BAO_0000218,9615.0,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,,Canis lupus familiaris,,,,
7411,1,A,BAO_0000218,9615.0,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
7412,1,A,BAO_0000218,9615.0,5210,Half-life of compound in plasma of dog was determined,,,Canis lupus familiaris,,Plasma,,
7413,1,A,BAO_0000218,9615.0,5210,Half-life of compound was determined in dogs,,,Canis lupus familiaris,,,,
7414,1,A,BAO_0000218,9615.0,2959,Half-life after administration of 4 mg/Kg oral dose in dog,In vivo,,Canis lupus familiaris,,,,
7415,1,A,BAO_0000218,9615.0,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,In vivo,,Canis lupus familiaris,,,,
7416,1,A,BAO_0000218,9615.0,5064,Half-life in Dog,,,Canis lupus familiaris,,,,
7417,1,A,BAO_0000218,9615.0,5147,Half-life in Dog,,,Canis lupus familiaris,,,,
7418,1,A,BAO_0000218,9615.0,5145,Half-life in dog,,,Canis lupus familiaris,,,,
7419,1,A,BAO_0000218,9615.0,6123,Half-life in dog after oral administration at 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
7420,1,A,BAO_0000218,9615.0,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,In vivo,,Canis lupus familiaris,,,,
7421,1,A,BAO_0000218,9615.0,4333,Half-life in dogs,,,Canis lupus familiaris,,,,
7422,1,A,BAO_0000218,9615.0,4333,Half-life in dogs; ND indicates not determined,,,Canis lupus familiaris,,,,
7423,1,A,BAO_0000218,9615.0,12500,Half-life in plasma of dog,,,Canis lupus familiaris,,Plasma,,
7424,1,A,BAO_0000218,9615.0,12500,Half-life in plasma of dog at dose of 3-10 mgkg,,,Canis lupus familiaris,,Plasma,,
7425,1,A,BAO_0000218,9615.0,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
7426,1,A,BAO_0000218,9615.0,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
7427,1,A,BAO_0000218,9615.0,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,In vivo,,Canis lupus familiaris,,,,
7428,1,A,BAO_0000218,9615.0,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,,Canis lupus familiaris,,,,
7429,1,A,BAO_0000218,9615.0,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,,Canis lupus familiaris,,,,
7430,1,A,BAO_0000218,9615.0,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,In vivo,,Canis lupus familiaris,,,,
7431,1,A,BAO_0000218,9615.0,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
7432,1,A,BAO_0000218,9615.0,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
7433,1,A,BAO_0000218,9615.0,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,In vivo,,Canis lupus familiaris,,,,
7434,1,A,BAO_0000218,9615.0,6227,t1/2 in dog,,,Canis lupus familiaris,,,,
7435,1,A,BAO_0000218,9615.0,14541,Half-life period measured in dogs,,,Canis lupus familiaris,,,,
7436,1,A,BAO_0000218,9615.0,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,,Canis lupus familiaris,,,,
7437,1,A,BAO_0000218,9615.0,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,Canis lupus familiaris,,,,
7438,1,A,BAO_0000218,9615.0,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,Canis lupus familiaris,,,,
7439,1,A,BAO_0000218,9615.0,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",In vitro,,Canis lupus familiaris,,Plasma,,
7440,1,A,BAO_0000218,9615.0,5444,In vivo half life period was calculated at 1 mg/kg in dog,In vivo,,Canis lupus familiaris,,,,
7441,1,A,BAO_0000218,9615.0,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,In vivo,,Canis lupus familiaris,,,,
7442,1,A,BAO_0000218,9615.0,17853,Longer half-life in dog (i.v.) at 0.5 mpk,In vivo,,Canis lupus familiaris,,,,
7443,1,A,BAO_0000218,9615.0,4353,Oral bioavailability in dog (dose 5 uM/kg),In vivo,,Canis lupus familiaris,,,,
7444,1,A,BAO_0000218,9615.0,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,,Canis lupus familiaris,,,,
7445,1,A,BAO_0000218,9615.0,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,,Canis lupus familiaris,,,,
7446,1,A,BAO_0000218,9615.0,16452,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,Canis lupus familiaris,,,,
7447,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,Mus musculus,,Lung,,
7448,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Lung,,
7449,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Lung,,
7450,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Lung,,
7451,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Lung,,
7452,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Lung,,
7453,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Muscle tissue,,
7454,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,Mus musculus,,Muscle tissue,,
7455,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Muscle tissue,,
7456,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Muscle tissue,,
7457,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Muscle tissue,,
7458,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Muscle tissue,,
7459,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Muscle tissue,,
7460,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Zone of skin,,
7461,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,,Zone of skin,,
7462,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Zone of skin,,
7463,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Zone of skin,,
7464,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Zone of skin,,
7465,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Zone of skin,,
7466,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Zone of skin,,
7467,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Spleen,,
7468,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,,Spleen,,
7469,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Spleen,,
7470,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Spleen,,
7471,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Spleen,,
7472,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Spleen,,
7473,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Spleen,,
7474,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,Mus musculus,,Stomach,,
7475,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,Mus musculus,,Stomach,,
7476,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,Mus musculus,,Stomach,,
7477,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,Mus musculus,,Stomach,,
7478,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,Mus musculus,,Stomach,,
7479,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,Mus musculus,,Stomach,,
7480,1,A,BAO_0000218,10090.0,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,Mus musculus,,Stomach,,
7481,1,A,BAO_0000218,10116.0,4689,Oral bioavailability in rat,In vivo,,Rattus norvegicus,,,,
7482,1,A,BAO_0000218,10116.0,4950,Tested for the bioavailability in rat,In vivo,,Rattus norvegicus,,,,
7483,1,A,BAO_0000218,10116.0,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,,Rattus norvegicus,,,,
7484,1,A,BAO_0000218,10116.0,406,Bioavailability in rat,In vivo,,Rattus norvegicus,,,,
7485,1,A,BAO_0000218,10116.0,12500,Bioavailability in rat,In vivo,,Rattus norvegicus,,,,
7486,1,A,BAO_0000218,10116.0,12500,Bioavailability in rat (dose 3-10 mg/kg),In vivo,,Rattus norvegicus,,,,
7487,1,A,BAO_0000218,10116.0,5247,Bioavailability in rat,In vivo,,Rattus norvegicus,,,,
7488,1,A,BAO_0000218,10116.0,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,In vivo,,Rattus norvegicus,,Plasma,,
7489,1,A,BAO_0000218,10116.0,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,In vivo,,Rattus norvegicus,,Plasma,,
7490,1,A,BAO_0000218,10116.0,6647,Half life after oral administration was determined in rats at 6 mg/kg,In vivo,,Rattus norvegicus,,,,
7491,1,A,BAO_0000218,10116.0,6484,Half life was determined,,,Rattus norvegicus,,,,
7492,1,A,BAO_0000218,10116.0,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,In vivo,,Rattus norvegicus,,,,
7493,1,A,BAO_0000218,10116.0,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,In vivo,,Rattus norvegicus,,Plasma,,
7494,1,A,BAO_0000218,10116.0,3307,Half life in rats,,,Rattus norvegicus,,,,
7495,1,A,BAO_0000218,10116.0,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,In vivo,,Rattus norvegicus,,Blood,,
7496,1,A,BAO_0000218,10116.0,8833,Hill coefficient of the compound,,,Rattus norvegicus,,,,
7497,1,A,BAO_0000218,10116.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,,Rattus norvegicus,,Blood,,
7498,1,A,BAO_0000218,10116.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,,Rattus norvegicus,,Blood,,
7499,1,A,BAO_0000218,10116.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,,Rattus norvegicus,,Blood,,
7500,1,A,BAO_0000218,10116.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,,Rattus norvegicus,,Blood,,
7501,1,A,BAO_0000218,10116.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,,Rattus norvegicus,,Blood,,
7502,1,A,BAO_0000218,10116.0,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,,Rattus norvegicus,,Blood,,
7503,1,A,BAO_0000218,10116.0,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,,Rattus norvegicus,,Blood,,
7504,1,A,BAO_0000218,10116.0,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,Rattus norvegicus,,,,
7505,1,A,BAO_0000218,10116.0,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,,Brain,,
7506,1,A,BAO_0000218,10116.0,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,,Brain,,
7507,1,A,BAO_0000218,10116.0,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,,Brain,,
7508,1,A,BAO_0000218,10116.0,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,,Brain,,
7509,1,A,BAO_0000218,10116.0,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,,Brain,,
7510,1,A,BAO_0000218,10116.0,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,,Thyroid gland,,
7511,1,A,BAO_0000218,10116.0,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,,Thyroid gland,,
7512,1,A,BAO_0000218,10116.0,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,,Thyroid gland,,
7513,1,A,BAO_0000218,10116.0,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,,Thyroid gland,,
7514,1,A,BAO_0000218,10116.0,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,,Rattus norvegicus,,Thyroid gland,,
7515,1,A,BAO_0000218,10116.0,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,,Blood,,
7516,1,A,BAO_0000218,10116.0,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,,Blood,,
7517,1,A,BAO_0000218,10116.0,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,,Blood,,
7518,1,A,BAO_0000218,10116.0,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,,Bone,,
7519,1,A,BAO_0000218,10116.0,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,,Bone,,
7520,1,A,BAO_0000218,10116.0,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,,Bone,,
7521,1,A,BAO_0000218,10116.0,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,,Heart,,
7522,1,A,BAO_0000218,10116.0,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,In vivo,,Rattus norvegicus,,Heart,,
7523,1,A,BAO_0000218,10116.0,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,Rattus norvegicus,,Heart,,
